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The tankyrases are poly(ADP-ribose)polymerases that are overexpressed in many 
cancers. They operate through three distinct mechanisms; they regulate the elong-
ation of telomeres, are a feature of Wnt-signalling (aberrant in many cancers) and are 
vital for the correct functioning of the mitotic spindle during mitosis. Thus the tank-
yrases are an intriguing target for a new therapy. A library of isoquinolin-1-ones with a 
variety of 3-substituents was synthesised using Pd-catalysed couplings, to probe the 
nicotinamide-binding site and adjacent hydrophobic pocket. Positions-4 and -5 were 
also accessed using carbanion chemistry.  
Preliminary ranging studies were conducted against tankyrase-2. Key Structure-Activity 
Relationship (SAR) features for potent inhibition included a para-substituted 3-aryl 
group and a small hydrophobic group in position-5. New inhibitors were designed with 
extensions and steric bulk in the 3-aryl region, designed to reach further into and test 
the capacity of the hydrophobic pocket. Removal of the 5-amine improved potency but 
worsened water-solubility. This was re-introduced through a basic tertiary aliphatic 
amine tethered to the 3-phenyl group. 
Molecular modelling and small-molecule crystal structures facilitated the under-
standing of the SAR. Steric clashes were apparent for inhibitors with bulky ortho-
substituted 3-aryl groups, whereas para-substituted 3-aryl groups fitted well into the 
hydrophobic pocket. Although ortho-substituents on the 3-aryl group confer a dihedral 
twist between the isoquinolin-1-one and 3-aryl group, this is not responsible for the 
loss of activity.  
Fifteen isoquinolin-1-ones were selected for fuller biological evaluation, based on 
potent activity, SAR features and superior pharmaceutical properties. IC50 values were 
measured against tankyrases-1 and -2 and a counter-screen conducted against PARP-1. 
A number of analogues were highly anti-proliferative in the human colon carcinoma 
HT29 cells and human FEK4 fibroblasts; however, inhibition of tankyrases did not 
always correlate with this activity. A subset of potent tankyrase-2 inhibitors 
demonstrated good selectivity for HT29 over FEK4 cells; these also showed good 
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Chapter 1.0 - Introduction to biological background 
1.1 Cancer – A global problem 
There is no greater threat to public health in the modern world than cancer. 
This truly global problem saw over 12.7 million people diagnosed with a primary 
episode of cancer and 7.6 million deaths from cancer in 2008 alone (CRUK website). Of 
those newly diagnosed, lung cancer contributes a remarkable 1.6 million cases (12.7% 
of the total for men and women), female breast cancer another 1.4 million (10.9% 
total for women), colorectal a further 1.2 million (9.7% of the total for men and 
women) and stomach cancers another 1 million (7.8% of the total for men and 
women); together these statistics account for over 40% of all new cases.  
Chemotherapy was a term and concept defined by the famous German chemist Paul 
Ehrlich in the early 1900s as the use of chemicals to treat disease.1, 2 Early work in 
Ehrlich’s laboratory on aniline dyes and alkylating agents and subsequent drug devel-
opment efforts throughout the early part of the 20th century made little impact on 
cancer treatment, with surgery and radiotherapy dominating therapy at this time. 
Chemicals were not seen as an effective therapeutic tool at this time; even the Nobel 
Prize winner Charles Huggins’ treatment of prostate cancers with hormones in 1939 
had little impact in changing this observation. The atrocities of World War II made for 
an unlikely scene in the breakthrough in new anti-cancer treatments; the accidental 
spill of sulfur mustard on troops during the bombing of a ship in Bari Harbour led to 
the observation that exposure to these toxic gases had a depletive effect on lymph 
nodes and on bone marrow. Research into this led to the publication of a seminal 
paper in 1946, in which marked regression had been observed in a non-Hodgkin’s 
lymphoma patient treated with nitrogen mustard. This led to a period of great excite-
ment with the realisation that chemicals did have the potential to cure cancer.  
Over the next few decades, this initial façade was tainted somewhat with the 
realisation of both the great toxicity of these chemicals and resilient nature of the 
cancers themselves; a great scepticism endured that a cure was achievable. By this 
time, a great deal of money and resources were being invested in finding a ‘cure’, with 
little evidence of any great consequence to justify this expenditure. The view of these 
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‘poisons’ was not much improved into the 1960s, with their use in anti-cancer treat-
ment often viewed with much hostility. The much needed breakthrough came, not 
only with the discovery of the potent activity of plant alkaloids by Eli Lilly Company, 
but also with the more aggressive use of chemotherapy suggested by Skipper3 and 
justified by his ‘Cell Kill’ hypothesis. This more aggressive use, along with the apparent 
advantage of combined, cyclical and scheduled treatments with adjuvant therapies, 
paved the way to a much desired cure, initially seen in childhood leukaemias and 
extended in 1970 to include advanced Hodgkin’s lymphoma. These initial results led to 
a flurry of research into combination chemotherapy and huge advancements in the 
treatment of breast and testicular cancers. Many very useful drugs were discovered in 
this era, including methotrexate, 5-fluorouracil, cyclophosphamide, vinblastine and 
bleomycin, which are still used today as part of combination treatments for many 
cancers. In addition to this, the screening of potential therapies against random targets 
has evolved through improved knowledge of cancer cell biology and has led to advan-
ced sophisticated screening campaigns against specific molecular targets. The first 
example of such a targeted approach came from the development of imatinib, an 
inhibitor of Bcr-Abl tyrosine kinase, which revolutionised the treatment of chronic 
myeloid leukaemia. 
Now, in the midst of the era of targeted medicines, this culture is underlying in all 
research efforts towards new anti-cancer therapies and is implicit in this project.  
1.2 Cancer – a natural advantage  
Cancer cells have many inherent advantages over ‘normal’ cells, allowing them to pro-
liferate in an uncontrolled manner and essentially rendering them immortal. It is this 
natural advantage that must be exploited in the search for new potent and targeted 
therapies – leaving non-cancerous cells as intact as possible, whilst selectively killing 
cancer cells.  
1.3 Telomeres – a biological clock 
“This is the beginning of the end” (Charles Maurice de Talleyrand, 1754-1838; 
announcing Napoleon’s defeat at Borodino)  
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On a molecular level, this drug discovery story begins with specialised nucleoprotein 
structures which form the ‘natural ends’ of our chromosomes and were named in 1938 
as telomeres 4 These conserved and highly specialist heterochromatic structures were 
first discovered in the 1930s by Muller and McClintock and were named after the 
Greek words telos and meros, translating as ‘end’ and ‘part of’, respectively.2, 4-7 Found 
in all eukaryotic cells, the telomere plays an essentially protective role for the integrity 
of the genome, in particular to the exposed ends of the transcribed region of the 
chromosomal DNA.2, 7-11 Indeed, a fitting analogy for describing the role of telomeres is 
to think of them as the aglets, or tips on a pair of shoelaces, preventing the fraying and 
unravelling of the main body of the laces which ultimately fulfil the global role (Figure 
1).12 
These protective structures, in mammals, consist of several kilobase-long, untrans-
cribed nucleotide sequence repeats which are identical for all chromosomes in any 
given organism. 4, 5, 8, 11, 13-15 Even in phylogenetically widely divergent eukaryotes, 
these tandem repeats have evolved as highly conserved and their length is specific to 
the species.2, 4, 11, 15 In Homo sapiens, they are consistently 5-15 Kb in length and 
consist largely of AGGGTT repeats.2, 6 Interestingly, the same telomeric repeat 
sequence is observed in several species of mould and protozoan parasites! 4 The G-rich 
strand (also known as the G-overhang), which is orientated 5’ to 3’ towards the 
chromosome end, continues beyond the double helix structure to form a single strand 
Figure 1: a, diagrammatic representation of a chromosome with telomeres labelled; b, Cells arrested in 
metaphase have their telomeres visualised using quantitative fluorescence in situ hybridisation (Q-
FISH) where a fluorescent probe binds specifically to telomeric sequences and can be used to 
determine their length.12  
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consisting of 150-200 nucleotides in humans. 2, 4, 6 This asymmetric strand composition 
is characteristic of telomeric DNA.  
Owing to the incomplete nature of DNA replication and the inability of the DNA poly-
merases to replicate right to the ends of linear DNA – a phenomenon known as the 
‘end-replication problem’ – the telomere essentially acts as a sacrificial entity or 
‘suicide repeats’. Described by Watson in the 1970s, the end replication problem sees 
telomeres shortening by up to 150 base-pairs during each round of DNA replication in 
the normal somatic cell, accounting for a lifetime loss of 2-4 Kb.2, 8-10, 14, 16 As the telo-
meres progressively shorten, through successive rounds of DNA replication, a critical 
length is eventually reached, also known as the Hayflick limit, eliciting a DNA-damage 
checkpoint response, through the tumour-suppressor protein p53, and subsequent 
replicative senescence. 6, 17, 18 At this point, the cell is rendered unable to replicate its 
genome safely and is thus removed delicately by apoptosis, with no damage to the 
integrity of adjacent cells. In this sense, the telomeres can be viewed as a biological 
clock, carefully controlling and timing the lifespan, aging and, ultimately, the fate of 
differentiated cells. Fundamentally, this process has evolved in order to protect the 
genome against potential oncogenic events and tumorigenesis, as carefully controlling 
the lifespan of a pre-malignant cell may prevent the accumulation of further mutations 
and subsequent development of tumours. 18, 19 
1.4 Telomerase – a specialised reverse transcriptase 
“….to make an end is to make a beginning” (T. S. Eliot, 1888-1965. Four Quartets: 
“Little Gidding”)  
Cells have a response to the ‘end-replication problem’ in the form of a telomere-synth-
esising enzyme known as telomerase, discovered in 1985 by Greider and Blackburn, 
which acts to compensate for attrition of the telomere by re-building the single-
stranded hexameric AGGGTT repeats that they lose during cell replication.5, 6, 11, 16, 20 
Telomerase, a ubiquitously expressed ribonucleoprotein enzyme, consists of two 
essential components; a protein reverse transcriptase (TERT), which catalyses the 
enzymatic reaction of DNA synthesis, and an RNA component (TER), which acts as the 
template for the synthesis of the lengthened telomeres (Figure 2).6 Both components 
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are essential to the function of this system; independent ribonuclease and protease 
treatment abolished the activity of the RNA and protein reverse transcriptase activity, 
respectively.4, 13, 16 The sequence of the RNA component of telomerase was originally 
identified as 3’-CAACCCCAA-5’ in the Tetrahymena extracts and they were found to act 
as templates for repeated rounds of copying and subsequent addition onto the 3’-ends 
of G-rich telomere termini.4 Specifically, the reverse transcriptase entity of the telo-
merase enzyme recognises the 3’-OH at the end of the G-strand overhang and leads to 
elongation of the telomere using TER as a template (Figure 2).5,13 
The first connection between cellular lifespan and telomerase activity occurred in 
1990, when experiments using an RNA-template mutation in Tetrahymena cells, which 
are normally immortal, showed shortening of the telomeres and cell division ceasing 
after 20-25 further divisions.4, 21 The cells had effectively switched from being immortal 
to mortal, an astonishing transformation.  
On the face of it, telomerase would appear to work in conflict with the protective 
process of cellular aging, known to allow older cells with potentially pre-cancerous 
mutations, to be removed delicately by apoptosis, maintaining the integrity of the sur-
rounding tissue. In truth, telomerase actually plays little part in the day-to-day man-
agement of the primary somatic cell. Telomerase levels are largely suppressed and are 
undetectable in mature somatic tissues; it thus interferes very little in the protective 
Figure 2: The first model for the action of the Tetrahymena telomerase, discovered by the 2009 Nobel prize 
winner in Physiology, Elizabeth H. Blackburn and colleagues. 4, 20 In this species, telomerase added tandem 
repeats of the telomeric DNA sequence, GGGTTG, onto the 3’ end of a variety of G-rich telomeric DNA 
sequence oligonucleotide primers.  
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anti-tumorigenic role of the telomeres in this instance.5, 10, 11, 16 In contrast to mature 
somatic tissue, immortalised cells (including cancer, embryonic stem and germ-line 
cells) exhibit high levels of active telomerase enzyme.11  In the case of embryonic stem 
cells, the advantage posed by enhanced telomerase activity was justified by a theoret-
ical increase in tissue functionality and longevity, an effect unwanted in adult tissue 
owing to its cancer-forming potential.5  
Consequently, the telomeres in these immortalised cell types are constantly being re-
built and repaired, never reaching the Hayflick limit and associated cell senescence, 
owing to complete avoidance of a telomere crisis (Figure 3).22 Indeed, it has been 
shown that progression of tumour cells is reliant on activation of telomerase and that 
expression of telomerase has been found in up to 90% of all cancers, including 
cancerous stem cells.4,5, 6, 13, 23, 24 In fact, telomerase was originally discovered in 
cervical cancer in 1989.2, 5, 8-10, 25  
The oncogenic stress forced upon a pre-cancerous cell will drive its proliferation, con-
ceivably leading to short telomeres, and, eventually, the onset of replicative senes-
cence due to activation of p53-dependent DNA damage check-points.14 In the absence 
of the appropriate checkpoints due to the stochastic loss of p53 or Rb function, senes-
Figure 3: Mature somatic cells have limited replicative potential due to their telomeres constantly shortening 
until they reach a critical length known as the Hayflick limit, at which point they undergo growth arrest and 
become senescent. Re-expression of telomerase or inactivation of the tumour suppressor proteins p53 and Rb 
can lead to cell crisis and widespread cell death. Cancer cells can maintain the length of their telomeres either 
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cence may be by-passed and the cell may progress rapidly towards becoming cancer-
ous.14 Re-activation of telomerase in this pre-cancerous cell may overcome the limited 
growth potential associated with short telomeres and provide it with an infinite capac-
ity for unconstrained proliferation and thus be cancer-promoting (Figure 3).4, 5, 14 In this 
instance, telomerase may, in addition to multiple genetic and epigenetic changes, pro-
vide the cancer cell with the most dangerous tools of all: immortality and the means to 
continuous replenishment.4  
Further proof of the essential role of telomerase in preventing cell senescence and 
death has been shown by experiments which forced the expression of telomerase in 
otherwise telomerase-negative human cells. In these cells, senescence and cell death 
was avoided and cell division continued, in contrast to the telomerase-negative cells 
which underwent these processes.8, 10, 26 This constitutive telomerase expression 
allows for the maintenance of shorter telomeres than would be acceptable in somatic 
cells and thus enables the uncontrolled proliferation seen in the early stages of human 
carcinogenesis. Interestingly, and in stark contrast to the ‘cancer’ model, some 
diseases, including congenital dyskeratosis, some aplastic anaemias and idiopathic 
pulmonary fibrosis, suffer from germ-line mutations in TER and TERT. This can lead to 
premature death and tissue loss due to accelerated telomere shortening.5  
Although the predominant mode of telomere repair is through telomerase, there is 
also an alternative, telomerase-independent pathway, thought to maintain telomere 
length in a small subset of human cancers.14 This pathway, known as the alternative 
lengthening of telomeres (ALT), is thought to be reliant on activation of the homo-
logous recombination (HR) repair pathway and is mechanistically largely unknown.14 
1.5 Specialised 3D structures – t/d-loops and G-quadruplex 
Although constitutively expressed in many tumours, telomerase does not hold a free 
pass to its required 3’-overhang at the telomeric site and has very limited access under 
normal circumstances.23 Part of the role of the telomeres is to disguise the ends of the 
chromosomal DNA from being recognised as double-strand breaks; events which 
would lead to recruitment of repair machinery and which could lead to further threats 
to the integrity of the DNA. To avoid this threat, the intact telomere can fold into 
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various 3D confirmations which render it unrecognisable to repair machinery in the 
cell. This unique ability of the telomere to adopt various non-canonical 3D conformat-
ions is, in large part, a consequence of its guanine-rich nucleic acid sequences, which 
have a high propensity to fold into different topologies.2, 6, 27, 28 Two forms of special-
ised structure are thought to exist; the G-quadruplex and the telomere- and displace-
ment-loops (t- and d-loop) (Figure 4).6 The t-loop, a ‘lasso-like’ structure, is formed 
through the folding back of the single-stranded telomeric terminus, otherwise known 
as the 3’-overhang, and its subsequent invasion into the double-stranded duplex-
repeat array of the telomeric DNA, thus forming a d-loop. The circular t-loop structure 
formed can vary in size from very small (ca. 1 Kb) to very large (> 25Kb); however, little 
is known with regards to its properties and it remains a largely speculative structure.2, 
5, 6 
Planar guanine tetrads (G-tetrads), which are formed by intramolecular H-bonding bet-
ween four guanine bases, known as Hoogsteen base-pairing and are stabilised by 
cations, stack characteristically to 
form G-quadruplexes. These have 
been recognised since the 1960s.2, 6, 7, 
28 These G-quadruplexes are then 
held together by four backbone 
strands, with several loops connec-
ting these strands.6, 7 This specialised 
structure has the propensity to 
arrange itself in different topologies 
with further G-quadruplexes; many 
different folding forms have been 
associated with the human telo-
mere.6 These two specialised 
structures can co-exist at the telo-
mere termini and may act in synergy 
to protect the telomere. Indeed, it 
has been suggested that the G-quad-
Figure 4: Diagrammatic representation of the 3D 
topologies that telomeres can adopt due to their 
guanine-rich nature. a, t-loop and d-loop formed by the 
folding back on itself (t-loop) and invasion of the single 
strand 3’-terminus into the double stranded telomeric 
DNA (d-loop), along with various telomere associated 
proteins; b, A G-quadruplex formed by multiple 
parallelograms of G-tetrads and neutralised by central 
cations such as K+ and Na+; c, Four guanine bases 
hydrogen-bonded to create a G-tetrad or G-quartet.  
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ruplex may be able to stabilise a large t-loop structure; its formation induces the 3’-
overhang to encroach into the double-stranded region.29 The loss of these defensive 
structures can lead to very rapid shortening of telomeres.  
1.6 The shelterin complex – a family of bodyguards 
The t- / d-loop and G-quadruplex have a role more crucial than the mere blocking of 
the action of telomerase; they also act to prevent the telomere from being recognised 
as a single-strand break by DNA-repair machinery which only recognises linear duplex 
DNA.6 This defends the telomeres from the potentially disastrous consequences of an 
untoward act of recombination, such as joining telomeres together or, worse still, 
fusing telomeres with genuine chromosomal breaks.8, 10, 12, 15 To help to avoid these 
untoward events, these specialised structures are maintained and nurtured and, in 
some cases, disrupted by a large complex of six telomere-specific proteins that are ass-
ociated with them, known as the shelterin or telosome complex5, 6, 14, 16, 30 (Figure 5). 
This complex acts as a physical buffer at the telomere termini, preventing its exposure 
and recognition as a DNA double-stranded break (DSB) and facilitating the role of the 
telomere as ‘gatekeeper’ against access by telomerase.4, 14 Not only this, the shelterin 
complex is fundamental to the integrity of the functional telomere; indeed, mutations 
in telomere-binding proteins can lead to loss of telomeric capping.5, 10, 31 In addition, 
complete abrogation of the complex results in early embryonic lethality.5, 10, 31 
Of the six members of this family, two of these, Telomeric Repeat-Binding factors-1 
and -2 (TRF-1 and TRF-2), are ubiquitously expressed and localise to the telomeres 
throughout the cell cycle.11,32 They bind directly to the TTAGGG double-stranded telo-
mere repeats and are involved in protection of the telomere and in maintenance of the 
t- / d-loop structures.11, 13, 32 Although related in their primary structure, the TRFs differ 
in their N-termini, with TRF-1 exhibiting acidic properties and TRF-2 with basic proper-
ties, which may account for their functional differences.6 Whilst TRF-1 is predominan-
tly associated with replication and capping of telomeres,33, 34 TRF-2 is involved in pro-
tection and recombination of telomeres;35 however, both are thought to contribute to 
regulation of the length of telomeres through their bodyguard roles.36 In addition, TRF-
2 represses Ataxia-Telangiectasia-Mutated (ATM) signalling, a distinct DNA-damage 
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repair pathway.14 Interestingly TRF-1 and TRF-2 act independently and have no inter-
action with each other.5 
Other members of the shelterin complex include telomere protein Protection of Telo-
meres-1 (POT-1), which is the only other member of the complex to recognise single-
stranded telomere DNA sequences directly, but not duplex DNA.6, 37 In addition to 
having a high sequence specificity with which it can bind the telomeric 3’ overhang, 
POT-1 may also be able to disrupt intramolecular G-quadruplex structures.6, 37 POT-1 is 
recruited by TIN2-Interacting protein-1 (TPP-1) when bound by TRF-1- and TRF-2-Inter-
acting Nuclear-2 (TIN-2), which then forms a linkage between the duplex component 
of the telomeres and the single-stranded overhang.6, 37 TIN-2 provides a direct interact-
ion between TRF-1 (through its C-terminus) and TRF-2 (through a hinge region at the 
N-terminus).6, 30 TPP-1 bridges the gap between POT-1 and TIN-2 and is critical for the 
association of POT-1 with telomeres.6 The sixth member of the complex, Repressor / 
Activator Protein-1 (RAP-1), associates predominantly with TRF-2 and relies solely on 
this interaction for binding to telomeres.6 
The crucial protective role of the various members of the shelterin complex is apparent 
from studies that show that overexpression of TRF-1 in a telomerase-expressing cell 
line that normally maintains stable telomeres led to progressive shortening of the telo-
Figure 5: The shelterin complex comprises the two major 
double-stranded telomere binding proteins TRF-1 and 
TRF-2, associating through TIN-2 and TPP-1, to the single-
stranded TTAGGG binding protein POT-1. When tankyr-
ase-1 poly (ADP-ribosyl)ates TRF-1 this leads to a more 
‘open’ configuration whereby telomerase has access to 
the single-strand G-rich overhang and can lengthen the 





Well packaged telomere. 
Less accessible to telomerase.
Open telomere. 
More accessible to telomerase.
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meres, independently of the activity of telomerase.11 Conversely, inhibition of binding 
of TRF-1 to telomeres leads to progressive shortening of telomeres.11 Likewise, specific 
deletion of Pot-1a in a mouse model not only provokes a DNA-damage response but 
also leads to an increase in telomere sister-chromatid exchange (T-SCE) and, 
unsurprisingly, triggers p53-dependent replicative senescence; this indicates the 
importance of POT-1 in repressing homologous recombination.38 Furthermore, 
another group looked at the co-depletion of POT-1a and POT-1b and found that 
telomere protection is lost in 70-80% of nuclei.39 Interestingly, unlike the murine 
model, the human genome comprises a single POT-1 locus and, therefore, 
comparisons must be drawn with some caution. Recombinant human POT-1, however, 
has been found to regulate telomerase activity negatively in vitro by hindering access 
of the substrate to the primer 3’ end.37 
Disruption to components of the shelterin complex, including TPP-1/POT-1 and TRF-2, 
has also been observed in ALT cells, which show characteristic hyper-telomere recom-
bination, demonstrating further the protective role of this complex when functioning 
correctly.14 An important feature of ALT is the T-SCE-type recombination that occurs 
between telomeres in the telomerase-negative cell.15 Likewise, uncapped mammalian 
telomeres, in a similar manner to short telomeres, attract attention from proteins 
normally involved in the repair of DSBs, such as the non-homologous end-joining 
(NHEJ) complex protein DNA-dependent protein kinase (DNA-PK).15 Cells deficient in 
the catalytic subunit of DNA-PK (DNA-PKcs) and with dysfunctional telomeres are 
prone to genomic instability and tumorigenesis.15 A clear example of this was the 
development of murine mammary carcinoma in BALB/c mice, which all have two 
single-nucleotide mutations in DNA-PKcs and are thus susceptible to radiation-induced 
telomere-DSB events.22 This research clearly demonstrates a link between genetic 
susceptibility and environmental insults.22 Interestingly, both the Ku-family and NBS-
MRE11-RAD50 complex, which are both known to be involved in sensing DNA breaks 
and in mediating repair, have also been found at telomeres.5, 12 
Although represented as a collection of proteins bound to the telomere in a particular 
order, the shelterin-telomere complex is actually a rapidly-changing dynamic but 
stable entity, with the composition of the complex constantly changing through rel-
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ease and replacement of various telomeric proteins. Indeed, this complex has been 
compared to a swarm of bees; the overall shape of the swarm is constant but the bees 
are constantly changing places and being replaced.4 
1.7 The PARPs - a superfamily of enzymes 
Pre-requisite to membership of the poly(ADP-ribose)polymerase (PARP) superfamily is 
the inherent ability to catalyse the transfer of single or multiple ADP-ribose subunits to 
their targets, using the co-enzyme found in all living cells, nicotinamide adenine dinucl-
eotide (NAD+). This post-translational modification, known as ADP-ribosylation and 
first described in the 1960s in relation to PARP-1 and its role in repair of damaged 
DNA, leads to structural changes and subsequent functional alterations in the target 
and is mainly observed in eukaryotes, with the exception of yeasts.17, 40 Subsequently, 
ADP-ribosylation has been found to be involved in multiple cellular processes assoc-
iated with apoptosis, transcriptional regulation, DNA methylation and in Wnt-signal-
ling.17, 41 A huge number of enzymes consume NAD+ in their catalytic process, of which 
the PARP superfamily is just one example. Known as ADP-ribosyltransferases, the PARP 
enzymes modify target proteins using this catalytic activity; however, other enzymes 
under this umbrella term can modify nucleic acids and small molecules.40  
NAD+ itself has two bonds liable to attack; the N-glycosidic bond and the pyrophos-
phate bond, both of which can break in enzymatic reactions.40 In the case of ADP-ribo-
sylation, it is the N-glycosidic bond that gets broken (Scheme 1). In the initiation reac-
tion, the first ADP-ribose unit is typically attached to the carboxylate side-chain of glut-
amic acid (Glu) or aspartic acid (Asp) residues on the acceptor protein via a covalent 
bond, using the substrate NAD+.42 Cleavage of nicotinamide off the NAD+ molecule 
generates an ADP-electrophile in the form of an oxonium ion.42 The incoming nucleo-
phile approaches from the α-face, hence the ADP-ribosyl linkage is of α-configuration; 
opposite to that of the substrate NAD+ as depicted in Scheme 1.9, 40 The addition of fur-
ther ADP-ribosyl groups is propagated via the two hydroxy groups of the two ribose 
rings, leading to long and branched poly(ADP-ribose) chains in the elongation reaction. 
Nicotinamide, the small molecule cleaved off NAD+ in the process, has become the rat-
ional starting point for the design of small molecule mimetics as it is the most tightly-
bound part of NAD+ in the enzyme catalytic site. The growing polymer chain confers a 
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significant negative charge to the acceptor protein, disrupting its conformation and 
interaction with its previous co-protein or substrate. In the case of PARP-1, it is the 
histone proteins that protect the integrity of the DNA that become ADP-ribosylated; 
hence, an electrostatic intermolecular repulsion is created between the negatively 
charged histones and the DNA itself.  
The PARP superfamily comprises seventeen structurally related proteins; six of these 
are known to exhibit traditional PARP catalytic activity, namely PARP-1, PARP-2, PARP-
3, PARP-4 (also known as vault PARP (vPARP)), tankyrase-1 (also known as PARP-5A) 
Scheme 1: Depiction of the catalytic activity of the PARP superfamily of enzymes. Cleavage of 
nicotinamide from NAD+, when bound in the acceptor site of the catalytic pocket of the enzyme, results 
in the formation of an ADP-ribose electrophile, which is then attacked by nucleophilic residues (glutamic 
acid or aspartic acid) in the target protein and a covalent bond is formed between them. Further ADP-
ribosyl groups are then attached via the hydroxy groups on the ribose ring, leading to the rapid assembly 
of long and branched poly(ADP-ribosyl) groups on the target protein, conferring significant structural and 
functional changes to the target protein.  
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and tankyrase-2 (also known as PARP-5B) which all catalyse the transfer of multiple 
ADPribose units onto target proteins (also known as PARsylation).43 The other subset 
of this large family, namely PARP-6, PARP-7 (also known as TIPARP), PARP-8, PARP-9 
(also known as BAL-1), PARP-10, PARP-11, PARP-12, PARP-13 (also known as 
ZC3HAV1), PARP-14 (also known as BAL-2), PARP-15 (also known as BAL-3) and PARP-
16 have recently been characterised more appropriately as catalysing the transfer of 
single ADP-ribose units onto target proteins.43 This has led to the suggestion of a new 
nomenclature for the classical PARP family by Hottiger and colleagues to reflect this 
understanding and is now being introduced in the general literature.43 Owing to the 
common ‘transferase’ activity exhibited by all seventeen members of the superfamily, 
the “ADP-ribosyltransferases diphtheria toxin-like” (ARTD) family was deemed a more 
appropriate name.  
PARP-1, the most abundant of the entire PARP superfamily, uses its zinc fingers to 
recognise DNA strand breaks, either occurring directly or indirectly through oxidation, 
alkylation, base excision and others, and is well documented as being one of the first-
line responses to this damage (Figure 6). This interaction vastly increases the activity of 
the catalytic domain of PARP-1 (up to several hundred-fold), leading to a rapid ADP-
ribosylation of acceptor proteins including histones and PARP-1 itself via its BRCT 
domain. 40 This hive of activity creates long-chain negatively-charged polymers which 
are thought to act almost like a molecular magnet or beacon, recruiting the base-excis-
ion repair (BER) machinery to the site of DNA damage. In addition to recruitment, 
Figure 6: Hyper-activation of PARP-1 can lead to necrotic cell death, compromising the integrity of the 
surrounding tissue. PARP-1 inhibitors can ‘switch’ the cell from a necrotic to an apoptotic cell death thus 
protecting the tissue from ischaemic injury.  
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PARP-1 activity is thought to relax the chromatin structure of the tightly packed DNA, 
allowing repair enzymes access to the damaged site. 40 This relaxation is thought to 
occur through the electrostatic repulsion between the ADP-ribosylated histones and 
the DNA itself. This results in either repair of DNA or, if the damage is too great, cont-
rolled cell death or apoptosis.40, 44-48 
Recruitment of DNA-repair enzymes to damaged DNA by PARP-1, however, is a 
double-edged sword, as hyper-activation of PARP-1, caused by excessive assault on 
DNA leads to severe depletion of pools of NAD+ and thus of ATP in the cytosol and 
nucleus, which can lead to rapid failure of the metabolic integrity of the cell and, ultim-
ately, to necrotic cell death or parthanatos (Figure 6).45, 47, 48 This latter predicament 
can compromise the integrity and survival of the adjacent cells and tissue, leading to 
further cell death and tissue failure. Conversely, PARP-1-knockout cells were found to 
be resistant to large doses of DNA-damaging agents (including alkylating and oxidising 
reagents), lethal to normal cells.40 Inhibition of PARP-1, therefore, would sensitise 
tumour cells to an assault by either radiation or chemotherapeutic agents and improve 
the response in cancer treatment.45, 47  
Likewise, the use of inhibitors of PARP-1 in the treatment of ischaemic injury, such as 
stroke, can be explained by their preventing catastrophic necrotic cell death affecting 
large areas of brain tissue.45, 47 In cells injured either oxidatively or nitrosatively, typical 
in ischaemic injuries, inhibition of PARP-1 can protect the tissue from necrotic cell 
death and switch to either an apoptotic conclusion or back to an apparently normal 
phenotype.45 It is the rapid consumption of cellular energy pools (ATP and phospho-
creatine) triggered by activation of PARP-1 due to excessive DNA damage and subse-
quent metabolic failure that causes widespread necrotic cell death.49 These conditions 
mimic those found in major organs during an acute assault, such as stroke, and in 
many inflammatory conditions, such as colitis. A large body of research supports the 
potential use of inhibitors of PARP-1 in reducing this excitotoxic cell death and have 
been found to be beneficial in many models of inflammation and ischaemia / reper-
fusion injury.50-59 
Inhibition of PARP-1 should not be a cytotoxic event per se, as failure to recruit one 
DNA repair mechanism may not negate the repair process entirely. This is because sev-
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eral DNA repair pathways are thought to exist, including non-homologous end joining 
(NHEJ), homologous recombination (HR), nucleotide excision repair (NER), mismatch 
repair (MMR), trans-lesion synthesis (TLS), as well as BER mentioned above.60 Indeed, 
inhibition of one repair pathway may hinder the ability of cancer cells to proliferate in 
an uncontrolled manner; however, it is likely that the cancer will become ‘addicted’ to 
a different repair pathway, thus side-stepping any attempt to halt its aberrant 
progress.60 On the face of it, this may represent a huge barrier to effective treatment; 
however, on the flip side, ‘addicted’ cancers may become very sensitive to inhibitors of 
repair pathways that they rely on in a concept known as synthetic lethality. This 
concept was first described in the 1940s by the geneticist Dobzhansky, and refers to 
the hypothesis that the individual deletion of either of two genes has no effect, wher-
eas the deletion of both is cytotoxic.60 One example of this is in cells carrying mutat-
ions in their BRCA gene, which play a key role in maintaining genomic integrity due to 
their involvement in HR. Mutations in BRCA1 or BRCA2 lead to a critical dependence 
on BER for DNA repair. As mentioned previously, PARP-1 is required for BER; therefore, 
inhibition of PARP-1, in this case, is synthetically lethal. 60-62 
Early PARP-1 inhibitors, such as nicotinamide (endogenous co-product), benzamide 
and substituted benzamides, such as 3-aminobenzamide, were identified in the 1980s 
and found able to radiosensitise cells to the effects of DNA-damaging chemothera-
peutic agents by hindering the ability of these cells to repair the damage inflicted upon 
their DNA.17, 60, 63 This triggered the development of further inhibitors with greater pot-
ency and selectivity, initially with their use intended as adjuvant radiosensitisers and 
chemosensitisers alongside traditional oncology treatments; however, monotherapy 
also proved fruitful in some cases.17 Several agents are currently in the advanced 
stages of the drug development pathway as both monotherapy in predefined patient 
populations and as combination therapies.17 Olaparib (AstraZeneca), for example, is 
currently undergoing phase I and II clinical trials in the potential treatment of platin-
sensitive ovarian cancer, BRCA-1 or BRCA-2 -mutant tumours (in combination with 
carboplatin), triple-negative breast cancer (single-agent or with carboplatin) and other 
solid tumours.48, 62 Other agents including veliparib (Abbott), rucaparib (Pfizer and 
Clovis), BMN-673 (biomarin) and MK-4827 (Merck and Co.) have paved the way for 
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inhibitors of the PARPs in the clinical setting and elicited further interest in other 
members of this superfamily, in particular the tankyrases. 
1.8 Tankyrase – a chance discovery 
Tankyrase-1 (Telomeric repeat binding factor-interacting ankyrin-related ADP-ribose 
polymerase) was initially discovered by Smith and de Lange and reported in a seminal 
paper in 1998.64 They used a yeast two-hybrid screen with human TRF-1 as bait and, 
through the interaction of ten ankyrin repeats on tankyrase-1 with full-length TRF-1, 
the group was able to capture and characterise this new protein.64 Interestingly, no 
interaction was observed between tankyrase-1 and TRF-2, owing to the absence from 
TRF-2 of the N-terminal acidic domain found to be crucial for the interaction between 
TRF-1 and tankyrase-1.11, 64 Although several features of this new protein pointed 
towards its inclusion in the ankyrin family, a group of closely related structural proteins 
known to link integral membrane proteins to internal cytoskeleton, the overwhelming 
homology between tankyrase-1 and the PARP superfamily of enzymes clearly placed it 
in this group. Although tankyrase-1 shares 28-30% amino-acid sequence identity with 
the catalytic domains of both human and Drosophila PARP-1 and includes those critical 
regions responsible for interaction with binding of NAD+ and catalysis, it also shows 
significant differences, not at all typical in the PARP family. In particular, tankyrase-1 
contains no DNA-binding motif, unlike the most characterised member of the family, 
PARP-1, and is thus unlikely to be activated by DNA damage.11,65 Expression of tankyr-
ase-1 was found to be ubiquitous throughout all body tissues, with the highest 
amounts found in the testes, ovaries and skeletal muscle and, not surprisingly, coin-
cides largely with the localisation of both TRF-1 and TRF-2.11 Indeed, immunofluores-
cence analysis performed by Smith and de Lange revealed that tankyrase-1, like TRF-1, 
is located in the close vicinity of metaphase chromosomes and is thus considered part 
of the human telomeric complex and is likely to be involved in telomere homeostasis.66 
Structurally, tankyrase-1 comprises a 142 KDa enzyme made up of four distinct 
domains (Figure 7). At the amino terminal, the first domain, known as the homopoly-
meric tract or HPS domain, is made up of histidine, proline and serine residues and is 
of unknown function. Adjacent to this is an ankyrin domain (ANK) comprising twenty 
four ankyrin repeats, arranged in five ankyrin-repeat clusters (ARC) and, like all 
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classical ankyrin domains, is responsible for protein-protein interactions with target 
proteins. Thirdly, a sterile α-motif (SAM) domain exists, capable of promoting the 
homo- and hetero-multimerisaton between the tankyrases. Lastly, at the carboxy 
terminus lies a catalytic ART domain (ADP-ribosyltransferase).42,67 In terms of cellular 
localisation, tankyrase-1 is an abundant cytoplasmic protein, lacking a nuclear 
localisation signal which would be required for its inclusion in the nucleus.19 This 
nuclear exclusion is, however, lifted temporarily during the S-phase of the cell cycle to 
allow for the continuation of successful DNA replication due to its interaction with TRF-
1.19 Evidence for this was shown in a tankyrase over-expression model, with an 
exogenous nuclear localisation signal, where telomere elongation was observed in 
telomerase-expressing cells consistent with a functional reduction in the ability of the 
TRF-1 complex to bind and protect these strutures.64 
A closely related homologue of tankyrase-1 is tankyrase-2; indeed, they are so closely 
related that they share 94% identity in their catalytic domains and 83% throughout 
their entire primary structure (Figure 7). Unsurprisingly, they have many overlapping 
functions.11, 42, 68 Notably, as well as almost complete sequence identity in most 
domains, the two isoforms are almost identical in the organisation of their catalytic 
domains.68 This isoform, discovered shortly after tankyrase-1 in a TRF-1 two-hybrid 
screen, retains all but the HPS domain of tankyrase-1.69, 70 The conserved ANK domain 
allows tankyrase-2 to make very similar protein-protein interactions to those observed 
Figure 7: Schematic representation of tankyrase-1 and -2 which depicts the significant homology between the 
two isoforms of tankyrase. The four distinct domains which comprise tankyrase-1 include the HPS domain 
which consists of homopolymeric tracts of histidine, proline and serine; Ankyrin-related domain (ANK) 
comprising twenty-four ANK repeats responsible for protein-protein interactions; Sterile alpha motif (SAM) 
and a carboxy terminal catalytic PARP domain.  
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for tankyrase-1, and, as such, means that both isoforms bind to the same selected 
binding partners.69  
Indeed, tankyrase-2 is ubiquitously expressed in a similar manner to tankyrase-1 in 
most human adult and foetal tissues, in HeLa cells and in human primary fibroblasts.11 
Homogenous gene expression has also been observed, with the exception of the plac-
enta, where tankyrase-2 expression is high but tankyrase-1 is not seen.11 It is likely that 
tankyrase-2 also operates in a similar way to tankyrase-1. Over-expression and 
increased activity of tankyrase-2 removes TRF-1 from the telomeres and eventually 
leads to telomere lengthening.10, 11 However, unlike tankyrase-1, endogenous tankyr-
ase-2 has not yet been found at the telomeres, making the discrete physiological role 
of this latter isoform still largely undetermined.9, 11, 69 The almost indistinguishable 
organisation of tankyrase-1 and -2 will make concurrent inhibition of both isoforms, 
using small molecules, almost inevitable. Far from being a disadvantage, this will allow 
for the development of dual-function inhibitors capable of a more global inhibition of 
tankyrases in general.  
1.9 Main protein targets of the tankyrases 
1.9.1 TRF-1 
The first-known and best characterised binding partner of tankyrase-1 is the telomere-
binding protein TRF-1, which acts predominately as a negative regulator of telomerase, 
acting to restrict its access to the telomere as opposed to having a direct influence on 
its expression.19, 64, 66, 71, 72 The mode of protein-protein interaction of tankyrase-1 with 
TRF-1 is well documented as being via the five ARCs of the ANK domain of the enzyme; 
specifically the most C-terminal ARC-V, is essential for subsequent PARsylation of TRF-
1.23, 67 Tankyrase-1 mediates its effects at the telomeric site by poly(ADP-ribosyl)ating 
itself and TRF-1; the effect of this abundance of negatively charged polymers is to alter 
the structure and thus DNA-binding ability of TRF-1 and its related shelterin proteins.11, 
73,74 
The post-translational modification and ubiquitin-dependent proteolysis of TRF-1 ult-
imately disrupts the protective shelterin complex, causing it to dissociate from the 
telomere.23, 75 The exposed telomere, now in an ‘open’ state, is vulnerable to elongat-
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ion by telomerase which ultimately can extend the longevity and proliferative potential 
of the cell (Figure 8).23, 68 Interestingly, despite the crucial role of tankyrase-1 in this 
process, it is entirely independent of the catalytic activity of telomerase. Tankyrase-1 
itself does not have free access to TRF-1, or indeed telomeres, as it lacks a nuclear 
localisation signal (NLS), and has been reported to co-localise with TRF-1 at the ends of 
human chromosomes in HeLa cells arrested during metaphase.64, 66  
A further study, by the same group, which looked at an asynchronous population of 
HeLa cells, noted the co-localisation of tankyrase-1 with TRF-1 throughout the cell 
cycle.66 TRF-1, which contains two NLSs effectively ‘piggy-backs’ tankyrase-1 and 
allows for its co-translocation into the nucleus and to the telomeres.  
Evidence for the role of TRF-1 in regulation of the lengths of telomeres was provided 
by its overexpression in a telomerase-expressing cell line, leading to progressive short-
ening of the telomeres. 11, 71 Of opposite consequence was the observation of length-
ening of telomeres with a dominant-negative TRF-1 that removes wild-type TRF-1 from 
telomeres.71 Indeed, tankyrase-1 has been shown to scavenge TRF-1 from DNA allow-
ing access for telomerase to the telomeres to add on telomeric repeats.8, 64, 68 Further 
to this, the forced over-expression of tankyrase-1 removes TRF-1 from telomeres, 
which results in ubiquitination and degradation of TRF-1 by proteasomes which is sim-
ilar to the endogenous process.11, 76,77 Further evidence for this was observed in HeLa 
Figure 8: Role of tankyrase-1 at the telomere, showing regulation of elongation of telomeres by poly(ADP-
ribosyl)ation of TRF-1. Poly(ADP-ribosyl)ated TRF-1 lifts from the telomere, allowing access of the elongating 
enzyme complex, telomerase. Poly(ADP-ribosyl)ated TRF-1 is then ubiquitinylated for destruction. Other 
members of the shelterin complex have been removed from this figure for clarity.  
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cells by Hatsugai and colleagues who noted that over-expression of tankyrase-1 elimin-
ates the presence of nuclear TRF-1, an effect reversed with 3-aminobenzamide (3-AB) 
(a known weak inhibitor of PARP-1 and tankyrases).67 This evidence, taken together, 
strongly suggests that tankyrase-1 is a positive regulator of telomere length, depend-
ent specifically on the ADP-ribosylating activity of tankyrase-1.11, 30 
Although traditionally classified as a telomeric protein, only ca. 10 % of tankyrase-1 is 
recruited to telomeres and the tankyrases have emerged more recently with many 
non-telomeric functions, including an involvement in Wnt-signalling and an important 
role in the assembly and function of the mitotic spindle.42 
1.9.2 NuMA 
One alternative subcellular site, occupied by tankyrase-1 and emerging as increasingly 
important is the mitotic centrosomes.78 A general summary of the main cellular stages 
of mitosis is depicted in Figure 9. Tankyrase-1 may play a very important role in mitosis 
through the assistance of separation and resolution of sister telomeres (Figure 10).15 
The first observation of tankyrase-1 at this non-telomeric location was by Smith et al., 
who demonstrated its 
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‘resting’ or non-dividing stage of the cell-cycle; however, importantly, up until this 
point, tankyrase-1 had not been observed on the mitotic chromosomes themselves.64 
Further work to decipher the exact localisation of tankyrase-1 during mitosis was per-
formed using the same fixation conditions described above but this time on an 
asynchronous population of HeLa cells.66 Interestingly, using anti-tankyrase antibodies, 
the same group found that there was a distinct pattern between co-localisation of 
tankyrase-1 and TRF-1 and the stage of the cell cycle.66 In addition to the expected 
localisation with TRF-1 to telomeres, tankyrase-1 was also found separate from TRF-1 
in nuclear pore complexes at the nuclear rim of interphase cells and at the 
centrosomes during mitosis.66 The centrosomal location of tankyrase-1 was 
characterised more accurately through the use of anti-tankyrase antibodies combined 
with antibodies directed against well-established centrosomal proteins which would 
allow for sub-compartmentalising the exact location and, indeed, deciphering the 
function of tankyrase-1 in this distinct location.66 Tankyrase-1 was found to not be 
associated with either centrin (a component of the centrioles) or -tubulin (a 
pericentriolar matrix 
protein), indicating that 
its role was not as part of 
the centrosome 
complex.66 
Interestingly the binding 
partner for tankyrase-1 in 
this location was found to 
be a spindle-pole protein, 
known as the nuclear 
mitotic apparatus protein 
(NuMA), which itself 
accumulates around the 
pericentriolar matrix 
during mitosis.66 NuMA 
appears to be essential 
Figure 10: Tankyrase-1 is required for complete separation of sister 
telomeres during mitosis, and progression through the cell cycle. In the 
absence of tankyrase-1, chromosomes separate at the arms and 
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for the correct functioning of the mitotic apparatus; indeed silencing of this protein 
leads to apoptotic disintegration of the cell nucleus.79 The co-localisation of tankyrase-
1 and NuMA indicated that the role of tankyrase-1 may involve the periphery of the 
mitotic centrosomes as opposed to being part of the complex itself. Further to this, 
localisation of tankyrase-1 to this location was found to occur in sync with nuclear 
envelope breakdown and reassembly; tankyrase-1 appears at the centrosomes in early 
prophase and remains there throughout mitosis until telophase.66 Unsurprisingly, the 
localisation of NuMA was found to be almost identical. Although the localisation of 
tankyrase-1 varies throughout the cell cycle, the total amount of protein within the cell 
remains constant, indicating a functional effect as opposed to simply an up-regulation.  
NuMA is a large coiled-coil protein that, depending on the stage of the cell cycle, is 
located either in the nuclear matrix or at the spindle poles; it is well-documented in 
having a key role in assembly and stabilisation of spindle-poles and spindles through 
interaction with a number of mitotic components.70,66, 78, 80 PARsylation of this key 
protein is likely to affect its conformational integrity and thus ability to make key inter-
actions with the mitotic apparatus. The effect of this is largely speculative; however, it 
is likely to effect the separation of sister telomeres and possibly mitotic progression.  
Telomeres that remain un-separated due to lack of tankyrase-1 activity may physically 
prevent progression of chromosome segregation and may trigger a checkpoint fault 
and thus arrest of the cell cycle. Evidence for this includes the mitotic arrest of HeLa 
cells caused by depletion of tankyrase-1 by siRNA (Figure 10).30, 81 In addition, cells 
depleted of tankyrase-1 were unable to resolve their telomeres, despite separation of 
sister chromatid arms and centrosomes.15,30, 78 All this evidence led to a hypothesis 
whereby absence of tankyrase-1 may cause an arrest in either pre-anaphase or early 
anaphase.30, 78, 81 A similar observation was made by Chang in 2005, who demonstrated 
that absence of tankyrase-1 (mediated by RNAi) resulted in a post-anaphase arrest in-
duced by a failure of telomeres to separate correctly.78 Mitotic arrest results in activat-
ion of the Mad2-dependent spindle check point.78 Abnormal morphology of the 
spindle and distributions of the chromosomes were also observed.78 Interestingly, 
these defects in the spindle were found to be due to loss of PARsylation activity, as 
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opposed to absence of the enzyme protein itself; however, PARsylation activity was 
found to not be a requirement for localisation of tankyrase-1 to the poles.78  
Interestingly, tankyrase-1 has no effect on expression of NuMA or its localisation to the 
spindle poles.78 Conversely, siRNA-knockdown of NuMA results in a complete loss of 
tankyrase-1 from spindle poles, which suggests that localisation of tankyrase-1 is 
dependent on NuMA. The consequences of this are not fully understood; however, it 
has been noted during biochemical studies that telomeric DNA and the telomeric bind-
ing protein TRF-1 associate with the nuclear complex where NuMA also resides during 
interphase. One possible reason may be that the PARsylation of NuMA by tankyrase-1 
allows for the release of telomeres from the nuclear scaffold at a time during the cell 
cycle when resolution of cohesion of sister telomeres is required. 78 
The interaction of tankyrase-1 with TRF-1 and with NuMA may not be discrete events; 
indeed, the breakdown of the nuclear envelope and of nuclear pore complexes during 
mitosis might allow for the release and translocation of tankyrase-1 to the nucleus and 
facilitate its access to telomere-bound TRF-1 at the telomeres.66 During interphase, it is 
possible that access of tankyrase-1 to the nucleus is facilitated through its interaction 
with TRF-1, leading to the hypothesis that lengthening of the telomere may be 
dependent on the stage in the cell cycle. One possibility is that localisation at the 
nuclear pore complexes provides a pool of tankyrase-1 ready to be transported into 
the nucleus by TRF-1.66 
1.9.3 AXIN – a component of the Wnt / β-catenin pathway 
An exciting development in our understanding of the tankyrases has been the more 
recent discovery of a key role in Wnt-signalling (Figure 11). This important and highly 
conserved biological pathway is crucial for embryonic development, specification of 
cell fate, regeneration of stem cells and neuronal migration in a number of stem-cell 
lines, including colon, intestine, blood, bone, muscle, fat and hair, and is often 
defective in tumorigenesis.17,82, 83 84, 85 
The Wnts are a family of nineteen cysteine-rich glycoproteins which regulate receptor-
mediated signalling cascades when bound to a specialised family of G-protein coupled 
receptors; the Frizzled family and another group of co-receptors, the low density lipo-
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protein receptor-related protein-5 (LRP5) and LRP6 on the cell surface.17, 86 In the Wnt 
/ β-catenin signal-transduction pathway, the proteolytic breakdown of the effector β-
catenin by the downstream β-catenin destruction complex is tightly regulated.5, 82, 87 
This destruction complex comprises of adenomatous polyposis coli (APC), glycogen 
synthase kinase (GSK3α/β) and the axin inhibition protein (AXIN; two isoforms; AXIN-1 
and AXIN-2). In normal circumstances, cytosolic β-catenin is kept at low levels by the 
destruction complex, in particular by targeted phosphorylation by GSK3α/β and 
subsequent degradation via the ubiquitin-proteasomal pathway.82 In addition, the 
efficiency of the destruction complex is largely controlled by the concentration-limiting 
factor AXIN, which is required to maintain a steady-state concentration for the 
maintenance of appropriate Wnt-signalling.88 Conversely, activation of Wnt signalling 
leads to dissociation of the destructor complex and a build-up of β-catenin in the 
nucleus (Figure 12). This, in turn, leads to the transcription of Wnt pathway-responsive 
genes, including MYC and cyclin D1 (CCND-1).17, 82 
Wnt-signalling pathways are not only thought to contribute to tumorigenesis, they are 
also believed to be crucial to the continuous proliferation of cancer cells both locally 
Figure 11: Shown on the left side of the figure; in the absence of Wnt-signalling, a destruction complex comprising 
of APC, AXIN and GSK3β phosphorylate (P) and target CTNNB-1 (encodes for β-catenin) for ubiquitylation (Ub) and 
proteosomal degradation. Right side; when Wnt binds to the frizzled receptor this activates the Dishevelled 
protein (DVL), which inhibits the destruction complex leading to accumulation of CTNNB-1. CTNNB-1 enters the 
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and metastatically. 86 Indeed, studies conducted nearly two decades ago identified that 
deregulation of canonical Wnt / β-catenin signalling through mutations in adenomat-
ous polyposis coli (APC) as a trigger-event in colon carcinogenesis. Not only this, Wnt-
signalling is also thought to act in cooperation with other signalling pathways, onco-
genes and tumour suppressors and, as such, is potentially an anti-cancer target of 
global importance. Indeed, disturbances in this vital pathway appear to act like a 
domino effect; triggering the de-regulation of many other pathways, all of which may 
contribute to carcinogenesis. Over-activation of this pathway, via multiple mechan-
isms, has been implicated in many cancers; for example, mutations in the tumour 
suppressor APC and CTNNB-1 genes (which encodes for β-catenin) are found in app-
roximately 95% of colorectal carcinomas.17, 82, 83,89 In fact, mutations in APC are 
thought to be the most frequent mutations in human cancers.84 
Such mutations, in general, lead to constitutive transcriptional activity of β-catenin and 
may inaugurate the early stages of tumorigenesis.17 Proof of this was found in mouse 
models where over-expression of constitutively active CTNNB-1 or loss of APC function 
can lead to colorectal tumorigenesis.90 Further to this, work by the Cancer Genome 
Atlas Network has identified other genes involved in the Wnt-pathway that have been 
postulated to activate perturbed signalling, including transcription factor 7-like 2 
(TCF7L2), CTNNB-1 and the Wilms’ tumour gene on the X chromosome (WTX), which is 
specifically associated with a paediatric renal cancer.84, 86 Unsurprisingly, the prospect 
of inhibiting this pathway is a potentially exciting anti-cancer strategy, in particular in-
hibiting β-catenin itself through either AXIN or APC, both tumour suppressors which 
negatively regulate its activity.  
A group at Novartis, in the search for novel modulators of this complex pathway, ident-
ified the small molecule XAV939 (1), capable of prolonging the half-life of AXIN and 
promoting β-catenin degradation (Figure 12). This novel agent was found to be 
working through inhibition of tankyrase-1.82  
Discovered in a high throughput screen using a Wnt-responsive Super-Topflash (STF) 
luciferase reporter assay, XAV939 strongly inhibited Wnt3a-stimulated STF activity in 
HEK293 cells, leading to a reduction in β-catenin abundance and an increase in AXIN 
levels. No effect in the same reporter assay was observed for a closely related anal-
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ogue LDW643 (2) (For structure see Section 2.7). XAV939 was subsequently shown to 
be preventing the tankyrase-1-mediated PARsylation of both AXIN-1 and AXIN-2, pre-
venting their proteasomal degradation and, in doing so, enhancing the activity of the 
β-catenin destruction complex.17  
Likewise, the effect was mirrored in SW480 cells, a colorectal line with an APC 
mutation, but with the additional effect of increasing the phosphorylation-dependent 
degradation and ubiquitination of β-catenin, suggesting a stabilising effect on the dest-
ruction complex. 82 Further to this, similar effects were observed with XAV939 in 
another colorectal cancer line with an APC mutation, DLD-1.  
Functionally, the effect of XAV939 is even more striking, with co-depletion of 
tankyrase-1 and -2 mimicking the effect of the agent and increasing protein levels of 
AXIN, whereas knockdown of PARP-1/-2 does not, thus providing convincing evidence 
that these former enzymes are indeed its cellular efficacy target. Further to this, whilst 
utilising other siRNAs, the group found that co-depletion of tankyrase-1 and -2 in-
creased β-catenin phosphorylation, decreases β-catenin abundance and inhibits the 
transcription of β-catenin target genes in SW480, HEK293 and DLD-1 cells.82 
Interestingly, it was found that the presence of both enzymes was crucial for their 
regulatory effects on AXIN-1/-2 levels, as single depletion of one isoform did not 
increase AXIN-1 or -2 levels.82 More specifically the catalytic effects of both isoforms 
were found necessary for the regulation of AXIN protein levels.82 
Not surprisingly, the interaction between the tankyrases and AXIN is mediated through 
the ankyrin-repeat domain (ARD) and, analogously to other protein targets of the tank-
Figure 12: Represented here as a seesaw; a delicate balance exists between CTNNB-1 (encodes for β-catenin) 
and AXIN such that when AXIN is degraded CTNNB-1 is stabilised and Wnt-signalling is turned on and vice versa. 
XAV939 (1), a tankyrase-1 inhibitor, has been reported to stabilise AXIN with the result of switching Wnt-
signalling off.  
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yrases, is succeeded by PARsylation, leading to ubiquitination and targeted degrad-
ation. Indeed, this interaction was confirmed in a crystal structure of a mouse tanky-
rase-1 fragment containing ankyrin-repeat clusters 2 and 3 in complex with the tanky-
rase-binding domain of mouse AXIN-1.91 The mode of binding was confirmed as 
bivalent, with two discrete tankyrase-binding segments discovered on AXIN-1, along 
with a conserved glycine residue ‘gate’, found to be crucial for tankyrase-AXIN 
interactions.91  
Notably, XAV939 inhibits the auto-PARsylation of tankyrase-1 and -2 in biochemical 
assays with half-maximal inhibitory concentrations (IC50) of 11 nM and 4 nM and 
shows a vast degree of selectivity over PARP-1 and -2 (IC50 = 2.2 µM and 0.1 µM 
respectively).82 LDW643 showed no inhibition of any of the same four isoforms (IC50 = 
>18.75 µM). Treatment with XAV939 in SW480 cells prolonged the half-life of AXIN-2, 
thus reducing its degradation by the ubiquitin-proteasomal pathway (Figure 12). In 
contrast, endogenous tankyrase-mediated PARsylation of AXIN triggers its ubiquitin-
ation and subsequent degradation and allows for the stabilisation of β-catenin and 
transcription of related genes.82 
Huang et al. hypothesised that this inhibition of β-catenin-mediated signalling might 
translate to an anti-proliferative effect in the whole cell. Consistent with this, the 
colony-forming ability of DLD-1 cells was significantly inhibited in low-serum growth 
conditions, an effect not observed in the β-catenin-independent RKO cells.82 
Interestingly, LDW643 did not affect colony formation in RKO or DLD-1 cells and was 
completely inactive.82 Although, proposed to have a role in the resolution of sister 
telomeres during mitosis (Section 1.9.2), treatment with XAV939 did not cause any 
obvious signs of a mitotic-arrest phenotype and thus the anti-proliferative effect in 
DLD-1 cells is unlikely to be operating through an antimitotic function.82 Indeed, this 
anti-proliferative effect was found to be due to AXIN-dependent inhibition of Wnt-
signalling. Further biological testing of this novel small molecule inhibitor by other 
groups has shown that its application attenuates Wnt-induced transcriptional 
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The discovery that XAV939 was inhibiting this de-regulated pathway through its activ-
ity against tankyrase-1 and -2 is an exciting breakthrough. It not only provides a 
druggable target for this specific pathway but it also extends the potential of tanky-
rase-1 and -2 as multi-facetted anti-cancer targets. Surprisingly, bearing in mind that 
Wnt-pathway de-regulation is a hallmark of most colorectal cancers, there are no Wnt-
specific inhibitors in the current pharmaceutical armamentarium and thus this repres-
ents an exciting new opportunity in drug discovery. Prior to the identification of 
XAV939, many difficulties had arisen in the quest to find inhibitors of this pathway, due 
to a lack of specific targets and the potential redundancy of many pathway compon-
ents. The discovery of XAV939 has, therefore, provoked much optimism amongst the 
medicinal chemistry community of finding further specific and selective inhibitors. 
1.10 Other protein targets of the tankyrases 
1.10.1 DNA-dependent protein kinase 
Recently, a role for tankyrase-1 has been suggested in the regulation of the repair 
protein DNA-dependent protein kinase (DNA-PK) although not necessarily in mediating 
the repair process itself. As previously mentioned, DNA-PK’s appears to have multiple 
roles in addition to DNA repair; one such role is maintaining appropriate end-capping 
of telomeres. The first indication of this new role was the observation that depletion of 
tankyrase-1 in telomerase-negative backgrounds led to increased levels of T-SCE. In 
addition to this, further evidence for this new role was provided by the increased 
sensitivity of tankyrase-1-depleted cells to ionised radiation-induced cell killing, 
mutagenesis, chromosome aberration and telomere fusion.15 Specifically, NHEJ is 
affected by depletion of tankyrase-1, due to rapid proteasome-mediated degradation 
of the catalytic subunit of DNA-PK (DNA-PKcs), indicating a stabilising effect on this 
protein mediated through PARsylation.15 In agreement with this observation, the 
application of XAV939 to tankyrase-1 siRNA demonstrated similar reductive effects on 
levels of DNA-PKcs.15 Interestingly, this effect was found to be entirely a tankyrase-1-
mediated effect as tankyrase-2 mRNA levels were not impacted by tankyrase-1 siRNA 
treatment, even though DNA-PKcs protein levels plummeted.15 Two other proteins 
involved in NHEJ, Ku86 and ATM, were unaffected by tankyrase-1 depletion.15  
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One explanation for these observations is that DNA-PKcs, with the aid of tankyrase-1 
PARsylation-mediated stabilisation, contributes to the end-capping of telomeres under 
normal cellular conditions. In contrast, under conditions of accelerated shortening of 
telomeres, e.g. in rapidly proliferating tissue such as cancer cells, tankyrase-1 functions 
to allow access to telomerase to extend the telomere length. This apparent yin-yang or 
two-faced role of tankyrase-1 may actually be of benefit in the clinical setting; the 
combination of reduced telomere lengthening in cancerous cells, doubled up with the 
potential sensitisation of damaged cells to radiation and other DNA-damaging agents 
may prove superior to mono-target therapies.  
1.11 Clinical potential of tankyrase inhibitors 
Biologically, tankyrase-1 is an intriguing molecular target as it appears to exhibit mult-
iple cellular effects, which are not entirely surprising due to its multiple protein-protein 
interaction motifs.78 First and foremost is the chemotherapeutic potential of these 
inhibitors in specifically exploiting a molecular weakness of the ‘cancerous’ cell over 
the ‘normal’ cell through tumour-specific Wnt-dependency, telomere dysfunction or 
mitotic acceleration, or a combination of these events.17 Due to these multi-faceted 
functions of the tankyrases, inhibition of these enzymes has become attractive in 
cancer therapeutics and indeed was first recognised as having potential in this clinical 
area following an observation in 2000 by Raymond et al. that tankyrase-1 activity was 
required for re-elongation of telomeres following replication of tumour cells.8  
Following this, many subsequent studies have shown over-expression of either one or 
both tankyrases in a number of different cancer models. MacNamara et al. were able 
to demonstrate a clear correlation between the mRNA expression of both hTERT and 
hTR and the mRNA expression of tankyrase-1 in high grade non-Hodgkin’s lymphoma; 
the significance of which was the suggested poor prognosis and shorter survival in 
highly malignant disease.93 In another study, levels of tankyrase-1 mRNA, measured 
using quantitative real-time PCR, were found significantly elevated in sixty-six breast 
cancers (isolated from the centre of breast tumours in sixty-six patients undergoing 
surgery in the Surgical Department of Florence Medical School) compared with normal 
tissues (P < 0.0001).94 Interestingly, no correlation was found with hTERT mRNA exp-
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ression in the same study.94 Consistent with the findings of this research Poonepalli et 
al. also observed significantly higher levels of tankyrase-1 mRNA expression in cancer-
ous tissues compared with normal adjacent tissues.95 In addition, an increase in exp-
ression was observed as the cancer grade advanced through the stages (Grade I to 
Grade III).95 Interestingly, this group also observed a decrease in TRF-1 expression syn-
ergistic with an increase in tankyrase-1 expression in higher grades of breast cancer, 
demonstrating the role of the latter in tumour progression and aggressiveness. 95 
Similarly, another group, whilst utilising anti-tankyrase-2 antibodies, found that tank-
yrase-2 is over-expressed in some breast tumours, whereas the surrounding normal 
tissue was immunohistochemically negative.96  
Moreover, tankyrase-2 mRNA levels were also found to be overexpressed in 100% of 
early stage colon tumours tested and were also found to be up-regulated (threshold 
1.5-fold change) in 71% of patients tested for colon cancer.97 Further proof of the 
involvement of tankyrase-1 in the progression and development of malignancy was 
shown in human gastric cancers where tankyrase-1 mRNA and protein expression was 
significantly up-regulated compared with non-cancerous adjacent tissue.98 Not only 
this, overexpression of tankyrase-1 also correlated with tumour stage and histology; 
increasing expression was observed as tumours incremented through the grades.98 In 
this study, telomerase activity also correlated strongly with expression of tankyrase-1, 
both of which are high in gastric cancer cells.98 In addition, another study has 
suggested a role for inhibition of tankyrases in BRCA-mutant cancers.99 
Although involvement of the tankyrases in the progression and development of many 
cancers has been predominately associated and justified by its effects at the telomeric 
complex, another study has found an association between up-regulation of tankyrase-
1 (measured by mRNA and protein expression levels) and β-catenin expression (meas-
ured using immunostaining) in human astrocytomas (central nervous system tum-
our).100 Enhanced expression of tankyrase-1 was also strongly correlated with worsen-
ing pathological grade of tumour, clearly suggesting an oncogenic role for the enzyme 
in astrocytoma carcinogenesis.100 The results of this particular study indicate that the 
Wnt / β-catenin pathway may contribute to the pathogenesis of this type of cancer 
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through the effects of tankyrase-1 and as such provides important evidence of the 
multi-target potential of clinical inhibitors. 
Tankyrase inhibitors may also have utility beyond cancer therapeutics alone. This may 
include a role in cherubism following an observation that a mutation in the tankyrase-1 
substrate SH3 domain-binding protein 2 (3BP2) drive the development of this dis-
ease.101, 102 Likewise, a role in the treatment of herpes simplex virus (HSV) has been 
proposed as treatment with XAV939 led to a 20- to 50-fold reduction in viral titres.103 
Tankyrase-1 is postulated to be required for HSV replication following phosphorylation 
by mitogen-activated protein kinase (MAPK) and localisation to the nucleus of HSV-
infected cells.103  
The more recent discovery of a role for the tankyrases in Wnt-signalling and the almost 
unanimous correlation between mutations in this pathway and colon carcinomas has 
further strengthened the potential clinical utility of inhibitors and accelerated the cam-
paign towards efficacious inhibitors. Further to this, in light of the significant assoc-
iation between tumour grades and over-expression of tankyrase-1/-2 in many 
studies,93, 95, 98, 100 it is possible that treatment with a tankyrase inhibitor could be 
matched to patients that would greatly benefit from its use. Likewise, with respect to 
Wnt-signalling in particular, a tumour-specific loss-of-function APC mutation could act 
as an ideal biomarker for a patient population likely to respond favourably to treat-
ment with a tankyrase inhibitor. This tailored treatment approach is likely to represent 
the future of cancer therapeutics as susceptible patients with such biomarkers are 
much more likely to respond favourably to targeted rather than random treatment 
with such an inhibitor.  
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Chapter 2.0 - Introduction to drug design 
2.1 Telomerase as a drug target? 
Telomerase is the most widely expressed tumour-associated gene of any cancers.6, 7 
This fact alone makes telomerase an important potential target in anti-cancer diag-
nosis and therapeutics and, indeed, it has been a major focus in cancer research since 
the mid-1990s.2, 7 The theoretical therapeutic advantage of inhibiting such a process is 
clear; low telomerase activity in the majority of somatic tissue versus a high activity in 
cancerous cells may lead to a highly desirable therapeutic ratio untypical of many 
current chemotherapeutic agents and is thus an exciting prospect.19  
Complex therapeutic strategies have had to be employed to attempt to target telo-
merase, predominately based on either RNA-i strategies or on stabilisation of the G-
quadruplex (Figure 13).2, 16, 28 Stabilisation of the G-quadruplex appears to be key to 
slowing the elongation of the telomeres by telomerase, probably due to unwinding of 
this complex structure being a prerequisite to telomerase binding to the telomeric 
DNA.2, 28 Indeed, early telomerase inhibitors were developed from the observation that 
telomestatin (3) shared many structural similarities with the G-tetrad and indirectly 
inhibited telomerase because of its ability to stabilise the G-quadraplex and sequester 
the single-stranded DNA primer required by the enzyme.28, 104, 105 Inhibitors include 
large planar structures, such as anthraquinones, fluorenones, acridines, cationic porph-
yrins and indoloquinolines. HXDV354 (4) and HXDL (5) are examples of these types of 
structures (Figure 14). 2, 7  
Consequently, from a drug-design perspective, these inhibitors tend to be macrocyclic, 
planar and not Lipinski-compliant molecules, thus not conforming to the requirements 
of maintaining molecular weight of less than 500 Da, having no more than five hydro-
gen-bond donors or ten hydrogen-bond acceptors and an octanol-water partition coef-
ficient (log P) of less than five.28 The majority of such ligands are thought to interact 
with the G-tetrad surfaces through π-π stacking; however, the mode of binding is 
inconsistent and alternative modes have been found.28 In addition to this, the 
discovery that quadruplex-prone sequences exist in multiple regions of the 
chromosome, including gene promoter regions, further complicates the ability to 
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target the telomeric G-quadruplexes specifically.28 Another major set-back with this 
class of inhibitors is the poor selectivity for binding to quadruplex versus duplex DNA. 2 
  Some efforts have been made towards the development of chemical inhibitors of 
telomerase itself using small-molecule nucleoside analogues, oligonucleotide 
derivatives and peptide and protein approaches. For example, the small molecule 
BIBR1532 (6) inhibited telomerase activity and caused the shortening of telomeres in 
vitro, with IC50 = 93 nM, and was found to be interacting and directly damaging the 
catalytic activity (hTERT) of the telomerase enzyme.2, 106 Likewise, the nucleoside 
analogue, azidothymidine (7) (AZT) has been used as a chain-terminating inhibitor of 
reverse transcriptases when they are incorporated into the DNA by telomerase. 
Although able to effect shortening of telomeres, this therapy was not sufficient to 
cause cell death and suffered from a profound lack of selectivity.2 Alternative 
strategies have seen the hTR component of telomerase targeted with oligonucleotides 
such as GRN163L (8), which prevents hTR from forming an active complex with hTERT.7 
The strong link between telomerase expression and cancer cells has also made it an 
immune target and peptide strategies have been developed with the intention of 
stimulating immune responses to cancer cells.2 
Although many of these strategies showed initial promise, they failed to demonstrate 
longevity as a therapeutic application and often failed to demonstrate a reasonable 
level of selectivity and clarity of cellular effect. In addition to this, it was quickly realis-
ed by several groups that an inherent limitation of targeting telomerase is that it takes 
several cycles of cell replication before the length of the telomeres will be such that 
Figure 13: Early targets in the quest for new anti-cancer agents; both the two major components of 
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the integrity of the cell is actually compromised.2, 5, 9 This may result in long treatment 
lag times in critically ill patients, where a quick response is often crucial to survival.  
Although predominately activated in cancerous tissues, telomerase is also found in 
stem and germ line cells and thus inhibition in these tissues could be potentially disast-
rous to growth and development of a cancer patient; especially to a young patient. An 
increase in understanding of telomere biology has alleviated this concern somewhat, 
with the knowledge that cancer cells maintain relatively short telomeres in comparison 
to stem cells and thus inhibition of telomerase would predictably have a much lesser 
effect on these cells over the same time period.19 In addition, the significantly slower 
proliferation rate of primitive stem cells compared with an aggressive tumour line 
means that any inhibition of telomerase or other proteins involved in telomere main-
tenance should enjoy a large therapeutic window.19  
Figure 14: Some early telomerase inhibitors designed to target either the G-
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Shorter telomeres, as seen in many cancer cell lines, may recruit telomerase more 
effectively due to the reduced binding potential for the shelterin complex. This 
theoretical advantage, however, has been observed to lead to telomere shortening 
only to a certain extent and may even lead to a stable shortened telomere, with avoid-
ance of cell crisis - an unwanted outcome in a cancer cell.19 This effect may be over-
come with the use of a tankyrase inhibitor, which could potentially abrogate the ability 
of the telomere to reach maintenance-length equilibrium.73 Seimiya and colleagues 
found this to be the case with high concentrations of a telomerase inhibitor MST-312 
(9) (2 µM) driving cells to crisis; however, lower concentrations of the same agent 
(0.75 µM) led to the observation of a new shorter but unfortunately stable telomere, 
which allowed for continual proliferation of cancer cells.73 The subsequent addition of 
the tankyrase-1 inhibitor 3-aminobenzamide (3-AB) (11) to 9 in the same study was 
found to disturb the telomere equilibrium sufficiently to drive the cells into crisis, and 
subsequent death. 73 
Monotherapy with a telomerase inhibitor, therefore, may not be efficacious; however, 
it may be possible that partial inhibition of telomerase, teamed up with partial tank-
yrase inhibition, may be fruitful and a possibility for a combined synergistic therapy. 
2.2 Tankyrase-1 as a drug target? 
Structurally, tankyrases-1/-2 are much more promising and attractive targets because 
they can be approached using small-molecule nicotinamide mimetics as a starting 
point; many of these have already been developed (e.g. PARP inhibitors). Although 
they may be subject to the same lag time that disadvantaged telomerase inhibitors in 
promoting telomere-shortening crisis, their additional effects within the cell (e.g. mito-
tic spindle and Wnt / β-catenin) may allow for multiple attacks on tumours from sev-
eral different angles. This potential multi-target utility of tankyrase-1/-2 inhibitors 
makes monotherapy feasible; however, it is possible that inhibitors would also be 
useful in various combined and alternating therapy schedules with other chemothera-
peutic agents, akin to PARP-1 inhibitors in the pharmaceutical pipeline. 
From the perspective of drug design, the tankyrase field is already armed with many 
drug discovery tools that could expedite the discovery of novel and potent inhibitors, 
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many of which originated in the PARP-1 and -2 drug-discovery campaigns. Previous 
work in our group on the PARP-1 campaign has generated a great deal of under-
standing of how small molecules can be designed and developed to inhibit PARP super-
family members and this should also aid progress towards inhibitors of the tankyrases. 
This includes a good knowledge of the possible synthetic routes to afford such small-
molecule nicotinamide mimetics with the potential to expand existing skeletons to 
include novel side-groups. In addition, many high-throughput biochemical assays to 
estimate PARsylation and recombinant and active human tankyrases are commercially 
available which will aid the rapid biological evaluation of potential inhibitors. Recently, 
three-dimensional structures of the catalytic domain of tankyrase-1 and -2 have been 
reported and are available in the Protein Data Bank (PDB) (Tankyrase-1 by Lehtiö et al. 
in 2008; PDB ID: 2RF568; tankyrase-2 by Karlberg et al in 2010; PDB ID: 3KR7107). 
Further to this Karlberg et al. reported the first ever substrate-bound complex of tank-
yrase-2 with XAV939 (1) (PDB ID: 3KR8) in 2010,107 closely followed by Narwal et al. in 
2012 who reported several more substrate-bound complexes of tankyrase-2 with 
various inhibitors and the endogenous by-product of PARsylation, nicotinamide (PDB 
ID: 3U9H).42 These studies will all aid the enhanced design and optimisation of inhibit-
ors using computational approaches such as molecular modelling and allow for a more 
rational drug-design approach to be adopted.  
Although the tankyrases represent an exciting and promising oncological target and 
benefit from much previous drug discovery efforts in the PARP field, they will still have 
certain challenges in their early development that will need addressing. Firstly, select-
ivity for tankyrase-1/-2 over other members of the PARP superfamily will be an issue 
that may be difficult to overcome completely and a small amount of cross-inhibition 
would be expected. Dual inhibition or partial inhibition of PARP-1 may not therapeutic-
ally be a huge problem, as inhibitors of PARP-1 are currently being explored in the 
clinic. Indeed pan-inhibition may prove to be synergistically advantageous; however, 
further research into the biological outcome of such poly-pharmacology is warranted. 
Unfortunately, inhibition of some other NAD+-requiring enzymes may not be so adv-
antageous; For example, NAD(P)H:quinone oxidoreductase 1 (NQO1), regulates the 
stability of the tumour-surpressor wild-type protein p54 which itself is responsible for 
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the removal of cells with DNA-damage via growth arrest or apoptosis.108, 109 The 
tumour-suppressing activity of wild-type p53 is abolished by mutations in the p53 gene 
that occur in >50% of human cancers.108, 110 Likewise inhibitors of NQO1 e.g. curcumin 
may induce p53 degradation and inhibited p53-induced apoptosis which may lead to 
global cytotoxicity.111 Ultimately, clean dual inhibition of tankyrase-1 and -2 alone is 
preferable and therefore the goal of this project.  
Another concern of inhibiting a process so implicitly linked to human ageing and dis-
eases of ageing is that this may indirectly allow the shortening of telomeres in normal 
healthy cells and what the consequences of this might be. Indeed, longer telomere 
length has been linked to more years of healthy life, in a cohort of people in their 
seventies.112 Telomere length, however, was not associated with overall survival or 
death from any specific underlying cause, including infectious diseases, cancer, or 
cardiac and cerebrovascular diseases.112 This may be explained in part by the low levels 
of telomerase normally associated with somatic tissue, in addition to the relatively 
slow proliferation rates of mature differentiated tissue, and may strengthen the select-
ivity argument for inhibitors of this pathway. Interestingly, telomere length may 
provide an indication of biological age as opposed to actual chronological age and may, 
in the future, provide some clinical indication of the general health of a person’s 
cellular population and possibly their likeliness of responding well to a therapy.4 
Although beyond the scope of this project, one further issue that may present at the 
pre-clinical stage of this drug discovery campaign is that rodent models may not be 
indicative of the true effect of tankyrase inhibitors, as murine TRF-1 does not bind to 
murine tankyrase-1. 113 Further studies are warranted to generate a better under-
standing of whether the roles of tankyrase-1/-2 in mitosis and in the Wnt-pathway are 
conserved between human and murine models. As mentioned previously, although 
some cross-inhibition with other PARP members may not be detrimental to clinical 
outcome, it will complicate the outcome of any clinical and pre-clinical trials and thus it 
is vital that potential new chemical entity’s (NCE) are potent, specific and efficacious 
with minimal cross-over activity for other cellular targets.  
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2.3 Early PARP-1 inhibitors – a good starting point for novel tankyrase inhibitors? 
As tankyrase-1 is a PARP isoform with many conserved features within the catalytic 
site, it was conceivable that those compounds that are good inhibitors of PARP-1 may 
also be inhibitors of tankyrase-1.73 Little distinct research has been performed to find 
specific inhibitors of tankyrase-1; those inhibitors that have been published tend to be 
PARP-1 or -2 inhibitors that happen to show tankyrase-1 inhibitory activity.65, 73, 114 This 
is hardly surprising, based on the significant structural homology shared by the various 
PARP isoforms e.g. PARP-1 and -2.65, 68, 107, 114-116 In addition, the principal secondary 
structure features in the crystal structure of PARP-1 and tankyrase-1 are largely 
conserved, with useful variation observed in the catalytic core region discussed further 
in the protein crystallography section of this report. 68, 107  
Much of the early drug discovery work in the hunt for an inhibitor of PARP-1 focussed 
on the co-product of the PARP catalytic process, nicotinamide (12) (Figure 15).62, 63, 117, 
118 A closely related analogue, benzamide, was the first reported inhibitor by Shall in 
1975.117 Although very similar to the endogenous co-product, benzamide had the 
added advantage of being unrecognisable by NAD+-biosynthetic enzymes.63 The limited 
aqueous solubility of benzamide drove the discovery in 1980 by Purnell and Whish 
(University of Bath) of the position-3-substituted analogues 3-methoxybenzamide and 
3-AB (11), with Ki values of 1.5 and 1.8 µM, respectively.63 Simple acylation of 3-AB 
gave 3-acetamidobenzamide (3-AAB) (13), with no loss of inhibitory activity; this 
compound showed promising anti-cancer activity as a post-irradiation sensitiser in 
mouse lymphoma cell lines and human-derived fibroblasts.118 In addition, 11 was 
shown to reduce the circulatory failure and organ dysfunction / injury associated with 
haemorrhagic shock but suffered from being a relatively weak inhibitor of PARP-1, with 
poor membrane permeability.56, 119, 120 
Following this seminal work, numerous PARP-1 inhibitors were synthesised, largely 
based upon either benzamide or purine structures (Figure 15).47, 48 Pharmacological 
inhibition of PARP-1 with PJ34 (17) showed improved myocardial contractility, vascular 
function and survival in a rodent model.47, 121, 122 Likewise, intracerebral injection of the 
quinazolin-4-one NU1025 (19) enhanced the antitumour activity of temozolomide 
(TMZ) and improved survival of mice bearing brain lymphoma.45, 49 In a separate study 
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in vivo, administration of the isoquinolin-1-one DPQ (21) led to a significant reduction 
in infarct volume in a rat ischaemia model, even when treatment was delayed until 
after onset of ischaemia.58 4-amino-1,8-naphthalimide (4-ANI) (22) was found to have 
protective effects in experimental diabetic neuropathy, with treatment leading to an 
improvement in nerve conduction and nerve blood flow, in complement to a reduction 
of PAR immunoreactivity and of depletion of NAD+.57 
2.4 5-AIQ – a seminal PARP inhibitor 
The requirement for PARP-1 inhibitor that would be physiologically compatible led to 
the discovery of 5-aminoisoquinolin-1-one (5-AIQ) (18) by Warner-Lambert Parke-
Davis in 1991 as a moderately potent inhibitor of PARP-1 activity (IC50 = 240 nM).123 
Although its potential was not initially realised, this agent has since proved to be sup-
erior in vivo to many other inhibitors, probably a consequence of its bioavailability and 
good aqueous solubility. Indeed 5-AIQ has demonstrated highly potent protection in 
numerous ischaemia/ reperfusion injury models including against organ damage in 
haemorrhagic shock (at 30 g Kg-1),56 reduction of infarct size in myocardial infarct-
ion,59, 124 protection of organ function during heart transplant,47, 121, 125 and protection 
against ischaemia-reperfusion injury to the liver, kidneys and brain.50, 55, 126-128 Further 
to this, a role for 5-AIQ has been demonstrated in conditions associated with severe 
and chronic inflammation including protection against bleomycin-induced lung 
injury,54 protection against acute lung inflammation,51, 129 alleviation of secondary 
damage in spinal cord trauma,130 reduction of damage in experimental colitis52 and 
reduction of damage in experimental periodontitis.131 More recently, 5-AIQ has also 
demonstrated strong anti-metastatic behaviour in an in vivo model of CT26 
tumours.132  
2.5 Would PARP-1 inhibitors also inhibit tankyrase-1? 
The postulate that PARP-1 inhibitors might also inhibit tankyrase-1 proved to be accur-
ate in some cases. One study found that many of the best known PARP inhibitors 
including TIQ-A (14), olaparib (23), ABT-888 / veliparib (16) and rucaparib (15), also 
bound to other PARP family members, including tankyrase-1 to varying extents, indic-
ating the potential promiscuity of these molecules.61 Indeed, in one study, TIQ-A in 
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particular appears to bind equally well in the catalytic domain of PARP-1, PARP-3 and 
tankyrase-1, measured using differential scanning fluorimetry (DSF; a binding assay), 
indicating its lack of selectivity for any of the PARP family members.61  
Similarly, the PARP-1 inhibitor 3-AB (11) was also found to enhance shortening of telo-
meres by inhibiting poly(ADP-ribosyl)ation of TRF-1 by tankyrase-1 in vitro. 73 Likewise, 
a different group found that 3-AB inhibited the auto-modification of tankyrase-1, with 
an IC50 value of 24 µM.114 Additionally, 4-ANI (22) and PJ34 (17), at 10 µM and 3 µM, 
respectively, inhibited release of TRF-1 from telomeres in HeLa cells to extents com-
parable with 3 mM of 3-AB.73, 133, 134 Again, these ‘PARP’ inhibitors were found to be 
inhibiting the auto-poly(ADP-ribosyl)ation of tankyrase-1.73 Furthermore, PJ34 demon-
Figure 15: Some first-generation and second-generation PARP inhibitors: Nicotinamide (12) (PARP-1 IC50 = 
210 µM); 3-AB (11) (IC50 = 30 µM); 3-AAB (13); TIQ-A (14); Rucaparib (15) (PARP-1 IC50 = 1.7 nM); ABT-
888/Veliparib (16)(IC50 = 5nM); PJ-34 (17) (PARP-1 IC50 = 17nM, tankyrase-1 IC50 = 0.57 µM) ; 5-AIQ (18); 
NU1025 (19); KU0058948 (20); DPQ (21); and 4-ANI (22). Olaparib (23) (PARP-1 IC50 = 5nM, PARP-2 IC50 = 1 
nM, tankyrase-1 IC50 = 1.5 µM), has shown promising single-agent activity against BRCA-1 and -2 mutant 
tumours in early clinical testing. IC50 values quoted are not directly comparable due to different 
experimental conditions employed in each case.17  
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strated significantly diminished elongation of telomeres in HeLa cells over-expressing 
tankyrase-1.73  
Another comparative study examined the IC50 values of the PARP-1 inhibitor DPQ (21) 
against PARP-1, tankyrase-1 and vPARP, finding that it had a similar inhibitory effect on 
all three isoforms with IC50 = 23, 33 and 281 nM, respectively.65 Moreover, NU1025 
(19) was also found to inhibit tankyrase-1 with an IC50 of 1.9 µM. These studies all 
demonstrate the propensity of established PARP inhibitors to also be proficient at 
inhibiting the tankyrase-1 isoform. 
2.6 Previous work from our group towards inhibitors of PARP-1  
Much previous work by our group has focussed upon the development and synthesis 
of a library of inhibitors of PARP-1 and PARP-2, largely based upon analogues of the 
lead compound 5-AIQ (18). 50, 52, 54-56, 59, 135-137 As tankyrase-1 is a member of the PARP 
superfamily, it was likely that many of the compounds in this established library of 
PARP-1/-2 inhibitors would also inhibit tankyrase-1 and -2 to some extent. As men-
tioned previously, inhibition of PARP-1 and PARP-2 should not be a cytotoxic or anti-
proliferative event in cells lacking mutant BRCA.136, 138-140 This was demonstrated with 
treatment of up to 1000 µM of 5-AIQ having few deleterious events associated with it 
in murine colon carcinoma CT26 cells.136  
However, one group of isoquinolin-1-ones, which showed moderate activity against 
PARP-1 and PARP-2 (IC50 in the range 0.1 – 5 µM for both isoforms 141), showed unex-
pected anti-proliferative activity against a range of tumour cell lines in vitro in an MTS 
assay (Table 1, 25-26) (Wood, P. J.; Threadgill, M. D. - unpublished results). One 
explanation for this unexpected result would be that this subset of PARP-1 inhibitors 
was inhibiting another enzyme in the cell. A comparison of the structures having this 
unusual effect revealed that they all contained a 5-amino group and an alkyl or (pre-
ferably) aryl substituent in position-3 of the isoquinolin-1-one core. Remarkably, the 
same subset of compounds showed potent inhibition of the activity of tankyrase-1 in a 
very preliminary range-finding assay (Table 1). (Lehtiö, L.; Woon, E. C. Y.; Threadgill, M. 
D. - unpublished results) 
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These preliminary data also suggested selectivity for inhibition of tankyrase-1 over 
PARP-1 and PARP-2. These data, along with the other comparative studies reported in 
the literature and described above that show the relative inhibition of various PARP 
isoforms versus tankyrase-1 isoforms provide SAR clues and help to navigate the drug 
design journey towards new inhibitors of tankyrase-1 and -2.65, 73, 114, 133, 134  
2.7 Current tankyrase inhibitors  
Very few analogues that have been described in the literature have shown tankyrase-
1/-2 inhibition as their predominant action. The vast majority of inhibitors thus far 
have tended to be PARP-1 inhibitors which have also been screened against tankyrase-
1 and show poor to moderate activity likely due to being un-selective for the various 
PARP family isoforms. There are, however, isolated reports of some serendipitous 
discoveries of tankyrase specific and selective inhibitors in the literature.  
Several recent studies have reported compounds that specifically show tankyrase-1 
Figure 16: Compounds identified in high-throughput screens; XAV939 (1), LDW643 (2) and flavone (27). 
Although published as the tautomers, 1 and 2 are drawn as above as this is the more likely form of these 
structures. 
Table 1: Examples of unexpected cytotoxicity and preliminary tankyrase-1-inhibition data 
of a subset of PARP inhibitors towards cancer cell lines, as shown by MTS assay; HT29 are 












1 IC50 (µM) 
18 5-AIQ H 0.94 >200 170 >10 
24 3-Et-5-AIQ Et 0.45 >200 101 ~10 
25 3-Ph-5-AIQ Ph 0.72 2 8 ~0.1 
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inhibition as their predominant action (Figure 16). Firstly, XAV939 (1), introduced 
above and discovered in 2009, blocked tankyrase-1 binding at 0.1 µM but only blocked 
PARP-1/-2 binding at 1 µM in a ‘compound competition’ experiment.82 Interestingly, 
LDW643 (2), identified in the same high-throughput screen and structurally very sim-
ilar to XAV939, had no effect in the same experiment. This type of experiment involves 
competing potential inhibitors against the endogenous substrate and measuring the 
concentration point at which binding of the endogenous substrate is blocked by the 
inhibitor. Further characterisation of this apparently potent tankyrase-1 inhibitor, 
using Cy5-labelled XAV939 and recombinant PARP proteins, revealed that XAV939 
binds very tightly to the catalytic (PARP) domains of tankyrase-1 and -2 (Kd = 0.099 µM 
and 0.093 µM).82 In stark contrast, XAV939 demonstrates a much poorer binding affin-
ity for recombinant PARP-1 (Kd = 1.2 µM).82 In biochemical activity assays, XAV939 
demonstrated 10- to 500-fold selectivity for tankyrase-1 and tankyrase-2 over PARP-1 
and PARP-2 with IC50 values of 0.011 µM and 0.004 µM versus 2.2 µM and 0.11 µM, 
respectively.82, 107 This was the first well-characterised tankyrase-1 inhibitor which 
demonstrated a high degree of selectivity for tankyrase-1 over other PARP isoforms. 
Notably, in the same biochemical activity assays, LDW643 showed no activity against 
all four isoforms with IC50 values of >19 µM for PARP-1 and PARP-2 and tankyrase-1 
and tankyrase-2, reiterating the lack of tolerance for bulky groups in the “North-West” 
region for inhibition of all PARP family members.82  
Encouragingly, XAV939 shows some remarkably similar structural features to those 
identified in our own compounds that showed tankyrase-1 activity. In particular, the 
aryl substituent in XAV939 occupies a very similar space to those of the aryl 
substituents in the series of compounds described above (Table 1).  
In another study, flavone (27) was identified in a high-throughput screen of ~7000 
purified chemicals from the RIKEN NPDepo library, as a tankyrase-1 inhibitor with an 
effective concentration required for inhibition of 0.1-10 µM.142 Selectivity was demon-
strated for tankyrase-1 as the effective concentration of flavone required for PARP-1 
inhibition was reported as 100 µM by another group in their assay in vitro.143 
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2.8 Tipping the selectivity bias towards tankyrase-1? 
More recently, Wahlberg and colleagues profiled the interactions between the 
catalytic domain of 13 human PARP proteins and a library of 185 small molecules, 
comprising known and potential PARP inhibitors.61 Using DSF as a binding assay, they 
determined the relative affinity of various small-molecule inhibitors towards different 
PARP catalytic domains.61 The generated data then allowed for analysis of a chemical-
space and classification of compounds that clustered in distinct regions of the plot into 
PARPs-1-4-selective, non-selective and tankyrase-1,2-selective. 61 Those compounds 
selective for PARPs 1-4, including olaparib (23), KU0058948 (20) and ABT-888/ 
veliparib (16) (See Figure 15 for structures), had generally, a higher molecular weight 
and hydrophilicity, with an extended polar surface area and low cLogP values. Con-
versely, those molecules occupying the chemical space that showed selectivity for 
tankyrase-1 and tankyrase-2 had low molecular weights and a higher degree of hydro-
phobicity (Figure 17, 28-30).61 Likewise the ligand envelope of both tankyrase-1 and -2 
was said to be smaller and more hydrophobic than that of PARP-1-4, justifying the 
observation that tankyrase inhibitors fail to bind into the nicotinamide pocket of these 
isoforms due to steric clashes.17, 42  
Of note, when studying the compounds that show selectivity towards tankyrase-1 and 
-2, the common structural features, in addition to the classical nicotinamide binding 
motif, include an aromatic substitution in the 3-aryl region of the scaffold (isoquinoline 
numbering) and a relatively small-sized inhibitor overall (Figure 17). These key features 
are in common to those observed by our own group when looking at a sub-set of 
PARP-1 inhibitors that appeared to be more anti-proliferative in an MTS assay against 
various cell lines than expected from classical PARP-1 inhibitors (Table 1). (Lehtiö, L.; 
Woon, E. C. Y.; Threadgill, M. D. - unpublished results) These combined observations 
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and SAR features can be adopted in this drug development project, and incorporated 
into the design of selective inhibitors of tankyrase-1 and -2.  
2.9 Selectivity bias towards PARPs-1-4 – SAR features to avoid? 
In contrast to those studies with compounds showing a preference for tankyrase-1/-2, 
some studies show entirely the opposite selectivity preference and are, as such as 
useful from a drug design perspective. In one such study, a series of aminoethyl-
pyrrolodihydroisoquinolinones were revealed as novel and potent inhibitors of PARP-1, 
with poor activity against tankyrase-1 (IC50 values of 25 nM (31), 27 nM (32) for PARP-1 
and > 500 nM for tankyrase-1) with the introduction of an additional piperazine or 
diazepane moiety respectively into the position-5 (isoquinoline numbering) region of 
the pharmacophore (Figure 18).44 This may indicate that bulky, inflexible groups such 
as a fused pyrrole ring, in the position-5 area (isoquinoline numbering) of the 
pharmacophore are not ideal for tankyrase-1 inhibitors. In addition, the amide linker 
and piperazine and diazepane moieties introduce the potential for hydrophilic 
interactions with this region of the enzyme active site and may be disadvantageous in 
the tankyrase-1/-2 pocket. Indeed, this observation would fit in with the desirable 
features for tankyrase-1/-2 inhibition noted by Wahlberg and colleagues.61  
As disclosed above by Wahlberg and colleagues, ABT-888/ veliparib (16) also showed 
significant selectivity for PARP-1-4 over either of the 
tankyrase isoforms in a DSF binding assay (See Figure 15 for 
structure).61 This finding was in agreement to that reported 
by Huang et al., where in a biochemical activity assay, ABT-
888/ veliparib strongly inhibited PARP-1 and -2 with IC50 
values of 0.0083 µM and 0.011 µM respectively but showed 
weak inhibitory activity for tankyrase-1 and -2 with IC50 
values of 14.97 µM and 6.52 µM, respectively.82 
Olaparib (23) (Figure 15) has shown initial promising single-
agent activity against BRCA-1 and BRCA-2 deficient mutant 
tumours in early clinical testing and is currently in phase-II 
Figure 18: Aminoethyl-
pyrrolo dihydroisoquinolin-
one analogues 31 and 32 
identified as novel PARP-1 
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clinical trials.48 Interestingly, this PARP-1 and -2 inhibitor (IC50 = 5 nM and 1 nM 
respectively), shows relatively little inhibition of tankyrase-1 activity (IC50 = 1.5 µM).48, 
144 This observation was in agreement with that reported by Wahlberg and colleagues, 
with olaparib fitting into the PARP-1-4 selective ‘chemical space’, mapped according to 
its relative affinity for various PARP isoforms in a DSF binding assay.61 The 
demonstration of selectivity bias diverting away from tankyrase-1/-2 inhibition may 
also be very useful in providing clues as to molecular design features to avoid.  
2.10 Tankyrase inhibitors – binding to an alternative site 
In addition to the classical nicotinamide mimetics that have formed the mainstay of 
inhibitors to date, some other reported inhibitors bind to an alternative site to elicit 
their inhibitory effects (Figure 19). The binding of these ‘alternative’ binding site inhib-
itors is facilitated by a flexible loop that lines the substrate-binding groove and is con-
ducive with accommodating non-classical inhibitors.42 
A recent study identified IWR1 (33) as a novel and potent tankyrase inhibitor (IC50 
tankyrase-1 = 131 nM, tankyrase-2 = 56 nM) that stabilises AXIN and inhibits Wnt-
signalling and proliferation in APC-null DLD1 cancer cells.82, 145 This compound was 
found not to bind in the classical nicotinamide binding site in a study of the tankyrase-




































Figure 19: A selection of novel tankyrase inhibitors that bind in the alternative non-classical binding site of 
the tankyrase-1/-2 pocket.  
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region of the catalytic site and induced a conformational change which effects the 
movement of the D-loop which, in turn prevents the binding of nicotinamide by 
affecting the secondary shape of the nicotinamide-binding site.42 
 As a relatively large inhibitor compared with classical nicotinamide mimetics, IWR1 
comprises three sections, namely amide, spacer and norbornyl, each of which traverse 
the binding pocket of the enzyme and create specific interactions in their individual 
‘zones’. Indeed all three regions of this molecule are required for potency as highligh-
ted by individual modifications in a recent SAR study using a cell-based assay.146 Specif-
ically, the quinolone ring was found to be crucial for maintaining potency; substitution 
with smaller aromatic groups such as phenyl, benzyl or pyridyl groups almost obliter-
ated activity (EC50 > 20 µM).146 It was proposed that this quinolone bicycle may be suff-
iciently large to affect the opening of the D-loop and fill the cavity effectively, whereas 
smaller groups may not be capable of such a transformation.42  
Binding of IWR1 through the induced-fit mechanism allows this inhibitor to be highly 
complementary to the new cavity. Interestingly, this alternative-binding site inhibitor 
appears to exhibit very little propensity to bind to other PARP isoforms (IWR1: IC50 
PARP-1 > 18.7 µM), probably due to the lesser flexibility observed in the D-loop of 
PARP-1, the greater degree of movement required from the PARP-1 domains to avoid 
steric clashes and the lack of specific interactions which are present in the tankyrase-2 
binding site. 42 
Further to this, a series of [1,2,4]triazol-3-ylsulfanylmethyl)-3-phenyl-[1,2,4] oxadiaz-
oles were discovered recently by Shultz and colleagues in a screening effort to find in-
hibitors of the Wnt-pathway.147 Through an intensive inhibitor-optimisation campaign, 
this group identified 34 as the lead compound with a tankyrase-2 IC50 of 33 nM and a 
PARP-1 and PARP-2 IC50 of greater than 19 µM.147 Although not confirmed, the lack of 
a classical nicotinamide-binding motif makes it highly likely that this novel inhibitor, 
akin to IWR1, also binds to an ‘alternative’ site. Specifically, this inhibitor was found to 
be making contact with the adenosine/diphosphate linker portion of the NAD+ donor 
site and made additional interactions in a hydrophobic ‘nook’ which lies adjacent to 
the diphosphate linker portion of the site.147 Interestingly, although 34 was found to 
have a greater ‘contact-area’ in the ligand binding site than that of XAV939 (1), the 
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latter was found to have more optimal binding.147 ‘Contact-area’ in this case was 
defined as the surface area of residues that lay in close proximity to the ligand and 
actually make contact with the ligand. Interestingly, the group found that a specific 
residue, Phe1188, which, owing to its proximity to both ligand-binding sites can make 
contact with both, moved significantly when bound to 34 or XAV939.147  
This degree of plasticity may suggest the possibility of dual-binding ligands that can 
access both the nicotinamide and other alternative sub-sites. In agreement with this 
observation is that two molecules of PJ34 (17) (See Figure 15 for structure), were 
surprisingly found to bind mutually in the catalytic domain of tankyrase-1 with one 
molecule bound in the nicotinamide sub-section of the catalytic pocket and the other 
in the alternative sub-site. 148 This ‘twin-binding’ was not observed when PJ34 is bound 
in PARP-1 and highlights the significant differences in these catalytic pockets further.148 
Analogously, Waaler and colleagues identified JW55 (35), JW67 (36) and JW74 (37) in a 
screen of 37,000 compounds in HEK293 cells as tankyrase-1 inhibitors, the result of 
which was diminished β-catenin in APC-truncated SW480 cells and consequentially 
reduced cell proliferation (Figure 19).149 These compounds were proposed to be acting 
through inhibition of tankyrase-1/-2 and consequentially leading to stabilisation of 
AXIN-2 and increased breakdown of β-catenin.149 These inhibitors were found to be 
moderately potent inhibitors of tankyrase-1 and -2 (JW55: IC50 tankyrase-1 = 1.9 µM, 
tankyrase-2 = 0.83 µM; JW74: IC50 tankyrase-1 = 2.55 µM, tankyrase-2 = 0.65 µM) and, 
like IWR1, poor inhibitors of PARP-1 (JW55 IC50 PARP-1 > 20µM).147, 149 On this 
occasion, molecular docking studies confirmed that the binding location of JW55 is 
analogous to that of IWR1 in the alternative sub-site of the tankyrase-2 catalytic 
pocket.149 
Altogether these very recent studies introduce an entirely new pharmacophore model 
and as such represent an exciting drug design prospect calling out for further 
exploration.82 The ‘alternative’ binding site raises the possibility of designing dual-
binding inhibitors that may reach into both the classical nicotinamide binding site and 
the alternative site described and may enhance both the selectivity and specificity of 
inhibitors for the tankyrases further still but is beyond the initial scope of this project. 
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This project therefore focusses solely on the development of inhibitors that bind into 
the classical nicotinamide-binding site. 
2.11 Protein crystallography studies 
All PARP catalytic domains, including those of tankyrase-1/-2, appear to consist of a 
donor site, which NAD+ occupies when it is first attached to Glu or Asp residues during 
the initiation reaction, and an acceptor site, which the acceptor protein occupies at 
first, followed by the growing PAR chain. It is this donor site, in particular the nicotin-
amide-binding cleft, which has been explored in the design of inhibitors.  
Much understanding of the basic requirements of an inhibitor can be elucidated from 
protein crystallographic studies. In addition, these studies can aid the development of 
selective inhibitors, crucial in modern drug development in order to minimise off-
target effects and simplify the outcomes of any future clinical trials.  
Nicotinamide (12), the starting point for the design of PARP inhibitors and the further 
development of tankyrase-1/-2 inhibitors, makes key interactions when bound in the 
active site of tankyrase-2, as depicted in the 
crystal structure obtained by Narwal and 
colleagues and illustrated in Figure 20.42 
The carboxamide forms key hydrogen 
bonds with the Ser1068 hydroxy group and 
with the main chain carbonyl and amide of 
Gly1032 and the pyridine ring participates, to 
some extent, in π-stacking with Tyr1071; 
however, this is inefficient in nicotinamide, 
as the aromatic ring is at an angle of 39° to 
the plane of the benzene ring of tyrosine.42 
In addition, nicotinamide forms three key 
H-bonds with water-molecule networks 
close to the catalytic Glu1138 and His1031 / 
Tyr1071; together these form the conserved 
H-Y-E motif. Altogether, these binding feat-
Nicotinamide (12) 
Figure 20: Crystal structure of nicotinamide bound 
to the active site of tankyrase-2 and showing the 
key H-bond motif between the carboxamide and 
Ser1068 hydroxy group and with the main carbonyl 
and amide of Gly1032. In addition nicotinamide 
forms H-bonds with water-molecule networks 
close to the catalytic Glu1138 and His1031/Tyr1071 
that form the conserved H-Y-E motif.42 
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ures are conserved in both PARPs and tankyrases. 68, 150 The majority of PARP 
inhibitors, to date, mimic the nicotinamide motif and thus make interactions with 
these conserved features.61 
The first crystallographic structure reported of the catalytic domain of tankyrase-1 was 
by Lehtiö et al. in 2008 (Figure 21). 68 Much of the catalytic domain of tankyrase-1 is 
structurally homologous to PARP-proteins; however, there are distinctly different 
features of potential interest in drug design. Importantly, the donor site, occupied by 
NAD+ when it is first attached to Glu or Asp, is not conserved between tankyrase-1 and 
other PARP members.  
Structurally, residues 1104-1314 comprise the catalytic domain of human tankyrase-1, 
which, in terms of secondary structure, includes two central β-sheets consisting of five 
and four strands respectively, which are surrounded by four α-helices and loops. 68 
The principal secondary structure features 
are, in general, highly conserved between 
previously described PARP enzymes and 
tankyrase-1 but there are significant 
differences, in particular around the 
adenosine sub-site of the catalytic core.68 
The open conformation of the ‘D-loop’ 
Phe1197-Gly1211 observed in PARP-1 chan-
ges to a closed conformation in tankyrase-
1 and is also three proline residues 
shorter, and may be a cause of steric hind-
rance seen when PARP-1 inhibitors are 
overlaid.42, 68,61, 107, 151, 152 Interestingly, the 
tankyrase-1 D-loop has higher temperat-
ure factors when compared with the 
entire protein, allowing for the possibility 
of reasonable flexibility of this structure 
when incorporating inhibitors. This agrees 
with that postulated earlier with the 
Figure 21: Crystal structure showing the donor site 
of both PARP-1 and tankyrase-1 for direct com-
parison by Lehtiö et al.68 The PARP-1 surface is 
shown in orange, whilst tankyrase-1 is shown as blue 
sticks to emphasise the almost complete closure of 
this binding site in comparison to PARP-1. Subsites 
of the NAD+ binding site are labelled: NI, 
nicotinamide binding site; PH, phosphate binding 
site; AD, adenosine binding site.  
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binding of IWR1 (33) and JW55 (35) being tolerated due to the plasticity of the D-
loop.68, 145, 149 In agreement with this is the observation that crystal structures of PARPs 
1-4 had longer D-loops, resulting in a wider pocket when compared with the narrow 
and hydrophobic pocket created by the shorter D-loop of tankyrase-1 and -2 which 
contains a non-conserved tyrosine, followed by isoleucine residue.61 These observat-
ions tie in nicely with the compounds in Figure 17, known to be selective for tankyrase-
1 and -2.  
Most noticeable is the lack of the N-terminal α-helical domain in tankyrase-1, thought 
likely to be responsible for modulating the activity of DNA-dependent PARPs. This may 
partly explain why tankyrase-1 is not thought to be involved in DNA repair. 150 Further 
differences include the deletion of a large 32-amino-acid ‘B-loop’ in the catalytic 
domain of PARP-1, replaced by a small four-amino-acid loop in tankyrase-1. 68 Further 
to this, the α3 helix, which provides a base for the adenosine sub-site through interact-
ions with its main chain residues, is shorter in tankyrase-1 due to deletion of a two-
amino-acid residue.68 The consequence of this deletion in terms of conformational 
changes is a narrowing of the binding pocket, caused by movement of the helix itself 
and a preceding loop in the sequence. Indeed, steric clashes were noted between the 
Phe1188 in this α3 helix region and PARP-1 inhibitors, which is likely to reduce their 
binding affinity in tankyrase-1.68 
Another loop feature, known as the G-loop (glycine-rich loop), also shows movement 
following the α4 helix, leading to further narrowing of the nicotinamide-binding site. 68 
This loop also forms a connection between the active site in tankyrase-1 and a novel 
zinc-binding motif and is unique to tankyrase-1 and -2. This finger-like motif, formed 
between residues 1224-1247, has unknown biological function; however, it is thought 
unlikely to perform any catalytic function, as it is too far away from the catalytic Glu1291 
and may have a structural or regulatory function.68 It has been suggested that this 
motif may form a platform for protein-protein interactions, possibly with some 
members of the shelterin complex, e.g. TIN-2, known to stabilise the tankyrase-1-TRF-1 
complex and to modulate PARsylation activity.68 
Taken together, these conformational differences may provide invaluable clues 
towards superior inhibitors, where exploiting subtle differences in the catalytic core 
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may allow for the design and optimisation of inhibitors to complement these differ-
ences. Using the conserved nicotinamide site as an anchor, it should be possible to 
probe for these subtle differences in the other domains, particularly with the non-con-
served D-loop and the narrow hydrophobic cavity formed as a result, with novel subst-
itutions in this region of the inhibitor framework providing both selectivity and 
potency.  
XAV939 (1), the selective tankyrase-1 and -2 inhibitor discovered by Huang and 
discussed earlier, has recently been reported in a complex with tankyrase-2 and the 
X-ray crystal structure is depicted in Figure 22.42 In common with the endogenous sub-
strate nicotinamide (12), this inhibitor makes the typical H-bond interactions between 
the pyrimidine N-H and carbonyl of XAV939 and Ser1068 and Gly1032.42 
In addition to these interactions, the pyrimidine ring of XAV939 forms π-π interactions 
with Tyr1071 and its phenyl side chain and para-trifluoromethyl substituent make 
further hydrophobic interactions with Tyr1050, Tyr1071 and Pro1034, Phe1035 and Ile1075, 
respectively. Justification for the excellent inhibitory activity of XAV939 was rational-
ised not only by its excellent steric fit into the active site but by these additional non-
polar interactions, not seen in the corresponding PARP-1 pocket where polar interact-
ions are known to dominate interactions with the active site.107 These hydrophobic 
XAV939 (1) 
Figure 22: Crystal structure of tankyrase-2 in complex with XAV939 (1) (PDP code 3KR8) adapted from 
Narwal et al. 42 showing key interactions as the pyrimidine N-H and carbonyl form H-bonds with Ser1068 and 
Gly1032 and Tyr1071 forms π-π stacks with the pyrimidine side chain. In addition many hydrophobic 
interactions are made as the phenyl ring interacts with the side chains of Tyr1050 and Tyr1071 and the 
trifluromethyl group with the side chains of Pro1034, Phe1035 and Ile1075. 
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interactions in this region of the pocket may, therefore, be the key to designing 
selective inhibitors of tankyrase-1/-2. 
The huge inhibitory difference between XAV939 (1) and LDW643 (2) discussed earlier 
seemed somewhat surprising, considering their modest structural divergence. Super-
imposing these two molecules into a crystal structure of tankyrase-2 suggested a steric 
clash between the N-acetyl moiety of LDW643 and Phe1061-Ala1062,107 thus streng-
thening the proposition that bulky substituents in this area are unlikely to be 
acceptable. Although utilising tankyrase-2, this group found no grounds for explaining 
selectivity over tankyrase-1, due to the highly conserved active site between the two 
isoforms.68  
In addition to appreciating favourable interactions within the active site it is also bene-
ficial to gain an understanding of unfavourable interactions that may cause a loss of 
potency and / or selectivity of potential inhibitor for the target. When looking at 
olaparib (23), a potent inhibitor of PARP-1 and PARP-2 (IC50 = 5 nM and 1 nM, respect-
ively), currently in clinical trials as discussed earlier, it shows significantly reduced act-
ivity for tankyrase-1 (IC50 = 1.5 µM). This major loss of potency against tankyrase-1 can 
be justified by examining the X-ray crystal structure of the complex of this inhibitor 
with tankyrase-2, where binding immediately induces a conformational change 
whereby the D-loop (especially residues Asp1045, His1048, Ala1049 and Tyr1050) is forced to 
move to an open confirmation, indicating an induced-fit model (Figure 23). Although 
some interactions are common with XAV939 and nicotinamide and follow the lock-
and-key model, including hydrogen bonding with Ser1068 and Gly1032 and π-stacking 
between Tyr1071 and the pyrimidine ring of XAV939, other interactions are quite 
divergent.  
Of note is that the fluorine of the fluorophenyl group interacts unfavourably with the 
D-loop; its electronegativity causing disruption close to the carbonyls of His1048 and 
Ala1049. In addition, the stacking observed with the fluorophenyl group itself and a diff-
erent tyrosine to that observed with XAV939 (1), Tyr1050, indicates the conformational 
changes that have occurred to incorporate this inhibitor. Although a good fit in the 
upper nicotinamide binding site, the lower end of the binding cavity suffers from many 
 
 
- 55 - 
 
steric and electronic clashes and this goes someway to indicate the avoidance of 
certain groups and flexibility in this region of potential inhibitors.  
At the start of this project, our collaborator Dr Lari Lehtiö (University of Oulu, Finland) 
solved crystal structures of those PARP-1 inhibitors (25-26, Table 1), designed in our 
group, yet found to have tankyrase-1/-2 activity, by soaking individual inhibitors into 
tankyrase-2 crystals (Figure 24, Lehtiö, L. - unpublished data). 5-AIQ (18), an 
established inhibitor of PARP-1 and PARP-2, makes the classical hydrogen-bond motif 
with the side chain of Ser1068 and the backbone carbonyl and amide of Gly1032 in the 
same manner as nicotinamide; however, no further interactions are made with the 
tankyrase-2 enzyme pocket, justifying its relatively poor inhibitory activity (IC50 >10 
µM) against tankyrase-1 (Figure 24). In addition to the classical hydrogen-bond motif 
observed in both nicotinamide (12) and 5-AIQ, further interactions were noted for 3-
phenyl-5-AIQ (25), including π-stacking of the 3-aryl substituent with Tyr1050 and 
Tyr1071, which shows the tolerance and indeed preference for hydrophobic groups in 
this region of the active site.  
This may, to some extent, indicate why some of these molecules (25-26) in particular, 
exhibited preference for the catalytic site of tankyrase-1 over PARP-1 in a very 
Figure 23: Crystal structure of tankyrase-2 in complex with olaparib (23) adapted from Narwal et al.42 
Although binding of this PARP-1 and -2 selective inhibitor in tankyrase-2 maintains the same H-bond inter-
actions with Ser1068 and Gly1032 and π-stacking with Tyr1071 in the nicotinamide binding site as for XAV939, it 
also induces movement of the entire D-loop (especially effects residues Asp1045, His1048, Ala1049 and Tyr1050) 
partly due to unfavourable interactions between the electronegative fluorine of the fluorophenyl group. This 
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preliminary range-finding assay (IC50 ~ 0.1 µM for both compounds against tankyrase-1 
vs. 0.72 µM and 0.19 µM against PARP-1, respectively), as the PARP-1 catalytic pocket 
in this region comprises more hydrophilic residues, such as aspartic acid and aspara-
gine. Although these molecules show some inhibition of PARP-1, they have no features 
in their position-3 region to allow them to bind well to this more hydrophobic region of 
the tankyrase-1 and -2 enzyme catalytic pocket and are thus promiscuous.  
Selectivity could indeed be an issue with the development of tankyrase inhibitors, due 
to some similarities in the catalytic domain of closely related enzymes such as PARP-1, 
and will be borne in mind during the design process. Indeed, as previously mentioned, 
PARP-1 inhibitors formed the basis of early inhibitor design and, as such, it is vital that 
subtle differences in the catalytic site are exploited as fully as possible to maximise 














Figure 24: Crystal structures of 5-AIQ (18) (right) and 3-Phenyl-5-AIQ (25) (left; originally designed within the 
Threadgill group as a PARP-1 inhibitor) in a complex with tankyrase-2 obtained by a collaborator Dr Lari Lehtiö 
(University of Oulu). The classical H-bond motif between the carboxamide and Ser1068 hydroxy group and main 
carbonyl and amide of Gly1032 is clearly maintained in both crystal structures. In addition the 3-phenyl side 
chain of 3-phenyl-5-AIQ, makes additional hydrophobic interactions including π-stacking of the 3-aryl 
substituent with Tyr1050 and Tyr1071, which may justify the improved inhibitory effect of 3-phenyl-5-AIQ 
compared with 5-AIQ which has none of these additional interactions in the tankyrase-2 pocket. 
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Chapter 3.0 - Aims and Objectives 
Ultimately, the global aim of any cancer drug-discovery programme is to provide an 
agent or agents with the potential to cure, alleviate suffering and improve the quality 
of life of millions of people suffering with cancer with a low ‘number needed to treat’ 
(NNT) score. This is an epidemiological score, described in 1988 and defined as the 
number of patients that need to be treated for one to benefit compared with a control 
in a clinical trial.153 
Although many cancer treatments do exist, most of these suffer from intolerable side 
effects including hair loss, nausea and vomiting, immunosuppression, a tendency to 
get serious infections, oral mucositis, loss of appetite, loss of fertility and depression to 
name but a few, and often make the patient feel worse than they did prior to treat-
ment. New therapeutics must be specifically targeted to the cancer cells themselves, 
identifying a weakness within their cellular mechanism that can be exploited, whilst 
maintaining the integrity of the adjacent non-cancerous tissue. This in turn should 
minimise off-target effects which lead to the global toxicity responsible for the many 
and often life-threatening side effects mentioned above. 
The aim of this project is to synthesise a diverse library of novel, potent (IC50 < 100 nM) 
and selective tankyrase-1/-2 inhibitors which demonstrate little propensity to inhibit 
other PARP isoforms (IC50 > 1 µM). Initial biological evaluation in vitro will be 
conducted to assess the relative inhibitory potential of new analogues against 
tankyrase-2 compared with existing compounds in the literature, e.g. XAV939 (1).  
The objective of this project is to explore a variety of synthetic chemical techniques to 
achieve the efficient synthesis of this library which will ideally be amenable to parallel 
synthesis to aid the rapid generation of analogues. Initially palladium-catalysed cross-
coupling chemistry will form the mainstay of reaction techniques adopted, as this 
chemistry has been used historically within the group to generate alternative com-
pound libraries and is known to be relatively efficient and amenable to parallel syn-
thesis. Following this, other synthetic chemical techniques will be employed as needed 
to achieve further analogues, the design of which will evolve as the project develops.  
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Alongside the chemical synthesis of the inhibitor library, evaluation in vitro using a 
biochemical assay developed in-house will be used as an initial screen to assess the 
crude biological activity of these inhibitors against tankyrase-2. The objective of this 
assay will be to provide a quick assessment of the inhibitory potential of analogues, to 
start to define the structure activity relationship (SAR) and to guide the advanced 
design of future inhibitors. These data will allow for the ‘make and test’ model of 
library evolution, thus allowing for the development of inhibitors with continually 
improving biological properties over the lifespan of the project. Inhibitors will be 
designed with the aim of maintaining good pharmaceutical properties according to 
Lipinski’s ‘rule of five’ guidelines, thus developing compounds with no more than five 
hydrogen-bond donors, no more than five hydrogen-bond acceptors, a molecular mass 
less than 500 Da and an octanol-water partition coefficient (log P) no greater than five. 
These ‘drug-like’ properties will help to protect such analogues from attrition further 
down the drug-development pipeline should early promise be shown.  
Figure 25 depicts the main structural features that will be explored initially in the early 
stages of the project. The isoquinolin-1-one framework will be maintained as a 
skeleton throughout the design of inhibitors. As discussed previously, this framework 
will exploit the key hydrogen-bond motif with the fixed lactam interacting with the 
side chain of Ser1068 and the backbone carbonyl and amide of Gly1032 (Figure 25, green 
box). Moving clockwise around the framework in Figure 25, the 3-aryl component (red 
box) will be expanded with the aim of exploring and probing the 3D shape of the 
hydrophobic pocket in this region of the tankyrase-1/-2 catalytic pocket, known to be a 
feature for potentially fine-tuning selectivity for tankyrase-1 and -2 enzymes over 
other PARP family isoforms such as PARP-1. 
Initially, the 3-aryl group will be decorated with a variety of substituents including 
electron-donating, electron-neutral, electron-withdrawing and polar groups in the 
ortho, meta and para positions in order to decipher the optimum SAR in this region. 
Additionally, substituted groups with the potential to donate and accept hydrogen 
bonds will be explored in order to probe for any additional interactions of this nature 
within the contact area of the enzyme catalytic pocket. Further to this, unusual bulky 
groups, such as ferrocene, will be incorporated into the framework to allow the 3D 
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boundaries of the enzyme pocket in this hydrophobic region to be explored fully and 
to determine the tolerance and flexibility of the pocket for accommodating larger 
groups.  
The purple box in Figure 25 indicates features that will be explored in the position-5 
region of the framework. Initially a primary amine will be maintained, partly for the 
benefit in solubility imparted by this hydrophilic group, but also because many known 
inhibitors of PARP-1 also have this functionality and, as previously mentioned, mark a 
good starting point for the design of inhibitors of tankyrase-1/-2. As the library evolves, 
other small groups including electron-donating, electron-neutral and electron-with-
drawing functionalities will be substituted into position-5 to fully explore the tolerance 
of the enzyme pocket in this region and to probe for any tankyrase-1/-2 specific 
interactions such as hydrogen-bonds. Previous studies have indicated that this region 
will not tolerate large groups; therefore, the aim will be to incorporate a variety of 
small groups at first, including methyl, methoxy, fluoro and hydroxy.44, 61 In common 
with both PARP-1 inhibitors and early reported tankyrase-1 inhibitors, extensions from 
positions-6, -7 and -8 of the framework appear to be poorly tolerated (Figure 25, blue 
box); therefore, this region of the framework will not be interrogated at this time as it 
is likely to have an adverse affect on the inhibitory potential of an analogue.82 
Using this consensus pharmacophore (Figure 25) as a design guide, a full explorative 
SAR will be developed through interrogation of all the aforementioned positions 
around the framework identified as having potential to improve specificity and 
selectivity for tankyrase-1/-2 over other PARP isoforms.  
Figure 25: Consensus 
pharmacophore adopted for 
the early design and 
modification of tankyrase-1/-2 
inhibitors in this project. 
Isoquinoline numbering is 
shown. Key features are 
shown in the coloured boxes; 
the locked carboxamide 
shown in green will be 
maintained, however the 
‘zones’ illustrated in red and 
purple will be explored with 
the aim of improving both 
potency and selectivity. 
Bulky aryl group 
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Molecular modelling will be used throughout the project to visualise and define the 
binding of inhibitors into the catalytic core of tankyrase-2 and will be used to fine-tune 
the design of future analogues with the benefit of this structural information. In 
addition, small molecule X-ray crystal structures are planned on suitable samples 
which will also help guide the molecular modelling process and ensure that key bond 
angles in the structures are being predicted correctly by the modelling software. This 
will be crucial for optimum binding in the enzyme pocket.  
Should there be sufficient time within the scope of the project, comprehensive biolog-
ical evaluation of ten to fifteen inhibitors, selected for their superior inhibitory and 
pharmaceutical properties, will be instigated. This will involve in vitro biological 
analysis of inhibitors against other enzyme isoforms including PARP-1 and tankyrase-1 
using a variety of commercially available biochemical ‘kit-form’ assays. In addition, the 
in vivo anti-proliferative activity of selected candidate molecules will be tested in both 
cancerous and non-cancerous cell lines such as HT29 and FEK4 cell lines respectively 
using MTS assays. The MTS assay, whilst elucidating the anti-proliferative effects of 
potential inhibitors, should allow for a correlation between this activity and inhibitory 
effects on tankyrase-2 to be defined crudely. A broader biological profile of selected 
inhibitors may also indicate towards a candidate drug molecule with potential for 
future investigation. In addition to research activities, results will be communicated to 
the scientific community both internally and externally and patent protection will be 
sought where necessary.  
On completion of this project, the ultimate aim is to have established a library of 
analogues with a clearly defined SAR related to their inhibitory effects on tankyrase-2. 
Several of these analogues will ideally show at least 80% inhibition of tankyrase-2 at 10 
nM in an initial range-finding assay. Further comprehensive biological analysis may 
allow for the selection of at least one candidate drug molecule with the potential to be 
taken forward into a drug discovery programme. This analogue will hopefully benefit 
from advantageous pharmaceutical properties and be relatively straightforward and 
high yielding to both synthesise and purify chemically, therefore rendering the agent 
amenable to scale-up activities necessary for future development.  
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Chapter 4.0 - Results and Discussion: Synthetic chemistry 
4.1 Introduction to synthetic chemistry 
In this chapter, a twenty-five year evolution of drug design from early non-specific 
inhibitors of PARPs to selective inhibitors of tankyrase-1/-2 will be presented, along 
with a historical view of the medicinal chemistry which has complemented this 
discovery pathway. As part of this, an overview of the synthetic chemistry developed 
within the Threadgill group will be presented and progressed to the point at which this 
project was initiated. Following this, the medicinal chemistry developed within this 
project will be discussed and rationalised in depth.  
Early inhibitors of PARP-1 were understood to mimic the nicotinamide moiety of the 
substrate NAD+ and, as such, fuelled the development of structure-activity relationship 
(SAR) studies that aimed to exploit and build on these key binding features which 
included a primary or secondary benzamide, with the amide N-H and carbonyl held in a 
constrained position relative to the benzene ring.154 Initially, substituted benzamides 
were at the forefront of the drug-discovery campaign towards inhibitors of PARPs, with 
optimum activity in this series observed when an electron-donating substituent was in 
position-3 and with no further substitutions around the benzene ring at positions-2 
and -4-6. 63, 123, 133, 155, 156 Indeed, the discovery of 3-aminobenzamide (3-AB) (11) was 
reported almost thirty-five years ago by Purnell and Whish.63  At the time, and for ten 
years following its discovery, this compound was to be the ‘gold standard’ inhibitor 
(IC50 = 22 µM).157 Further to this discovery, subsequent investingations progressed to 
looking at 5-substituted isoquinolin-1-ones,50, 56, 59, 123, 126, 133, 137, 158, 159 3,4-
dihydroisoquinolin-1-ones123, 160 and 2,8-disubstituted quinazolin-4-ones (including 
those shown in Figure 26).158, 160-162  
These more advanced structures were superior to the original benzamides with 5-hyd-
roxyisoquinolin-1-one (38) and 8-hydroxy-2-methylquinazolin-4-one (19) showing 
much more potent inhibition of PARP-1 than did 3-AB (IC50= 0.14 µM and 0.44 µM, res-
pectively, compared with 22 µM for 3-AB).133 It became apparent from these superior 
inhibitors that constraining the conformation of the heterocyclic ring so that the N-H 
bond is trans to the carbonyl-arene bond. In addition to the many inhibitors being dev-
eloped that contain the presence of a covalent bond to hold the aforementioned con-
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formation in place, one group has used an intramolecular hydrogen bond in a series of 
benzoxazolecarboxamides to achieve this (Figure 26, 39).162 The substitution of a 
covalent bond for a fixed hydrogen bond maintained good inhibitory activity for PARP-
1 (39: IC50 = 2.1 µM). 137 By this time, the consensus pharmacophore for inhibitory 
activity against PARP-1 was well established and fuelled the evolution of future drug 
design. Early developmental work within the Threadgill group focussed upon this key 
principle and synthesis of 3-substituted benzamides and 5-substituted isoquinolin-1-
ones as potential inhibitors of PARP ensued.116, 135, 137, 140, 163 At this stage, little was 
known with regards to the different isoforms of PARP.  
This early excitement and subsequent rush by many groups to synthesise new 
inhibitors of PARP was tainted somewhat with the realisation that many of the early-
reported structures suffered from undesirable pharmaceutical properties, in particular 
poor water-solubility.133 This would potentially lead to poor dissolution and bioavailab-
ility and the requirement for administration with a biocompatible , which could compl-
icate the outcome of an in vivo trial.157 Although a consensus pharmacophore had 
been established by this time for optimum inhibitory activity, ironically this pharmaco-
phore also dictates a certain degree of water-insolubility onto the inhibitor due to its 
tendency to form H-bonded dimers in the crystalline state, lowering the energy of the 
solid state.157 There was thus a requirement for a balance between inhibitory activity 
and optimum biopharmaceutical properties. X-ray crystallographic data reported by 
Costantino and colleagues164 had demonstrated that there was a H-bond interaction 
between Glu988 (PARP-1 active site) and the amino group of 4-amino-1,8-naphthal-
imide (4-ANI) (22; see Figure 15 for structure) and that the incorporation of this 
solubilising entity had, in no way, reduced the potency of this inhibitor (IC50 = 0.18 
µM). Moreover, position-4 on the naphthalimide framework corresponded with 
Figure 26: Structures of 
early known inhibitors of 
PARP-1. Each structure 
maintains the benzamide 
pharmacophore; however, 
bicyclic ring systems 
proved to be 10- to 50-
fold more potent as 
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position-5 of the isoquinolin-1-one; a separate class of inhibitors that had attracted 
considerable attention. 5-aminoisoquinolin-1-one (5-AIQ) (Figure 15; 18) which had 
been first reported by Suto and colleagues in 1991,123 became a very interesting 
analogue for further investigation in the Threadgill group. Ironically, the potential of 5-
AIQ had not been anticipated by Suto and colleagues in the first instance; they had 
instead selected an alternative analogue 5-methyl-3, 4-dihydroisoquinolin-1-one as a 
clinical candidate, although this was later dropped owing to off-target toxicity in 
animal studies. 123 The superior pharmaceutical properties of 5-AIQ led to a race to 
develop a reliable synthesis of this inhibitor as it was not commercially available.  
Much developmental work was then conducted in the Threadgill lab towards a reliable 
synthesis of this promising new inhibitor. This included attempts to further enhance its 
pharmaceutical properties through conversion of the 5-amino group of 5-AIQ (18) to 
its highly water-soluble hydrochloride salt. Many routes investigated proved to be un-
reliable and poor yielding;56, 165-167 however, eventually, a reliable and relatively short 
synthesis was developed with no requirement for complex purification.116 This signific-
ant synthetic success allowed the Threadgill group to collaborate with many other 
groups and conduct many investigations into the pharmacological effects of this new 
inhibitor in many different models of disease in vivo, including animal models of myo-
cardial infarction59 ischaemia-reperfusion injury of the liver126 and kidney50, acute lung 
inflammation51, neurological damage 55, 130 and, most recently, in a murine model of 
cancer where it was found to be remarkably anti-metastatic.168 Overall, 5-AIQ demon-
strated encouraging therapeutic benefits in these models, further enhancing its value 
as a new inhibitor.  
As part of the evolution of the PARP-1/-2 drug discovery campaign it became desirable 
to progress towards 5-AIQs substituted at positions-3 and -4, in order to probe and 
explore the PARP-1/-2 catalytic pocket further in an attempt to pick up more inter-
actions within the nicotinamide-binding site and hopefully improve potency and select-
ivity of future inhibitors. Unfortunately, none of the reported synthetic routes towards 
5-AIQ (18) had any potential for incorporation of additional substituents around the 
isoquinoline ring and, as such, limited its usefulness in the further design of selective 
inhibitors. Five independent chemical strategies were employed within the Threadgill 
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group with this aim in mind, initially with substitutions designed in position-3 and -4 
(to target specifically PARP-1 and PARP-2, respectively) which will be discussed below.  
Finally, the evolution to the current project will be discussed. Serendipitously, it was 
noticed that a subset of 3-substituted 5-aminoisoquinolin-1-ones (25-26) were partic-
ularly cytotoxic in a range of human tumour cell lines (Wood, P. J.; Sunderland, P. T.; 
Woon, E. C. Y.; Threadgill, M. D. unpublished results; Table 1). As inhibition of PARP-1 
should not be a cytotoxic event per se in BRCA-normal cells,60, 136, 138, 139 it was 
postulated that the inhibitors exhibiting this unexpected result might be acting on 
another enzyme within the cell. Preliminary enzyme inhibition assays by a collaborator, 
Dr. Lari Lehtiö (University of Oulu, Finland) found that these inhibitors were also inhib-
iting an alternative PARP isoform, tankyrase-1. Specifically, the 3-aryl substituent of 
this subset of inhibitors appeared, according to preliminary modelling studies, to lie in 
a hydrophobic pocket adjacent to the nicotinamide-binding site common to all PARP 
inhibitors. This interesting observation gave a starting point for the development of 
selective inhibitors of tankyrase-1/-2 and along with the promising therapeutic potent-
ial of tankyrase-1/-2 inhibitors fuelled a new voyage of drug discovery, to which this 
project was destined.  
A library of new inhibitors based on the isoquinolin-1-one scaffold was thus required 
to answer a series of structural questions about the shape of the catalytic pocket and, 
in particular, the hydrophobic pocket of this new isoform; specifically with regards to 
how selectivity over other PARP isoforms could be developed with little sacrifice in 
potency for the target enzymes. Initially, palladium-catalysed cross-coupling reactions 
were used to introduce a variety of 3-aryl groups bearing electron-withdrawing, 
electron-neutral or electron-donating substituents in the ortho, meta and para 
positions. In these compounds, the 5-amino group was retained for solubility. In addit-
ion, bulkier substituents were selected that would test the length and breadth of the 
hydrophobic pocket. Rapidly, with the ‘make and test’ approach to evolution of the 
inhibitors, positions-3 and -5 of the isoquinolin-1-one scaffold were explored at first 
with a variety of different substitutions introduced. Later, substitutions in position-4 
were also explored. Positions-6, -7 and -8 were deliberately left untouched, owing to 
the loss of activity suffered when substitutions are introduced here.82, 154 Alternative, 
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carbanion chemistry was then employed to afford a parallel series of inhibitors with 
modifications in the position-5 substituent. These were designed to probe this region 
of the nicotinamide-binding site for additional interactions; potentially enhancing the 
potency of inhibitors through optimisation of this section of the isoquinolin-1-one 
scaffold. This drug-discovery journey is discussed in-depth below. 
4.2 Early syntheses of 5-substituted isoquinolin-1-ones 
Early work in the Threadgill group focussed on the synthesis of a variety of 5-substit-
uted isoquinolin-1-ones, in the light of the apparent biological superiority of inhibitors 
with a ‘locked’ benzamide pharmacophore and a carbon substituent at position-5 with 
the potential for further expansion and transformation. Following the synthesis of 5-
cyanoisoquinolin-1-one (42) reported by Wenkert et al., which is initiated by the con-
densation of 1,3-dicyanotoluene (40) with ethyl formate under basic conditions, 
followed by an acid hydrolytic workup gave a mixture of a very poor yield of the 
desired 42 and a significant amount of the side-product 5-cyanoisocoumarin (41) 
(Scheme 2). 169  
 Alternative approaches saw 40 
selectively transformed to the 
corresponding monocyanobenz-
amide (43) using hydrogen per-
oxide-mediated hydration; how-
ever, further treatment with di-
methylformamide dimethyl acetal 
afforded a high yield of the benz-
oylformamidine (44), owing to 
condensation with the carboxamide 
alone (Scheme 2). Attempts to 
complete the cyclisation of this 
compound by condensation under 
acidic conditions gave the insoluble 
N1,N3-diacylformamidine (45) 
Scheme 2: Routes to 5-cyanoisoquinolin-1-one (42). 
Reagents and conditions: i, EtOCHO, KOBut; ii, H2O2, NaOH, 
EtOH, H2O; iii, (MeOH)2CHNMe2, DMF; iv, TsOH, PhMe; v, 
HCl, MeOH; vi, KOH, EtOH.  
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alone. The absence of any isoquinolin-1-ones in the crude mixture indicated that the 
carboxamide of 44 was acting as the sole nucleophile in the reaction. To avoid this, 
condensation of dimethylformamide dimethyl acetal with the methyl group of 40 gave 
46, with no opportunity for the cyano groups to take part. Cyclisation was then 
effected using methanolic hydrogen chloride, followed by an aqueous workup, giving 
the desired 42 in high yield. Interestingly, subsequent treatment of 42 in forcing 
aqueous acidic conditions failed to afford the corresponding ester; however, the nitrile 
was hydrolysed with potassium hydroxide in ethanol to give the carboxylic acid 47, 
which proved insoluble in common solvents and, as such, was not convenient for 
further transformations.  
It became desirable to access other functionalised 5-substituted isoquinolin-1-ones 
where diversity could be introduced at as late as stage in the synthesis as possible, 
ideally using parallel synthesis. It was thought that the Heck reaction would allow for 
the introduction of functionalised carbon chains at position-5 using metal–mediated 
carbon-carbon bond formation and 5-halogenated isoquinolin-1-ones were sought as 
key intermediates (Scheme 3). Starting with 2-iodobenzyl alcohol (48), oxidation with 
pyridinium dichromate provided the corresponding aldehydes 49a and 49b. 
Scheme 3: Synthesis of 5-substituted isoquinolin-1-ones 56a-c. Reagents and conditions: i, pyridinium 
dichromate, DCM; ii, CH2(CO2H)2, piperidine, pyridine; iii, HC(OEt)3, SOCl2, EtOH; iv, H2C=CHCO2H, 
Pd(OAc)2, Et3N, EtCN; v, SOCl2, DMF; vi, EtO2CCl, Et3N, Me2CO; vii, NaN3, H2O, 1,4-dioxane or acetone; viii, 
heat, Ph2O or (MeOCH2CH2OCH2CH2)2O; ix, CH2CHCO2H, Pd(OAc)2, Et3N, EtCN.  
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Condensation of 49a with malonic acid gave 
the desired iodocinnamic acid 52a. 2-Methyl-
benzaldehyde (49b) was first converted into 
its diethyl acetal 50 for efficient condensation 
to give 52b under Knoevenagel-Doebner 
conditions.170 The corresponding 2’-bromo-
cinnamic acid (52c) was accessed by an 
iodine-selective Heck coupling between 2-
bromoiodobenzene (51) and propenoic 
acid.171  
The 2’-iodocinnamic acid (52a) and 2’-
methylcinnamic acid (52b) were then converted into the corresponding acid chlorides 
53a and 53b and thence to the acid azides 54a and 54b (Scheme 3). The 2’-
bromocinnamic acid (52c) was similarly transformed using a mixed anhydride. From 
the acid azides 54a-c, the isoquinolin-1-ones 56a-c were obtained in a convenient one-
pot Curtius rearrangement and subsequent cyclisation at 280°C, using conditions first 
described by Eloy and Deryckere172 in 1969 and modified by using boiling dry tetra-
glyme instead of the original boiling diphenyl ether solvent. This alternative solvent 
allowed for the facile isolation of the product through precipitation in water during 
work-up whereas previously, using the original solvent, column chromatography was 
required for its removal. 171 
Heck coupling of 56c with propenoic acid in boiling propanenitrile gave the desired 
isoquinolinone-5-propenoic acid (57) in excellent yield (Scheme 3); however, other 
couplings with more functionalised 5-carbon alkenes were significantly less successful 
owing to migration of the C=C double bond and poor regioselectivity, leading to a 
complex separation of products and poor yields.137  
Although only moderately successful in affording the desired range of 5-substituted 
isoquinolin-1-ones, those compounds synthesised were screened for effects on PARP-1 
in vitro (Table 2). All isoquinolin-1-ones strongly inhibited PARP-1 at ca. 10 µM, with 
almost complete abrogation of enzyme activity by 5-iodoisoquinolin-1-one (56a) and 
5-bromoisoquinolin-1-one (56c).  
Table 2: Results of preliminary studies of 




5-substituent Inhibition of 
PARP-1 activity 
at ca. 10 µM 
47 CO2H 79% @ 13.2 µM 
56a  I 96% @ 8.0 µM 
57 C=CCO2H 81% @ 11.6 µM 
56c Br 95% @ 11.2 µM 
18      
(5-AIQ) 
NH2 92% @ 4.0 µM 
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4.3 Reliable synthesis of 5-aminoisoquinolin-1-one (5-AIQ) (18) 
Early studies recognised the superiority of isoquinolin-1-ones over the benzamide 
pharmacophore, owing to the constrained confirmation of the amide group greatly 
increasing the biological activity of these compounds.123, 133 Unfortunately, this benz-
amide pharmacophore, although largely responsible for the biological activity of these 
compounds, also renders them largely insoluble in water; a feature that is highly un-
desirable in any new drug. This pharmacophore owes its water-insolubility to the tend-
ency of compounds bearing this fixed lactam entity to form hydrogen-bonded dimers 
in the solid state leading to very-high-melting-point crystalline solids. 157 Good water 
solubility allows for rapid absorption of a drug molecule across biological membranes 
and contributes to good bioavailability. Not only this, good water-solubility also allows 
a drug to be administered to a patient via the oral route which is not only advanta-
geous in early clinical trials but also for the future utility of a new therapeutic entity. 
Although the early benchmark inhibitor 3-AB (11) had only moderate PARP-1 inhibitory 
activity, most early pharmacological studies used this inhibitor, not only because of its 
selectivity for its target enzyme but also due to its superior water-solubility compared 
with many other inhibitors available at the time.157 It became apparent that mainten-
ance of a water-solubilising entity alongside the pharmacophore needed for potency 
was vital in providing the balance needed for a successful inhibitor. With this in mind, 
enzyme-inhibitor interaction studies discovered that 4-ANI (22) (Refer to Figure 15 for 
structure) had superior inhibitory activity (IC50 = 0.18 µM) to that of 3-AB, whilst main-
taining water-solubility.164  
This desired balance between water-solubility and potency of a PARP-1 inhibitor led to 
the closer examination of 5-AIQ (18) which had been discovered by Suto et al. in 
1991,123 although not pursued as an interesting analogue at the time. 5-AIQ was a 
potent inhibitor of PARP-1, inhibiting the activity of the enzyme in a cell-free 
preparation from calf thymus (IC50 = 240 nM).123 
In another enzyme inhibition study, conducted by Watson et al.,137 5-AIQ 
demonstrated an IC50 of ca. 300 nM, which was comparable to that reported by Suto et 
al.,123 even though a different assay and different source of enzyme were employed 
(Table 2). For this particular assay, PARP was extracted from nuclei isolated from L929 
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cells (mouse areolar and adipose tissue cells) and PARP activity was estimated by the 
incorporation of radioactive [3H]adenosine-NAD+ into acid-insoluble 
macromolecules.137 Not only this but selectivity studies conducted at the same time 
revealed that 5-AIQ has over 200-fold selectivity for inhibiting PARP activity over 
inhibiting the mono-ADP-ribosylating activity of diphtheria toxin (IC50 ca. 300 nM 
compared with ca. 80 µM).  
The potential biological and pharmacological superiority of this new inhibitor deman-
ded multigram quantities and, as there was no commercial supply of the inhibitor 
available, an efficient synthesis became important. It was also likely that, when com-
mercial supplies did become available, they would be prohibitively expensive, which 
proved to be the case (1.0 mg = £56.60; Sigma-Aldrich catalogue). Much of this devel-
opmental work on both the synthesis and biological potential of this new inhibitor was 
conducted in the Threadgill laboratory and led to the publication of numerous papers 
and the development of expertise on the manipulation and chemical behaviour of 
these heterocycles.116, 135, 137, 140, 141, 163, 165-167, 173 At this point in time, although there 
was an abundance of available literature on isoquinolin-1-ones, there had been very 
little research performed on 5-aminoisoquinolines.  
Early attempts to synthesise 5-AIQ (18) reported by Wenkert et al. in 1964 had started 
with N-oxidation of 5-nitroisoquinoline (58) with hydrogen peroxide in acetic acid, foll-
owed by an unreliable Polonovski rearrangement triggered by acetic anhydride, to 
afford 5-nitroisoquinolin-1-one (60) (Scheme 4).169, 174 This reaction, first reported by 
the Polonovski brothers in 1927,175 describes the rearrangement of one alkyl group of 
an alkaloid N-oxide attached directly to a nitrogen atom in the presence of either 
acetic anhydride or acetyl chloride. The trapping of the iminium ion intermediate with 
an acetate nucleophile, formed following the activation of the tertiary amine N-oxide, 
is known as the Polonovski rearrangement. Subsequent reduction of the nitro of 60 led 
to low overall yields of 5-AIQ (18).137, 169 In this sequence, the limiting factor is the un-
reliability of the rearrangement; the other steps were satisfactory. Following the inves-
tigation of the Polonovski rearrangement as a route towards 5-AIQ, the thermolytic 
Curtius rearrangement and cyclisation was then explored by Watson et al.137 for the 
general synthesis of 5-substituted isoquinolin-1-ones (Scheme 3). Unfortunately, this 
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route was also not amenable to the synthesis of 5-nitroisoquinolin-1-one; the desired 
pre-cursor to 5-AIQ. Although in the first step the Curtius rearrangement progresses 
well with the 2’-nitrocinnamoyl azide, the subsequent required cyclisation is prevented 
by the strongly electron-withdrawing nature of the nitro group. 137, 172 
As none of the aforementioned synthetic routes had been successful in providing the 
required multigram quantities of 5-AIQ in sufficient purity or yield, several more appro-
aches were investigated (Scheme 4). It was proposed that the introduction of the iso-
quinolin-1-one 2-N and 3-C could be achieved at a higher oxidation level, as cyanide.135 
Initially, a radical bromination at the Ar-Me of 2-methyl-3-nitrobenzoate (61) gave 62 
in high yield.176 The displacement of the bromine atom using cyanide was attempted 
using two separate methods. Firstly, nucleophilic substitution with cyanide, as tetra-
ethylammonium cyanide, gave 63 in good yield. Alternatively, treatment with potas-
sium cyanide and tetrabutylammonium bromide in methanol gave the desired product 
in modest yield; however, this was contaminated with a trace amount of a side prod-
uct, 3-methoxy-5-nitroisoquinolin-1-one. This side-product was thought to have occur-
red due to a Pinner reaction between the solvent and nitrile component of 63, 
followed by attack of the imidate N on the nearby ester.  
Scheme 4: Preparations of 5-AIQ (18) by four routes. Reagents 
and conditions: i, H2O2, AcOH; ii, Ac2O, ∆; iii, H2, Pd/C, EtOH, 
HCl; iv, DMFDMA, DMF, ∆; v, wet silica; vi, NH3, 
MeOCH2CH2OH, ∆; vii, Br2, (PhCO2)2,CCl4, hv, reflux; viii, 
Et4NCN, MeCN or KCN, Bu4NBr, MeOH; ix, Bu
i
2AlH, DCM, -78C; 
x, HNO3, H2SO4; xi, AcOH, H2O; xii, RCOCl, pyridine, 90°C; xiii, 
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Further transformation of 63 to the desired isoquinolin-1-one was achieved by 
selective reduction of the nitrile with DiBAL-H at low temperature and cyclisation of 
this intermediate imine with the ester afforded 60 in 23% overall yield (Scheme 4).135 
The tolerance of this route to steric bulk was explored by DiBAL-H reductions of two 
further analogues of 63, one bearing a benzyl group attached to the methylene group 
of 63 by deprotonation with lithium hexamethyldisilazide, followed by quench with 
benzyl bromide to give 64. In the case of 64, reduction with DIBAL-H gave only the 
aldehyde 65 leaving the nitrile group intact, thus allowing no potential for cyclisation 
towards the desired isoquinolin-1-ones. It would appear that the approach of the bulky 
DiBAL-H is hindered by the presence of the large benzyl group, preventing any 
reduction of the nitrile group. Only slow reduction of the ester is observed to reveal 
the corresponding aldehyde.  
The isopropyl ester 66 was explored as a bulkier starting material (Scheme 4). Bromin-
ation of 61 and subsequent conversion to the nitrile afforded the desired intermediate 
66 as for 63. Unfortunately, treatment of this intermediate with DiBAL-H at -78°C gave 
only 5-nitroisoquinoline (58), formed by reduction of both the ester and the nitrile. 
Unusually, the increased steric bulk of the ester appears to enhance the likelihood of 
its reduction. This occurrence is likely to be due to the relative rate with which each 
functionality is reduced by DiBAL-H. In the case of 63, reduction of the nitrile is rapid 
and is followed by intramolecular attack of the intermediate imine which is also likely 
to occur at very quickly. Reduction of the simple ester in comparison is slow and 
cannot compete. In contrast, although the initial reduction of the nitrile of 66 occurs 
rapidly, subsequent intramolecular attack by the imine nucleophile is hindered by the 
bulky isopropyl ester, and as such allows time for the ester itself to reduce to the 
corresponding aldehyde prior to any cyclisation occurring. Once transformed to the 
aldehyde, cyclisation can only afford 58.  
For several years, the most useful synthesis was condensation of 61 with dimethyl-
formamide dimethylacetal (DMFDMA), reported by Askam and Keeks177 in 1969, to 
give the enamine methyl 2-(2-Z-dimethylaminoethenyl)-3-nitrobenzoate (67) (Scheme 
4). Hydrolysis of the intermediate 67 and cyclisation during chromatography (through 
sufficient acidic catalysis by silica gel) revealed the functionalised isocoumarin 68. It 
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was then rationalised that conversion of 68 to the desired isoquinolin-1-one would be 
achievable by treatment with ammonia at high temperatures but in the absence of 
high pressure, in contrast to previously reported conditions.137, 178 As anticipated, 
replacement of the heterocyclic O in 68 with ammonia did afford 5-nitroisoquinolin-1-
one (60), whence reduction gave the desired reduced product 18.56 This improved 
synthesis affords an 18% overall yield of 5-AIQ in with no requirement for difficult 
reagents or reaction conditions.56 
Interestingly, whilst exploring the scope and mechanistic detail of this route it was 
found that the more bulky isopropyl ester 72, although it condenses in much the same 
manner as its non-bulky counterparts e.g. 61 to give 67, fails to cyclise proficiently 
during chromatography on silica gel leading to very poor yields.165 This is probably due 
to simple steric obstruction by the bulky isopropyl group during the cyclisation step.165  
In an attempt to introduce substituents at position-3 using the same route, analogous 
condensation of the esters 61 and 72 with dimethylacetamide dimethylacetal (1, 1-di-
methoxyethyldimethylamine, DMADMA) did not proceed in the same way as with 
DMFDMA. Surprisingly, instead of the expected pale yellow 3-methyl-5-nitroisocoum-
arin (68), a deep red solid was isolated 
from this reaction, later identified as the 
tri-substituted naphthalene 76.165 The 
proposed mechanism underlying this 
transformation is shown in Scheme 5. 
The initial condensation of 61 and 72 
with DMADMA occurs in an analogous 
fashion to that with DMFDMA, with the 
identical intermediate enamines 74a 
and 74b identified. At this point 
however, divergence occurs, due to the 
ability of the C-Me enamine 74a-b to 
tautomerise to the alternative enamine 
75a-b, thus providing an additional 
nucleophilic carbon conveniently 
Scheme 5: Two routes from reactions with 2-methyl-3-
nitrobenzoate esters and orthoamides.165 Reagents 
and conditions: i, DMFDMA, DMF, 150°C, 16h; ii, SiO2, 
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located to attack the ester carbonyl.165 Based upon this mechanistic study, 
condensations with 61 and dimethylacetals of N,N-dimethylbenzamides would be 
expected to lead to isocoumarins, due to the absence of a reactive α-methylene or α-
methyl; however the preparation of these N,N-dimethylbenzamide acetals is difficult. 
Although an interesting outcome and indeed still the most efficient synthesis of 5-AIQ 
until 2011, these mechanistic studies precluded this route as a method of incorporat-
ing substituents into position-3 of the isoquinolin-1-one framework. As such, this route 
had only moderate utility for the purposes of refinement of inhibitors; a feature crucial 
for further development. 
Very recently, a new synthesis improved the yield and obviated the need for scale-
limiting steps such as chromatography in preparing multigram quantities of 5-AIQ. 
Sunderland et al., in the quest for synthesising selective inhibitors of PARP-2 required a 
large-scale preparation of 5-AIQ which would allow for introduction of diversity at as 
late a stage as possible in the synthesis.116 Remarkable selectivity for PARP-2 had been 
claimed by Pellicciari et al. for a series of 5-benzoyloxyisoquinolin-1-ones, 5-phenacyl-
oxyisoquinolin-1-ones, and 3,4-dihydroisoquinolin-1-ones.179 Many of these analogues 
bear large position-5 benzoyloxy or phenacyloxy groups, thought likely to be less able 
to bind to PARP-1 optimally due to their larger bulk not fitting into the small cavity in 
this region of this isoform, compared with the larger cavity in the same region of PARP-
2; this structural feature thus explains the selectivity of these larger analogues for the 
latter enzyme. 
The new synthetic method began with selective nitration, under strongly acidic condit-
ions of 1-chloroisoquinoline (69) to afford 1-chloro-5-nitroisoquinoline (70) only 
(Scheme 4).116 Direct nitration of isoquinolin-1-ones would occur at position-4. In 
contrast, in 69, the heterocyclic nitrogen is protonated, deactivating the nucleophilic 
reactivity of the 4-position. Consequently, nitration occurs selectively at the 5-C in 
excellent yield. In addition, although both the 8-C and the 5-C are likely to be the most 
nucleophilic of the carbocyclic ring, the 8-C is likely to be sterically blocked by the large 
peri-chlorine atom.  
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The isoquinolin-1-one was then revealed by hydrolysis of 70 by heating with acetic acid 
to give 60 in high yield, whence catalytic hydrogenation of the nitro group afforded 5-
AIQ (18).116 This new route benefited from two intermediate recrystallisations and no 
column chromatography and is hence a high-yielding and reproducible synthesis (54% 
overall yield) with potential for scale-up.116 Although highly successful in delivering a 
small library of 5-acylaminoisoquinolin-1-one inhibitors (71a-n; Scheme 4) aimed at 
selective inhibition of PARP-2, this route is not amenable to further substitutions 
around the isoquinolin-1-one framework. As such a new synthesis was required that 
would be adaptable to the incorporation of position-3 substitutions in addition to an 
existing substitution in position-5.116  
4.4 Previous synthetic approaches to 3-substituted 5-AIQs 
It became imperative in the drug-discovery campaign towards selective and potent 
inhibitors of PARP-1 to expand on the 5-AIQ skeleton and to explore the potential of 
inhibitors with substitutions around the heterocyclic ring; in particular in the position-3 
direction. This was, in part due to the observation that several clinical candidates 
including rucaparib (15) and veliparib (16) (Refer to Figure 15 for structures) that had 
bulky substitutions off the heterocyclic core in this position-3 ‘space’ were anticipated 
to be making additional interactions in the enzyme catalytic pocket and thus enhancing 
their inhibitory potential.  
The facile introduction of substituents into position-3 of the 5-AIQ core was thus 
fundamental to the development of this library of inhibitors and, from a synthetic 
perspective, is most efficiently achieved at a late stage in the synthesis. Five indep-
endent routes have been reported previously by the Threadgill group for the synthesis 
of 5-nitro-3-phenylisocoumarin (79b), which would lead to 3-phenyl-5-AIQ (25) by 
replacement of the heterocyclic oxygen with nitrogen.  
One early method, in the campaign to introduce a 3-methyl group into the 5-AIQ 
framework, started with suitable 1,2,3-trisubstituted benzenes. Coupling of 2-
bromobenzoic acid had been attempted with various β-diketones and β-ketoesters in 
the presence of copper catalysts in a Hurtley reaction to form the corresponding 
arylated β-dicarbonyl compounds. 141 In this reaction, reported in 1929 by Hurtley, the 
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copper-catalysed displacement of bromine in ortho-bromobenzoic acid occurs with the 
enolates of β-diketones. 180 Either copper-bronze or copper acetate is required for the 
reaction; whilst the latter is reported to be the more aggressive catalyst, the former 
was shown to deliver purer products and was thus the catalyst of choice at the time.180 
More recently, several mechanistic studies have revealed that the carboxylate of the 
aryl component is essential, and that bromine is the optimum halogen for displace-
ment during the reaction.181, 182 Ames and Ribeiro extended the reaction further by 
forcing a retro-Claisen condensation and ring closure on the Hurtley products with 
sodium chloride at 170°C to afford 3-substituted isocoumarins in moderate yields from 
a two-step synthesis.183 This synthetic route has recently been shortened further to a 
one-pot preparation of isocoumarins reported by Cai et al., where the reaction of 2-
iodo- or 2-bromobenzoic acid with β-diketones, in the presence of copper(I) iodide and 
potassium phosphate in dimethylformamide, is performed under forcing conditions in 
a sealed tube.184 At this stage, no 5-substituted analogues had been reported.  
To address this problem, Woon et al. attempted to expand the scope of this reaction 
to incorporate a 5-nitro substituent whilst obviating the need for sealed-tube condit-
ions. 141 In a preliminary study with 2-bromo-3-
nitrobenzoic acid (77) and 1-(4-trifluoro-
methylphenyl)butane-1, 3-dione (78a), under 
classical Hurtley reaction conditions, in addition to 
a modest yield of the desired isocoumarin 79a, 
side-products containing both ester and mono-
ketone groups were isolated. It was rationalised 
that the base used, ethoxide, may be too 
nucleophilic and cause retro-Claisen cleavage of 
the starting β-diketone through direct attack of 
the carbonyls of 1-(4-trifluoromethylphenyl)-
butane-1,3-dione (Scheme 6).141 A less 
nucleophilic base, potassium tert-butoxide in 
boiling tert-butanol, prevented this premature 
cleavage from occurring. Subsequently, tandem 
Scheme 6: Tandem Hurtley-retro-
Claisen cyclisations in the absence of 
forcing sealed tube conditions of 77 
with various methyl β-diketones to 
afford 3-substituted-5-nitroisocoum-
arins.141 Reagents and conditions: i, Cu 
powder, KOBut, reflux.  
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Hurtley-retro-Claisen-cyclisation reactions of this starting benzoic acid 77 and various 
methyl β-diketones led to a mixture of 3-substituted-5-nitroisocoumarins (Scheme 6, 
79a-h). 141 
Although this was a good conversion to the desired intermediates, which were readily 
separable with column chromatography, the yields were modest.141 Diversity in the 
final structure had to be introduced at the very start of the synthesis through the 
various β-diketones, each of which had to be synthesised in Claisen condensations. In 
addition, 3-(electron-poor aryl)isocoumarins could not be prepared by this method.141, 
185, 186 These intermediates were transformed to the corresponding 3-substituted-5-
nitroisoquinolin-1-ones in good yield through treatment with ammonia in boiling 2-
methoxyethanol. Treatment of these isoquinolin-1-ones with tin(II) chloride afforded 
the desired target 3-substituted-5-aminoisoquinolin-1-ones. 
It was claimed by Stephens and Castro in 1963 that the Cu-catalysed Castro-Stephens 
coupling of 2-iodobenzoic acid with Cu-C≡C-Ph was followed by in situ cyclisation to 
give 3-phenylisocoumarin via the 6-endo-dig route.187 This claim was later corrected to 
state that the product was the benzylidine phthalide, formed via 5-exo-dig cyc-
lisation.188 Further to this, isocoumarins have been synthesised using this route; how-
ever, mixtures with phthalides formed via 5-exo-dig cyclisation were often obtain-
ed.189, 190 It was postulated by Woon et al. that the introduction of a strongly electron-
withdrawing nitro group ortho to the alkyne might affect the electron distribution in 
the alkyne and favour the desired 6-endo-dig cyclisation.166 The effect of this would be 
to increase the electrophilicity of the alkyne carbon distant from the nitro group.  
To test this hypothesis, 2-iodo-3-nitrobenzoic acid (80) was treated with copper(I) 
phenylacetylide (prepared from phenylethyne and copper(I) iodide) under classical 
Castro-Stephens187 conditions (boiling pyridine), followed by a conventional work-up 
to give the single cyclisation product 5-nitro-3-phenylisocoumarin (79b) (Scheme 7). In 
this one-pot synthesis, Castro-Stephens coupling was followed by in situ Cu-catalysed 
6-endo-dig cyclisation ring closure to give the isocoumarin. Unfortunately, this 
apparently convenient synthesis was limited to 3-phenyl, 3-(4-methylphenyl)- and 3-(4-
methoxyphenyl)isocoumarins; diversity was also introduced early, through the phenyl-
ethynes, which were not generally commercially available.166 
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Due to the apparent limit-
ations of the above route, 
an alternative cyclisation 
strategy was attempted in 
the quest for a synthesis 
adept at allowing diversity 
in the final analogue. 
Sonogashira coupling of 
the iodoarene 81 with 
phenylethyne gave the 
disubstituted alkyne 82a, 
albeit in poor yield 
(Scheme 7). Cyclisation, catalysed by Hg2+ under acidic conditions, gave 3-phenyliso-
coumarin (79b).166 This sequence, however could not be extended to Hg2+-catalysed 
cyclisation of analogous alkynes, such as methyl 3-nitro-2-trimethylsilylethynyl-
benzoate (82b), which hydrated to afford only methyl 2-acetyl-3-nitrobenzoate in 
modest yield following chromatography.166  
Cyclisation of the alkyne 82a, again in the 6-endo-dig mode, with an alternative 
electrophile, iodine monochloride, afforded 4-iodoisocoumarin 83, from which the 
iodine was removed reductively, giving 79b.166 Again, only the phenylalkyne 82a gave 
an identifiable product; the corresponding products from the trimethylsilylalkyne 82b 
and the monosubstituted alkyne 82c showed no evidence of either isocoumarins or 
isobenzofuranones.166 Alternatively, phenylselenyl chloride also achieved this 
cyclisation; on this occasion, both the phenylalkyne 82a and trimethylsilylalkyne 82b 
analogues underwent 6-endo-dig cyclisation to afford the corresponding isocoumarins; 
however, the monosubstituted alkyne 82c failed to react.166  
More recently, a series of 4-acyl-5-nitroisocoumarins were prepared under Friedel-
Crafts condition (Scheme 8).167 It was expected that Friedel-Crafts acylation of 5-
nitroisocoumarin (68) would lead to 4-substituted 5-nitroisocoumarins due to 
deactivation of the carbocyclic ring by the nitro group, leaving the 4-position as the 
most nucleophilic, as it is formally an enol ester.167 Unexpectedly, treatment of 68 with 
Scheme 7: Castro-Stephens and Sonogashira couplings towards 3-
substituted 5-AIQs.166 Reagent and conditions: i, PhCCCu, pyridine, 
reflux; ii, MeOH, H2SO4;iii, (PPh3)2PdCl2, PhCCH or HC≡CSiMe3, CuI 
Pri2NH, THF; iv, HgSO4, H2SO4, acetone, ∆; v, ICl, DCM; vi, HCO2H, 
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aromatic acyl chlorides gave the 3-aryl-5-nitroisocoumarins (79a-c, e and 90a-b) under 
Friedel-Crafts conditions and not the 4-acylisocoumarins as expected. Mechanistic 
studies revealed that although the first step in the reaction is the expected Friedel-
Crafts acylation of position-4 to generate 85 (Scheme 8), this is then susceptible to ring 
opening by attack of either a chloride or, possibly, triflate nucleophile at the carbonyl 
carbon of 85 leading to 86. Subsequent tautomerisation to the alternative enol 87 
allows for cyclisation to occur, leading to the 4-formyl-3-phenylisocoumarins 88a-f. 
The loss of the formyl group prior to isolation of the observed product (79a-c, e and 
90a-b) is likely to occur either through direct 
decarbonylation of the aldehyde or oxidation to 
the carboxylic acid 89a-f and subsequent 
decarboxylation under forcing conditions. The 
reaction conditions were optimised for a 
temperature of 150°C, SnCl4 as Lewis acid, in 
nitrobenzene as solvent.  
Unfortunately, this new route to 3-aryl-5-nitro-
isocoumarins was limited to aroyl chlorides 
Scheme 9: The two final steps common to 
all five routes towards 3-substituted 5-
aminoisoquinolin-1-ones. Reagents and 
conditions: i, NH3, MeOCH2CH2OH; ii, H2, 
Pd/C, EtOH or SnCl2, EtOH. 
Scheme 8: Formation of 3-aryl-5-nitroisocoumarins 79a-c, e and 90a-b from 68 and aroyl chlorides 
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carrying electron-neutral and electron-withdrawing substituents; electron-rich benzoyl 
chlorides and aliphatic acyl chlorides failed to reaction in the Friedel-Crafts step.167 In 
all routes towards 3-substituted 5-aminoisoquinolin-1-ones, two further high-yielding 
transformations (conversion of the isocoumarins 79a-c, e and 90a-b to isoquinolin-1-
ones and reduction of the nitro group) were required to generate the final compounds 
25, 26 and 91a-d (Scheme 9).  
4.5 Previous synthetic approaches to 4-substituted 5-AIQs 
In the evolution of design of 
isoform-selective inhibitors of the 
PARPs, it became desirable to 
extend this campaign to include 4-
substituted 5-aminoisoquinolin-1-
ones. This was in part due to 
exploration of all positions around 
the heterocycle but examples of potent inhibitors already reported in the literature 
included the 4-benzylphthalazin-1-ones 92, the tricyclic lactams 93 and the benzimid-
azole-4-carboxamides 94 (Figure 27).163 For each type of inhibitor, it could be argued 
that the substitution away from the skeleton of the heterocycle in each case, is orient-
ated in the 4-position (isoquinoline numbering). Specifically, the Threadgill group 
focussed on 4-methyl and 4-benzyl-5-aminoisoquinolin-1-ones.163 Following a report 
that the isoquinolin-1-one ring could be formed through cyclisation of N-allyl-2-iodo-
benzamides using an intramolecular Heck reaction with a palladium catalyst, this 
approach was applied to the synthesis of 4-alkyl-5-nitroisoquinolin-1-ones.191 Previous 
syntheses had reported that the products of these cyclisations were either direct Heck 
products (4-methylideneisoquinolin-1-ones) or products of Heck coupling with migrat-
ion of the C=C bond observed before or after the coupling (4-methylisoquinolin-1-
ones).191 Up to this point, none of the studies had used a 3-substituted N-allyl-2-iodo-
benzamide. Moreover reports as to how and why migration into the heterocyclic ring 
occurs, which would be required for the desired analogues, were ambiguous and 
required further exploration.163  
Figure 27: Three different types of structural analogues; the 4-
benzylphthalazin-1-ones 92, the tricyclic lactams 93 and the 
benzimidazole-4-carboxamides 94 which are all reported to be 



























mol %) and triethylamine 
in boiling acetonitrile led 
to a high yield (78%) of an 
inseparable mixture of the 
isomers 96 and 97 in the 
molar ratio 1:2 
respectively (Scheme 10).163 It was rationalised that the former isomer was made by 
palladium-catalysed migration of the C=C double bond into conjugation with the amide 
nitrogen before or after cyclisation whereas the latter isomer was formed by direct 
Heck coupling. However, no interconversion of isomers was evident during exposure of 
the products to the cyclisation conditions with various ligand/ catalyst conditions for 
prolonged periods of time and at elevated temperatures.163  
Adapting to the synthesis of the 4-benzylisoquinolin-1-one series, an alternative N-
protecting group, benzhydryl, was utilised to provide steric bulk. Treatment of N-
cinnamyl-N-diphenylmethyl (98) with tetrakis(triphenylphosphine)palladium(0) (5 mol 
%) and triethylamine in boiling propanenitrile for 2 days led to a moderate yield of an 
inseparable mixture of the isomers 99 and 100. Furthermore, neither the allyl nor 
benzhydryl protecting groups could be removed. 163 
It was postulated that cylisations of the corresponding secondary amides might be 
more successful (Scheme 11).163 Reaction of the monoallyl amide 101 with Pd(PPh3)4 
under the same conditions gave 
a somewhat improved 1:1 ratio 
of 4-methyl-5-nitroisoquinolin-1-
one (102) and 4-methylene-5-
nitro-3,4-dihydroisoquinolin-1-
one (103).163 The conditions for 
this reaction were optimised and 
Scheme 11: Palladium-catalysed Heck cyclisations of secondary 
N-allyl amides.163 Reagents and conditions: i, (PPh3)4Pd (5 
mol%), Et3N, Bu4NCl, DMF, 150°C (rapid heating), 16 h 
















Scheme 10: Palladium-catalysed Heck cyclisations of N-allyl and N-
cinnamyl tertiary amides.163 Reagents and conditions: i, (Ph3P)4Pd, Et3N. 
MeCN, 80°C, 48 h; ii, (Ph3P)4Pd, Et3N, EtCN, 100°C, 48 h.  
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it was found that rapid heating to 150°C during < 1 min led to solely 102 in the mixture; 
slow heating to the same temperature led to significant amounts of 103 in the 
mixture.163 Prolonged heating at 150°C following rapid heating led to the destruction 
of 102 in the crude reaction mixture and as such careful timing was required.163 
4.6 Development of syntheses in the current project 
In the current project, a series of 3-substituted isoquinolin-1-ones was required to 
explore fully the hydrophobic pocket present adjacent to the nicotinamide-binding site 
in tankyrase-1/-2. As none of the previous routes towards 5-AIQ allowed for the late 
introduction of diverse functional groups at position-3, palladium-catalysed couplings 
to suitable 3-haloisoquinolines were investigated. These studies were guided by earlier 
work on introduction of alkyl and aryl groups to the 4-position.140  
It was anticipated that a halogen could be introduced into the starting material 5-nitro-
isoquinolin-1-one and that this halogen would then provide an appropriate ‘handle’ for 
palladium-catalysed reactions to introduce alkyl and aryl groups onto the scaffold 
(Scheme 12).140 Although other groups had achieved selective halogenation of isoquin-
olin-1-ones at position-4, no structures had been reported bearing a 5-nitro substit-
uent.192, 193 Iodination at position-4 of 5-nitroisoquinolin-1-one proved impossible.140 
Fortunately, bromination of 5-nitroisoquinolin-1-one (104) with bromine in hot acetic 
acid occurred readily, affording the desired 4-bromo-5-nitroisoquinolin-1-one (106) 
albeit contaminated by the 3-hydroxy-3,4-dihydro compound 105.140 
Unfortunately, attempts to cross-couple with 4-bromo-5-nitroisoquinolin-1-one (106) 
using Sonogashira, Stille and Suzuki reactions failed under a wide variety of conditions 
(Scheme 12).140 To rule out obstruction by the bulky peri-nitro group as the reason for 
the failure, the nitro group was reduced to give the corresponding smaller 5-amino 
compound 107.140 Again, all attempted palladium-catalysed couplings to this alter-
native starting material also failed and it was rationalised that the poor solubility of 
these compounds in suitable reaction solvents was responsible.140 
Masking the fixed lactam, known to confer poor solubility to the pharmacophore, 
might alleviate this problem and allow for coupling reactions to proceed in standard 
solvents. At first, the lactam was proposed to be disguised as a 1-methoxyisoquinoline. 
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This was effected by treatment of 106 with the Vilsmeier reagent to furnish the 1-
chloroisoquinoline 108 (Scheme 12). Displacement of the chloride with methoxide 
gave the desired 4-bromo-1-methoxy-5-nitroisoquinoline (109). Although initial Stille 
couplings using the traditional Pd(PPh3)4 catalyst failed, the superior Pd2(dba)3 / SPhos 
catalyst / ligand system furnished the coupled product 110 in 72% yield. This new 
catalyst / ligand system was introduced by Buchwald in pursuit of enhancing the yields 
of Suzuki couplings.194 Similar success was also observed with Suzuki-Miyaura coup-
lings of 109 with phenylboronic acid and with 4-triflurophenylboronic acid using this 




oline (114).140 Reagents 
and conditions: i, BnOH, 
NaH, DMF, 100°C; ii, 4-
MeOPhB(OH)2, Pd2(dba)3, 
SPhos, K3PO4, PhMe, 
100°C; iii, Pd/C, H2, EtOH; 
iv, phenanthrene-9-boron-
ic acid, Pd2(dba)3, SPhos, 
K3PO4, PhMe, 100°C.  
Scheme 12: Palladium-catalysed couplings to 4-bromo-1-methoxy-5-nitroisoquinoline (109) and subsequent 
transformations to the target compounds 112 and 113a-b.140 Reagents and conditions: i, Br2, AcOH, 60°C; ii, 
SnCl2, EtOH, 80°C; iii, (COCl)2, DMF, (CH2Cl)2, 80°C; iv, Na, MeOH, reflux; v; SnMe4, Pd2(dba)3, SPhos, PhMe, 
100°C; vi, PhB(OH)2, 4-F3CPhB(OH2) or 4-OMePhB(OH)2, Pd2(dba)3, SPhos, K3PO4, PhMe, 100°C; vii, aq. HBr, 
80°C; viii, H2, Pd/C, EtOH, aq. HCl; ix, aq. HBr, 50°C; x, H2, Pd/C, EtOH.  
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new catalyst / ligand system. All successfully coupled compounds (110, 111a and 111b) 
were demethylated with hydrogen bromide, affording the unmasked lactam, followed 
by catalytic hydrogenation of the 5-nitro to afford the target compounds (112, 113a 
and 113b). 
For a number of analogues, including 1-methoxy-4-(4-methoxyphenyl)-5-nitroisoquin-
olin-1-one (111c), demethylation with hydrogen bromide was anticipated to occur at 
the 1-methoxy group and the 4’-methoxy substituent. There was thus a requirement 
for an alternative protecting group and a benzyloxy group was investigated (Scheme 
13). Treatment of 108 with sodium benzyloxide in boiling DMF gave the required 1-
benzyloxy compound 114 but with significant amounts of 115 also isolated. Following a 
successful Suzuki-Miyaura coupling of 114 with 4-methoxyphenylboronic acid to afford 
116, removal of the benzyloxy protecting group and reduction of the 5-nitro group was 
achieved in one step to give 113c. The tolerance of this newer more bulky protecting 
group on 114, in addition to a peri-nitro group to the incorporation of large bulky 
arenes was investigated with an attempt to couple to phenanthrene-9-boronic acid. 
Preparation of highly hindered biaryls using Suzuki-Miyaura cross-coupling reactions 
has historically been challenging.194 Pleasingly, this coupling, performed under 
standard conditions with the new catalyst / ligand system was successful; a moderate 
yield (42%) of 117 was achieved.140 
Interestingly, biological evaluation of 113b against PARP-1 and PARP-2 revealed that, 
although its inhibitory activity against the former was somewhat weaker than that of 
5-AIQ (18), activity against the latter was somewhat greater, indicating a promising 
degree of selectivity for this isoform (7.6-fold selective for PARP-2 over PARP-1).140  
4.7 Three common first steps 
Adapting this sequence, 3-chloro-1-methoxy-5-nitroisoquinoline (121) was selected as 
a common intermediate. In this molecule, the 1-methoxy represents the masked 
(solubilised) lactam and the nitro is the precursor for the 5-amino of the target 
compounds. Although chlorine is not generally reactive enough to be a coupling 
partner in Suzuki-Miyaura cross-couplings, on this occasion it is appropriately activated 
by the adjacent ring-nitrogen, as this withdraws electron-density from the 3-carbon.  
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  Firstly, synthesis of this key intermediate was required, whence Suzuki couplings 
would allow for incorporation of diversity into the target analogues at as late a stage in 
the synthesis as possible. The first three steps are common to the synthesis of all 
target derivatives using the commercially available starting material, 1, 3-dichloroiso-
quinoline (119) and represent a good opportunity for scale-up and optimisation.  
Under strongly acidic nitrating conditions, selective nitration of 119 was achieved at 
position-5, owing to the deactivation of the heterocyclic ring by protonation of the ring 
nitrogen (Scheme 14). The greatest electron density is therefore at positions-8 and -5; 
however, due to steric hindrance by the chlorine in position-1, electrophilic aromatic 
substitution is observed only at position-5, with no multiple nitration encountered. 
Interestingly, nitration of isoquinoline under similar conditions is well known to afford 
a mixture of 5-nitroisoquinoline (major isomer) and 8-nitroisoquinoline (minor 
isomer).195, 196 This demonstrates the significant steric influence of the 1-chloro atom 
on the approaching nitronium ion. The reaction of 120 with sodium methoxide is also 
regioselective for position-1, with methoxide anion adding at this position, followed by 
elimination of chloride, providing a convenient mask for the lactam. The reason for this 
selectivity at position-1 is poorly understood; however, it may, in part, be due to the 
benzylic nature of position-1, with resonance forms of the Meisenheimer intermediate 
retaining aromaticity. The location of the methoxy group of 121 was confirmed by 2D 
NMR studies, which show a nuclear Overhauser effect (nOe) between 8-H and the 
OCH3 protons. A cross peak between 1-C and the OCH3 protons is also seen in HMBC 
experiments.  
4.8 Suzuki-Miyaura cross-coupling reactions 
The remaining chlorine at position-3 in 121 now provides an ideal coupling partner for 
a Suzuki-Miyaura cross-coupling reaction. Pioneered in 1979 by A. Suzuki and N. 
Miyaura, this reaction was first reported for the stereoselective synthesis of arylated E-
Scheme 14: Synthesis of the key 
intermediate 1-methoxy-3-chloro-
5-nitroisoquinoline (121). Reagents 
and conditions: i, H2SO4, HNO3, 0°C 
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alkenes by the reaction of 1-alkenylboranes with aryl halides in the presence of a 
palladium catalyst (Scheme 15).197 
This apparently facile and powerful synthetic reaction between an organoboron 
compound and an organic halide or triflate generates sp2-sp2 carbon-carbon bonds and 
provides the synthetic tools for the potential generation of an enormous number of 
organic molecules. 198, 199 Indeed, the contribution and central importance of this 
reaction to organic chemistry was recognised in 2010 with the award of the Nobel 
Prize in Chemistry to Heck, Negishi and Suzuki.199 An example of the importance of the 
Suzuki coupling in the pharmaceutical industry is the efficient synthesis of the potent 
natural anti-tumour agent (+)-dynemicin A (124) which uses this cross-coupling 
reaction in a key carbon-carbon bond-forming step (Scheme 16).200 
The Suzuki-Miyaura cross-coupling reaction has many advantages over some other 
well-known coupling reactions, such as the Stille coupling, including the mild reaction 
conditions that can be adopted, the commercial availability of a huge variety of ‘pre-
decorated’ boronic acids, the relative ease of removal of inorganic by-products of the 
reaction and the 
tolerance of water by 
many of the starting 
materials. In addition, 
the tolerance of a wide 
variety of functional 
groups on the boronic 
acid components make 
them ideal for incor-
porating diversity at as 
late a stage in the 
Scheme 16: An efficient 
Suzuki coupling towards 
the overall synthesis of 
the anti-tumour agent 
(+)-dynemicin A (124).200  
Scheme 15: Simplified view of the Suzuki-Miyaura cross-coupling reaction.197 R1 = alkyl, allyl, alkenyl, 
aryl; R = alkyl, OH, O-alkyl; R2 = alkenyl, aryl, alkyl; X = Cl, Br, I, OTf; base = Na2CO3, K3PO4, Cs2CO3, K2CO3.  
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synthetic process as possible. Further to this these organoboron compounds benefit 
from being highly stable, weakly nucleophilic, have low toxicity and pose a minimal 
threat to the environment; an advantage in the progress towards ‘greener’ chemistry. 
199  
The catalytic cycle, shown in Scheme 17, can be split into four distinct stages. Firstly, 
the oxidative addition of the organohalide to the Pd(0) species occurs (R2-X to Pd(0)), 
which generates an organopalladium compound (XPd(II)R2). Zero-valent palladium 
atoms are required to enter the catalytic cycle and are provided either directly as Pd(0) 
in the form of Pd/C, Pd/Al2O3 and Pd2(dba)3 or indirectly from sources of Pd(II), such as 
PdCl2 and Pd(OAc)2 where a reductive step from Pd(II) to Pd(0) is required.  
Henceforward, during metathesis, the anion (X) that is attached to the palladium is 
exchanged with the anion (-OR) attached to the base.197 Next, the organic group 
attached to boron is transferred to Pd(II) by transmetallation to form a new complex. 
At this point, the Pd(II) effectively forms a bridge between two organic compounds, 
holding them together through palladium-carbon bonds.197 Finally, in reductive 
elimination, generation of the new C-C sigma single bond occurs simultaneously with 
regeneration of Pd(0) from Pd(II) which is now available for subsequent catalysis.197  
Scheme 17: Catalytic cycle of the Suzuki-Miyaura cross-coupling reaction.197  
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 Under normal circumstances, boronic acids do not readily undergo transmetallation 
until their nucleophilicity is improved by quaternisation of the boron atom with a 
further anion; this then accelerates the transfer to the palladium in the transmetallat-
ion step.197 The presence of base in the reaction is thus crucial for both the metathesis 
step and for activation of the boronic acid; indeed, without base the reaction does not 
proceed at all. 
The reaction of arylboronic acids was found to be more efficient than that of their vinyl 
counterparts and even a weak base (2-3 equivalents) affected the reaction effici-
ently.197, 199 Similarly, the choice of ligand for the Pd(0) is paramount for the success of 
cross-coupling reactions; bulky and electron-rich ligands are preferred, as they in-
crease the reactivity of otherwise unreactive aryl chlorides, known to react sluggishly. 
In addition, these ligands are carefully designed to ‘cradle’ the Pd(0), protecting the 
metal while optimising its available “surface area” and thus efficiency in the reaction.  
Bromo- or iodo-arenes are normally required for effective Suzuki couplings as oxidative 
addition of palladium into a carbon-halogen bond occurs in the order of I > Br >> Cl >> 
F and is directly based upon the strength of the carbon-halogen bond.201, 202 Indeed, 
aryl chlorides are generally known to be unreactive towards oxidative addition of 
palladium in the absence of specialised ligands and conditions.201, 202 In addition, the 
inappropriate competitive binding between the substrates and the metal centre of the 
catalyst results in the formation of catalytically inactive complexes.203, 204  
More recently, however, the coupling of both aryl and heteroaryl chlorides with aryl-
boronate esters in high yield has been reported (Scheme 18).194 One example was the 
coupling of 2-chloro-1,3-dimethylbenzene (125) with the pinacol boronate ester 126 
using a 1% Pd(OAc)2 / SPhos catalyst / ligand system which gave an isolated yield of 
94% of 127 in just thirty minutes at 100C.194 Likewise, coupling of 4-chloroquinoline 
(128), which is activated to some extent by the quinoline nitrogen, with the pinacol 
boronate ester 129 under identical conditions afforded the desired coupled product 
130 in excellent yield.194 
Limitations of coupling to aryl chlorides still remain.205-207 Some of these limitations 
included the requirement for a very strong base (NaOt-Bu) and the slow addition of 
the aryl chloride due to it being highly prone to de-halogenation.205 In other cases 
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coupling was successful with a milder base (KF) but only when activated aryl chlorides  
(heterocyclic and electron-poor) were used. 207 Further to this Barder and colleagues 
were able to increase the scope of couplings with aryl chlorides and boronic acids 
using a new ligand 2-(2’,4’,6’-triisopropylbiphenyl)diphenylphosphine; this superior 
ligand / catalyst system allowed a very mild base (K3PO4.H2O) to be utilised.194 Not only 
this, but the generalised conditions employed allowed for the coupling of very 
hindered boronic acids and electron-rich aryl chlorides, with no requirement for the 
slow addition of any reagents.194  
Using these superior conditions, catalyst loading as low as 0.05% effected the coupling 
of 3-chlorobenzonitrile (131) with 2-biphenylboronic acid (132) to give 133 in 93% 
isolated yield (Entry 1, Scheme 19).194 Couplings with electron-rich substituents in 
position-3 relative to the chloride, e.g. 134, could be conducted at room temperature, 
due to substitutions in this position having minimal influence over the chloride (Entry 
2, Scheme 19).194 Only electron-rich aryl chlorides, such as 1-chloro-4-methoxybenzene 
(137) and 1-chloro-2,6-dimethoxybenzene (139), required higher temperatures (40°C, 
compared with room temperature) to effect the coupling successfully; probably due to 
the slower oxidative addition of aryl chlorides with electron-donating groups in the 2- 
and 4- positions (Entries 3 and 4 respectively, Scheme 19). 194  
It was postulated, following this seminal work by Barder and colleagues194, that the 
most important factor for the successful coupling of unactivated aryl chlorides was the 
use of a biaryl-derived phosphine ligand such as SPhos; able to deliver the maximal 
concentration of the mono-ligated palladium species within the catalytic cycle and 
consequently vastly accelerate this step in the catalytic cycle.194, 197, 208 Although 
Scheme 18: Suzuki-Miyaura 
couplings of aryl and 
heteroaryl chlorides with 
pinacol aryl boronates. 
Reagents and conditions: 1 
equiv. aryl chloride, 1.5 
equiv. pinacol boronate 
ester, 2 equiv. K3PO4, 
toluene: H2O (10:1), 1% 
Pd(OAc)2, 2% SPhos, 100°C, 
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expensive, SPhos is superior to any ligand reported to date and, at the small 
concentrations used, along with the low catalyst loadings required and mild conditions 
employed, is an expense well justified in a small-scale research laboratory. This ligand 
works by cradling the Pd(0), supporting it adequately to prevent the coagulation and 
formation of palladium metal, while still exposing sufficient of the co-ordination 
sphere of the palladium to allow catalysis to take place.  
The 3-chloroisoquinoline 121 is appropriately activated by the adjacent heterocyclic 
ring nitrogen and hence should be a suitable coupling partner under mild condit-
ions.140, 194 This reactivity is due to the electron-deficient nature of the pyridine ring 
compared with the analogous halobenzenes withdrawing electron density from the 
halogen-carbon bond.201 An example of the superior reactivity of a six-membered 
nitrogen-containing heterocycle is the Suzuki coupling of the highly electron-deficient 
2-chloropyrimidine with 5-indoylboronic acid, which occurred readily, even when using 
a less reactive catalyst (tetrakis(triphenylphosphine) palladium(0)).209 Moreover, Jung 
and colleagues reported excellent yields for the coupling of heteroaryl chlorides, in-
cluding 2-chloropyridine and 1-chloroisoquinoline, with various arylboronic acids with 
a new β-ketoiminatophosphanyl-palladium complex catalyst.210 Indeed, 2-chloropyr-
Scheme 19: Suzuki-Miyaura couplings to both activated and unactivated aryl chlorides.194 Reagents and 
conditions: All entries: 1 equiv aryl chloride, 1.5 equiv boronic acid, 3 equiv K3PO4.H2O, THF, Pd(OAc)2 (1, 
0.05%; 2, 0.1%; 3, 0.25%; 4, 0.5%), 2-(2’,4’,6’-triisopropylbiphenyl)diphenylphosphine, temperature (1 
and 2, rt; 3 and 4, 40°C).  
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idine was coupled to 4-methoxyphenylboronic acid, 2-methylphenylboronic acid and 2-
methoxyphenylboronic acid in excellent yields (92%, 91% and 86%, respectively).210 
4.8.1 Investigation of Suzuki couplings to 3-chloro-1-methoxy-5-nitroisoquinoline 
(121) 
It was rationalised that, with a carefully selected combination of ligand and catalyst 
and the use of an activated aryl chloride, in this case the 3-chloroisoquinoline 121, 
Suzuki couplings might progress satisfactorily under mild conditions. As excellent yields 
had been reported with the use of SPhos, a ligand which conferred excellent activity 
for the coupling of many hindered aryl compounds, often at low temperatures and 
catalyst-loading;194 it was adopted in this work as the ligand of choice. 
Couplings were carried out under dry conditions, using the chloroisoquinoline 121, the 
appropriate arylboronic acid, Pd2(dba)3 (10 mol%), SPhos (20 mol%) and potassium 
phosphate in toluene at reflux overnight under argon (Scheme 20). A ‘Starfish’ five-
plate reactor was used to increase throughput as shown in Figure 28. Using this 
strategy, it was possible to incorporate a diverse range of functionality into position-3 
of the intermediate compound (Table 3; 141a-141l). 
Figure 28 and Scheme 20: 
Photographic illustration of equip-
ment set up in the fume cupboard 
in the medicinal chemistry 
laboratory of the Department of 
Pharmacy and Pharmacology at the 
University of Bath. The ‘Starfish’ 
hot plate system allows for parallel 
reactions to be run under identical 
conditions; ideal for cross-coupling 
reactions where several analogues 
can be generated quickly. Using 
this set-up, Suzuki couplings of the 
key intermediate 121 were cond-
ucted in parallel. Reagents and con-
ditions: ArB(OH)2, K3PO4, SPhos, 
Pd2(dba)3, toluene or DMF, 100°C 
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As little was known with regards to the ‘ideal’ 
substituent for binding in this 3-aryl region of the 
catalytic pocket, boronic acids bearing a variety of 
substituents including electron-withdrawing 
groups, electron-donating groups, polar and non-
polar groups were selected with the aim of elicit-
ing this particular information. Firstly, to begin to 
ascertain the ‘shape’ of the tankyrase-1/-2 catal-
ytic pocket, phenylboronic acids were selected 
bearing the same substituent in the ortho-, meta- 
and para-positions to allow for a direct 
comparison of this orientation on inhibitor 
binding. Secondly, the tolerance of the catalytic 
pocket to electron-donating groups, such as 
amino and methoxy, and electron-withdrawing 
groups, such as cyano and trifluoromethyl, would 
allow for a more detailed interpretation of the 
amino-acids lining the perimeters of the catalytic 
pocket that may make additional interactions 
with an inhibitor. Similarly, substituents which 
may either donate or accept hydrogen bonds, 
such as amino and hydroxy, were explored, with 
the aim of probing for complementary amino-
acid residues. 
Table 3: Compounds synthesised by Suzuki 
coupling to the chloroisoquinoline 121 
(Scheme 20). Reagents and conditions: 
ArB(OH)2, K3PO4, SPhos, Pd2(dba)3, toluene 
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It is known that the coupling of hindered arylboronic acids, especially those with ortho 
substitutions, is often inefficient, due to the steric crowding surrounding the boron 
atom inhibiting the quaternisation step required for the efficient transfer of the 
boronic acid to the palladium in the transmetallation step.194 This effect is clear when 
looking at the results in Table 3. In all cases, the isolated yield from the coupling is imp-
roved as the substituent moves from ortho to meta to para suggesting a clear steric 
influence on the coupling efficiency. In general, the coupling efficiency of boronic acids 
bearing electron-donating groups appears to be superior to those with electron-
withdrawing groups; however, one must bear in mind that the results in Table 3 are 
isolated yields and may not be representative of the extent to which the product 
actually formed in the reaction. Interestingly, there was no evidence that any coupling 
of either 4-bromo- or 4-fluoroboronic acids to the 3-chloro intermediate 121 had 
occurred. This may be due, in the case of the 4-bromoboronic acid, to a high incidence 
of homocoupling between the more reactive bromo-carbon bond and the boronic acid 
functionality on another molecule.  
A significant drawback in these cross-coupling reactions was the difficulty in purifying 
the coupled products from the crude reaction mixture. At no stage did the reaction 
approach completion, even after several days of reaction, with several products shown 
by thin layer chromatography (TLC). Indeed, cross-coupling reactions are known to 
form side-products from self-coupling and from dehalogenation of the haloarene 
component.197 In addition, the presence of excess base in the reaction may allow for 
side-reactions to occur, contributing to further unwanted compounds in the crude 
Table 4: Preliminary investigation of the effects of stoichiometry and time of addition on the coupling 
reaction between 1-methoxy-3-chloro-5-nitroisoquinoline (121) and 3-chlorobenzeneboronic acid. In all 
cases, the ligand SPhos and the base (K3PO4) were kept at 0.2 and 2.0 equivalents, respectively. 
Entry Boronic acid 
(equiv.) 
Pd catalyst (Pd2dba3) 
(equiv.) 
Catalyst added in 
portions 
Isolated yield (%) 
1 2 0.1 1 22 
2 1.5 0.05 1 9 
3 3 0.1 1 34 
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reaction mixture. 197, 208 
The starting 3-chloroisoquinoline 121 was very difficult to separate from the 3-
arylisoquinoline products using column chromatography, as the Rf values are very 
similar, with very little pure product obtained in some cases (Table 3). With some 
examples, no product could be isolated with these reaction conditions, with only 
starting material being recovered. Attempts were made to drive the reaction to 
completion (thereby eliminating the need to separate from starting material) by 
optimising the conditions, reagents and reacting equivalents used, as shown in Table 4. 
One must interpret the results shown in Table 4 with some caution, as isolation of the 
products proved to be the biggest problem in all cases. The yields quoted are isolated 
yields and thus may not be representative of the extent to which product was formed 
during the reaction. There are, however, trends that can be observed, including the 
yield improving greatly as the number of equivalents of boronic acid is increased from 
two to three. Adding the catalyst in two separate portions, in an attempt to reduce 
potential ‘clumping’, that may be inhibiting the formation of product, also made little 
difference to the overall yield. Alternative approaches to chromatography were also 
investigated in an attempt to improve resolution. Unfortunately, both dry flash 
chromatography and preparative plate TLC failed to provide a much improved 
separation over standard chromatographic techniques.  
The failure of changing the stoichiometry of the catalyst and the boronic acid to drive 
the coupling to completion instigated further optimisation studies into changing the 
organoboron and aryl chloride components independently.  
4.8.2 Cross-coupling with trifluoroboronate salts - a better method? 
Since increasing the amount of the boronic acid to super-stoichiometry improved the 
yield somewhat, although no boronic acid remained at the end of the reaction, it was 
proposed that the boronic acid was insufficiently reactive and was decomposing under 
the reaction conditions. Indeed, it is well-known that boronic acids are prone to cyclic 
trimerisation, leading to uncertainties in the exact stoichiometry in the reaction 
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Further to this, boronic acids are prone to protiodeboronation; a particular problem 
with arylboronic acids bearing ortho-substituents.211 This may, along with possibly 
steric influences, explain to some extent the poorer yields observed with ortho-substit-
uted coupled isoquinolines (Table 3). For example, when comparing the isolated yield 
of 1-methoxy-5-nitro-3-(2-methoxyphenyl)isoquinoline (141b) and 1-methoxy-5-nitro-
3-(3-methoxyphenyl)isoquinoline (141c) (58% and 81%, respectively) it is clear that the 
position of the substitution is having an effect on the coupling efficiency. Additionally, 
boronic acids, especially those which are electron-poor, tend to homocouple, espec-
ially in reactions where the progress of coupling is slow.211 Taken together, along with 
the poor reactivity of boronic acids in the transmetallation step, investigation of a 
more stable and reactive organoboron system was warranted. Potassium trifluorobor-
onate salts were considered based upon their superior reactivity and stability comp-
ared with their boronic acid counterparts. Indeed, they are reported to be indefinitely 
stable in air and water and should not undergo dimerisation (homocoupling) in situ.194, 
211 
Efficient Suzuki-Miyaura coupling of some potassium aryltrifluoroboronates has been 
reported by Molander and Biolatto under extremely economical conditions with a low 
loading of ligandless Pd(OAc)2 in aqueous solvents in the presence of air (Scheme 
21).211 Upon optimising the conditions for the coupling of 1-bromonaphthalene to 
potassium phenyltrifluoroboronates (ligandless 0.5 mol% Pd(OAc)2, 3 equiv. K2CO3 in 
methanol), the group went on to explore the coupling of potassium phenyltrifluoro-
Scheme 21: Cross-coupling reactions of potassium phenyltrifluoroborate (142) with various electron-
poor and electron-rich aryl halides.198 Reagents and conditions: Pd(OAc)2 (0.5 mol %), K2CO3 (3 equiv), 
MeOH, reflux, under N2.  
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boronate (142) with electron-poor bromoarenes, including 1-bromo-4-nitrobenzene 
(143) (Entry 1, Scheme 21), 1-bromo-4-trifluoromethylbenzene (145) (Entry 2, Scheme 
21) (Isolated yield = >99% and 79%, respectively) and with electron-rich substrates, 
including 1-bromo-4-methoxybenzene (147) (Entry 3, Scheme 21) and 1-bromo-4-hyd-
roxybenzene (149) (Entry 4, Scheme 21) (Isolated yield = 95% and 40%, 
respectively).211 
Further to this, coupling of many bromoheteroarenes was also observed, including 2-
bromopyridine (151) and 7-bromoindole (153) (Isolated yield = 70% and 44%, respect-
ively) (Scheme 22).211 With some more sterically hindered bromoarenes, for example 
1-bromo-2, 4-dimethoxybenzene, the addition of a simple ligand in a 1:1 ratio with the 
catalyst improved the yield from 50% under ligandless conditions to a 75% isolated 
yield in the presence of PPh3.211 Although the majority of the study was conducted on 
bromoarenes, coupling of the electron-deficient 2-chloropyrazine (156) with 1-naph-
thyltrifluoroborate (155) afforded the desired product 157 in an isolated yield of 85% 
(Scheme 23). 211 
It was anticipated that adopting these alternative conditions might improve the out-
comes of some previously attempted couplings. The 3-chloroisoquinoline should be 
sufficiently activated to couple with potassium aryltrifluoroboronate salts. Reaction of 
the 3-chloroisoquinoline 121 with potassium phenyltrifluoroboronate, under the con-
ditions reported by Molander et al.198 gave a mixture of products (Scheme 24). 1H NMR 
analysis of the crude mixture allowed preliminary characterisation and quantification 
Scheme 22: Reported 
cross-coupling reactions of 
potassium phenyltrifluoro-
borate and heteroaryl 
bromides. Reagents and 
conditions: Pd(OAc)2 (0.5 
mol %), K2CO3 (3 equiv.), 


















Scheme 23: Cross-coupling reactions of 
potassium 1-naphthyltrifluoroborate (155) and 
2-chloropyrazine (156).198 Reagents and 
conditions: PdCl2(dppf).CH2Cl2 (1.0 mol %), 
Et3N (3 equiv.), EtOH, reflux.  
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of the products. Whereas earlier couplings using arylboronic acids had given mixtures 
of the starting chloroisoquinoline and the product 3-arylisoquinoline, the mixture ob-
tained here consisted of a trace of product 141a, a small amount of starting material 
121, a large amount of unreacted potassium phenyltrifluoroboronate 142 and 1-meth-
oxy-5-nitroisoquinoline 158, with molar ratios of 1:12:26:16, respectively (Scheme 24).  
The formation of this de-halogenated isoquinoline 158 shows that palladation of the 
chloroarene had occurred in the oxidative addition stage of the catalytic cycle. It would 
appear, however, that the potassium phenyltrifluoroboronate failed to transmetallate 
with the palladium and thus failed to couple with the isoquinoline. This allows the aryl-
Pd to persist and eventually undergo reductive cleavage.163, 166 This is in stark contrast 
to the prediction made prior to trying this reaction, where the poor reactivity of the 
aryl halide had been blamed for the failure of the reaction to go to completion.  
Even though the multiple side products obtained were more easily separable and 
identifiable than the side products produced in the corresponding Suzuki couplings 
with boronic acids, the overall outcome of the this reaction was no more advantag-
eous; indeed, it was even lower yielding with respect to the desired product and thus it 
was abandoned as an alternative method.  
4.8.3 Investigation of Suzuki couplings to 3-bromo-1-methoxy-5-nitroisoquinoline 
(164) 
The strategies adopted in Sections 4.8.1 and 4.8.2 were of limited success in producing 
clean and high-yielding Suzuki-Miyaura cross-coupling reactions and thus an alterna-
tive was sought. It is a logical step to investigate the higher reactivity of a 3-bromoiso-
quinoline as an alternative coupling partner, to increase conversion and thus simplify 
purification of the coupled products. The corresponding dihaloisoquinoline, 1, 3-di-
Scheme 24: Pd-catalysed reaction of 121 with potassium phenyltrifluoroboronate (142). Reagents and 
conditions: PhBF3
- K+, Pd(OAc)2, K2CO3, MeOH, reflux, 36 h. 
 
 




available, is expensive (1.0 g 
= £453) and a strategy was 
devised for its synthesis. It 
was planned that the 
dibromo compound could be 
prepared from homophthal-
imide (isoquinoline-1,3-
dione (160)) (Scheme 25), 
which is also prohibitively 
expensive.  
Commercially available 
homophthalic acid (159) (1.0 g = £0.66) became the starting point for the synthesis and 
when heated strongly (175 – 185 C) with finely ground urea (1.0 g = £0.11) in solvent 
free conditions produced homophthalimide (160) in good yield (Scheme 25).212 One 
might not expect the carboxylic acid of the homophthalic acid and the NH2 group of 
the urea to react readily, owing to the poor electrophilicity and nucleophilicity of these 
groups, respectively. However, at high temperature, cyclisation occurs to produce 
isocoumarin-1, 3-dione (homophthalic anhydride). This anhydride is a powerful 
electrophile and will react either directly with the urea or with ammonia generated by 
thermal decomposition of urea.  
From here, treatment with PBr3 at reflux gave 1,3-dibromoisoquinoline (162) in 
moderate yield (Scheme 25). However, this P(III) reagent also led to formation of small 
amounts of 3-bromoisoquinoline (161), an unwanted side-product which had to be 
separated chromatographically. It is likely that a deoxygenation has taken place at 
position-1, as P(III) reagents are strong reducing / de-oxygenating reagents.213 Chang-
ing the brominating reagent to a P(V) compound, POBr3 gave 162 alone with no side-
products or chromatography required for its isolation. The synthesis of this extremely 
expensive starting material was thus achieved in two steps without chromatography.  
Scheme 25: Facile and inexpensive route to homophthalimide (160), 
from which the synthesis of the alternative 3-bromo-1-methoxy-5-
nitroisoquinoline (164) key intermediate is achieved. Reagents and 
conditions: i, urea, 175-185°C, 15 min; ii, POBr3, 1,4-dioxane, reflux, 
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4.8.4 Does dibromoisoquinoline behave like dichloroisoquinoline?  
An important consideration of the use of the 1,3-dibromoisoquinoline (162) was the 
behaviour of the compound when subjected to the same original common steps as for 
the 1,3-dichloroisoquinoline (119). Nitration was achieved selectively at position-5 in 
the usual way with concentrated nitrating mixture. No multiple nitration was observed 
(Scheme 25).  
One concern during the above steps was that the higher electrophilic reactivity of the 
1,3-dibromo-5-nitroisoquinoline (163) may diminish the selectivity for incorporation of 
the methoxide at position-1 only. Careful TLC monitoring revealed, after ten minutes 
at reflux with sodium methoxide in methanol, a new spot with apparent consumption 
of all starting material and the reaction was stopped abruptly. Although 1H NMR 
analysis of the crude product mixture showed that a small amount of the starting 
material 163 remained, there was no evidence of the second bromine being displaced. 
Further attempts saw this reaction run for up to 16 h with no displacement of the 3-
bromine (Scheme 25). In addition, 2D NMR analysis revealed through-space nOe 
connectivity between the OCH3 protons and the 8-H, confirming the location of the 
sole methoxy group of 164 to be the 1-position, as for the chloro analogue 121. A 
HMBC cross-peak was also observed connecting the OCH3 protons and 1-C. 
4.8.5 Suzuki-Miyaura cross-coupling to the 3-bromo intermediate 164 
The potential superiority of this alternative intermediate was investigated under the 
same Suzuki-Miyaura conditions described in Section 4.8.1 (Scheme 20). Initially, 
coupling with 4-chlorophenylboronic acid gave a much cleaner crude reaction mixture, 
with apparently no bromoisoquinoline 164 starting material remaining, as shown by 
TLC and 1H NMR. Straightforward chromatography gave pure 141m in high yield (98%) 
with no contamination with starting material (Table 5). Adopted as a superior coupling 
partner in the Suzuki-Miyaura reaction, the 3-bromo 164 analogue appeared to facilit-
ate the reaction to go further towards completion than with the 3-chloro 121 counter-
part. In addition, any remaining starting material had greater resolution on TLC from 
the product and thus enabled efficient separation using standard chromatographic 
techniques. Several analogues synthesised using both the 3-chloro 121 and 3-bromo-
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isoquinoline 164 starting material under the original conditions showed significantly 
improved isolated yields with the latter. This included the coupling of 4-bromophenyl-
boronic acid with 3-bromoisoquinoline 164 which gave a much improved, albeit mod-
erate, isolated yield of 24% of 141j compared with 0% with the 3-chloro 121 counter-
part (Table 4 and 5). This result may demonstrate that the more reactive bromine 
atom partakes in palladation during oxidative addition more quickly, thus progressing 
to transmetallation more rapidly; homocoupling between boronic acid molecules is, 
therefore, less likely to occur owing to a reduced contact time.  
Whilst attempting to synthesise the 3-(4-hydroxyphenyl) analogue 141l using the 3-
bromo coupling partner 164, an unexpectedly low yield (9%) was achieved (Table 5). 
Given the superior reactivity of 164, it was unlikely that this was hindering the prog-
ression of the coupling; however, it is known that electron-donating groups in the aryl 
unit of the boronic acid increase the likelihood of protiodeboronation.211 It was thus 
postulated that the poorer solubility of this more polar boronic acid in the non-polar 
toluene might be limiting its availability in the reaction for coupling, allowing more 
protiodeboronation to occur. Changing to a polar aprotic solvent should improve the 
solubility of the 4-hydroxyphenylboronic acid and improve its availability in the reac-
tion. Dimethylformamide (DMF) was employed as the solvent of choice; its high boiling 
point compared with similar solvents, e.g. tetrahydrofuran (THF), allows for greater 
forcing conditions to be employed in a reaction.  
These adapted Suzuki conditions proved fruitful, with an 86% yield achieved for form-
ation of 141l in DMF, compared with only 9% in toluene (Table 5). Of interest was that 
141l was deep red, in contrast to the typical yellow colour of all other 
nitroisoquinolines synthesised. This was due to the ‘push-pull’ effect of the strongly 
electron-withdrawing nitro group and the strongly electron-donating hydroxy group 
through the conjugation of the bicyclic system. Indeed, this same observation had 
been made in our group for 1-methoxy-3-dimethylamino-5-nitronaphthalene.165 This 
phenomenon is well known for the naphthalene chromophore e.g. in simple 2-nitro-
ethenamines,214 laser dyes and dark red 1-nitro-7-aminonaphthalenes.215-218  
To explore further the effect of changing the solvent, the original 3-chloroisoquinoline 
coupling partner 121 was treated with 4-hydroxyphenylboronic acid under these new 
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conditions in DMF and gave a good isolated 
yield of 141l of 54% (Table 4). This was 
remarkably high, considering some of the 
lower yields observed with this less reactive 
organohalide and suggested that, for some 
organoboron compounds, especially polar 
examples, that DMF was a superior solvent in 
which to conduct the reaction. These con-
ditions were then adopted for further coup-
ling reactions. Much success was seen with 
the combination of using a more reactive 
organohalide and the adoption of a superior 
solvent; able both to solubilise the starting 
materials and allow for greater forcing 
conditions to be used in reactions where 
necessary.  
The cross-coupling of the following boronic 
acids: 2-chlorophenylboronic acid, 3-chloro-
phenylboronic acid, 2-trifluoromethylphenyl-
boronic acid, 3-trifluoromethylphenylboronic 
acid, 4-fluorophenylboronic acid, 4-nitro-
phenylboronic acid and 2,6-dichlorophenyl-
boronic acid with the 3-bromoisoquinoline 
164 progressed well under these new 
conditions (Table 5). The formation of this 
latter analogue 141p, demonstrated that that 
these superior conditions allowed for the 
coupling of even very sterically encumbered 
boronic acids.  
Some boronic acids, namely the 
cyanophenylboronic acids, proved 
Table 5: Series of compounds synthesised 
using the 3-bromo key intermediate 164 
using general conditions in Scheme 20. 
Reagents and conditions: ArB(OH)2, K3PO4, 
SPhos, Pd2(dba)3, toluene or DMF*, 100°C or 
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troublesome to couple with both 3-bromo- and 3-chloroisoquinoline starting materials 
with poor yields achieved in both cases (12% isolated yield for both 2-cyano and 3-
cyanophenylboronic acid and 3-bromoisoquinoline 164 to give 141f and 141g; Table 5). 
This is probably due to the cyano group co-ordinating to the catalyst in the reaction, 
thus precluding the coupling process. Even with the superior reactivity of the 3-bromo 
intermediate as a coupling partner, some boronic acids failed to couple. These 
included biphenyl-4-boronic acid and pyridine-3-boronic acid. In the case of the 
former, it is unlikely that its large bulk precluded its coupling as firstly the bulk is not 
surrounding the boron atom (which is the region of the molecule where the reaction 
takes place) and secondly the coupling of 2,6-dichlorophenylboronic acid, where a 
significant amount of steric bulk surrounds the boron atom itself, afforded the desired 
analogue 141p. In the case of the pyridine-3-boronic acid, its electron-deficient nature 
may have inhibited the addition of base to the organoboron compound during the 
transmetallation stage and as such halted the catalytic cycle prematurely. Another 
possible reason for the failure of this boronic acid to couple is that it may provide 
inadequate co-ordination through the nitrogen atom. 
4.9 Reduction and unmasking - or vice versa? 
The steps that remain in the approach to the target 3-aryl-5-AIQs 167a-i, k-p are un-
masking of the lactam and reduction of the nitro group to the 5-amine (Scheme 26). 
The first approach was to cleave the methyl ether to reveal the lactam before reduc-
tion of the nitro group. Aqueous hydro-
gen bromide did effect this demethyl-
ation but further investigation revealed 
that using 33% HBr in acetic acid was a 
higher-yielding transformation with a 
more straightforward work-up. This was 
followed by reduction of the nitro fun-
ctionality using traditional 
hydrogenation conditions to give the 
amine in position-5. However, this Scheme 26: Unmasking the lactam and amino 
funtionalities. Reagents and conditions: i, HBr / AcOH, 
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sequence suffered from problems of poor solubility of the intermediate 3-aryl-5-nitro-
isoquinolin-1-ones during the reduction step. Thus the steps were reversed (reduction 
followed by demethylation), leading to higher yields in both steps, as the intermediate 
5-amino-3-aryl-1-methoxyisoquinolines 166a-q was considerably more tractable.  
In the case of both 167b and 167c, selective demethylation of the 1-methoxy occurred, 
leaving the phenyl-methoxy intact, as desired. This selectivity, although initially unex-
pected, can be justified by the ability of the electrons to move onto the heterocyclic 
ring nitrogen when the carbon of the methoxy group is attacked by bromide ions. It is 
likely that demethylation of the phenyl-methoxy may also occur to reveal a hydroxy 
group, albeit at a much slower rate after several hours of heating at reflux.  
Difficulty was encountered, however, with the hydrogenation step of 1-methoxy-5-
nitro-3-(2-chlorophenyl)isoquinoline (141d) and 1-methoxy-5-nitro-3-(3-chlorophenyl)-
isoquinoline (141e) as the chlorine had been cleaved reductively from the compound, 
forming 5-amino-1-methoxy-3-phenylisoquinoline (Scheme 26). Hydrodechlorination 
of chloronitrobenzenes is known to be difficult to avoid when using metal catalysts in 
organic solvents.219 Attempts to overcome this have seen the use of inhibitors to 
suppress the level of hydrodechlorination; however, these tend to lower the overall 
rate of hydrogenation and often lead to more complex purification efforts to remove 
additives.220 
Performing these two final steps in the original order is also unlikely to prevent this 
from happening, as reduction of 3-chloro-5-nitroisoquinolin-1-one (168) gave 5-AIQ 
(18) under the same conditions. It had been reported by JMCatalysts that selective 
hydrogenation of the nitro group without loss of the halogen in halonitroaromatics 
was possible, using platinum rather than palladium as catalyst (Johnson Matthey; 
Catalysis and Chiral Technologies). A proof-of-principle experiment was carried out, 
examining the reduction of the simple molecule 4-chloronitrobenzene (169) with a 
Pd/C (10%) catalyst and with a Pt/C (1%) catalyst. Treatment of 169 with the former 
catalyst led to a mixture of two products; aniline (170) and 4-chloroaniline (171) in 
equal amounts. Adopting the platinum catalyst, only one product, the desired 171 was 
isolated. Using this alternative reduction strategy, all halogen-containing 3-substituted 
isoquinolines were subjected to the Pt/C reduction conditions with no loss of halogen.  
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Further difficulties were encountered with the deprotection of 5-amino-1-methoxy-3-
(3-cyanophenyl)isoquinoline (166f) and 5-amino-1-methoxy-3-(4-cyanophenyl) iso-
quinoline (166g) using 33% HBr in acetic acid. Although the lactam was revealed as 
desired, the nitrile group in both cases was also hydrated to a primary carboxamide. 
This is likely to have occurred owing to the acidic conditions. Although not anticipated, 
this transformation is not entirely futile, as these analogues will still provide useful 
information about the nature of the hydrophobic pocket, especially with a group which 
could both accept and donate hydrogen bonds with residues in this region of the 
catalytic pocket. For two examples, demethylation was performed to provide the 5-
nitroisoquinolin-1-ones 165n and 165k, to allow for analysis of the effect of the 
electron-withdrawing nitro group on their biological activity.  
Following a successful campaign to generate novelty and diversity at as late a stage as 
possible in the synthesis of 3-arylisoquinolin-1-ones, a library of nineteen final com-
pounds was synthesised and isolated in preparation for biological evaluation (Scheme 
27; 165n, 165k and 167a-q). This synthetic route did suffer some limitations; namely 
the difficulty in separating pure product from starting material following the Suzuki 
cross-coupling reactions, especially when adopting the 3-chloroisoquinoline 121 as a 
coupling partner. Increasing the stoichiometry with regards to boronic acid only gave a 
modest improvement in isolated yield (Table 4) and potassium trifluoroboronates 
Scheme 27: A summary of the main synthetic transformations from the Suzuki cross-coupling of the key 
intermediates 121 and 164 to generation of final compounds 165a,k,n and 167a-q. Reagents and 
conditions: i, ArB(OH)2, 3-chloroisoquinoline 121 or 3-bromoisoquinoline 164, K3PO4, SPhos, Pd2(dba)3, 
toluene or DMF, 100°C or 135°C, 16 h; ii, H2, Pd/C or Pt/C, EtOH, rt, 3-5h; iii, HBr / AcOH, 65C, 5-6h. 
*=Analogue was synthesised by Dr P. T. Sunderland.185  
 
 
- 104 - 
 
were investigated as superior organoboron coupling partners, due to their reported 
higher reactivity however, these failed to couple efficiently under the conditions 
used.211 Adding the catalyst in two separate portions also made no difference to the 
isolated yield and thus was also abandoned as an alternative strategy.  
Finally, it was proposed that the 3-chloro intermediate 121 may not be sufficiently 
reactive to drive the reaction as far towards completion as necessary for both effic-
iency and ease of purification. This was, to some extent, overcome by the use of a 
superior coupling partner, the 3-bromo intermediate 164; the greater reactivity along 
with a greater disparity between the resolution of the starting material and product 
gave a cleaner and higher isolated yield of desired product in almost all cases. In 
addition to a superior coupling partner, an alternative, higher-boiling solvent in the 
form of DMF was investigated, which allowed greater forcing conditions to be adopted 
and improved coupling efficiencies somewhat. 
4.10 Sonogashira cross-coupling to the 3-bromoisoquinoline intermediate 164 
Protein crystallography (See Section 2.11) revealed that the 3-substituent of the iso-
quinolin-1-one framework sits in an ovoid cavity and thus it became desirable to 
extend beyond merely a substituted aryl ring in position-3 of the final isoquinolin-1-
ones to probe and explore the distal end of this cavity. It was proposed that 
incorporating a linker between the isoquinolin-1-one framework and the 3-aryl group 
would extend into this pocket and may create further favourable interactions with 
hydrophobic residues lining this region of the pocket.  
 In order to maintain the orientation of any additional linker group and further substit-
ution with respect to the main isoquinoline scaffold, a triple-bond linker was desirable 
as the sp-hybridisation maintains bond angles of 180°C. This alkyne linker was ideally 
suited for incorporated into the framework using a Sonogashira coupling reaction. This 
facile cross-coupling reaction, reported by K. Sonogashira and colleagues in 1975, sees 
Scheme 28: Simplified outline of the Sonogashira cross-coupling reaction.197 R1: aryl, alkenyl, heteroaryl; X: 
Cl, Br, I, OTf; R2: H, alkyl, aryl, alkenyl, SiR3; Pd-catalyst: Pd (PPh3)2Cl2 or Pd(PPh3)4; Cu(I)-salt: CuI or CuBr; 
Base: Et2NH, Et3N, (i-Pr)2NEt; solvent: MeCN, THF, EtOAc.  
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the copper-palladium-catalysed coupling of terminal alkynes with aryl and vinyl halides 
to yield arenynes and enynes (Scheme 28).197, 208, 221-223 Indeed, this reaction can be 
considered as a catalytic version of the traditional Castro-Stephens coupling used 
previously by the Threadgill group to synthesise of 3-substituted-5-AIQs.166 
An advantage of the Sonogashira cross-coupling over its more traditional counterpart 
is the far milder conditions that can be adopted, in contrast to the forcing conditions 
required for the Castro-Stephens coupling. In addition to this major benefit, this cross-
coupling only uses a catalytic amount of a commercially available copper (I) salt, the 
solvents used do not need to be meticulously dry and the reaction tolerates a wide 
variety of functional groups on the aromatic and vinyl halide substrates.221-223  
Like the Suzuki-Miyaura cross-coupling reaction above, the Sonogashira cross-coupling 
is thought to follow the oxidative addition-reductive elimination pathway. Initially, the 
generation of a co-ordinatively unsaturated Pd(0) species from Pd(II) by either 
reduction with the alkyne substrate or with an added phosphine ligand was thought to 
occur, followed by subsequent oxidative addition with the aryl halide and then trans-
metallation by the copper(I)-acetylide.224 Subsequent reductive elimination gives the 
coupled product and regenerates the catalyst. The precise role of the Cu catalyst and, 
indeed, the structure of the catalytically active species are still largely speculative in 
the Sonogashira reaction but it is thought that the metalloorganic compounds that are 
Scheme 29: Sonogashira 
coupling to 3-bromo-1-
methoxyisoquinolines 
164 and 177. Reagents 





THF then phenylethyne, 
50°C, 16 h; ii, Na, MeOH, 
toluene, sealed tube, 
110°C, 1.5 h; iii, Pd/C 
10%, H2, EtOH, rt, 6 h; iv, 
SnCl2.2H2O, EtOAc, 77°C, 
4 h; v, SnCl2.2H2O, EtOH, 
78°C; vi, SnCl2.2H2O, 
conc. HCl, MeOH/ EtOAc, 
rt, 16 h; vii, In, InCl3, 
THF/ H2O, 50°C, 6 h; viii, 
HBr /AcOH, 40 °C or 
65°C, 5 h.  
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generated in situ, are likely to be heterocuprate e.g. (RC≡CCuI) R3NH+ and are formed 
in catalytic amounts from terminal acetylenes due to the effect of base and CuI.197, 208, 
224  
Traditional Sonogashira conditions effected the coupling of 3-bromo-1-methoxy-5-
nitroisoquinoline (164) with phenylethyne in excellent yield to give 172a (Scheme 29). 
The reduction conditions used for other members of the 5-amino library reduced the 
5-nitro functionality; however, the triple bond was also reduced, giving 173. Although 
not the intended outcome, this alternative final product 175 may still provide inform-
ation in structure-activity relationships. In contrast to the alkynyl linker, the flexible 
two-carbon linker between the isoquinoline scaffold and aryl substituent will not be 
fixed in its orientation within the catalytic site and may clash with the edges of the 
pocket. This unsurprising chemical transformation warranted a milder reduction 
strategy to achieve the desired analogue with the alkyne intact.  
The first attempt to achieve this selective reduction used four molar equivalents of 
tin(II) chloride in ethyl acetate at reflux; required as the oxidation of tin (II) to tin (IV) 
provides two electrons and the reduction of nitro to amino requires six electrons 
(Scheme 29). TLC monitoring revealed several side-products being generated in the 
reaction mixture and, after work-up, an inseparable mixture of at least two unidentifi-
able products was revealed by crude 1H NMR spectroscopy.  
The failure of this strategy, in part, may have been due to the lack of solubility of the 
starting material in ethyl acetate; therefore, the solvent was changed to ethanol and 
the same approach was tried again (Scheme 29). Again, an inseparable mixture of com-
pounds was apparent in the 1H NMR spectrum of the crude product mixture. It was 
postulated that an improvement in the reaction outcome could be achieved through 
the addition of conc. aq. HCl in a 1:1 ratio with the solvent ethanol. Although a far 
cleaner reaction mixture was obtained on this occasion, a mixture of starting material 
172a, desired product 176 and the demethylated lactam 174c was observed by both 1H 
NMR and mass spectrometry. Clearly, the conditions had been sufficiently acidic to 
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Further to this an alternative strategy, reported by Kim et al., using four equivalents of 
indium and 0.4 equivalents of indium(III) chloride in aqueous tetrahydrofuran at 50°C, 
effected the transformation of 2-(2-arylethynyl)anilines 179 from 1-(2-arylethynyl)-2-
nitroarenes 178 in excellent yields whilst leaving the triple bond linker completely 
intact (Scheme 30). 225 These mild conditions were thus deemed suitable for the 
required reductive sole transformation of the nitro group of 172a; however a mixture 
of three products with mainly starting material apparent by 1H NMR with no clear 
evidence of the desired analogue.  
As this particular 3-arylalkynyl analogue 174c proved difficult to synthesise with the 5-
amino group in the framework, attempts were made to access an analogue with only H 
in position-5 (Scheme 29; 174b). Sonogashira cross-coupling of 3-bromo-1-
methoxyisoquinoline (177) with phenylethyne gave the desired coupled product 172b 
in moderate yield. Unfortunately, demethylation with HBr in acetic acid at 40°C gave a 
mixture of inseparable products all lacking a methoxy group at  ca. 4.2 in the 1H NMR 
spectrum as expected; however, none of these unknown compounds contained a 
triple bond as there was no indication of two peaks at  ca. 88-90 in the 13C NMR 
spectrum. This indicated that the strongly acidic conditions may have completely dest-
royed the alkyne. Attempts to maintain an intact triple bond linker in position-3 of the 
isoquinoline framework were thus abandoned. Although Sonogashira coupling 
provides a facile route for introduction of the desired alkynyl functionality, the further 
transformations, i.e. reduction of the nitro group and demethylation to reveal the 
lactam could not be conducted on the molecule whilst maintaining the integrity of this 
delicate linker.  
Scheme 30: Reduction of 1-(2-arylethynyl)-2-nitroarenes 178 to 2-(2-arylethynyl)anilines 179. Reagents 
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4.11 Moving away from an amine at position-5 of the isoquinolin-1-one: Synthesis of 
5-methyl, 5-methoxy and 5-fluoro isoquinolin-1-ones 
Further to the library of 5-aminoisoquinolin-1-ones, it became desirable to devise a 
synthesis to incorporate other small groups into position-5 of the isoquinolin-1-one 
framework. Further to this, a thorough drug-design campaign required exploration of 
different groups in position-5 to build up a comprehensive structure-activity 
relationship for inhibitors bound within the catalytic site. Several methods were 
proposed to achieve the desired analogues with parallel synthesis; ultimately, the goal 
to produce a large library as quickly as possible. It was postulated that the synthesis of 
this subset of the inhibitor library could be approached from four different routes.  
In route one, owing to the facile synthesis of 1,3-dibromoisoquinoline (162) (Scheme 
25), it was proposed that this compound may be a potentially suitable starting material 
for the synthesis of a new library of 3-substituted-5-methylisoquinoline analogues. Un-
fortunately, no appropriately substituted analogues of homophthalic acid (159) were 
commercially available; however, this starting material could be approached using 3-
substituted-2-methylbenzoic acids 180a-b (Scheme 31).  
Only a limited number of appropriately 3-substituted benzoic acids were commercially 
available; the 3-bromo, 3-methoxy and 3-hydroxy. Further to this, the 3-bromo of the 
benzoic acid starting material (which would become 5-bromo in the isoquinoline) 
Scheme 31: Route one towards 5-substituted-3-arylisoquinolin-1-ones 187a-b, adapting from the 
synthesis of 1,3-dibromoisoquinoline (162). Reagents and conditions: i, LDA, THF, -50°C then ClCO2Et; ii, 
H2SO4, ∆ or aq. NaOH, ∆; iii, Urea, 170-180°C; iv, POBr3, 1,4-dioxane, reflux; v, NaOMe, MeOH, reflux; vi, 
Standard Suzuki-Miyaura cross-coupling conditions; vii, HBr in glacial acetic acid 33%, 65°C.  
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would, in addition to the desired 3-bromo (of 
the isoquinoline) be a suitable Suzuki coupling 
handle, which would complicate the outcome 
of the Suzuki cross-coupling planned later in 
the synthesis (Scheme 31). The poor 
availability of suitably diverse analogues of 
both 180 and 183, combined with the 
relatively long-winded synthesis led to 
alternative routes being sought.  
The second suggested route utilised commer-
cially available 2-bromo-3-methylbenzoic acid 
(188) as a starting material (Scheme 32). It was 
expected that 2-bromobenzoic acids bearing 
different 3-substituents could be Sonogashira 
coupled to various substituted phenylethynes. 
However, when 188 was subjected to traditional Sonogashira cross-coupling conditions 
with phenylethyne, this did not lead to the expected coupled product 189, with 1H 
NMR analysis revealing recovery of starting materials only. The corresponding ester 
190 which was utilised similarly, also failed to couple. A similar route had previously 
been exploited in an early synthesis of 3-substituted-5-nitroisocoumarins (Scheme 7), 
with Sonogashira coupling of methyl 2-iodo-3-nitrobenzoate with phenylethyne.166 
Even with the superior reactivity of the iodine and activation by the electron-
withdrawing nitro group, this coupling was only effective for two examples 
(phenylethyne and trimethylsilyethyne).166 The coupling of bulkier alkynes was too 
difficult with the already sterically hindered ortho, ortho-disubstituted iodoarene.166 
Thus this route was abandoned due to the likely difficulty of incorporating any form of 
diversity in the 3-aryl substituent as this increased bulk would have an adverse effect 
on cross-coupling.  
The third potential route to 5-substituted-3-arylisoquinolin-1-ones followed conditions 
developed by Zhong and colleagues in the palladium-catalysed oxidative cycloaddition 
of N-alkoxyisoquinolin-1-ones via double activation of C-H and N-H bonds.226 The 
Scheme 32: Route two towards 5-
substituted-3-arylisoquinolin-1-ones 192. 




ethyne, THF; ii, SOCl2, MeOH; iii, HgSO4, 
Me2CO, conc. H2SO4 ∆; iv, NH3, 
MeO(CH2)2OH, reflux.  
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group reports treatment of a 
series of benzamides with 
diphenylethyne with Pd(OAc)2 as 
catalyst to give the isoquinolin-1-
one 194 (Scheme 33). Although 
only trace amounts of products 
were observed when the group used benzamide, N-methylbenzamide or N-phenyl-
benzamide, treatment of N-methoxybenzamide 193 did result in formation of the 
desired product in 27% yield. 226 Further optimisation of reagents and conditions led to 
the introduction of alkali metal salts as reaction additives; sodium iodide (NaI. 2H2O; 
1.5 equiv.) was a particularly effective additive, probably due to the soft ligand exch-
ange process and, when it was included in the reaction mixture, the isolated yield was 
improved greatly (86% compared with 27% in an additive-free reaction).227 Diverse 
benzamides were explored, bearing either electron-withdrawing or electron-donating 
groups. The reaction of these analogues with various di-substituted alkynes, including 
some with sp3-hybridised substituents, generated a series of N-methoxyisoquinolin-1-
ones. Deprotection with NaH gave the final isoquinolin-1-ones.226  
These conditions were then adopted in the approach to 5-substituted-3-arylisoquinol-
in-1-ones. A number of appropriately 3-substituted benzoyl chlorides were available. 
3-methoxybenzoyl chloride (195a) was selected at first; later demethylation would 
allow access to the equivalent 5-hydroxyiso-
quinolinones. Treatment of 195a under the 
conditions described by Zhong226 gave 196a 
in reasonable yield (52%; Scheme 34). 
Treatment of this intermediate N-
methoxybenzamide 196a with 1-phenyl-1-
propyne gave the isoquinolin-1-one 197a in 
poor yield (19%).  
Unfortunately, the 3-methoxy in the N-
methoxybenzamide 197a ends up solely in 
position-7 of the final isoquinolin-1-one, in-
Scheme 33: Synthesis by Zhong and colleagues226 of 
isoquinolin-1-one 194 from N-methoxybenzamide (193) and 
diphenylacetylene. 
Scheme 34: Proposed route three synthesis 
towards 5-substituted-3-arylisoquinolin-1-ones 
198a-b. Reagents and conditions: i, 
methoxyamine hydrochloride, pyridine, DCM; ii, 
Pd(OAc)2, NaI, 1-phenylpropyne, DMF; iii, NaH 
(60% in mineral oil), DMF.  
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stead of the desired position-5, with no mixture of isomers evident by 1H NMR studies. 
During the catalytic cycle, a C-H bond adjacent to the amide is activated and this 
process is subject to directing group participation.228 Both the C-H bonds to 2-H and 6-
H are available for activation; however, the latter is less sterically crowded than the 
former, which is situated between two large substituents on the benzene ring. Once 
the palladium is incorporated into the intermediate adduct, the position-3 substituent 
in the starting material benzoyl chloride will be directed into position-7 of the 
isoquinolin-1-one. Another disadvantage of this synthesis towards isoquinolin-1-ones 
is that reactions with terminal alkynes would not progress at all with no obvious 
products isolated. 226 This negated the potential to incorporate changes at position-3 
and position-4 of the final isoquinolin-1-one independently, thus limiting further the 
utility of this reaction.  
In terms of SAR, position-7 substituents in the isoquinolin-1-one are thought to be 
undesirable for optimum binding, as binding studies with PARP-1 and -2 suggest that 
there is no room to accommodate any substituents in this region of the enzymes’ 
active sites.154 Analogously to this and based on early modelling studies, it is also 
expected that groups projecting from positions-6, -7 and -8 will also be undesirable for 
optimal binding to tankyrase-1 and -2 and should be avoided (see Section 2.7 for more 
discussion).82, 229 Overall, this route proved futile and was abandoned.  
The fourth route proposed in the 
quest towards 5-substituted-3-
arylisoquinolin-1-ones was based 
upon a study conducted by Cho 
on the synthesis of anti-tumour 1-
amino-3-arylisoquinoline derivat-
ives (Scheme 35). 230 The group 
required diverse modifications in 
the isoquinoline pharmacophore, 
following the serendipitous 
observation that 7,8-dimethoxy-
2-methyl-3-(4,5-methylenedioxy-
Scheme 35: Preparation of 
3-arylisoquinoline 
derivatives 203 by Cho and 
colleagues.230 Reagents and 
conditions: i, PCl5 then 
NHMe2; ii, R
1PhCN, LDA, -
78°C, THF; iii, POCl3; iv, N-
methylpiperazine, K2CO3.  
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2-vinylphenyl)isoquinolin-1-one demonstrated excellent anti-tumour activity against 
human tumour cell lines (IC50 = 0.2 nM: SK-MEL-2).231 The activity of this compound 
was thought to be due to it being a bioisostere of benzo[c]phenanthridine, an alkaloid 
known to demonstrate anti-tumour activity through inhibiting topoisomerase I or II.232 
In this study, the group prepared a series of modified isoquinolines using intermolec-
ular cyclisation of the dimethylamide 200 via quench of the anion (formed by removal 
of the most acidic proton with lithium diisopropylamide (LDA)) with various benzo-
nitriles as a key step (Scheme 35).233 Following this transformation, chlorination of the 
isoquinolin-1-one 201 with phosphorus oxychloride gave the 1-chloroisoquinolin-1-one 
202, followed by treatment with N-methylpiperazine to give 203.230 
Adapting this route to the present project, it was anticipated that the first two steps 
could lead to the desired isoquinolin-1-ones (Scheme 36). A variety of 3-substituted-2-
methylbenzoic acids were readily available, of which the 3-methyl 180c, 3-methoxy 
180a and 3-fluoro 180d analogues were selected. De-protection of the methyl group of 
the 3-methoxy would also access the 3-hydroxy analogue. The 3-substituents on these 
benzoic acids should be incorporated at position-5 of the final isoquinolin-1-ones. 
These derivatives were selected to be in contrast to the previously explored polar 5-
amino series, with both hydrophobicity and substituent size being further examined 
(Section 4.8 and 4.9).  
At this stage, it was desirable to 
change the nature of the sub-
stituent i.e. hydrophilic for hydro-
phobic by incorporation of a 
methyl group. It was also of inter-
est to start to explore the toler-
ance of steric bulk in this region of 
the catalytic pocket of tankyrase-
1/-2, through incorporation of a 
small group i.e. fluoro group 
(which would occupy no greater 
space than a hydrogen atom) and 
Scheme 36: Route four to 5-substituted-3-arylisoquinolines. 
For detail of R1 and R2 in 206a-m, 207a-i and 208a-g refer to 
Table 6. Reagents and conditions: i, SOCl2; ii, aq. Me2NH, DCM; 
iii, n-BuLi, Pri2NLi, R
2arylCN, -78°C → rt; iv, BBr3 then NaOH.  
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also a larger group i.e. the methoxy which, due to its extended size (compared with a 
methyl group alone) would start to probe further into the available space. This 
selection of position-5 groups would help to build-up a clear SAR picture in this local 
area of the tankyrase-1/-2 catalytic pocket. 
Treatment of these benzoic acids 180a, 180c and 180d with thionyl chloride formed 
the corresponding acid chlorides 204a-c in excellent yield (Scheme 36). Slow drop-wise 
addition of 204a-c to a stirred solution of 40% aqueous dimethylamine in DMF formed 
the N,N,2-trimethylbenzamides 205a-c.  
Treatment of the intermediate 205a-c at low temperature (-78°C) with the powerful 
non-nucleophilic base LDA (which was generated in situ by addition of n-BuLi to diiso-
propylamine) removes a proton from the most acidic 2-methyl, generating the anion 
and a distinctive bright red colour in the reaction mixture (Scheme 36). Removal of the 
acidic 2-methyl proton is aided by chelation of the lithium between the tertiary amide 
oxygen and the CH2 group. The CH2- anion generated is particularly stabilised owing to 
its location ortho to an electron-withdrawing group (EWG). The anion is then quenched 
with an appropriately substituted benzonitrile at -78°C for 1h and then warmed to 
room temperature for 16h. Quench with water caused precipitation of product in most 
cases, whence recrystallisation with EtOH gave the desired target compounds (Table 
6). Alternatively, the product was extracted with dichloromethane and the solid was 
recrystallised.  
Of note is the large number of appropriately substituted benzonitriles available, 
facilitating incorporation of diversity in the 3-aryl region of the isoquinolin-1-one 
framework. At first benzonitriles were selected with substitutions akin to those in the 
5-amino series of compounds. For this reason, benzonitrile, 4-bromobenzonitrile, 4-
methylbenzonitrile and 4-trifluoromethylbenzonitrile were all investigated. This would 
allow for a direct comparison of the SAR effect of the position-5 substituent change 
alone, whilst maintaining an identical group in the 3-aryl region of the analogue. 
Further to this, benzonitriles were selected with a variety of substituents including 
electron-donating groups, electron-withdrawing groups, polar and non-polar groups so 
that diversity could be introduced into the position-3 region of the isoquinolin-1-one 
framework. Diversity in this region of the isoquinolin-1-one framework would assist in 
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developing a comprehensive SAR of 
the ideal position-3 substituent, which 
will potentially make additional 
interactions within the hydrophobic 
pocket adjacent to the nicotinamide-
binding site of tankyrase-1 and -2.  
Similarly, the steric influence of 
moving the substituent around the 3-
aryl ring, i.e. ortho, meta and para, on 
binding affinity was also explored for 
this series with the 2,6-dichloro-
benzonitrile, 3-chlorobenzonitrile and 
4-chlorobenzonitrile. In addition, the 
ortho and meta substituted 
benzonitriles used in these reactions 
would also stretch and test the 
tolerance of this new route for 
sterically hindered benzonitriles. 
Finally, 5-cyanobenzo-1,3-dioxole and 
4-(t-butyl)benzonitrile were selected 
as these bulky groups would further 
probe into the hydrophobic pocket and 
explore both its shape and length. 
This route proved amenable to 
reaction of a wide range of ortho-, 
meta- and para-substituted benzo-
nitriles, which facilitated the gener-
ation of a diverse library of twenty-
nine analogues very quickly (Table 6). 
A range of yields was obtained in this versatile reaction, probably a reflection of not 
only the nature of the benzonitrile used in each case but also the inconsistency in 
Table 6: Series of 5-substituted-3-arylisoquinolin-1-
ones 206a-m, 207a-i and 208a-g synthesised using 
route four (Scheme 36). Reagents and conditions: 
Pri2NLi, R
2arylCN, -78°C → rt, THF. - reaction not 
attempted. 
R2-group Cpd. Number (% isolated yield) 
R1 = Me  
 
R1 = OMe R1 = F 
 206a 
(20) 
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collecting the product via precipitation. Markedly, when a moderate to poor yield is 
obtained for a particular position-5 substituent (R1 in Scheme 36 and Table 6), it is 
generally also moderate to poor for both other analogues, reflecting the influence of 
the benzonitrile on the reaction outcome as opposed to the influence of the position-5 
substituent (position-3 in starting benzoic acid) on the reaction.  
Electron-withdrawing groups on the benzonitrile e.g. trifluoromethyl group and 
electron-poor benzonitriles e.g. pyridine-4-nitrile confer greater electrophilicity to the 
nitrile group. Although this may make the cyclisation less effective, by stabilisation of 
the intermediate imine anion 211 (Scheme 37), this is not the rate-limiting step of the 
reaction and the reaction proceeds well, with generally good to excellent yields 
obtained (Table 6). Indeed, initial attack of the benzonitrile 212 by the anion on the 
dimethylbenzamide 210 might be facilitated by an electron-withdrawing group on the 
benzonitrile increasing the electrophilicity of the nitrile carbon (Scheme 37). This is 
likely to be the rate-limiting step of this reaction and may justify the higher yields 
obtained when electron-withdrawing or electron-poor groups are incorporated in the 
benzonitrile starting material. 
In contrast, electron-donating groups on the starting benzonitriles e.g. methoxy and 
electron-rich groups e.g. benzodioxole do not appear to proceed as well in this 
reaction with poorer yields obtained regardless of the nature of the position-3 
substituent in the dimethylbenzamide (Table 6). Although theoretically, an electron-
donating or electron-rich group would improve the cyclisation step of the reaction, by 
Scheme 37: Mechanism for reaction between 2-methyl-N,N-dimethylbenzamides 205a-c and benzonitriles 
212. The anion generated from removal of the most acidic methyl proton attacks the electrophilic carbon of 
the cyano group. Subsequently, ring closure occurs through attack from the nucleophilic nitrogen anion 
(originally from the benzonitrile) to the carbonyl carbon, expelling dimethylamine as a leaving group and 
generating the desired isoquinolin-1-one. Refer to Table 6 for R-group detail.  
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de-stabilising the intermediate imine anion 211, this appears to have minimal effect on 
the reaction outcome. The influence of these groups is likely to be greater in the initial 
attack of the nitrile carbon by the 3-methyl anion of the dimethylbenzamide 210, 
where they would reduce the electrophilicity of the nitrile carbon and the tenacity of 
attack (Scheme 37). This would justify the poorer yields obtained for the 4-
methoxybenzonitrile and 5-cyanobenzo-1,3-dioxole starting materials regardless of the 
position-3 substituent on the dimethylbenzamide (Table 6).  
In addition to the influences of electron-withdrawing groups and electron-donating 
groups on the progress of the reaction, it is also clear that steric hindrance plays a sign-
ificant role. Although the coupling of 4-chlorobenzonitrile with the dimethylamide 
205b gave the desired product 206b in high yield (>99%), the 2-chlorobenzonitrile and 
3-chlorobenzonitrile analogues failed to elicit the same effect (isolated yields 206c and 
206d; 2% and 11% respectively). This is probably due to the bulky chlorine atom restr-
icting the access of the approaching anion to the carbon of the nitrile group. Unsurpris-
ingly, this effect is particularly poignant for 2-chlorobenzonitrile and 2,6-dichloro-
benzonitrile where poor isolated yields of 2% and 10% were achieved for 206c and 
206e, respectively. These particularly low yields demonstrate the negative influence of 
steric bulk close to the nitrile reaction centre. This effect was also apparent with the 
thiophene-3-carbonitrile, where the position of the bulky sulphur atom equates to a 
meta-substituted phenyl ring, with poor isolated yields obtained (6% and 14% yield for 
206m and 207i respectively).  
In general, the influence of the position-5 group (position-3 in the starting N,N-di-
methylbenzamide) appears to be minimal on the outcome of the reaction, compared 
with the influence of the starting benzonitriles. There are, however, trends that can be 
identified. The reaction of a benzonitrile bearing a para-electron-withdrawing group, 
thought to be optimal for reaction outcome, progresses differently for all three N,N –
dimethylbenzamides 205a, 205b and 205c with 4-trifluoromethylbenzonitrile (47%, 
27% and >99% yields for 206f, 207c and 208c respectively). The same reaction with a 
benzonitrile bearing an electron-donating group in the para position e.g. 4-methoxy, 
also shows a range of yields between the different starting benzamides 205b and 205c 
(17% and 3% for 206i and 208f, respectively).  
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These results demonstrate that the position-3 substituent on the starting dimethyl-
benzamide does have some influence on the reaction outcome. Although there 
appears to be little difference in the isolated yields from either the 3-fluoro 205c or 3-
methylbenzamide 205b starting materials; the 3-methoxy-N,N-dimethylbenzamide 
205a in almost all cases is lower yielding. This is probably due to the strongly electron-
donating nature of the 3-methoxy group disfavouring formation of the anion electron-
ically, and not due to any steric effect of the slightly larger methoxy group compared 
with the 3-fluoro and 3-methyl groups.  
Although there are some trends apparent, these are complicated to some extent by 
the method of purification. Recrystallisation was used to purify these analogues from 
the crude reaction mixture. On each occasion the recrystallisation conditions used, 
product solubility and temperature fluctuations in the laboratory may have influenced 
the isolated yield obtained. Optimisation might involve the development of standard-
ised recrystallisation conditions. This would allow for a more accurate, direct compar-
ison of analogues synthesised using this route.  
In general, this reaction provided a facile and convenient route for the generation of 
diverse analogues through parallel synthesis. The above reactions of carbanions 
derived from N,N,2-trimethylbenzamides with benzonitriles afforded many of the 
target compounds, with a wide range of substituents on the 3-aryl group of the iso-
quinolin-1-one core (Scheme 36 and Table 6). Compounds carrying methyl, methoxy 
and fluoro at position-5 were accessed by this route but this set of 5-substituents lacks 
a hydrogen-bond donor. To set up an electron-donating hydrogen-bond donor, de-
methylation of the 5-methoxy group to the corresponding hydroxy derivative was 
investigated (Scheme 36). Unfortunately, treatment with HBr in acetic acid, which had 
been so effective in unmasking the lactam from 1-methoxyisoquinolines by de-methyl-
ation, above, failed at moderate temperatures. Even at high temperatures (up to 
120°C) and after 5 days, only an inseparable mixture of mainly starting material and 
some product remained, as shown by 1H NMR spectroscopy. Of course, the de-methyl-
ation of the 1-methoxyisoquinolines had been facilitated by the lactam unit being a 
better leaving group than the simple phenol at position-5. In this latter case, a more 
vigorous reagent was required and treatment of the 5-methoxyisoquinolin-1-ones 
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207a and 207c with the Lewis-acid boron tribromide in dichloromethane, followed by 
hydrolysis of the intermediate borate with sodium hydroxide, revealed the 5-hydroxy 
group of 209a and 209b cleanly and in good yield.  
Although this versatile chemistry led to the formation of isoquinolin-1-ones with the 
majority of substituted benzonitriles explored, there were some analogues that failed 
to lead to the desired product. Firstly, quench of the anion 205b with methyl 4-cyano-
benzoate led to only trace amounts of the desired product by 1H NMR. The majority of 
the mixture was made up of unidentifiable impurities, likely due to the more electro-
philic nature of the ester compared with the nitrile. Quench of the anion 205b with 3-
cyanofuran and with thiophene-2-carbonitrile also failed to give the desired isoquin-
olin-1-one. In both cases the crude 1H NMR spectra revealed that, in addition to un-
changed 3-cyanofuran and 2-thiophenecarbonitrile in the corresponding reaction 
mixtures, another product with five distinct methyl peaks was apparent.  
Further investigation revealed that this side-product 213 was formed by the attack of 
the ArCH2- anion derived from one benzamide on the carbonyl of another (Figure 29). 
This molecule had not been observed in other reactions, suggesting that its formation 
is slow and, when the nitrile is suitably reactive, it does not have the opportunity to 
form. Altogether, this suggests that 2-cyanofuran and 2-thiophenecarbonitrile are 
unreactive towards attack by the anion 205b probably owing to their electron-rich 
nature pushing electron-density towards the nitrile carbon, thus reducing its 
electrophilicity. Quench of the anion 205a and 205b with 3-thiophenecarbontrile did 
afford the desired isoquinolin-1-ones 206m and 207i (Isolated 
yields of 6% and 14% respectively); on this occasion, the sulfur 
atom is one position further away from the nitrile-carbon and 
has less of an electronic influence. 
4.12 Synthesis of 4,5-dimethyl-3-phenylisoquinolin-1-one 
(215) using carbanion chemistry 
Owing to the success of using carbanion chemistry towards 
isoquinolin-1-ones, this method was adapted for incorporation 
of substituents into position-4 of the isoquinolin-1-ones. The 




(213) formed during 
quench of the anion 
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Scheme 38: Synthesis of 4,5-dimethyl-3-phenylisoquinolin-1-one 
(215). Reagents and conditions: i, Pri2NLi, MeI, THF; ii, sec-BuLi, 
PhCN, THF.  
Figure 30: The structure of a peri-
disubstituted naphthalene 216 




rationale for introducing a 4-methyl substituent was as follows. As discussed in the 
following chapter, the presence of a chlorine in the ortho-position of the 3-phenyl 
substituent in 167d, 206c and 206e causes the phenyl to rotate about its axis to give a 
significant dihedral angle between its plane and the plane of the isoquinolin-1-one; 
this is to relieve steric clashes of the chlorine with either the 2-H or the 4-H. This tests 
the ability of the hydrophobic pocket to accept this out-of-plane twist but any change 
of inhibitory activity may be due to one or both of two factors: the dihedral angle itself 
between the two ring systems or the presence of the bulky chlorine making 
unfavourable steric interactions in this region of the pocket. To test which factor may 
be operating, the chlorine was omitted from the 3-phenyl but the dihedral twist of the 
phenyl relative to the isoquinolin-1-one was retained by having a bulky methyl group 
(approximately isosteric with chlorine) in position-4 of the isoquinolin-1-one in 215, 
“ortho” to the phenyl. This methyl would also make a peri-steric interaction with the 5-
methyl, potentially buckling the isoquinolin-1-one.  
This effect is likely analogous to the unique ‘proximity effects’ observed in peri-
disubstituted naphthalenes (substitutions in both positions-1 and -8) where the 
otherwise rigid planar structure of un-substituted naphthalene is forced to change 
(Figure 30).234 Crystallographic studies of 3-bromo-1,8-dimethylnaphthalene (216) 
reveal that the peri-methyl groups bend away from each other by 0.42 Å but remain 
within the aromatic plane of the naphthalene bicycle by an in-plane bending of the C-
CH3 bonds of 4°.234 In addition, a noticeable increase in the non-bonded distance is 
seen between the two peri-methyl groups (2.56 Å) compared with the distance 
between C4 and C5 (2.44 
Å).234 Considerable buckling of 
ring A is also observed as the 
bond angles attempt to stay 
consistent with those 
observed in naphthalene.234 
Ring B, however shows con-
siderable differences in bond 
angles, likely due to the large 
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bromine atom preventing the ring from losing planarity but introducing considerable 
ring strain as a consequence.234  
N,N,2,3-Tetramethylbenzamide (205b) was deprotonated at the 2-CH3, using the basic 
conditions as above (LDA in THF at -78C) (Scheme 38). Quench of this anion with iodo-
methane gave 2-ethyl-N,N,2-trimethylbenzamide (214) in moderate yield. It was prop-
osed that further treatment of this analogue with LDA would correspondingly remove 
a ArCH2Me proton; the subsequent anion should then react with benzonitrile and the 
intermediate should cyclise to afford the desired 4,5-dimethyl-3-phenylisoquinolin-1-
one (215). Unfortunately, no product was observed in the 1H NMR spectrum of the 
crude isolated material; the major identifiable peaks were to the starting material 214. 
This may be due to a failure to remove the ArCH2Me proton, as the anion derived from 
the 2-methyl analogue 205b and lithium diisopropylamide was intensely red but no 
such colour was observed in the present reaction mixture after treatment with the 
same base (only a dull orange colour was observed).  
To test this theory, the 2-ethyl compound 214 was treated with LDA under the same 
conditions, followed by a quench with deuterium oxide. NMR analysis revealed no in-
corporation of deuterium into 214, showing that no deprotonation had occurred. This 
implied that the ArCH2Me protons were less acidic than the corresponding ArCH3 
protons and that the LDA was sufficiently basic to remove the latter but not the 
former. A stronger base was therefore required. sec-BuLi did remove the desired 
proton and, following quench with benzonitrile, afforded the required 4,5-dimethyl-3-
phenylisoquinolin-1-one (215) in moderate yield (Scheme 38). The success of this 
reaction allows for the design of further inhibitors where changes in position-4 of the 
isoquinoline framework are preferable. One-pot reactions may also be possible 
starting from the 2-methyl educt 205b: (i) deprotonation with sec-BuLi, (ii) alkylation 
with an appropriate haloalkane (to introduce the 4-substituent), (iii) a second addition 
of sec-BuLi and (iv) addition of an appropriate benzonitrile (to provide N-2, C-3 and the 
appended 3-aryl substituents). 
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4.13 Position-3 extensions in 5-substituted isoquinolin-1-ones using carbanion 
chemistry 
Following the synthesis of the diverse library of 3-arylisoquinolin-1-ones, it became 
apparent from molecular modelling efforts that exploration deeper into the large 
hydrophobic ovoid-shaped cavity located in the proteins towards position-3 of the iso-
quinolin-1-ones may lead to more interactions in this region and to an improved 
profile of potency and selectivity (See Section 5.4.11). Attempts to synthesise an 
analogue with a rigid ethynyl spacer between the 5-aminoisoquinolin-1-one and the 
phenyl ring failed (See Section 4.10). It was proposed that the versatility of the carb-
anion chemistry used to synthesise the 5-methyl-, 5-methoxy- and 5-fluoroisoquinolin-
1-one libraries might also be amenable to the synthesis of new extended analogues. 
The absence of an acidic α-proton in the substrate nitriles was essential, as the inter-
mediate ArCH2- anion is very basic and would be expected to remove any acidic -
proton in preference to reacting with the weakly electrophilic nitrile. Attempting to 
introduce a 3-(E-2-phenylethenyl) substituent, the anions generated from the 2-
methyl-N,N-dimethylbenzamides 205a and 205b were treated with E-3-phenylprop-
enenitrile (trans-cinnamonitrile) (Scheme 39), with the added precaution of conducting 
the experiment in the dark to avoid trans-cis photoisomerisation of the product (a 
problem previously observed with 3-(2-
phenylethenyl)quinoline-8-carbox-
amide).154 Unfortunately, column 
chromatography isolated unchanged 
cinnamonitrile and N,N-dimethyl-
benzamide 205a and 205b starting 
materials. In the case of 3-methoxy-
N,N,2-trimethylbenzamide (205a), a 
side-product was obtained which was 
identified as 219 by both 1H NMR and 
mass spectrometry (Scheme 39). Akin 
to the observations for some weakly 
reactive nitriles above, this result 
Scheme 39: Attempts to incorporate a 2-carbon linker 
into position-3 of the isoquinolin-1-one. Reagents and 
conditions: i, n-BuLi, Pri2NLi, 3-phenyl-2-propynenitrile, 
-78°C → rt; ii, n-BuLi, Pri2NLi, cinnamonitrile, -78°C → 
rt. The side-product 219 was observed in a crude 
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shows the poor reactivity of the cinnamonitrile, as the anion has been forced to attack 
the otherwise poorly electrophilic dimethylbenzamide carbonyl. This is a particularly 
surprising result, as, even though the nitrile appears to be insufficiently electrophilic 
for the desired reaction to occur, there is an alternative soft but reactive conjugate 
electrophile available at the alkene carbon adjacent to the benzene ring. This 
conjugate addition would be predicted to be irreversible, as it forms a C-C bond. No 
conjugate addition products were observed in any case. 
Similar attempts were made to incorporate a phenylethynyl unit at position-3 of the 
target isoquinolin-1-ones by using 3-phenyl-2-propynenitrile as the electrophilic comp-
onent (Scheme 39). Both attempts to synthesise this analogue failed to lead to the 
desired product; instead a mixture of compounds were obtained, with the N,N-dimeth-
ylbenzamide starting material 205a and 205b being the most abundant in the crude 
reaction mixture by 1H NMR. In common with the cinnamonitrile, it is likely electrophil-
icity of the nitrile carbon is compromised by conjugation with the electron-rich alkyne. 
This will reduce the propensity of the nitrile carbon to be attacked by the 2-methyl 
anion of the dimethylamide starting material. In addition, akin to cinnamonitrile, an 
alternative soft conjugate electrophile is available at the alkyne carbon adjacent to the 
benzene ring. Again, no products of conjugate addition were observed.  
As incorporating a two-carbon ‘linker’ group (alkene or alkyne) between the isoquinol-
in-1-one scaffold and 3-aryl group was proving challenging, an alternative approach to 
extending the molecule in the 3-
aryl direction was proposed 
(Scheme 40). Although not 
directly comparable with the 
aforementioned compounds, an 
analogue was designed so that 
the two-carbon linker would sit 
between two phenyl rings, thus 
situated away from the weakly 
electrophilic nitrile moiety and 
unable to participate in con-
Scheme 40: Synthesis of extended 3-
arylisoquinolin-1-one 222. Reagents and 
conditions: i, CuI, sodium ascorbate, 
PdCl2(Ph3P)2, THF, Pr
i
2NH, 50°C, 30 min 
then phenylacetylene, 50°C; ii, Pri2NLi, 
221, THF.  
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jugate addition. Such an analogue would extend and probe further into the ovoid 
hydrophobic pocket than the originally planned analogues but would still provide valu-
able information on potential interactions. This would also explore the possibility of 
extending the binding into the narrow tunnel at the end of the hydrophobic pocket 
remote from the isoquinolin-1-one. The rigid 4’-phenylethynylphenyl unit was thus 
assembled.  
The required 4-phenylethynylbenzonitrile 221 was not commercially available but was 
accessed using a Sonogashira coupling reaction between 4-bromobenzonitrile (220) 
and phenylethyne in excellent yield (Scheme 40). Compound 221 was then added to 
the anion derived from N,N,2,3-tetramethylbenzamide (205b) under the usual condit-
ions (LDA, THF, -78°C) to provide 222 in a moderate isolated yield (31%). Unfort-
unately, quench of the equivalent anion derived from 3-methoxy-N,N,2-trimethylbenz-
amide (205a) with 4-phenylethynylbenzonitrile (221) only produced a trace amount of 
product (evident in the crude 1H NMR spectrum) with mainly 221 apparent in the 
mixture. This was not unsurprising, as this 3-methoxybenzamide 205a had, in general, 
given poorer yields than the corresponding 3-methylbenzamide 205b, regardless of the 
benzonitrile employed.  
The synthesis of 222 represented a facile route to extend the 3-aryl region adjacent. As 
this analogue is larger, more rigid and more hydrophobic than the majority of other 
compounds in the library, solubility may prove to be a limitation in its biological 
assessment. Indeed, as previous studies42, 68, 82, 107, 154 and our own molecular model-
ling indicate a preference for bulky, hydrophobic groups in position-3 of the isoquin-
olin-1-one framework, a balance between the Lipinski-compliant nature of inhibitors 
and incorporating these optimal functional groups will be required.  
4.14 Water-soluble analogues (tertiary amines) 
Owing to the poor aqueous solubility exhibited by many of the analogues synthesised 
using the carbanion chemistry (Schemes 36, 38 and 40), due to the lack of the solubilis-
ing 5-amine of the earlier series, it was desirable to improve this important biopharma-
ceutical property through the incorporation of an alternative solubilising entity. Good 
aqueous solubility is an important property for a new drug; not only does it make pre-
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formulation and formulation studies much easier, it also markedly reduces the likely-
hood of attrition through pre-clinical, Phase I, II and III trials. A solid dosage form that 
is orally bioavailable is highly desirable and indeed more acceptable to patients and 
clinicians alike. It is important that these factors are taken into consideration at as 
early a stage as possible in drug development. 
Attempts to introduce a water-solubilising amine group in the para-position of the 3-
aryl group (isoquinoline numbering) by Nathubhai et al. in a series of quinazolin-4-ones 
were successful (Scheme 41).229 Acylation of 223 with 4-nitrobenzoyl chloride (224) 
and subsequent cyclisation of 225 under basic conditions gave 226, whence transfer 
hydrogenation gave the primary aniline of 227.229 Although a reasonably good inhibitor 
of the tankyrases (IC50: Tankyrase-1 = 35 nM and tankyrase-2 = 3.3 nM), the aniline 227 
is unlikely to be protonated at physiological pH and these results merely indicate the 
tolerance of the hydrophobic pocket to a small substituent with the potential to 
donate a hydrogen bond.  
Seeking to introduce a more basic primary aliphatic amine which would be protonated 
and ionic at physiological pH (pKa of conjugate acid ca. 10), Nathubhai designed the 
benzylamine 232.229 In pursuit of the desired analogue, Nathubhai protected the prim-
Scheme 41: Synthesis of 2-arylquinazolin-4-ones 227 and 232.229 Reagents and conditions: i, pyridine; ii, 
aq. NaOH (0.5 M), 60°C; iii, NH4
+
 HCO2
-, Pd/C, MeOH, DMF; iv, CbzCl, aq. K2CO3; v, SOCl2; vi, pyridine; vii, 
aq. K2CO3 (1.0 M), 100°C; viii, HBr, AcOH.  
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ary amine of 4-aminomethylbenzoic acid (228) with Cbz and formed the acyl chloride 
229.229 The anthranilamide 223 was acylated with 229 to give the intermediate amide 
230, followed by cyclisation with the aqueous potassium carbonate to give 231.229 
Removal of the Cbz group of 231 with HBr gave 232.229 Interestingly, the Cbz-protected 
compound 231, in which the 2-aryl-substituent on the quinazolin-4-one is greatly 
extended, had good inhibitory activity (IC50: Tankyrase-1 = 73 nM and tankyrase-2 = 44 
nM). However, the activity of 232, in which the primary aliphatic amine would be 
protonated at physiological pH, was completely abrogated (IC50: Tankyrase-2 = ~100 
nM).229 Unsurprisingly, the former compound 231 suffers from poor solubility, whereas 
the latter 232 is much more soluble but not sufficiently active. This indicates that the 
residues lining the hydrophobic pocket in this region may not tolerate very polar 
charged functionalities, although it was considered that a (protonated) tertiary aliph-
atic amine may be acceptable.  
Adapting to the current project, it was planned that a series of tertiary aliphatic amines 
could be incorporated into a benzonitrile, so that this entity could be introduced into 
the isoquinolin-1-one framework using established chemistry (Scheme 42). These iso-
quinolin-1-ones should benefit from improved aqueous solubility through protonation 
of the ring nitrogen at physiological pH. They should also be less polar than 232 and 
thus make desirable hydrophobic interactions in this region of the pocket, leading to a 
better fit. Four aliphatic 
tertiary amines 234a-d 
were planned to be 
introduced into the 3-aryl 
region of the isoquinolin-
1-one scaffold via a one-
carbon link in the para-
position of the 3-phenyl 
group. The smallest 
possible aliphatic amine, a 
dimethylaminomethyl 
group, was investigated 
Scheme 42: Synthesis of water-soluble isoquinolin-1-one analogues 
236a-d. Reagents and conditions: i, cyclic amine, base, rt, 16h; ii, n-BuLi, 
Pri2NLi, RCN, -78°C → rt; iii, 6M aq. HCl, rt, 16h. 
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initially at the para-position of the phenyl. The saturated cyclic amine substituents 
pyrrolidin-1-ylmethyl and piperidin-1-ylmethyl were selected owing to their significant 
hydrophobicity. Increasing in size from a five to a six-membered saturated ring would 
also allow the tolerance of the hydrophobic pocket to steric bulk to be explored. Not 
only is the increase is size important, but the change in shape as the saturated ring 
goes from five- to six-membered may be significant. A five-membered ring will occupy 
either an ‘envelope’ or ‘twist’ conformation, whereas a six-membered fully saturated 
ring will be almost always be a ‘chair’ conformation.235 In addition, and unlike any 
analogues made previously, the saturated cyclic amines would be attached via a single 
CH2 carbon linker, which will increase the relative basicity of the tertiary amine. This 
linker also allows two rotatable bonds within the hydrophobic pocket which may cause 
steric clashes, however this effect should be minimal compared with that observed 
with the two-carbon linker of 175. Finally, 4-methylpiperazin-1-ylmethyl was selected 
as the inclusion of two nitrogen atoms within the ring structure may give double 
protonation at physiological pH, thus potentially improving water-solubility further. 
Stirring dimethylamine, piperidine, pyrrolidine and 1-methylpiperazine with 4-bromo-
methylbenzonitrile (233) at room temperature, in the presence of base, converted 
these secondary amines into the corresponding 4-(dialkylaminomethyl)benzonitriles 
234a-d (Scheme 42). Quench 
of the anion of N,N,2,3-
tetramethylbenzamide (205b) 
(generated with LDA at -78°C 
in THF as previously described 
in Scheme 36) with benzo-
nitriles 234a-d gave the 
desired products 235a-d in 
poor to moderate yield (235a 
= 4%; 235b = 9%; 235c = 21%; 
235d = 2%). The poor yields 
obtained are probably a result 
of difficulty in isolating the 
Figure 31: Pre-formulation exercise to compare the solubility of 
the neutral tertiary amine 235c with its corresponding 
hydrochloride salt 236c.  
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product using recrystallisation as opposed to a failure to react, as no starting material 
was observed in the crude 1H NMR. Treatment of 235a-d with aqueous hydrochloric 
acid gave the desired hydrochloride salts 236a-d. 
4.15 Solubility studies 
In order to ascertain whether the incorporation of a hydrochloride salt would lead to 
an improvement in the solubility, compared with the neutral tertiary amine 
compounds 235a-d, a small pre-formulation exercise was undertaken (Figure 31). This 
study involved the timed addition of a fixed volume of water (100 µL) every 5 min to a 
sample vial containing 1 mg of 235c and 236c over a total time period of (50 min), with 
qualitative changes in the appearance of the mixture noted at each time point. 
Unsurprisingly, the hydrochloride salt 236c dissolved more rapidly than its neutral 
amine counterpart 235c, with a clear solution observed after the addition of 500 µL of 
distilled water. This equated to an apparent aqueous solubility of 2.0 mg mL-1 for 236c, 
compared with the neutral tertiary amine 235c which had a solubility of < 1 mg mL-1. 
According to the United States Pharmacopoeia definition of solubility the 
hydrochloride salt 236c would be defined as ‘slightly soluble’; a category better than 
the neutral amine 235c which is only ‘very slightly soluble’. This small improvement 
will result in these analogues (236a-d) being considerably more tractable. This should 
lead to more facile manipulation of these analogues for biological testing.  
4.16 Can old compounds be made using new tricks? 
Owing to the success of the carbanion chemistry for the synthesis of diverse isoquinol-
in-1-ones (Scheme 36), it was of interest whether this route could be adapted to the 
synthesis of 5-aminoisoquinolin-1-ones (167a-q) that had previously been made using 
palladium-catalysed coupling chemistry.  
Treatment of 2-methyl-3-nit-
robenzoic acid (237) with 
thionyl chloride, then addition 
of the subsequent acid 
chloride dropwise to 
Scheme 43: Attempts to synthesise 5-nitro-3-phenylisoquinolin-1-
one (165a) using carbanion chemistry. Reagents and conditions: i, 
SOCl2 then aq. Me2NH, CH2Cl2; ii, n-BuLi, Pr
i
2NLi, PhCN, -78°C → rt.  
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dimethylamine gave the desired dimethylbenzamide 238 cleanly and in excellent yield 
(Scheme 43). Although de-protonation of the 2-methyl group of 238 with LDA 
(generated in situ) seemed likely to have occurred (due to the intense red colour 
formed in the reaction mixture), no 5-nitro-3-phenylisoquinolin-1-one (165a) was 
observed following addition of benzonitrile. This may be due to the strongly electron-
withdrawing nitro group located adjacent to the 2-methyl, drawing electrons away 
from the anion generated at this position. This would reduce the nucleophilicity of the 
anion, reducing its propensity to attack the weakly electrophilic carbon of the benzo-
nitrile. Only starting materials were observed in the crude 1H NMR spectrum of the 
reaction mixture. Therefore, this route was unlikely to be an alternative to the 
palladium-catalysed coupling chemistry previously adopted to lead to 5-amino-3-aryl-
isoquinolin-1-ones in this series.  
4.17 Incorporation of alternative bulky, hydrophobic substituents at position-3 of the 
isoquinolin-1-one scaffold 
Examination of the crystal structures of the catalytic site of tankyrase-2 and, indeed, 
some selective inhibitors of tankyrase-1 and -2 previously described, had indicated the 
requirement for a hydrophobic substituent in position-3 of the isoquinolin-1-one 
framework, owing to the abundance of hydrophobic residues around the pocket in this 
region. The precise shape of this hydrophobic pocket and its tolerance to occupation 
by bulky substituents had not been fully explored. Although the tolerance of the 
hydrophobic pocket to (substituted) phenyl groups is extensively tested above, includ-
ing modulating the dihedral angle between the planes of the isoquinolin-1-one and the 
3-phenyl (Section 4.12), extending from the 3-phenyl deeper into the hydrophobic 
pocket (Section 4.13) and introducing water-solubilising groups off the 3-phenyl 
(Section 4.14), there has been no investigation to date of incorporating a hydrophobic 
3-substituent with three-dimensional bulk. 
4.17.1 Synthesis of the 3-ferrocenyl analogues 242 and 262 
It was proposed that the incorporation of a bulky ferrocenyl group into position-3 of 
the isoquinoline framework might pose some of these questions of the active site and 
provide useful clues for further design. This organometallic ‘sandwich’, consisting of 
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two cyclopentadienyl rings bound on opposite 
sides of an iron atom has attracted considerable 
attention recently, owing to the considerable 
biological activity exhibited by some analogues 
containing this functionality.236-238 One promising 
example included a ferrocene-chloroquine 
analogue 239 (Figure 32), which had part of a 
carbon chain replaced with a ferrocenyl group and, as a result, showed increased 
activity against resistant strains of malaria including Plasmodium falciparum, P. berghei 
N and P. yoelii NS.239, 240 
Various palladium-catalysed cross-coupling reactions have been explored in the literat-
ure to introduce ferrocenyl groups into organic compounds with varying success, alth-
ough compounds with a ferrocene bonded directly to either quinoline or isoquinoline 
are scarce.241 Prior to the discovery that the ferrocenyl group could contribute to the 
activity of potential drug molecules, it was an important entity in asymmetric 
catalysis242, 243 and materials science244 and early syntheses to incorporate this moiety 
were for these industries exclusively. The recent resurgence of interest in the synthesis 
of aryl-substituted ferrocenes has seen the investigation of numerous new cross-coup-
ling routes to obtain them.245, 246 Long and colleagues studied the scope of the Suzuki-
Miyaura reaction for this purpose and optimised conditions for the coupling of ferro-
ceneboronic acid with 4-methylphenyltriflate using tetrakis(triphenylphosphine)pallad-
ium(0) and potassium phosphate in dioxane at reflux to give 4-methylphenylferrocene 
in an isolated yield of 90%.247 A large number of diverse aryl-substituted ferrocenes 
bearing both electron-withdrawing and electron-donating groups were then synth-
Figure 32: Substitution of a part of a 
carbon chain for a ferrocenyl group in 
239 showed activity against resistant 
strains of Plasmodium falciparium, P. 





Scheme 44: Attempted Suzuki and Negishi cross-coupling reactions towards the 3-ferrocenylisoquinolin-1-
one 242. Reagents and conditions: i, ferroceneboronic acid, SPhos, Pd2(dba)3, K3PO4,dry DMF, 125°C, 16 h; ii, 
ferroceneboronic acid, Pd(PPh3)4, K3PO4, dry dioxane, 101°C, 70 h; iii, bromoferrocene, n-BuLi in dry hexane 
then ZnCl2, Pd(dppf)Cl2, dry THF or hexane, rt; iv, H2, Pd/C or Pt/C, EtOH, 3-5 h; v, HBr / AcOH, 65C, 6h. 
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esised using these conditions, demonstrating the convenience of this route.247 
It was therefore planned that a Suzuki-Miyaura cross-coupling reaction would intro-
duce the ferrocenyl moiety conveniently into position-3 of the isoquinoline framework. 
Unfortunately, attempts to couple ferroceneboronic acid to both 3-chloroisoquinoline 
121 and 3-bromoisoquinoline 164 under conditions optimised for the synthesis of the 
3-aryl-1-methoxy-5-nitroisoquinolines (SPhos, Pd2(dba)3, K3PO4 in dry DMF) failed to 
give any desired product (Scheme 44, reaction i). This was confirmed by 1H and 13C 
NMR and high-resolution mass spectrometry where both the halogenated starting 
material and dehalogenated 1-methoxy-5-nitroisoquinoline were observed (with both 
3-bromoisoquinoline 164 and 3-chloroisoquinoline 121 starting materials), indicating 
that oxidative addition was occurring to some extent but that a failure to 
transmetallate was halting the catalytic cycle. Adopting the same conditions reported 
by Long et al. 247 also failed to result in any evidence of cross-coupling; only starting 
materials were observed in the crude 1H NMR spectrum (Scheme 44, reaction ii).  
Kasák and colleagues, in an attempt to synthesise a binaphthyl-bridged ferrocene for 
applications in stereoselective catalysis, investigated a variety of palladium-catalysed 
cross-coupling reactions.248 Of all cross-couplings investigated, the Negishi coupling of 
the dizinc 244 with the diiodide 243 gave enatiopure 245 in the highest isolated yield 
(35%) (Scheme 45).248 This important reaction, discovered by Negishi and co-workers 
in 1976, sees the cross-coupling of organozincs with aryl-, alkenyl- or alkynyl halides in 
the presence of a palladium or nickel catalyst.197, 208 
Adapting to the current project, it was proposed that a ferrocenyl-zinc would be 
coupled into the desired isoquinoline scaffold more easily than would the boronic acid 
equivalent. The ferrocenyl-zinc was prepared by treatment of bromoferrocene with n-
BuLi under strictly anhydrous conditions, followed by quench with zinc chloride in 
tetrahydrofuran (Scheme 44, reaction iii). Then, using the conditions described by 
Scheme 45: Synthesis of 1, 
1’-binaphthyl-2,2’-diyl-
bridged ferrocene 245 using 
a Negishi cross-coupling 
reaction.248 Reagents and 
conditions: Pd(dppf)Cl2, THF, 
rt, 3 d.  
 
 
- 131 - 
 
Kasák and colleagues 248, the ferrocenyl-zinc was added to the 3-bromoisoquinoline 
164 and stirred at room temperature. After 5 days of stirring and monitoring by TLC, 
only unchanged bromoferrocene was apparent in the crude 1H NMR, indicating that 
the lithium-bromine exchange had failed. This may have been due to the limited solub-
ility of bromoferrocene in hexane; however an identical reaction conducted in THF, in 
which bromoferrocene was freely soluble, also gave the same result.  
It seemed likely that the relatively mild cross-coupling conditions adopted thus far 
were not sufficiently vigorous to effect the desired coupled product and an alternative 
route was sought. It was postulated that the transmetallation stage of the catalytic 
cycle might be hindering the progress of these cross-coupling reactions, especially 
owing to the de-halogenated isoquinoline observed in some cases. The Stille cross-
coupling reaction was proposed as an alternative method.  
The Stille reaction, pioneered by J. K. Stille, is the cross-coupling of an organostannane 
and an organic alkenyl, aryl or acyl halogen or triflate under mild conditions to form a 
new C-C sigma bond. Although the organotin compounds are tolerant to a large variety 
of functional groups and are not sensitive to either moisture or oxygen, the Stille 
coupling has become less popular of late, owing to the toxicity of organotin com-
pounds and the difficulty in removing their by-products from the reaction mixture.197, 
208 That said, the Stille cross-coupling reaction remains a powerful synthetic tool in 
organic chemistry to date.197, 208 
The functionalisation of ferrocene through lithiation of the cyclopentadienyl rings, 
followed by selective transmetallation with the tributylstannyl group, has been used to 
synthesise new ferrocenyl ligands for decades.249 More recently, the cross-coupling of 
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Liu and colleagues250 required the intermediate tributylstannylferrocene 247 which 
was prepared according to Wright’s249 procedure of dilithiation of ferrocene with n-
BuLi, followed by treatment with tributyltin chloride. This intermediate was then 
coupled to a variety of bromoquinolines 246a-e in a one-step procedure in generally 
excellent yields (Scheme 46).250 Although the cross-couplings progressed for the 
majority of electron-deficient mono-heterocyclic systems, electron-rich heterocyclic 
bromides did not couple well and a co-catalyst, copper (II) oxide, significantly improved 
the yields from such compounds.250 
Adapting these conditions to the current project, sufficiently pure tributylstannylferro-
cene (247) was generated following Wright’s procedure (a small amount of contamin-
ation with di-substituted ferrocene 251 and ferrocene 249 is always inevitable but 
these are adequately removed using column chromatography) (Scheme 47).249 This 
intermediate was then stirred with the 3-bromoisoquinoline 164 under the conditions 
described in Scheme 47. Although the crude reaction mixture comprised of a 10:1 ratio 
of 3-butyl compound 252 to the desired 3-ferrocenyl product 240, the latter was 





247. Reagents and 
conditions: 
PdCl2(PPh3)2, dry 
DMF, 120-130°C.250  
Scheme 47: Stille cross-coupling reactions towards 3-ferrocenylisoquinoline 240. Reagents and conditions: 
i, n-BuLi (1 equiv.), TMEDA, hexane, 0°C → rt, 4 h; ii, Bu3SnCl, 0°C → rt, 4 h; iii, CuO, Pd(PPh3)4, SnBu3-
ferrocene (247) in dry DMF, 125°C, 16h; iv, SPhos, SnBu3-ferrocene (247) or SnMe3-ferrocene, Pd2(dba)3 in 
dry toluene, 101°C, 72h. 
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apparent by 1H NMR spectroscopy. The transfer of a butyl group to the binaphthyl 243 
was also observed by Kasák when attempting to couple to tributylstannylferrocene 247 
which they rationalised was due to the sensitivity of the Stille cross-coupling reaction 
to steric factors.248 In this case, the result demonstrates the arduousness of this 
coupling, as the transfer of a butyl group, generally known to be highly un-transfer-
able, occurred preferentially over the ferrocene.  
Owing to the trace amount of desired product 240 generated in this Stille coupling, it 
was anticipated that modifying the conditions might lead to a greater proportion of 
this compound in the reaction mixture. Traditional Stille conditions of tris(benzylidene-
acetone)dipalladium (0) and SPhos in toluene at 101°C were employed and the desired 
coupled product 240 was the major product observed, albeit in ca. 7% yield (Scheme 
47, reaction iv). Unfortunately, all fractions collected from column chromatography 
were contaminated with the 3-butyl compound 252; the almost identical Rf values of 
this contaminant and desired product 240 making separation almost impossible. 
Although 240 was not able to be isolated in a pure state, evidence that the ferrocene 
Figure 33: 1H-13C HMBC spectrum of 240 demonstrating the attachment of the ferrocenyl moiety to the 
isoquinoline through a cross-peak (red circle) which connects the ferrocene 1-C through three bonds to 
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was directly connected to the isoquinoline framework was clear; 2D NMR studies in 
this case clearly show via HMBC connections that the 4-proton of the isoquinoline 
connects through to the ferrocenyl 1-carbon (Figure 33) and a nOe interaction 
between the ferrocenyl-2 and -5 protons and the 4-proton shows their close vicinity in 
space (Figure 34). Mass spectrometry confirmed the presence of the molecular ion.  
Owing to the difficulty in separating the desired product 240 from the 3-butyl side-
product 252, it was proposed that the use of an alternative tin reagent, trimethyltin 
chloride might obviate this problem. Although the transfer of a methyl group to 
position-3 of the isoquinoline is still possible, the resulting Rf of this side-product is 
likely to be sufficiently different from that of the desired product 240 and should 
facilitate its efficient separation by column chromatography. On this occasion, the 
trimethylstannyl ferrocene was made by treatment of bromoferrocene with n-BuLi, 
followed by quench with trimethyltin chloride to afford the functionalised ferrocene. 
Unfortunately, when adopting the same Stille conditions as in Scheme 47 (Entry iv), the 
Figure 34: A 1H-1H NOESY NMR spectrum of 240 which shows that the 4-proton on the isoquinoline is close 
in space to the ferrocenyl-2 and 5 protons, giving evidence that the ferrocenyl moiety is attached as desired.  
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cross-coupling of 3-bromoisoquinoline 164 and trimethylstannylferrocene failed to 
provide either the desired 3-ferrocenylisoquinoline 240 or the expected side-product 
3-methylisoquinoline; rather, an indistinguishable mixture of several compounds was 
apparent in the crude 1H NMR spectrum and thus this route was abandoned.  
The failure of the Stille reactions conducted thus far to afford clean coupled product 
240 in high yield, led to the proposal that the isoquinoline could be transformed into a 
Stille reagent, rather than the ferrocene component. It was postulated that this may 
circumvent the issue of poor transferability of the ferrocene component, as isoquinol-
ine itself should be much more transferable than the butyl groups. Hirschäuser and 
colleagues had reported similar transformations onto an isoquinoline framework 253 
in their investigation towards a new modular synthesis of cytisine and, therefore, these 
conditions were modified and adopted for this work (Scheme 48).251  
Attempts to stannylate position-3 of 3-bromo-1-methoxy-5-nitroisoquinoline (164) 
using conditions reported by Hirschäuser and colleagues251 failed to give any desired 
product 257, with only recovery of starting materials apparent in the crude 1H NMR 
spectrum (Scheme 49). It was postulated that the very low temperatures (-78°C) 
employed in this reaction may have slowed the reaction down and prevented 
stannylation from occurring. A subsequent attempt saw the addition of 
tributyltinchloride at a higher temperature (0°C); on this occasion, multiple 
stannylation appears to have occurred in both the desired position-3 of the 
isoquinoline and unexpectedly, in position-6 adjacent to the 5-nitro functionality, 
Scheme 48: Stannylation of 3-bromoisoquinoline 253.251 Reagents and conditions: i, n-BuLi, THF, -
78°C then Bu3SnCl; ii, Pd(PPh3)4, CuCl, LiCl, THF, 70°C, 24 h. 
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according to the crude 1H NMR spectrum. This 
surprising result may indicate the ability of the 
ortho-nitro group to co-ordinate with the 
lithium and direct the lithiation / stannylation. 
It would appear than an intermediate 
temperature (between -78°C and 0°C) might 
be required to effect the mono-stannylation 
of 257 alone. Although the effect of the ortho-
nitro group on the stannylation step was not 
clear, it was apparent that it was confounding 
the outcome of the above reactions and 
therefore a further stannylation of 3-bromo-1-
methoxyisoquinoline (253), lacking the 5-nitro 
group, was attempted. 
Treatment of 3-bromo-1-methoxyisoquinoline 
(253) with n-BuLi in THF at -78°C, followed by 
the slow addition of tributyltin chloride did not provide the desired stannylated iso-
quinoline; rather the isolation of 1-methoxyisoquinoline demonstrated that halogen-
lithium exchange had probably occurred but that the anion had been subsequently 
quenched with a proton and not with the required tin reagent (Scheme 49). This may 
demonstrate that either the anhydrous conditions had not been maintained strictly 
enough or that the tin reagent had degraded. A second attempt with fresh reagents 
under strictly anhydrous conditions did not give the desired stannylated product with 
only 253 isolated from the crude reaction mixture. The apparent difficulty in 
functionalising the isoquinoline itself in preparation for a cross-coupling reaction led to 
this route being abandoned.  
Although the majority of traditional palladium-catalysed cross-coupling reactions 
attempted had failed to effect the desired 3-ferrocenylisoquinoline 240, limited 
success had been achieved through a Stille cross-coupling reaction (Scheme 47). Un-
fortunately the low yield and contamination with the side-product 252 meant that this 
route was not convenient for general use towards this desired product 240. In 
Scheme 49: Attempts to functionalise the key 
isoquinoline intermediate 164 using 
conditions reported by Hirschäuser.251 R = 
NO2 / H. Reagents and conditions: i, n-buLi, 
SnClBu3 in dry THF, -78°C→rt; ii, bromo-
ferrocene, SPhos, Pd2(DBA)3 in dry toluene.  
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addition, two further transformations would be required to reveal the final product; 
reduction of the nitro functionality to give 241 and de-protection of the fixed lactam to 
give 242 (Scheme 44). 
Owing to the proficiency and tolerance of the carbanion chemistry used to synthesise 
the diverse range of 3-aryl-5-substituted-isoquinolinones in effectively a two-step syn-
thesis (Section 4.11 and Scheme 36), it was proposed that this route might be suitable 
for the incorporation of a 3-ferrocenyl functionality. In addition to being tolerant to a 
range of substituted benzonitriles, the final compound is revealed after two steps, 
without complex purification. The required ferrocenenitrile was not commercially 
available and a method was devised for its synthesis (Scheme 50). Treatment of ferro-
cenecarboxylic acid (259) with oxalyl chloride revealed the corresponding acid 
chloride, which, when added dropwise to a stirred solution of ammonia in diethyl 
ether, gave the amide 260 in excellent yield. Treatment of 260 with excess POCl3 
affected complete transformation to the desired nitrile 261. 
N,N,2,3-Tetramethylbenzamide (205b) was then deprotonated with LDA in THF 
at -78°C as described previously (Section 4.11). Subsequent quench of this anion with 
ferrocenenitrile (261) at -78°C for 1 h and then warmed to room temperature for 16 
hours afforded the desired novel 3-ferrocenylisoquinolin-1-one (262) in moderate yield 
with no requirement for any complex purification (Scheme 50). The connection 
between the ferrocene and the isoquinoline scaffold was seen through 1H-13C HMBC 
peaks between the 4-H of the isoquinoline-1-one and the 1-C of the ferrocene. In 
addition, an nOe interaction was observed between the 4-H of the isoquinoline 
scaffold and the 2,5-
H2 of the ferrocene. 
This method 
represents the first 
known attachment of 
a ferrocene to an 
isoquinoline using 
this type of 
chemistry.  
Scheme 50: Carbanion 
chemistry towards 3-
ferrocenylisoquinolin-1-one 
262. Reagents and conditions: 
i, (ClCO)2 in dry DCM then NH3 
in ether, 15 min, rt; ii, POCl3, 
120°C, 2h; iii, n-BuLi, Pri2NLi, 




- 138 - 
 
4.18 Summary of synthetic chemistry 
In total, a library of fifty-six isoquinolin-1-ones was synthesised using diverse synthetic 
chemistry (Figure 35). This has included palladium-catalysed cross-couplings (Suzuki-
Miyaura, Negishi, Sonogashira and Stille reactions) and carbanion chemistry. The 
analogues have been specifically designed with diversity in mind; focussed on 
Figure 35: Candidate library of potential 
tankyrase-1/-2 inhibitors split into six 
distinct groups based on the 5-
substituent. One further analogue 215, is 
not shown here (Structure shown in 
Scheme 38).  
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challenging the nicotinamide binding-site and its adjacent hydrophobic pocket (which 
the 3-aryl component occupies) in different and often subtle ways.  
Early analogues were designed with a 5-amino solubilising group and a diverse range 
of substitutions on the 3-aryl group that moved from ortho-meta-para around the 
aromatic ring and varied in both size and electronic effect. Both polar and non-polar 
substituents were also synthesised, with the aim of probing the hydrophobic pocket 
for any additional interactions that could be made with amino-acid residues. Further to 
this, analogues bearing extensions from the 3-aryl component of the isoquinolin-1-one 
framework were synthesised, with the aim of eliciting more information with regards 
to the length, breadth and constitution of the hydrophobic pocket. While the 3-aryl 
region of the isoquinolin-1-one scaffold was explored and extended the 5-amino group 
remained a constant feature; this functionality gave the analogues a degree of water 
solubility which is desirable for the biological testing and future development. Intro-
ducing alternative groups into position-5 of the isoquinolin-1-one scaffold, e.g. 5-
methyl, 5-methoxy (precursor to 5-hydroxy) and 5-fluoro, using carbanion chemistry 
allowed the exploration of both the size of this cavity and the nature of the 
surrounding residues. Taking away the solubilising 5-amino had a predictably negative 
effect on solubility and, owing to the importance of this parameter in the drug 
development pathway, solubility was reincorporated into the isoquinolin-1-one 
scaffold via a series of tertiary cyclic amines attached through a one carbon-linker to 
the 3-aryl component of the molecule. The hydrochloride salts of these analogues 
rendered them sufficiently soluble in a small pre-formulation study.  
Attempts to synthesise the 3-ferrocenylisoquinoline analogue, designed to challenge 
the hydrophobic pocket with a bulky 3D entity, brought together all the synthetic 
techniques that had been applied at different stages of the project thus far. Palladium-
catalysed cross-coupling reactions were of limited success in providing the desired 3-
ferrocenyl analogue and an alternative strategy was required. Applying the carbanion 
chemistry that had been so effective for previous analogues to this example proved 
fruitful with generation of the desired analogue. Further to this, having thoroughly 
explored a diverse range of substituents in both positions-3 and -5 of the isoquinolin-1-
one scaffold, it became desirable to explore the effect of introducing a 4-position 
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substituent. This would not only introduce a further degree of bulk to the scaffold but 
would also change the dihedral angle between the isoquinolin-1-one framework and 3-
phenyl, in order to accommodate the additional 4-methyl group. Carbanion chemistry 
was used successfully to access the 4-position and the synthesis of 4,5-dimethyl-3-
phenylisoquinolin-1-one (215) (not shown in Figure 35) showed that this position was 
accessible via this chemistry. Altogether a large and diverse library of potential 




- 141 - 
 
Chapter 5.0 - The biological evaluation of potential tankyrase-1/-2 Inhibitors 
5.1 Introduction to NAD+-requiring enzymes 
Following a campaign to synthesise a diverse library of potential tankyrase-1/-2 inhib-
itors, it was necessary to conduct a biological evaluation of these analogues. Not only 
is this assessment required in order to identify potent compounds with potential for 
further development but also to develop our understanding of the structure-activity 
relationship (SAR). The greater the potency, the less inhibitor would be required to 
elicit a biological response and this may reduce the tendency for off-target effects. 
Together with a measure of potency for the target itself, it is also important to ascer-
tain the propensity of the inhibitor to bind to and to inhibit other similar enzymes, in 
this case other nicotinamide adenine dinucleotide (NAD+)-requiring enzymes, such as 
PARP-1 and oxidoreductases, e.g. inosine monophosphate hydrogenase-2 (IMPDH-2 is 
itself the target of the active metabolite of the experimental agent tiazofurin252 and 
metabolites of the therapeutic agents 6-thioguanine and 6-mercaptopurine253). A high 
potency for the target enzyme along with equal affinity for similar enzymes is highly 
undesirable as this may lead to off-target effects and may complicate the rational-
isation of outcomes of early pre-clinical and clinical trials. It is important, therefore, 
that counter-screening is conducted to determine the exact selectivity profile of 
individual inhibitors.  
NAD+ is an important cofactor / coenzyme required for many cellular oxidases and 
reductases and several types of enzymes consume NAD+ in their enzymatic reactions. 
Enzymes that consume NAD+ and transfer ADP-ribose to proteins and, as a result, 
modify their function are known as ADP-ribosyltransferases.40 Such enzymes that 
cause the translational modification of a target protein are of great interest in pharma-
ceutical research as their ability to control and regulate biological processes may be of 
key importance in the treatment or halting of disease.40 ADP-ribosyltransferases that 
modify proteins is an umbrella title for a number of important sub-families and all 
members must be considered at this stage. The family can be further split into poly-
(ADP-ribose) polymerases (PARPs), mono(ADP-ribose) transferases (ARTs) and NAD+-
dependent deacetylases.  
 
 
- 142 - 
 
The family of PARP proteins comprises seventeen isoforms of PARP and includes 
tankyrase-1 and -2.40, 61, 107 This important sub-group of enzymes consumes NAD+ 
through the transfer of a first ADP-ribosyl group to the carboxylate side chain of a Glu 
or Asp residue in the target protein.40 As the name suggests, propagation of the ‘poly’ 
ADP-ribose (PAR) chain is conducted through addition of further ADP-ribosyl groups to 
the two hydroxy groups on the two ribose rings, leading to a long and branched 
chain.40 The ADP-ribosyl links created in this process were determined to be in the α-
configuration; opposite to that of the substrate NAD+.40 Early structural alignment with 
the catalytic domain of diphtheria toxin suggested that the PARP catalytic domain 
comprised of both a NAD+ binding site and an acceptor site. 40 The generation of long 
PAR chains confers structural changes to the proteins to which they are attached and 
leads to the unique functions of this sub-group of enzymes.  
Another important sub-group of the ADP-ribosyltransferases that modify proteins are 
the mono(ADP-ribosyl)transferases or ARTs.40 Although the ARTs also consume NAD+ 
in a presumably similar enzymatic reaction to that of the PARPs, their functions are 
quite different.40 In contrast to the poly(ADP-ribosyl)transferases, the ARTs attach a 
single ADP-ribose to a side-chain of a proteins, typically Arg, Cys or, very occasionally, 
Asn, although the enzymatic reaction is assumed to be almost identical.40 Five eukar-
yotic ARTs have been identified which are all ecto-enzymes, as they are anchored to 
the cell membrane with their active sites are outside the cell.40 This specific location 
leads to distinct functions, such as the modification of immune specific proteins, e.g. 
CD27, CD43 and CD44 in T-cells and various growth factors including fibroblast growth 
factor-2.40 Due to their extracellular location, it is unlikely that this group of enzymes 
modifies any intra-cellular proteins. 
The final distinct sub group of ADP-ribosyltransferases that modify proteins are the 
NAD+-dependent deacetylases.40 This specialist branch of enzymes, known as sirtuins, 
couple the hydrolysis of NAD+ with deacetylation of acetylated histones and, as such, 
have a function in regulating transcription. 40 Although NAD+ is also consumed by this 
group of enzymes, their physiologically relevant mode of action is deacetylation and, 
intrinsically, they have quite distinct activity from that of the PARPs and ARTs. The first 
NAD+-dependent deacetylase discovered was Silencing Information Regulator 2 (Sir2), 
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which is responsible for the transcriptional silencing of certain regions of the yeast 
chromosome including ribosomal DNA and telomeres.254 This ability of Sir2 to silence 
genes was not fully understood until a seminal piece of research by Guarente et al. 
uncovered a link between its deacetylation activity in the presence of NAD+ and 
repression of transcription.255 Sirtuins also have the ability to ADP-ribosylate both 
themselves and other proteins, including histones and bovine serum albumin.256 
In addition to the modification of proteins, some other ADP-ribosyltransferases modify 
nucleic acids. This group of enzymes includes the NAD+-dependent tRNA 2’-phospho-
transferases, which catalyse the removal of a phosphate group from tRNA molecules 
added to the molecule during splicing in yeast.257 The DNA ADP-ribosylating proteins 
are also included in this sub-group of enzymes; the first of which discovered was 
pierisin-1, an apoptosis-inducing protein which catalyses the ADP-ribosylation of dG 
residues in DNA.258  
The final group of enzymes in the ADP-ribosyltransferases are those that modify small 
molecules. The most prominent sub-family of enzymes within this group are the ADP-
ribosyl cyclases. As their name suggests, the ADP-ribosyl cyclases generate cyclic ADP-
ribose (cADPR) from the substrate NAD+. Two mammalian ADP-ribosyl cyclases have 
been identified: CD38 and CD157 which are both ecto-enzymes with active sites 
located outside the cell membrane.40 The cyclic ADP-ribose (cADPR) generated from 
this enzymatic reaction is a potent secondary messenger, which is involved as a 
general mediator in Ca2+ signalling in various cells including T-cells and pancreatic β-
cells.40, 259, 260 This has led to analogues of this enzyme being intensively researched 
during the last two decades as potential candidate drugs. 261, 262 
As many hundreds of biological processes use the small molecule NAD+, it is imperative 
that a potential inhibitor for a specific NAD+-requiring enzyme is designed very care-
fully to pick up as many distinct binding opportunities as possible within the binding 
site of the enzyme of choice. This should optimise the selectivity for the target enzyme 
and reduce the potential promiscuity towards other NAD+-requiring enzymes. Funda-
mentally, there are distinct differences in the groups of enzymes that utilise NAD+, 
which will be exploited in the design of tankyrase-specific inhibitors. Ultimately, the 
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global effect of an inhibitor would be investigated in vivo firstly in live cells and then in 
a whole animal system in order to assess the function of such inhibition.  
It was proposed that the entire library of candidate inhibitors (Shown in Figure 35) 
would be screened initially for activity against tankyrase-2 in a biochemical assay 
developed in-house. This initial assessment would help to guide the design of future 
inhibitors and allow for reduction of the library of fifty-six compounds to ca. ten-
fifteen that would be subjected to a comprehensive biological assessment, including 
counter-screening and assays of anti-proliferative activity against tumour cells. The 
condensed library would comprise those inhibitors that showed the greatest promise 
in terms of potency against the target, along with other analogues that showed 
interesting ‘Structure Activity Relationship’ (SAR) features warranting further explor-
ation. In addition to this, some of the water-soluble analogues developed would be 
included owing to their potential advantage in respect to their future pharmaceutical 
development.  
5.2 Molecular modelling and small-molecule crystal structures 
During the evolution of the library of small-molecule inhibitors of the tankyrases, 
molecular models were generated and used to rationalise the design of candidate 
inhibitors and to develop a comprehensive understanding of the SAR. Molecular 
models were also used to rationalise the biological outcome of candidate inhibitors, 
especially if an unexpectedly positive or negative result was achieved in the bio-
chemical enzyme assays. 
Owing to the similarity in structure between the analogues synthesised in this project 
and XAV939 (1), it was postulated that similar interactions would be made with 
residues in distinct regions of the catalytic domain of tankyrase-2. A crystal structure of 
XAV939 bound to this isoform was published in 2010 by Karlberg and colleagues107 and 
has provided a useful insight to the key interactions involved (Figure 36). The classical 
PARP binding motif is clearly maintained in the binding of XAV939 to tankyrase-2, with 
hydrogen-bonding of the lactam carbonyl oxygen with the hydroxy of the Ser1068 and 
the NH of Gly1032 and from the lactam NH to the carbonyl oxygen of Gly1032. Further π-
stacking interactions are made between the lactam to Tyr1071 and the side-chain tri-
 
 
- 145 - 
 
fluoromethylphenyl is in a hydrophobic cavity, making key hydrophobic interactions 
with Pro1034, Phe1035 and Ile1075.  
Molecular models were generated using the published structure of truncated tankyr-
ase-2 protein (NAD+-binding domain and SAM domain) in complex with XAV939 from 
the Protein Data Bank (PDB: 3KR8) as a starting structure, owing to the expected 
structural similarities between this inhibitor and candidate inhibitors synthesised in 
this project. The complex is represented as a dimer within the Protein Data Bank, 
which was reduced to a monomer by deletion of one of the two complexes using the 
SYBYL 2.0 software suite (SYBYL associates). Surface water molecules, counter-ions and 
crystallisation co-solvents were also deleted at this point and charges were set at 
appropriate points around the protein. The area immediately around the XAV939 was 
also checked for potential water molecules that were involved in “water-bridged 
hydrogen bonds”, as these could be incorporated into the new complexes with our 
novel compounds (There was none found within the tankyrase-2-XAV939 complex). 
The XAV939 structure was then used to guide the docking of the compounds which 
had previously undergone molecular mechanics optimisation and charge distribution 
calculations (Gasteiger-Hückel) within SYBYL. The tankyrase-2 was also prepared within 
SYBYL, correcting charges and ionisation of several amino-acid residues. Once the new 
drug structure was docked over the XAV939, the XAV939 residue was deleted, leaving 
the new inhibitor alone docked within the pocket. Where large position-3 side-chains 
were present (e.g. 222), these were pre-modelled into the approximate conformation 
Figure 36: Representation of 
the X-ray crystal structure of 
XAV939 (1) bound into the 
nicotinamide-binding catalytic 
domain of tankyrase-2.107 Key 
residues are highlighted and 
hydrogen bonds represented 
as a green dashed line. 
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required for binding into the pocket, avoiding significant steric clashes upon docking. 
Once initial models had been created with the docked ligands in place, the complexes 
were minimised initially minimising position-3 side-chains, then the bound ligand and 
finally the complete docked complex. The models were then visualised in Chimera 
(UCSF Chimera; version 1.6.2).  
To assist in generating as accurate a molecular model as possible, it was advantageous 
to obtain some small-molecule crystal structures of candidate inhibitors. Suitable 
crystals were selected and small-molecule crystal structures were determined by Dr. 
Mary F. Mahon (Department of Chemistry, University of Bath). Both small-molecule 
crystal structures and molecular modelling will be discussed throughout the initial 
biological tankyrase-2 screening results and not in isolation, as they were used 
experimentally in this way. 
5.3 Tankyrase-2 biochemical assay developed in-house 
It was desirable to develop a tankyrase assay in-house to facilitate the rapid screening 
of inhibitors as they were synthesised, allowing for the evolution of drug design 
through biological insights throughout the lifetime of the project. In addition, due to 
the prohibitive expense of commercially available assays, it was preferable to perform 
the initial biological screen without excessive cost being a barrier. Initially, it was 
planned to prepare recombinant full-length tankyrase-1 and incorporate this into an 
ELISA-style assay with the telomeric binding protein TRF-1. Unfortunately, several 
attempts to prepare full-length tankyrase-1, by my co-supervisor Dr Matthew D. Lloyd 
(University of Bath), failed to afford the required stable protein construct in sufficient 
quantity or purity. 
An alternative assay was proposed using commercially available recombinant 
truncated tankyrase-2 enzyme (BPS Bioscience and AMS Bioscience Ltd. Catalogue No. 
80515), which became available during the project period. This truncated enzyme was 
lacking the HPS and ANK domains, which therefore negated its ability to be incorpor-
ated into an assay with one of the several binding partners of tankyrase-2 known to 
interact with the enzyme through the ANK domain, e.g. TRF-1. Importantly, the 
catalytic and SAM domains of the enzyme were fully intact and thus allowed for the 
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development of an auto-PARsylation assay, with substrate NAD+. Owing to the almost 
identical nature of the catalytic domains of tankyrase-1 and tankyrase-2, this was seen 
as an acceptable substitution. Indeed, to identify key trends between the SAR of 
inhibitors and biological outcomes, this alternative assay should fulfil the role as 
effectively as the initially planned tankyrase-1 assay. Further to this, it has been 
recently shown that biochemical auto-PARsylation assays which utilise either full-
length or truncated (catalytic domain only) are comparable.114 Indeed, the majority of 
inhibitory data and structural analysis published thus far on tankyrase inhibitors 
reports data generated using tankyrase-2-based biochemical assays.42, 61, 82, 107, 147, 149, 
229  
In ELISA-quality half-volume high-binding 96-well plates (Greiner bio-one), truncated 
tankyrase-2 in a suitable buffer was immobilised onto the surface of the wells over-
night (Figure 37). Following a buffer wash, a suspension of dried skimmed milk powder 
(Marvel®) in a suitable buffer (5% w/v) was added to the wells to block non-specific 
Figure 37: Flow diagram showing the main stages of the in-house developed tankyrase-2 auto-PARsylation 
assay. Firstly, tankyrase-2 is loaded into each well (apart from background wells) and left overnight to attach 
to the surface of the wells. Following a PBS-T wash, a 5% milk (Marvel®) suspension is added to each well in 
order to block non-specific protein-protein interactions and reduce the background value. Following an hour 
at room temperature, the wells are washed with PBS-T and the pre-diluted inhibitors are added to the 
appropriate wells, followed by addition of a mixture of cold- and biotinylated-NAD+. After incubation at 30°C 
for 2 hours, the wells are washed with PBS-T and a colorimetric endpoint is generated using a standard 
streptavidin/ HRP system.  
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protein-binding sites on the surfaces of the wells. After one hour at room temperature, 
the milk suspension was removed with a buffer wash. Inhibitors (pre-diluted in DMSO) 
were then added to a fixed volume of appropriate buffer, designed to maintain a 
representative physiological pH, in the required wells, to give an initial range of three 
concentrations within which the IC50 was predicted (1 µM, 100 nM and 10 nM initially 
for most candidate inhibitors). To this was then added a mixture of biotinylated NAD+ 
(where a biotin molecule is attached through the adenine of NAD+) and natural 
substrate (cold) NAD+ in equimolar concentrations (both at 1.0 mM). During a two-
hour incubation period at 30°C, ADP-ribose units, some bearing the biotin tag, will 
become attached to the SAM domain of the tankyrase-2 enzyme (through auto-
PARsylation).  
The extent to which auto-PARsylation has occurred is then measured using a strept-
avidin-horseradish peroxidase conjugate, in which the streptavidin binds tightly to the 
biotin tag which is attached to approximately 50% of the poly-ADP ribose units. Follow-
ing an equilibrating period, a substrate solution containing 3,3,5,5-tetramethylbenz-
idine (TMB) (263) (as a chromogenic substrate) and H2O2 is then added. TMB acts as a 
hydrogen donor for the reduction of H2O2 by the peroxidase enzyme. The oxidation of 
263 leads to the formation of a diimine 264 which is blue (which could be measured 
spectrophotometrically at 650 nM), owing to the conjugation through the entire 
structure (Scheme 51). The peroxidase reaction is then halted by the addition of aq. 
H2SO4 (STOP solution; 1.0 M), which changes the colour of the solution in the wells to a 
yellow colour. Detection of the intensity of transmitted light is then read using a 
spectrophotometer at 450 nM; the darker the yellow colour the greater the amount of 
auto-PARsylation that has occurred and the less active the inhibitor. In contrast a pale 
yellow colour would indicate a low level of auto-PARsylation and a more active 
inhibitor; able to block the nicotinamide-binding site effectively.  
Scheme 51: The 
reduction of H2O2 to 
H2O by the peroxidase 
enzyme is facilitated by 
donation of hydrogen 




- 149 - 
 
5.4 Discussion of results obtained in tankyrase-2 biochemical assay 
Table 7: Ranging studies conducted using the in-house tankyrase-2 auto-PARsylation assay. Values are the 
mean from three wells in one experiment, expressed as percentage inhibition with standard deviation. * = 
averaged from two wells due to an anomalous result; ** = synthesised by Dr Peter T. Sunderland.185 
Cpd. No. Inhibition @ 1.0 
µM 
Inhibition @ 100 
nM 
Inhibition @ 10 nM 
1 (positive control) 97% ± 10% 87% ± 10% 53% ± 2% 
18 16% ± 8% 18% ± 7% 9% ± 20% 
167a  92% ± 2% 60% ± 8% 18% ± 1% 
167b 48% ± 10% 0% ± 12% 21% ± 17% 
167c 76% ± 12% 54% ± 14% 11% ± 18% 
167d 40% ± 7% 15% ± 7% 10% ± 12% 
167e 89% ± 2% 57% ± 4% 36% ± 6% 
167f 20% ± 7% 11% ± 32% 32% ± 19% 
167g 100% ± 1% 92% ± 5% 80% ± 8% 
167h  1% ± 10% 8% ± 27% 15% ± 20% 
167i  82% ± 1% 33% ± 6% 27% ± 6% 
167k 100% ± 2% 85% ± 4% 55% ± 1%* 
167l  100% ± 4% 100% ± 8% 58% ± 10% 
167m 94% ± 2% 88% ± 0% 65% ± 4% 
167n 100% ± 1% 97% ± 2%  60% ± 1%* 
167o  100% ± 8%  100% ± 2%  84% ± 4%  
167p 4% ± 4% 0% ± 29% 8% ± 15% 
167r** 73% ± 16% 41% ± 2% 0% ± 26% 
175 78% ± 8% 38% ± 22% 20% ± 12% 
165k 47% ± 32% 70% ± 19% 55% ± 14% 
165n  93% ± 13% 72% ± 9%  44% ± 27% 
206a 100% ± 2% 94% ± 3% 86% ± 3% 
206b 98% ± 2% 88% ± 7% 70% ± 6% 
206c 87% ± 7% 17% ± 12% 0% ± 14% 
206d 95% ± 10% 81% ± 2% 22% ± 24% 
206e 0% ± 21% 1% ± 26% 5% ± 5% 
206f 100% ± 1% 100% ± 1%* 98% ± 1%  
206g 100% ± 0% 100% ± 2% 100% ± 1% 
206h 95% ± 26% 100% ± 10% 88% ± 12% 
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In each tankyrase-2 assay, the 96-well plate included control wells comprising [enzyme 
with no inhibitor and no DMSO], [enzyme + 1% DMSO with no inhibitor], [no enzyme, 
no DMSO, no inhibitor] and a positive control [enzyme + 1% DMSO + XAV939]. Table 7 
summarises the initial screens performed on the entire library of candidate inhibitors 
(Refer to Figure 35 for compound structures). The key trends identified in this 
206j 100% ± 9% 100% ± 16% 20% ± 20% 
206k 91% ± 34% 88% ± 18% 78% ± 12% 
206l 95% ± 10% 98% ± 11% 51% ± 17% 
206m 87% ± 17% 77% ± 5% 49% ± 15% 
215 100% ± 4% 90% ± 32% 68% ± 16% 
222 100% ± 10% 100% ± 2% 71% ± 25% 
236a 100% ± 9% 100% ± 20% 70% ± 3% 
236b 60% ± 12% 41% ± 12% 0% ± 14% 
236c 100% ± 29% 100% ± 11% 61% ± 3% 
236d 100% ± 6% 79% ± 12% 61% ± 8% 
262 67% ± 10% 54% ± 10% 0% ± 1% 
207a 100% ± 2% 100% ± 13% 88% ± 5% 
207b 100% ± 12% 100% ± 15%  100% ± 10% 
207c 100% ± 25% 100% ± 2% 100% ± 14% 
207d 100% ± 17% 100% ± 20% 100% ± 2% 
207e 76% ± 8% 65% ± 2% 58% ± 5% 
207f 73% ± 17% 50% ± 27% 14% ± 2% 
207g 100% ± 4% 90% ± 12% 74% ± 8% 
207h 91% ± 26% 87% ± 8% 57% ± 15% 
207i 94% ± 10% 73% ± 9% 53% ± 4% 
209a 100% ± 0.5% 86% ± 5% 59% ± 9% 
209b 85% ± 5% 69% ± 5% 50% ± 9% 
208a 100% ± 3% 100% ± 10% 87% ± 12% 
208b 100% ± 17%  100% ± 22% 83% ± 17% 
208c 100% ± 11% 79% ± 8% 21% ± 17%* 
208d 95% ± 8% 91% ± 5% 54% ± 5% 
208e 73% ± 7% 92% ± 7% 73% ± 5% 
208f  98% ± 19% 98% ± 7% 66% ± 14% 
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preliminary screen will be discussed in detail below, with key examples from the 
inhibitor library highlighted. These trends were then used to aid development of a 
comprehensive and refined SAR, which, in turn, would allow for a more sophisticated 
approach to the design of future inhibitors.  
5.4.1 Trend 1 –Effect of position-5 substituent on inhibitor potency 
The first trend identified from conducting a 
biochemical screen of tankyrase-2 inhibition 
by the candidate analogues was the effect of 
changing the substituent in position-5 (Figure 
38). When focussing on this position of the 
isoquinolin-1-one framework in a series of six 
compounds (165n, 167n, 206f, 207c, 208c 
and 209b) where the position-3 group is 
maintained as a 4-trifluoromethylphenyl, it would appear that the potency of anal-
ogues is increased in the order of F < NO2 < OH < NH2 < Me = OMe, as illustrated in 
Figure 40 and Table 7. Indeed, this trend is also mirrored through the entire inhibitor 
library of fifty-six compounds when the position-3 group is maintained whilst the 
position-5 substituent is altered. Encouragingly, the results obtained in this series of 
isoquinolin-1-ones also reflect those obtained in a similar series of 2-arylquinazolin-4-
ones synthesised by another member of the Threadgill research group, Dr Amit 
Nathubhai, and tested in an identical tankyrase-2 assay (Figure 39).229 When compar-
ing a similar range of substituents in the position-8 of the quinazolin-4-one (equivalent 
to position-5 of the isoquinolin-1-one 
and with a consistent 2-(4-chloro-
phenyl) group), a very similar pattern 
emerged with a methyl group in 
position-8 giving the greatest potency, 
compared with merely a hydrogen 
atom (49% and 2% inhibition of 
Figure 39: Series of 2-
arylquinazolin-4-ones 
synthesised by Dr A. 
Nathubhai229 and with 
quinazolin-4-one 
numbering shown for 
clarity. A similar pattern 
of inhibitory potential 
against tankyrase-2 is 
obtained in this series as 
in the isoquinolin-1-one 

























Figure 38: Proposed pharmacophore introduced 
in Section 3.0 with position-5 highlighted. A 
variety of groups were introduced at this 
position, designed to probe for interactions with 
residues in this region of the enzyme active site.  
Potential for 
selectivity/ 
solubility – what 
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tankyrase-2 at 10 nM for 265b and 265a respectively).229  
These initial results strongly indicate towards the preference for a hydrophobic 
electron-donating, e.g. methoxy in 207c, or electron-neutral group, e.g. methyl in 206f 
(98% and 100% inhibition of tankyrase-2 activity at 10 nM, respectively) and not a 
group with the potential to donate a hydrogen bond, e.g. amino in 167n or hydroxy in 
209b (60% and 50% inhibition of tankyrase-2 activity at 10 nM, respectively) (Figure 
40). Polar and electron-donating groups in position-5, including amino and hydroxy in 
167n and 209b, respectively, appear to confer a slightly weaker inhibitory effect on 
tankyrase-2 than 206f and 207c, indicating that no specific interactions such as 
hydrogen bonds are being made with residues in this region of the catalytic pocket to 
enhance the binding of such groups. The equal preference for a 5-methyl or 5-methoxy 
group, in 206f and 207c, respectively, indicates that there may be some space to 
extend into in this region of the nicotinamide-binding site of the enzyme. In addition, it 
appears to make little difference whether an electron-donating hydrophobic group or 
electron-neutral hydrophobic group is incorporated, which suggests that electronics do 
not play a large part in the binding potential of a substituent in this region.  
That said, significantly poorer activity is seen with the introduction of a hydrophobic 
electron-withdrawing 5-nitro group in 165n (44% inhibition of tankyrase-2 activity at 
10 nM), suggesting that, in this case, electronics are playing a part (Figure 40). It is 
likely that it is the electron-withdrawing nature of the nitro group that confers its 
poorer activity as in terms of steric capacity this group should not occupy a greater 
100% 
50% 21% 98% 
60% 44% 
Figure 40: Illustration of the key trends observed in position-5 of the isoquinolin-1-one framework, in this 
case with a position-3 4-trifluoromethylphenyl group kept constant. Inhibition of tankyrase-2 activity is 
expressed as a percentage at 10 nM concentration of candidate inhibitors.  
Increasing tankyrase-2 inhibition 
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space than either the 5-methyl or 5-methoxy groups. In addition, other hydrophobic 
groups, e.g. 5-methyl, are very well tolerated.  
Even weaker inhibition is observed for the 5-fluoro analogue 208c (21% inhibition at 10 
nM) (Figure 40). This is probably due to its very small size, meaning that it occupies a 
similar chemical space to that of a proton. This small group is unlikely to be making any 
specific interactions with the tankyrase-2 enzyme pocket in this region or filling the 
void effectively. This result was not surprising, when comparing with the results obt-
ained for a series of 2-arylquinazolin-4-ones in an identical assay. 229 When merely a 
hydrogen atom is incorporated into position-8 of the quinazolin-4-one (corresponding 
to position-5 in isoquinolin-1-one), a very poor level of inhibition of tankyrase-2 
activity is observed (2% inhibition for 265a at 10 nM) (Figure 39). 229 Indeed, this poor 
result in the quinazolin-4-one series made the synthesis of the position-5 hydrogen 
series of isoquinolin-1-ones unnecessary in the current work.  
The incorporation of five different substituents in position-5 of the isoquinolin-1-one 
has allowed for a clear trend to become apparent in the tankyrase-2 ranging studies. 
Through closer examination of a series of six compounds (each with a 3-(4-trifluoro-
methylphenyl) group maintained for consistency), it is clear that there is a distinct pre-
ference for candidate inhibitors with either electron-neutral or electron-donating 
hydrophobic groups in position-5. Hydrophobic groups that are electron-donating in 
position-5 e.g. nitro in 165n show significantly poorer inhibitory activity and should 
thus be excluded from a potential candidate inhibitor. Further to this the steric occup-
ation of the position-5 group appears to be of some importance owing to the extreme-
ely poor inhibitory activity observed for 208c, suggesting that a small amount of bulk is 
required for optimum binding to the tankyrase-2 catalytic site in this region. These 
results also complement those obtained for a similar series of 2-arylquinazolin-4-
ones,229 strengthening the argument for the inclusion and exclusion of certain substit-
uents for future inhibitor design.  
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5.4.2 Trend 1 – Rationalisation of the 
influence of changing the position-5 
substituent on activity using 
molecular modelling  
The trends observed above when 
changing the position-5 substituent 
were rationalised through molecular 
modelling (See Section 5.2 for detail). 
As expected, the fixed lactam of this 
series of inhibitors (165n, 167n, 206f, 
207c, 208c and 209b) make the class-
ical hydrogen bonds with the Ser1068-
Gly1032 motif, anchoring the inhibitors 
firmly in the nicotinamide-binding 
site. In addition, π-stacking is 
observed between the 3-(4-trifluoro-
methylphenyl) group (kept consistent 
in all inhibitors in this trend) and 
Tyr1050 in the hydrophobic pocket and 
it makes additional hydrophobic 
interactions with Pro1034, Phe1035 and Ile1075; identical to those observed in the crystal 
structure of XAV939 (1). 
Unfortunately, no clear comparison can be drawn between inhibitors bearing a posit-
ion-5 substituent and XAV939 as the latter has no substitution in this region and, as 
such, makes no notable interactions in the published crystal structure (Figure 36). 
There do not appear to be any specific interactions between groups in this region and 
residues on the surface of the small cavity of tankyrase-2. Size appears to be of greater 
importance in this region, demonstrated clearly by the poorly active 5-fluoro 208c 
compared with the very active 5-methyl 206f (21% and 98% inhibition of tankyrase-2 
activity at 10 nM, respectively). Although not considered a bulky group, the 5-methyl 
appears to ‘fill’ the cavity compared with the 5-fluoro atom, which cannot (Figure 41). 
Figure 41: Molecular model showing the analogue from 
the perspective of position-5. In this case the 5-methyl of 
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This ‘filling’ of the cavity may be crucial as it may preclude hydrophilic water molecules 
from occupying the space, which would be unfavourable in a hydrophobic 
environment.  
The almost identical inhibition observed for the 5-methoxy compound 207c and 5-
methyl analogue 206f (100% and 98% inhibition of tankyrase-2 activity at 10 nM, res-
pectively) demonstrates that there is room to accommodate a slightly larger group in 
the hydrophobic cavity in this region of the catalytic pocket (Figure 41). In addition, the 
flexible 5-methoxy group projects further into this small hydrophobic cavity than the 5-
methyl group, which demonstrates that a small amount of flexibility is tolerated in this 
hydrophobic cavity and does not clash with the edges of the cavity. Both the 5-methyl 
of 206f and 5-methoxy of 207c are able to fill the cavity effectively and make weak van 
der Waals interactions and hydrophobic entropically-driven interactions with residues 
in this region including Tyr1060, Tyr1050, Tyr1071 and Ile1075. The excellent inhibitory result 
and molecular model generated for 206f indicates that the poor result obtained for the 
5-nitro compound 165n is likely to be a reflection of the electronics of this substituent 
as opposed to its steric bulk not being accommodated in this region of the nicotin-
amide-binding site.  
The 5-amino compound 167n and the 5-hydroxy analogue 209b demonstrate slightly 
weaker inhibition of tankyrase-2 (60% and 50% inhibition at 10 nM, respectively) com-
pared with the superb activity noted for 207c and 206f (100% and 98% inhibition of 
tankyrase-2 activity at 10 nM, respectively). The 5-amino group has been incorporated 
into PARP-1 inhibitors, e.g. 5-AIQ (18), which was superbly potent in vivo; 50-56, 59, 130, 136 
probably due to the superior solubility of this analogue. These results may reflect the 
differences in the catalytic pockets of PARP-1 and tankyrase-2 in this region of the 
nicotinamide-binding site. Firstly, there is a noticeably smaller cavity in this region of 
tankyrase-2, compared with the corresponding region in PARP-1,61, 68, 107 likely only to 
accommodate smaller groups. Further to this, this cavity in PARP-1 is lined with mainly 
hydrophilic residues, which rationalises why the 5-amino in 5-AIQ is tolerated so well. 
In contrast, the same region of the tankyrase-2 pocket is dominated with hydrophobic 
residues and, as such, does not tolerate polar and hydrophilic groups so well. Further 
to this the larger cavity in this region of the nicotinamide-binding site of PARP-1 is 
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likely to accommodate molecules of water within it and, as such, will improve the 
binding of 5-amino groups through additional hydrogen-bond interactions. The smaller 
hydrophobic cavity in tankyrase-2 may not tolerate water molecules, in contrast to 
that observed in PARP-1, and may further rationalise the preference for small hydro-
phobic groups. A group that fails to occupy the space sufficiently, e.g. the fluorine 
atom in 208c, allows water molecules to fill the cavity and, as such is unfavourable, 
owing to the hydrophobic nature of the cavity in tankyrase-2, there is some room to 
incorporate a larger group than this.  
5.4.3 Trend 2 – Effect of changing the 3-aryl substituent on potency of tankyrase-2 
inhibition 
A clear trend is observed in the effect 
on inhibition of tankyrase-2 activity 
when changing the 3-aryl substituent 
and the position of atoms / groups 
attached to this 3-aryl substituent 
(Figure 42 and Table 7). Inhibitory 
activity increases dramatically as the 
substitution changes from ortho to meta to para. This is illustrated in the 3-(chloro-
phenyl)-5-methylisoquinolin-1-one series (Figure 43). In this series, the 3-(4-chloro-
phenyl) compound 206b shows 70% inhibition at 10 nM, whereas the 3-(3-chloro-
phenyl) compound 206d shows 22% inhibition at this concentration and the 3-(2-
chlorophenyl) compound 206c is effectively inactive. Correspondingly, the 3-(2,6-di-
chlorophenyl) compound 206e is also inactive at this concentration. This trend of 
activity (para-substitution > meta-substitution > ortho-substitution) is evident in other 
sets of isoquinolin-1-ones where different positional isomers around the 3-phenyl 
were prepared. For example, in the 5-amino-3-(chlorophenyl) compounds, the para-
isomer 167m shows 65% inhibition at 10 nM, the meta-isomer 167e shows 36% 
inhibition at 10 nM and the ortho-monochloro isomer 167d and the ortho,ortho-di-
chloroisomer 167p are inactive at this concentration (Figure 43).  
Figure 42: Proposed pharmacophore for tankyrase-1/-2 
inhibitors with the 3-aryl position highlighted, indicating 
the structural features that would be explored in the 
region of the framework.  
Effect of 
changing the 
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The same trend is also evident when the substituent on the 3-phenyl is methoxy 
(compounds 167b, 167c and 167r), trifluoromethyl (compounds 167h, 167i and 167n) 
or carboxamide (compounds 167f and 167g) (refer to Figure 35 for structures). Two 
explanations are possible for this clear effect of position of substitution. Firstly, the size 
and shape of the hydrophobic pocket (lined by Pro1034, Phe1035 and Ile1075 and other 
aromatic hydrophobic residues) may be too small and narrow to accommodate 
sterically significant substituents on the ortho- and meta-positions of the phenyl. In 
other words, there may be steric clashes between the ortho- and meta-substituents 
and the walls of the pocket. Secondly, although the 3-phenyl and the isoquinolin-1-one 
are both aromatic and should be conjugated, steric clash between the 2,6-(ortho) 
substitutions on the phenyl and the 4-H and N-H on the isoquinolin-1-one will force a 
dihedral twist of the phenyl ring out of the plane of the isoquinolin-1-one. The loss of 
activity may be due to this twist, if the hydrophobic cavity is more ovoid-shaped than 
spherical; the phenyl would then not fit well. This is discussed further in later sections. 
5.4.4 Trend 2 – Rationalisation of inhibitory activity using small-molecule crystal 
structures of 206e and 207d 
The inhibitor pattern observed in Trend 2 indicates the significant influence of the 
isomeric positioning of the substitution around the 3-aryl ring on inhibitory activity of 
analogues against tankyrase-2. The dramatic difference in inhibitory effect between an 
8% 10% 36% 65% 
5% 0% 22% 70% 
Figure 43: Illustration of the key trend observed when the position of the substituent on the 3-aryl group is 
changed, whilst maintaining either a 5-methyl (top line) or 5-amino (bottom line). Inhibition of tankyrase-2 
activity is expressed as a percentage at 10 nM concentration of candidate inhibitors.  
Increasing tankyrase-2 inhibition 
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ortho-substituted 3-aryl group compared with a para-substituted 3-aryl group 
warranted further investigation. To examine the effect of ortho-substituents on the 
conformation of the 3-arylisoquinolin-1-ones, two small-molecule X-ray crystal 
structures were determined for 206e and 207d by Dr Mary F. Mahon (X-ray 
Crystallographic Suite, Department of Chemistry, University of Bath). The structures 
are shown in Figure 44 (Data in Appendix C). Both isoquinolin-1-ones are present as 
dimers in the unit cell, with hydrogen bonds from the N-H of one isoquinolin-1-one to 
the carbonyl oxygen of its partner. This tight hydrogen-bonding dimerisation may well 
be responsible, in part, for the high melting points (and poor aqueous solubilities) of 
many of the isoquinolin-1-ones.  
The dihedral angle between the phenyl and the isoquinolin-1-one in 5-methoxy-3-(4-
methylphenyl)isoquinolin-1-one (207d) (with a para-substituent only) is shown to be 1° 
(shown as B in Figure 44), confirming that the two planar aromatic rings are almost co-
planar. By contrast, the corresponding dihedral angle in the 3-(2,6-dichlorophenyl)iso-
quinolin-1-one (206e) is 67° (shown as A in Figure 44), indicating that the sterically 
Figure 44: Small-molecule X-ray crystal structures of 206e and 207d generated in an attempt to help 
rationalise the significant difference in inhibitory effect on tankyrase-2 between these two analogues. The 
dihedral angle between the isoquinolin-1-one framework and the 3-aryl component is represented as A 








Dihedral angle A: 67°  
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bulky chlorine atoms force a major twist (with loss of conjugation) to avoid steric clash 
with the 4-H and the N-H of the isoquinolin-1-one. It is highly likely that this dramatic 
contrast in conformation between 206e and 207d is causing the disparity in inhibitory 
activity between these two analogues.  
It is not clear at this stage whether the loss of activity in analogues with ortho-
substituents is owing to the dihedral twist itself or due to steric clash of the ortho-
substituents with the wall of the hydrophobic pocket. This question could be 
addressed by designing an analogue in which the dihedral twist is induced but which 
lacks an ortho-substituent on the 3-phenyl unit; such a compound would induce the 
twist by having a bulky group at position-4 of the isoquinolin-1-one core. Alternatively, 
molecular modelling may shed some light on the relative roles of the dihedral twist 
and the steric demands of the ortho-substituent(s). 
5.4.5 Trend 2 – Rationalisation of inhibitory activity of positional isomers on the 3-
phenyl ring using molecular modelling 
Figure 45: Molecular models generated for 206e and 206b in an attempt to rationalise the significant 
inhibitory difference on tankyrase-2 activity demonstrated by these two analogues. The ligands are 
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Molecular models were constructed (Figure 45), as described previously, for two 
analogues 206e and 206b in this series, in an attempt to rationalise the significant 
difference observed in inhibition of tankyrase-2 activity between analogues bearing 
different positional isomers on the 3-aryl substituent. Small-molecule crystal structures 
generated on related analogues (206e and 207d) clearly demonstrated the dramatic 
difference in dihedral angle between an ortho-substituted and para-substituted 3-aryl 
group on the isoquinolin-1-one framework.  
One rationalisation for the poorer activity of the ortho-substituted 3-aryl analogues, 
e.g. 206c and 206e, is that the ortho-groups themselves may be causing steric clashes 
with the edges of the hydrophobic pocket. Figure 45 shows the results of molecular 
modelling studies in which 3-(2,6-dichlorophenyl)-5-methylisoquinolin-1-one (206e) 
and 3-(4-chlorophenyl)-5-methylisoquinolin-1-one (206b) are bound into the 
nicotinamide-binding site (and adjacent pockets) of tankyrase-2. These are 
comparable, as the 5-methyl group is constant. The 3-(2,6-dichlorophenyl) compound 
206e was chosen, rather than the 3-(2-chlorophenyl) analogue 206c, as the latter 
would have given two enantiomeric atropisomeric structures, which would have 
bound differently with different steric interactions (leading to unnecessary 
complications).  
The model of the active 3-(4-chlorophenyl) inhibitor 206b (70% inhibition of tankyrase-
2 activity at 10 nM) shows the two aromatic rings as almost co-planar (as in the small-
molecule crystal structure of the 3-(4-methylphenyl)-5-methoxyisoquinolin-1-one 
(207d) above) with a dihedral angle of 24° measured (Figure 45). This is different to the 
equivalent dihedral angle measured in the small-molecule X-ray crystal structure of 
207d (1°; Figure 44) and demonstrates that the almost co-planar nature of these two 
aromatic rings is not maintained as such when the analogue is bound within the 
nicotinamide-binding site and adjacent hydrophobic pocket. The difference in dihedral 
angle between that measured in the small-molecule crystal structure and the 
molecular model is 23° and indicates that the 3-aryl group is slightly twisted out of 
plane from the isoquinolin-1-one framework in order to be accommodated in the 
nicotinamide-binding site and adjacent hydrophobic pocket. It is possible that the 
nicotinamide-binding site and adjacent hydrophobic pocket imposes a certain amount 
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of constraint on the molecule when it is bound, justifying the difference in measured 
dihedral angle between the molecular model of 206b (24°) and small-molecule X-ray 
crystal structure of 207d (1°). It is also possible that the tight crystal-packing within the 
small-molecule X-ray crystal structure imposes an artificial constraint on the molecule.  
The para-substituted 3-aryl group on 206b projects into the centre of a large hydro-
phobic pocket where it can potentially make interactions with aromatic residues in this 
region including Tyr1050, Tyr1060 and Pro1034 (Figure 45). Further to this, on the opposite 
face of the hydrophobic pocket is a narrower hydrophobic tunnel that leads through 
towards solvent water, in which the para-chloro atom itself sits in the inner edge, 
potentially creating further hydrophobic interactions and weaker van der Waals forces. 
By contrast, the phenyl ring of the biologically inactive 2,6-dichlorophenyl compound 
206e (5% inhibition of tankyrase-2 activity at 10 nM) lies at a marked dihedral angle of 
78° relative to the isoquinolin-1-one bicycle in the molecular model generated (Figure 
45). This is in agreement with the dihedral angle measured in the small-molecule 
crystal structure of the same analogue (64°; Figure 44). In this case, the difference in 
the measured dihedral angle between the small-molecule crystal structure and the 
molecular model is only 14° but demonstrates that the 3-aryl component of the 
analogue is still very much out of plane with the isoquinolin-1-one framework when 
bound in the nicotinamide-binding site and adjacent hydrophobic pocket. The severe 
twist imposed on the 3-aryl component relative to the isoquinolin-1-one bicycle of 
206e brings the two chlorine atoms into strong steric clashes with the lining of the 
hydrophobic pocket, predominately clashing with Tyr1071, His1031 and Ile1075 in the 
molecular model (Figure 45). This suggests that the entire 3-aryl portion of this 
inhibitor does not fit well into the hydrophobic cavity in this region of the tankyrase-2 
catalytic pocket and, as such, may justify the poor activity demonstrated. Further to 
this, the 2,6-dichloro analogue 206e has no potential to occupy the additional narr-
ower hydrophobic tunnel on the opposite face of the main hydrophobic pocket. Thus 
this modelling study strongly suggests that the origin of the inactivity of the 3-(ortho-
substituted phenyl) isoquinolin-1-ones is direct steric clash from the ortho-substituents 
(after the dihedral twist), rather than the dihedral twist per se. Studies on the 4-methyl 
compound 215, discussed below, will confirm this explanation. 
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Overall, these preliminary results indicate that the best candidate inhibitors are likely 
to be those with para-substituted 3-aryl groups which allow the two aromatic rings to 
maintain an almost co-planar conformation, thus avoiding severe steric clashes with 
the edges of the hydrophobic pocket when ortho-substituents are incorporated. In 
addition, a para-substituent appears to sit within the inner edge of a narrower hydro-
phobic pocket or tunnel, situated on the opposite face of the main large hydrophobic 
pocket, and may make additional hydrophobic interactions in this region, further cont-
ributing to the binding of an analogue. Thus maintaining this almost co-planar orientat-
ion between the two aromatic rings of the candidate inhibitors will be the focus of 
further design, with a para-substituent incorporated in each case. 
5.4.6 Trend 2 – Protein X-ray crystallography (207b) 
Further characterisation of the mode of binding of 207b in the catalytic domain of 
tankyrase-2 was conducted through protein X-ray crystallography studies performed 
by a collaborator, Dr Lari Lehtiö (University of Oulu, Finland). The catalytic ART domain 
of human tankyrase-2 protein was crystallised using a sitting-drop vaporisation-
diffusion method in a 96-well plate following conditions reported by Narwal et al.42 
Within a week, crystals of a sufficient size had grown and were then soaked in a 
solution (0.1 M Tris, pH 8.5, 0.2 M Li2SO4, 250 mM NaCl and 22% PEG 3350) 
supplemented with 100 µM 207b and left for 24 h. Crystals were collected and diffrac-
tion data were obtained (Figure 46). The classical hydrogen-bonding motif is apparent 
in the X-ray crystal structure with the key binding of the lactam carbonyl O with Ser1068 
and with the N-H of Gly1032 and 
of the lactam N-H with the C=O 
of Gly1032. Further to this the 
expected aromatic π-π stacking 
interactions are made between 
Tyr1071, Tyr1050 and Tyr1060 and 
the 3-phenyl group in 207b. 
Interestingly the 5-methoxy 
group in 207b appears to be 
orientated towards a Glu1138 
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residue with potential for a hydrogen-bond interaction between the carboxylic acid 
group hydrogen and 5-methoxy group oxygen. That said, the carboxylic acid side chain, 
with a pKa ~4, is probably ionised at physiological pH and as such no hydrogen-bonding 
would be possible. The improvement in activity between the 5-methoxy analogue 
207b (100% inhibition of tankyrase-2 activity at 10 nM) and the 5-methyl analogue 
206b (70% inhibition of tankyrase-2 activity at 10 nM) suggests that this interaction 
may be contributing to a superior fit of the former analogue in the nicotinamide-
binding site; however, this trend of an improvement in activity between 5-methoxy 
analogues and 5-methyl analogues is not consistent across the library and in most 
cases there is no difference in activity between compounds containing these position-5 
groups (Table 7).  
It is clear from the X-ray crystal structure of 207b (Figure 44) that the para-substituted 
3-phenyl group is held in a co-planar conformation to the isoquinolin-1-one scaffold 
and that no apparent twist between these two sections of the inhibitor is observed. 
This is in agreement with that predicted in the molecular model (Figure 45) and gives 
firm evidence that para-substituted 3-phenyl groups on potential inhibitors are 
optimal for avoidance of steric clashes within the nicotinamide-binding site and 
associated adjacent hydrophobic pocket.  
5.4.7 Trend 3 – Effect of incorporating a 4-methyl group in 215 on the twist angle of 
the 3-aryl group relative to the isoquinolin-1-one core and its subsequent biological 
activity 
The biological inactivity of 3-(2,6-dichloro-
phenyl)-5-methylisoquinolin-1-one (206e) 
(5% tankyrase-2 inhibition at 10 nM), 
warranted further investigation. One exp-
lanation for this result was that the di-
ortho substituents are a steric hindrance to 
optimum binding and clash with the edges of the hydrophobic pocket. Indeed, the 
molecular model generated for 206e (Figure 45) suggests that this is the likely 
rationalisation for the poor activity, as clashes in the hydrophobic pocket are clear. 
Effect of 4-methyl 
on twist angle of 
3-phenyl and 
inhibitor activity
Figure 47: Proposed consensus pharmacophore 
with the 4-methyl highlighted.  
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Another possible explanation is that the dihedral twist imposed by the large chlorine 
atoms on the 3-phenyl ring disrupts its almost co-planar conformation with the 
isoquinolin-1-one ring; observed with para-substituted 3-phenyl rings. Either 
explanation may have a contributory effect to the loss of activity in 206e. With this in 
mind, 4,5-dimethyl-3-phenylisoquinolin-1-one (215) was synthesised using carbanion 
chemistry (Section 4.12 and Figure 47). The additional 4-methyl of 215 will impose a 
degree of dihedral twist on the molecule, both on the isoquinolin-1-one framework, in 
order to keep the 3, 4 and 5 substitutions apart, and to twist the 3-phenyl group out of 
plane with the isoquinolin-1-one, as seen with 206e. In this analogue, however, the 
absence of any substituents on the 3-phenyl group will avoid steric clashes with the 
edges of the hydrophobic pocket caused by the substituents themselves. The 
inhibitory activity of this analogue should allow for differentiation between the two 
possible contributory effects described above.  
Interestingly, inhibitory activity was not completely abolished in 215 (68% inhibition of 
tankyrase-2 activity at 10 nM) compared with 206e (5% inhibition of tankyrase-2 
activity at 10 nM); however, it was somewhat poorer than for 206a, which lacks the 4-
methyl group (86% inhibition of tankyrase-2 activity at 10 nM). These results suggest 
that the incorporation of an additional 4-methyl group in 215 forces the isoquinolin-1-
one bicycle to adopt a buckled conformation so that the 3-phenyl, 4-methyl and 5-
methyl avoid clashing with each other. This ‘buckling’ of the isoquinolin-1-one may not 
be favourable for optimum binding in the nicotinamide-binding site and adjacent 
hydrophobic pocket.  
5.4.8 Trend 3 – Rationalisation of the biological effect of incorporating an additional 
4-methyl group into 215  
It is clear from the molecular model constructed for 215 (Figure 48) that a certain 
degree of twist is placed on the isoquinolin-1-one framework by the presence of three 
substitutions in positions 3, 4 & 5. The close proximity of these groups sees an alter-
nation in their orientation away from plane of the isoquinolin-1-one framework, which 
disrupts the normally planar bicyclic ring.  
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This staggering of substituents in positions-3, -4 and -5 around the isoquinolin-1-one 
ring of 215 imposes a buckling or twist on the bicycle that occurs in order to avoid 
steric clashes between the substituents and will be the lowest energy conformation for 
the analogue. This ‘buckling’ of the isoquinolin-1-one bicycle was measured in the 
molecular model and is illustrated in Figure 49. In addition, a noticeable twist is 
imposed between the 3-phenyl group and isoquinolin-1-one framework of 215 with a 
measured dihedral angle of 78°. The significant degree of twist imposed on this part of 
the analogue disrupts the almost co-planar orientation observed in all other para-
substituted 3-phenylisoquinolin-1-one analogues and may rationalise the slightly 
poorer activity of this analogue compared with the almost identical analogue 206a 
(which lacks the 4-methyl group). Interestingly, the dihedral angle measured between 
the 3-phenyl and isoquinolin-1-one bicycle in the molecular model of 215 (78°) is 
identical to the equivalent angle measured in the 2,6-dichlorophenyl analogue 206e. 
This was unexpected as it was anticipated that the two large ortho-chlorine atoms 
would impose a greater degree of 
twist on this part of the analogue, 
especially once bound within the 
nicotinamide-binding site and 
adjacent hydrophobic pocket. This 
suggests that the very poor activity 
of 206e (5% inhibition of tankyrase-2 
activity at 10 nM) is more likely to be 
a reflection of a severe steric hind-
rance inflicted in the hydrophobic 
pocket by the two bulky chlorine 
atoms as opposed to the dihedral 
twist between the 3-phenyl 
component and isoquinolin-1-one 
framework in the light of the 
maintenance of reasonable activity in 
Figure 48: Molecular model of 215 demonstrating the 
twist angle imposed on the 3-phenyl group by 
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215 (68% inhibition of tankyrase-2 activity at 10 nM).  
It is also apparent in the molecular model that the degree 
of twist observed between the isoquinolin-1-one 
framework and the 3-phenyl group in 215 is not sufficiently 
severe to abolish biological activity owing to no steric 
clashes being apparent (Figure 48). That said, it is possible 
that the slight twist of the 3-phenyl ring with respect to the 
isoquinolin-1-one may not allow the 3-phenyl group to 
make as many aromatic interactions in the hydrophobic 
pocket, e.g. π-πstacking in this region of the pocket inclu-
ding Tyr1050. This is in contrast to the molecular model of 
206e where steric clashes are apparent between the large bulky chlorine atoms and 
the edges of the hydrophobic pocket (Figure 45). Pleasingly, the maintenance of 
inhibitory activity of 215 demonstrates that a degree of twist between the isoquinolin-
1-one and the 3-aryl group is tolerated within the hydrophobic pocket. That said, it is 
unlikely that when a 4-methyl group and a larger group in the 3-aryl position e.g. 2,6-
dichlorophenyl are both present in an analogue that any activity will be maintained 
owing to the severe twist that is likely to be imposed on the molecule in order to keep 
these groups sufficiently apart.  
The buckling of the isoquinolin-1-one ring is clear in the molecular model constructed 
(Figure 48) and appears to be largely tolerated within the nicotinamide-binding site 
owing to the maintenance of good activity of 215 compared with 206a (68% and 86% 
inhibition of tankyrase-2 activity at 10 nM respectively). Although no severe steric 
clashes are apparent, it is possible that 215 does not fit as ‘snugly’ within the nicotin-
amide-binding pocket as other inhibitors with no 4-position substitution e.g. 206a. 
Interestingly, there are no obvious steric clashes observed with the 4-methyl group of 
215, which indicates that there is sufficient space in this region of the nicotinamide-
binding site to accommodate this relatively small group.  
78°10°
5°10°
Figure 49: A diagram 
showing the dihedral angle 
measured in the molecular 
model of 215 between the 
3-phenyl and isoquinolin-1-
one bicycle (red line). A 
significant buckling of the 
isoquinolin-1-one bicycle is 
also observed (Green, blue 
and purple lines) 
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5.4.9 Trend 3 – Protein X-ray 
crystallography (215) 
Crystals of the catalytic ART domain 
of tankyrase-2 were soaked in a 
solution with 100 µM of 215 and co-
crystals were formed over 24 h 
using the method described prev-
iously.42 The X-ray crystal structure 
of 215 is shown in Figure 50. This 
structure was solved by molecular replacement using the apo-tankyrase-2 structure 
(PDB code: 3KR7) as a model. The dihedral twist between the isoquinolin-1-one 
scaffold and the 3-phenyl group of 215 is clear in Figure 50 and appears to have a 
similar conformation to that predicted in the molecular model (Figure 48). In contrast 
to the conformation suggested by the molecular model, the two methyl groups in 
position-4 and -5 of the isoquinoline-1-one appear to be in plane with one another and 
not as staggered as predicted (Figure 48). A slight buckling of the two rings of the 
isoquinolin-1-one is apparent in the model; however, this does not appear to alter 
drastically the overall shape of the inhibitor within the tankyrase-2 nicotinamide-
binding site. This would justify the reasonable activity of this inhibitor as any buckling 
of the fused ring system appears to have minimal influence on the key binding inter-
actions around this part of the inhibitor in the X-ray crystal structure, e.g. hydrogen 
bonding of the lactam carbonyl O with Ser1068 and with the N-H of Gly1032 and of the 
lactam N-H with the C=O of Gly1032. The 3-phenyl group also appears to be 
participating in key hydrophobic interactions e.g. π-π stacking with three Tyr residues; 
Tyr1060, Tyr1050 and Tyr1071 in addition to a further hydrophobic interaction with Pro1034. 
There is no clear evidence from the X-ray crystal structure to rationalise the slightly 
poorer activity of 215 compared with 206a (68% and 86% tankyrase-2 inhibition at 10 
nM respectively). The dihedral angle between the plane of the 3-phenyl and the 
isoquinolin-1-one in 215 is measured as 50° in the X-ray crystal structure (Figure 50). 
This suggests that the dihedral angle between the plane of the 3-phenyl and 
isoquinolin-1-one is not as severe as that predicted in the molecular model (78°; Figure 
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48). This would justify the only moderate loss of activity when an additional 4-methyl 
group is incorporated into the isoquinolin-1-one scaffold. 
5.4.10 Trend 4 – Effect of changing the nature of the para-substituent on the 3-aryl 
group on inhibition of tankyrase-2  
Following the observation that para-
substituents (or lack of ortho- and meta-
substituents) on the 3-aryl group appear to 
be favourable for greater inhibition of 
tankyrase-2, the next key feature to examine 
was the effect of the nature of the substit-
uent itself (Figure 51). Figure 52 illustrates 
the general trend observed across the 5-
amino, 5-methyl and 5-methoxy series of 
analogues and, indeed, is representative of the trend observed across the entire library 
of inhibitors. It is clear from these data that the nature of this para-substituent exerts a 
modest effect on the overall inhibitory potential of the analogue compared with the 
nature of the position-5 substituent, with poorer inhibition of tankyrase-2 observed for 
all analogues shown in the 5-amino series, as discussed earlier in Trend 1.  
In general, para-methyl, e.g. on 206g and 207d, and para-trifluoromethylphenyl 
substituents, e.g. on 206f and 207c, appear to be the most favourable for binding in 
the hydrophobic pocket adjacent to the nicotinamide-binding pocket across all series 
of compounds, regardless of the nature of the 5-substituent (100%, 100%, 98% and 
100% inhibition of tankyrase-2 activity at 10 nM, respectively) (Figure 52). These 
groups are all of a similar size and are hydrophobic in nature; this indicates that it is 
mainly hydrophobic interactions that dominate in the region of the pocket that these 
substituents lie in. Indeed, it is thought that these substituents occupy the inner end of 
a narrower hydrophobic tunnel that leads away from the opposite face of the 
hydrophobic pocket towards solvent water.  
Figure 51: Proposed consensus 
pharmacophore with the para-substituted 
position on the 3-phenyl highlighted to 
indicate the structural feature that will be 
explored in this section. 
Nature of para-
substituent? What 
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The results for the para-trifluoromethylphenyl substituents, e.g. in 206f and 207c, are 
not entirely surprising, considering that the potent and selective tankyrase-1 and -2 
inhibitor, XAV939 (1), bears a para-trifluoromethylphenyl moiety in the same region of 
the molecule.82 However, it would appear that the para-methyl is the superior substit-
ution in the para-position across all series of compounds synthesised (regardless of the 
position-5 substitution). These results are also in agreement with data for a series of 2-
(4-substituted-aryl)quinazolin-4-ones synthesised by Dr Amit Nathubhai, where both 
265c and 265d were also the most potent in a tankyrase-2 inhibition study (IC50 = 6.7 
nM and 10 nM, respectively) (Figure 39).229 
Other groups that led to a slightly lower level of inhibitory activity against tankyrase-2 
included the para-chlorine atom in 206b, the para-bromine atom in 206h and the 
para-t-butyl group in 206k (70%, 88% and 78% inhibition of tankyrase-2 activity at 10 
nM, respectively) (Figure 52 and Table 7). These results may demonstrate that a larger 
atom or group in the para-position may not fit as easily within the narrower hydro-
phobic tunnel and may need to be accommodated elsewhere in the hydrophobic 
100% 100% 100% 88% 
86% 70% 98% 100% 
18% 65% 60% 84% 
Increasing inhibition of tankyrase-2 activity 
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pocket. That said, the results are still very promising and should not exclude the 
further development of these analogues. This trend is also mirrored in the series of 
quinazolin-4-ones described earlier, where the para-chlorophenyl analogue 265b (IC50 
= 33 nM) has a lower inhibitory activity against tankyrase-2 than other analogues with 
smaller groups in the para-position, e.g. 265c and 265d (IC50 = 6.7 nM and 10 nM, 
respectively) (Figure 39).229 In contrast to the results in this series of compounds, the 
2-(para-bromophenyl)quinazolin-4-one 265e is one of the most active compounds in 
the series (IC50 = 5.5 nM).229  
Interestingly, the electronics of the para-substituent appear to have minimal influence 
on the inhibitory effect of the individual analogue. The electron-donating para-meth-
oxy group in 206i led to a very similar level of inhibitory activity over tankyrase-2 as 
the electron-withdrawing para-trifluoromethyl group in 206f (98% and 90% inhibition 
of tankyrase-2 activity at 10 nM, respectively). This is in agreement with a series of 
quinazolin-4-ones, where the equivalent analogues 265e and 265d show an almost 
identical inhibitory activity against tankyrase-2 (IC50 = 12 nM and 10 nM, respectively) 
(Figure 39).229 
Further to this, the polar electron-donating 3-(4-hydroxyphenyl) in 167l also shows no 
difference in inhibitory activity compared with that of the electron-withdrawing 3-(4-
trifluoromethylphenyl) analogue 167n of the same series (58% and 60% inhibition of 
tankyrase-2 activity at 10 nM, respectively) (Table 7). Again, akin to the isoquinolin-1-
one series, the polar para-amino group in the quinazolin-4-one 265g inhibited 
tankyrase-2 activity to a similar extent to that of a non-polar para-methyl group in the 
quinazolin-4-one 265c (IC50 = 3.3 nM and 6.7 nM, respectively) (Figure 39).229 At 
physiological pH neither the hydroxy or amino groups would be charged; it is the 
neutral species that will be present in the assay and in vivo and thus must be consid-
ered at this stage. The 4-hydroxyphenyl group in 167l would have the potential to both 
donate and accept hydrogen-bonds within the hydrophobic pocket; the 4-aminophenyl 
in 265g would only potentially donate a hydrogen-bond (Figure 39). It is highly unlikely 
that any such interactions are being made in this region of the hydrophobic pocket 
owing to these polar groups showing no superior activity in terms of tankyrase-2 
inhibition over other non-polar substituents, e.g. trifluoromethyl and methyl groups. 
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This would also explain why the mildly electron-withdrawing para-carboxamide in 
167g, which could potentially both accept and donate hydrogen bonds is not superior 
to non-polar groups incorporated in the same position (80% tankyrase-2 inhibition at 
10 nM) as there are no residues within the immediate vicinity with which to make such 
interactions. 
Despite these excellent results, when there is no substituent in the para-position e.g. 
206a and 207a (with only an un-substituted 3-phenyl) good activity is still maintained 
(86% and 88% tankyrase-2 inhibition at 10 nM respectively) (Figure 52) which 
demonstrates that this effect in the hydrophobic pocket is not as influential as the 
orientation of the substituent on the 3-aryl group (as discussed in Trend 2). That being 
said, it is clear that the presence of a 
substituent in the para-position on the 3-
aryl group improves tankyrase-2 inhibition 
in nearly all cases and across all series of 
inhibitors. In all cases, regardless of the 
nature of the para-substituent the 5-amino 
series demonstrate poorer inhibitory 
activity against tankyrase-2 than the 5-
methyl and 5-methoxy counterparts, e.g. 
167a versus 206a (18% and 86% inhibition 
at 10 nM, respectively), 167n versus 206f 
(60% and 98% inhibition at 10 nM 
respectively) and 167o versus 206g (84% 
and 100% inhibition at 10 nM, 
respectively). This, as discussed earlier 
reinforces the fact that the nature of the 
para-substituent, although influential, is 
not the most important feature of the 
analogues in terms of overall inhibitory 
potential. Overall a variety of substituents 
are tolerated in the para-position of the 3-
Figure 53: Molecular model with 3-(4-t-butyl)-5-
methylisoquinolin-1-one (206k) in the tankyrase-2 
nicotinamide-binding pocket from the 
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phenyl substituent of the isoquinolin-1-one framework.  
5.4.11 Trend 4 – Rationalisation of the effect of the nature of the para-substituent on 
the 3-phenyl group using molecular modelling 
It is not immediately clear from molecular models generated of analogues with a 
variety of para-substituted 3-aryl groups why some substituents are superior to others. 
Closer examination of larger groups incorporated into the para-position e.g. t-butyl 
(Figure 53) reveals that the hydrophobic tunnel that leads towards solvent water away 
from the hydrophobic pocket is considerably narrower that the large ovoid-shaped 
pocket to which it is attached.  
In the case of 206k (Figure 53), the t-butyl group appears to fit into the opening of this 
narrower tunnel but with little room to spare and some minor steric clashes are likely. 
Indeed, the lower inhibitory activity of 206k compared to inhibitors with smaller para-
substituents, e.g. 206f and 206g, may be rationalised by the former clashing slightly 
with the edges of the narrow tunnel whereas the latter analogues avoid such conflicts. 
It is clear from the results in this trend and the molecular model generated (Figure 53) 
that only moderately narrow substituents will be tolerated in this local environment, 
irrespective of polarity or capacity to accept or donate hydrogen-bonds. 
That said, the fact that any para-substituent, examined within this trend, appears to be 
superior to merely a 3-phenyl group suggests that any minor steric clashes are not of 
major consequence in terms of inhibitory loss. It is possible that larger groups 
incorporated in this position do not obliterate activity completely as they are not ‘long’ 
enough to probe entirely the narrower hydrophobic tunnel; they may merely occupy 
the inner face and, as such, maintain a reasonable level of inhibitory activity.  
The superiority of analogues with para-substituents over those with an un-substituted 
3-phenyl, e.g. 206a, suggests that there must be additional hydrophobic interactions 
taking place within the hydrophobic pocket. Indeed the para-trifluoromethylphenyl 
group of the potent tankyrase-1 and -2 inhibitor XAV939 (1) makes additional 
hydrophobic interactions with Pro1034, Phe1035 and Ile1075 in this region of the enzyme 
pocket.82, 107 It is likely that these same hydrophobic interactions are also being made 
between analogues in this library with either a para-trifluoromethyl, e.g. 206f and 
 
 
- 173 - 
 
207c, and para-methyl groups, e.g. 206g and 207d, and, as such, may justify their 
apparent superiority in terms of inhibition of tankyrase-2 enzyme activity. This is in 
contrast to other groups unable to make these interactions, e.g. 3-phenyl 206a, which 
does not probe the narrower hydrophobic tunnel at all. 
Overall, the molecular models generated (including Figure 53) rationalise the incorpor-
ation of a relatively small and narrow para-substituted group on the 3-phenyl of the 
isoquinolin-1-one. This region of the hydrophobic pocket appears to be highly tolerant 
of the nature of the para-substituent with electron-withdrawing, electron-donating, 
polar and non-polar groups all being acceptable substituents. It is the size of the 
substituent which appears to be the most influential feature in this region of the 
pocket. Further investigation of the extent to which substituents in the para-position 
can be extended into the hydrophobic pocket e.g. with the incorporation of a series of 
tertiary cyclic amine analogues (236a-d) and a rigid hydrocarbon extension with 222 
will be discussed in Trend 6. 
5.4.12 Trend 5 - The effect of incorporating a heterocycle or an organometallic into 
position-3 of the isoquinolin-1-one on inhibitory activity against tankyrase-2 
Further to an initial exploration of the 
effect of a large variety of substituents in 
the para-position in Trend 4, it was 
desirable to investigate the effect of 
incorporating both heterocycles and 
organometallics into position-3 of the 
isoquinolin-1-one (Figure 54). A hetero-
atom, e.g. nitrogen in a pyridine ring, may be able to make additional interactions 
within the hydrophobic pocket without increasing the steric bulk of the 3-aryl group 
significantly. Other organometallic groups, e.g. ferrocene, would test further the 
tolerance of this region of the catalytic pocket to steric bulk. Interestingly, all the 
heterocycles and organometallics incorporated into position-3 of the isoquinolin-1-one 
exhibited poorer inhibitory activity against tankyrase-2 than merely a 3-phenyl 
substituent, e.g. 206a (86 % inhibition of tankyrase-2 activity at 10 nM compared with 
Figure 54: Proposed consensus pharmacophore with 
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the values quoted in Figure 55). This demonstrates, to some extent, that there are no 
significant additional interactions being made between any heteroatom incorporated 
and residues in the hydrophobic pocket. The inhibitory effect increases in the order 
ferrocene < pyridine < thiophene < benzo-1,3-dioxole, as shown for the 5-methyl series 
in Figure 55; however, an identical trend is also observed in the 5-methoxyisoquinolin-
one series of inhibitors (Table 7).  
Firstly, activity is entirely abolished with incorporation of the bulky 3-ferrocenyl moiety 
in 262 (0% inhibition of tankyrase-2 activity at 10 nM) (Figure 55). This analogue was 
designed with the aim of increasing the 3D steric bulk of the 3-substituent whilst 
retaining aromatic character. It is clear from this result that this 3D bulk is not well 
tolerated in the hydrophobic pocket adjacent to the nicotinamide-binding pocket, 
despite maintenance of aromatic character. This result suggests that the bulky 
ferrocene clashes badly with the edges of the hydrophobic pocket and that its 3D 
shape is not tolerated at all in this region.  
Slightly improved inhibitory activity is observed for the 3-pyridin-4-yl compounds 206j, 
207f and 208g (20%, 14% and 15% inhibition of tankyrase-2 activity at 10 nM, respect-
ively) over 262 (Figure 55 and Table 7). This was a surprisingly poor result, as the incor-
poration of a small heteroatom into the 3-phenyl ring has significantly reduced the 
inhibitory activity compared with merely a phenyl ring in 206a (86% inhibition of 
tankyrase-2 activity at 10 nM). 
It is unlikely that the pyridinyl moiety occupies a much greater steric space than the 
phenyl ring and thus it is likely that it is the electronic effect of the former that is 
causing the poor inhibitory activity. The pyridine nitrogen has the potential to be prot-
onated under certain conditions which would potentially reduce the binding potential 
51% 20% 0% 49% 
Increasing tankyrase-2 inhibition 
Figure 55: Illustration of the key trends observed when incorporating a heterocycle or an organometallic into 
position-3 of the isoquinolin-1-one framework.  
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in a hydrophobic pocket dominated by non-polar residues. At physiological pH, how-
ever, it is likely that this weakly basic group (pKa of the conjugate acid of pyridine = 
5.25) is predominately not protonated and, as such, its poor inhibitory activity cannot 
be entirely explained in this context. Electronically, a pyridine ring is more electron-
poor than a phenyl ring, which should enhance its ability to π-stack with electron-rich 
tyrosine residues in the hydrophobic pocket. This does not in any way rationalise the 
poorer activity of 206j compared with 206a (20% and 86% inhibition of tankyrase-2 at 
10 nM). It is possible that the lone pair of electrons on the pyridine nitrogen in 206j, 
which is in the plane of the heterocycle, in some way disrupts the binding in this region 
of the hydrophobic-pocket. This poor activity also confirms the earlier observation that 
there are no residues in the hydrophobic pocket capable of making hydrogen-bond 
interactions, which the lone pair on the pyridinyl nitrogen would be capable of making.  
Further to this, the incorporation of a thiophen-3-yl group was explored in the 3-aryl 
region (Figure 55 and Table 7). Known to be a conservative replacement for a benzene 
group, the thiophene was anticipated to generate a similar inhibitory effect against 
tankyrase-2. In contrast, its inhibitory effect was somewhat poorer (49% and 53% 
compared with 86% inhibition of tankyrase-2 activity at 10 nM for 206m and 207i, 
compared with 206a, respectively). It is clear that the size of the heterocycle itself is 
not the most influential factor on inhibitory activity as the thiophene in 206m is no 
larger than a 3-phenyl. This somewhat poorer activity, however, could be due to the 
bulky sulfur atom being located in a position analogous to that of the chlorine in the 
meta-chlorophenyl analogue 206d or 167e. Steric bulk in the meta-position is already 
known to be detrimental to inhibitory activity owing to steric clashes with the edges of 
the hydrophobic pocket with such analogues (see Trend 2). This may explain the 
poorer activity observed with 206m and 207i compared with 206a. The bulky sulphur 
atom of the thiophen-3-yl in 206m and 207i may disrupt the ability of this heterocycle 
to π-stack effectively with key tyrosine residues (Tyr1060, Tyr1050 and Tyr1071) in the 
hydrophobic pocket. Moreover, thiophene is a marginally more electron-rich ring than 
a phenyl ring alone and as such may not participate in π-π stacking as effectively as 
analogues with a 3-phenyl group, e.g. 206a.  
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Finally, a benzo-1,3-dioxole moiety was incorporated into the 3-aryl position in 206l 
and 207h, following the observation by Narwal and colleagues that this group 
conferred tankyrase-1 and -2 selectivity over other PARP family members.42 This 
heterocycle demonstrated a similar level of tankyrase-2 inhibition activity to that of 
the thiophen-3-yl in 206m and 207i (51% and 57% inhibition of tankyrase-2 activity at 
10 nM for 206l and 207h, compared with 49% and 53% for 206m and 207i) (Figure 55 
and Table 7). The electron-rich nature of the benzo-1,3-dioxole of 206l and 207h may 
disrupt the ability of this group to participate in effective π-π stacking with Tyr1060, 
Tyr1050 and Tyr1071 in the hydrophobic pocket, reducing its activity relative to merely a 
3-phenyl substitution e.g. in 206a. In addition, the ‘dioxole’ portion of the benzo-1,3-
dioxole group in 206l and 207h is positioned in effectively the meta-position, akin to 
that of the sulfur in the thiophen-3-yl and will also potentially clash with the edges of 
the hydrophobic pocket and disrupt the effectiveness of this group toπ-stack. 




Figure 56: Molecular modelling showing the two conformations that the 3-benzodioxole of 206l may adopt 
within the hydrophobic pocket of the tankyrase-2 nicotinamide-binding site.  
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incorporating a benzo-1,3-dioxole group or a thiophen-3-yl.  
There is apparently no benefit in inhibitory activity against tankyrase-2 when any of 
the aforementioned groups are incorporated in the 3-aryl region compared with a 3-
phenyl ring. Indeed, the inhibitory activity actually worsens in every case indicating 
that the incorporation of bulky heterocycles and organometallics can actually disrupt 
the close binding and hydrophobic interactions such as π-π stacking observed with 
analogues with a 3-phenyl group, e.g. 206a.  
5.4.13 Trend 5 – Rationalisation of the inhibitory effect of incorporating a heterocycle 
or an organometallic into position-3 of the isoquinolin-1-one using molecular 
modelling 
The poorer inhibitory activity demonstrated when a heterocycle or organometallic is 
incorporated into position-3 of the isoquinolin-1-one, compared with a 3-phenyl ring, 
can be rationalised using molecular modelling. In the example shown, the benzo-1,3-
dioxole group in 206l can predictably be orientated in two distinct conformations 
within the nicotinamide-binding site (Figure 56). In one conformation (Figure 56, right 
picture) the benzo-1,3-dioxole moiety is orientated towards the middle of the hydro-
phobic cavity, whereas, in the other conformation, possible steric clashes are observed 
between the CH2 protons and the edges of the pocket (Figure 56, left picture).  
This observation may explain, in part, the moderate activity of 206l against tankyrase-2 
as one binding conformation of this inhibitor may be far superior compared with the 
other. In addition, the clashes observed (Figure 56, left picture) are similar to those 
observed when a meta-substituent is incorporated into the 3-phenyl group, e.g. 206d, 
which suggests, along with the molecular model that it is steric clashes that confer the 
poor activity of the benzo-1,3-dioxole moiety in 206l and 207h as opposed to an 
electronic effect related to the oxygen atoms in the heterocycle itself. There is no 
specific evidence from the molecular models generated of any specific interactions 
between the heterocyclic oxygen atoms and residues in the hydrophobic pocket that 
might improve its binding profile. Indeed, this is not surprising considering the poorer 
inhibitory activity observed compared with 3-phenyl analogues, e.g. 206a and 207a.  
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5.4.14 Trend 6 – The inhibitory effect of extending further into the hydrophobic 
pocket  
It became desirable to explore the length and 
depth of the hydrophobic pocket following the 
observation that para-substituted 3-phenyl-
isoquinolin-1-ones, e.g. 206f and 206g (Figure 
52), were not only highly potent but that the 
para-substituent appeared to be occupying the 
inner edge of a narrower hydrophobic tunnel 
leading away from the main hydrophobic 
pocket towards solvent water (Figure 57). The further occupation of this narrower 
hydrophobic tunnel might lead to enhanced inhibitor binding through the creation of 
additional hydrophobic interactions between the inhibitor and residues lining the inner 
surface of the tunnel. As substituents in the para-position of the 3-phenyl ring were 
thought to occupy the inner edge of this tunnel, it was important to explore fully the 
tolerance of this narrower tube to different substituents.  
Extending the isoquinolin-1-one scaffold further beyond a substituted phenyl ring at 
position-3 elicits an interesting pattern of inhibition data (Figure 58). Firstly, 
hydrophobic extensions made up of only carbon and hydrogen were incorporated in 
order to provide further hydrophobicity to the extended analogue, e.g. 175 and 222. 
These extensions were anticipated to be well-tolerated in the nicotinamide-binding 
site owing to the hydrophobic nature of both the main pocket within which the 3-aryl 
Figure 57: Proposed consensus 
pharmacophore with extension of the 3-
aryl group highlighted.  
Extension of 3-
aryl group into 
hydrophobic 
pocket
Figure 58: Illustration of the Inhibition of tankyrase-2 activity is expressed as a percentage at 10 nM 
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group sits and the narrower hydrophobic tube leading away from this. 
The incorporation of a flexible two-carbon linker between the isoquinolin-1-one 
scaffold and the 3-phenyl of 175 does not lead to good inhibitory activity (20% 
inhibition of tankyrase-2 activity at 10 nM) (Figure 58). That said, this activity is very 
similar to that observed with the 3-phenyl compound 167a in the 5-amino series (18% 
inhibition of tankyrase-2 activity at 10 nM), however much poorer activity than that 
observed for the 3-phenyl compound 206a in the 5-methyl series (86% inhibition of 
tankyrase-2 activity at 10 nM) (refer to Figure 35 for structures). This poor activity is 
also likely to be due to the flexibility of this two-carbon linker group and its subsequent 
ability to adopt different conformations within the hydrophobic pocket. The bulky 
phenyl group anchored to the end of this two-carbon linker group may be able to 
‘swing’ from one confirmation to another within the hydrophobic pocket and as such 
cause unfavourable clashes with the edges of the pocket. It is also likely that the 
CH2CH2 linker pushes the terminal phenyl group towards the narrower hydrophobic 
tube, which it is too bulky to occupy.  
In contrast, the 3-phenylethynylphenyl analogue 222 demonstrates a promising level 
of inhibitory activity (71% inhibition of tankyrase-2 activity at 10 nM) (Figure 58). This 
may in part be a reflection of this analogue having both a ‘near’ phenyl group, able to 
make key interactions such as π-π stacking with Tyr1060, Tyr1050 and Tyr1071 in the 
hydrophobic pocket and also a terminal phenyl group able to make further 
hydrophobic interactions. The rigid alkynyl linker between the ‘near’ and ‘terminal’ 
phenyl groups hold the entire position-3 of this analogue in a linear confirmation 
which is likely to fit through the hydrophobic pocket, thus avoiding potential steric 
clashes with the edges of the pocket. Although the presence of a second phenyl group 
in position-3 of the isoquinolin-1-one scaffold should increase the potential of an 
inhibitor to make hydrophobic interactions within the hydrophobic pocket e.g. 
aromatic π-π stacking, it is clear that this is unnecessary for tankyrase-2 inhibition as a 
single 3-phenyl substitution e.g.in 206a is a superior inhibitor (86% tankyrase-2 
inhibition at 10 nM). This may indicate that this extended analogue is unnecessarily 
large. Indeed it is likely that the terminal phenyl group sits deep within the 
hydrophobic pocket towards solvent water on the perimeter of the active site which 
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may be detrimental to its activity. Further to this manipulation of this particular 
analogue proved difficult due to its limited solubility in water and tendency to 
precipitate out of solution.  
In the quest for inhibitors that would have improved aqueous solubility whilst main-
taining a good degree of hydrophobicity as desired for tankyrase-2 binding, a series of 
tertiary amines was designed (See Section 4.14, compounds 236a-d). Since a solubilis-
ing group in position-5 of the isoquinolin-1-one, e.g. amino, had proved inferior for 
binding to tankyrase-2, compared with hydrophobic groups, e.g. methyl (Trend 1), it 
was proposed that a chargeable group might be better tolerated towards the end of 
the hydrophobic pocket as it approaches solvent water. Further to this, it was planned 
that a CH2 linker between a ‘near’ phenyl group and tertiary cyclic amine would raise 
the pKa of the protonated form of the conjugate acid. This linker, therefore, has the 
effect of increasing the basicity of the amine. Direct attachment of the tertiary cyclic 
amine to the ‘near’ phenyl group would result in this group being much less basic.  
Encouragingly, the charged piperidine moiety in 236c which is anchored to a 3-phenyl 
group through a single carbon linker maintains reasonable inhibition of tankyrase-2 
(61% inhibition at 10 nM) (Figure 58). This same promising result is also observed for 
the 4-methylpiperazinylmethyl in 236d (61% inhibition of tankyrase-2 activity at 10 
nM) which, under physiological conditions, will have two charged nitrogen atoms.  
This encouraging activity is in stark contrast to a primary aliphatic amine incorporated 
into the same position of a quinazolin-4-one 232 (Figure 59) which demonstrated 
relatively poor tankyrase-2 inhibitory activity activity (IC50 = ~100 nM).229 It is clear 
from these data that an exposed basic amine, as in 232, which would be charged at 
physiological pH, causes a major loss of activity against tankyrase-2. Although the 
piperidine in 236c would also be charged at physiological pH owing to a pKa (conjugate 
acid) of approximately 10, it would appear that the 
lipophilicity provided by the six-membered CH2 cycle 
helps to maintain good inhibitory activity. The 
moderately rigid chair shape of the piperidine moiety 
attached via a single ‘kinked’ carbon linker only 
allows for rotational mobility and would appear to be 
Figure 59: The quinazolin-4-one 232 
was designed to test the tolerance 
of tankyrase-2 to a polar cation.229  
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well tolerated. It is likely that the terminal piperidine moiety of 236c occupies at least 
part of the hydrophobic tunnel that leads away from the main hydrophobic pocket, 
and is possibly in contact with solvent water on the perimeter of the pocket. Improved 
activity is also observed for the dimethylamino analogue 236a (70% inhibition of 
tankyrase-2 activity at 10 nM) (Figure 35 for structure). This analogue is very similar in 
the 3-aryl region of the molecule (isoquinoline numbering) to 232 in the quinazolin-4-
one series, which indicates that a small amount of lipophilicity around a charged entity 
is more favourable than an exposed highly polar cation of 232 (Tankyrase-2 IC50 = ~100 
nM). That said, a direct comparison is difficult owing to the overall lower activities of 
the entire quinazolin-1-one series compared with the isoquinolin-1-one series. 229 
Surprisingly, activity is completely abolished for the charged pyrrolidine 236b (0% 
inhibition of tankyrase-2 activity at 10 nM) (Figure 58). The charged status of this anal-
ogue compared with the piperidine 236c is likely to be identical, owing to a very similar 
pKa (conjugate acid) of approximately 10 and thus cannot explain this vast difference 
in activity. The shape of the pyrrolidine in 236b is different to the moderately rigid 
chair shape of the piperidine in 236c; however, this would not be expected to elicit a 
dramatically different biological response. The piperidine in 236c may be able to make 
more hydrophobic interactions in the hydrophobic pocket than the pyrrolidine in 236b 
owing to the additional CH2 group but this alone in unlikely to explain this unusual 
result. Altogether it is not clear why these two analogues demonstrate a huge 
difference in their inhibitory activity against tankyrase-2.  
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5.4.15 Trend 6 – Rationalisation of the effect of extending into the hydrophobic 
pocket using molecular modelling 
The molecular models generated for the two analogues 175 and 222, which reach 
further into the hydrophobic pocket with non-polar extensions (made of hydrogen and 
carbon atoms only) help to rationalise the tankyrase-2 inhibitory activity observed in 
the ranging assays (Figures 60 and 61). Firstly, the poor activity noted for 175 (20% 
inhibition of tankyrase-2 activity at 10 nM) can be rationalised by its poor fit into the 
tankyrase-2 nicotinamide-binding site and adjacent hydrophobic pocket (Figure 60). 
The flexible two-carbon linker situated in between the isoquinolin-1-one framework 
and the phenyl group in 175 leads to two possible conformations of the 3-(2-phenyl-
ethyl) group within the hydrophobic pocket (Figure 60, right- and left-hand pictures).  
5-Amino-3-(2-phenylethyl)isoquinolin-1-one  
Figure 60: Molecular models showing both possible conformations of the 3-(2-phenylethyl) group of 175 in 
the hydrophobic pocket of tankyrase-2.  
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In one conformation (Figure 60, left-hand picture) the 3-(2-phenylethyl) side-chain 
appears to project almost cleanly through the hydrophobic pocket with a minor clash 
expected at the perimeter of the protein. In contrast, in the other possible 
conformation (Figure 60, right-hand picture), the bulky phenyl group has ‘swayed’ 
completely into the surface of the protein in the hydrophobic pocket and is causing 
many unfavourable steric clashes. 
It is likely that the poor activity of 175 (20% tankyrase-2 inhibition at 10 nM) is likely 
due to these steric clashes. That said, such severe clashes with the edges of the 
hydrophobic pocket may preclude the compound from adopting this poorly fitting 
conformation within the hydrophobic pocket and as such only allows the inhibitor to 
adopt the favourable conformation. The small amount of activity shown by 175 is 
probably due to the reasonable fit of the analogue in one of the two possible 
conformations.  
In contrast, the long linear shape of the 
4-phenylethynylphenyl in 222 projects 
nicely through the hydrophobic pocket 
adjacent to the nicotinamide-binding 
site, with little or no steric hindrance 
apparent in the model (Figure 61). This 
explains the good activity of 222 
analogue compared with 175 (71% and 
20% tankyrase-2 inhibition at 10 nM 
respectively). Although a good ‘fit’ within 
the tankyrase-2 nicotinamide-binding 
site and adjacent hydrophobic pocket it 
was necessary to move a portion of the 
protein temporarily in order to 
accommodate the bulky side-chain of 
222. This was not surprising as a 
collaborator, Dr Lari Lehtiö, whilst 




Figure 61: Molecular model of 222 bound in the 
nicotinamide-binding site and adjacent hydrophobic 
pocket of tankyrase-2.  
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structure of 222, had been unable to get this bulky inhibitor to enter the tankyrase-2 
protein crystal. This may suggest that the access of this inhibitor to the nicotinamide-
binding site in the full-length enzyme may be somewhat limited by its large size, even 
though it ‘fits’ nicely, once positioned in the molecular model.  
Promisingly, the water-soluble piperidinyl analogue 236c demonstrated a good level of 
inhibitory activity (61% tankyrase-2 inhibition at 10 nM) (Figure 58). It is clear from the 
molecular model generated for 236c (Figure 62) that the analogue actually fits very 
snugly into the hydrophobic pocket with the small amount of rotational flexibility 
tolerated well. No steric clashes are obvious from the model; in fact the rotational 
twist caused by the single carbon linker appears to orientate the piperidin-1-yl side 
chain of 236c through the hydrophobic pocket and it appears to sit within the 
narrower hydrophobic tunnel on the far side.  
 It is likely that the 4-methylpiperazinylmethyl 236d also occupies the hydrophobic 
pocket in much the same way, which 
accounts for its identical inhibitory activity 
(61% inhibition of tankyrase-2 activity at 10 
nM). A second ‘charged’ nitrogen does not 
appear to be detrimental to activity; in fact it 
is likely that this ‘far’ charged nitrogen 
projects through the narrower hydrophobic 
tunnel and may interact with solvent water 
at the far end. Although in the case of 236c, 
there is no ‘far’ second nitrogen as in 236d, 
the model provides clear evidence that this 
second nitrogen would sit at the far end of 
the narrower hydrophobic tunnel towards 
solvent water. These potential additional 
interactions with solvent water are a 
promising feature for future inhibitor design.  
There do not appear to be any residues 




Figure 62: Molecular model showing the 
piperidin-1-yl side chain of 236c bound in the 
hydrophobic pocket of tankyrase-2. 
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in the molecular model of 236c that would be capable of forming specific interactions 
with this charged entity; indeed, the narrower tunnel leading away from the main 
hydrophobic pocket is also dominated by hydrophobic residues (Figure 62). The far 
superior activity of 236c and 236d compared to 232 may indicate how intolerant the 
far end of the hydrophobic pocket and entrance to the hydrophobic tunnel are to 
exposed polar cations. This charged cation, however, when incorporated within a 
highly lipophilic saturated ring structure, e.g. piperidine in 236c or methylpiperazine in 
236d, does not appear to cause the same level of disruption at the far end of the 
hydrophobic pocket and entrance to the hydrophobic tunnel and is well-tolerated. This 
is an encouraging result as the incorporation of a solubilising entity in this region of the 
analogue will improve the pharmaceutical properties of an inhibitor. It would appear 
that incorporating a solubilising group within a lipophilic ring in position-3 of the 
isoquinolin-1-one is better tolerated in the hydrophobic pocket than the incorporation 
of a solubilising group in the position-5 region (discussed in Trend 1). Inhibitors with 
such functionality, e.g. 236a or 236c, can benefit from improved water solubility whilst 
also incorporating a lipophilic group in position-5 of the isoquinolin-1-one; known to 
be optimal for tankyrase-2 binding in this region.  
Interestingly, the pyrrolidinylmethyl compound 236b showed a vastly lower activity to 
that of its piperidinylmethyl counterpart 236c (0% inhibition of tankyrase-2 activity at 
10 nM compared with 61% respectively) that cannot be justified through examining 
the molecular models. This result cannot be explained by differences in basicity or 
charge of the tertiary amine groups in 236b and 236c as these would be virtually 
identical. Similarly, differences in steric bulk between the pyrrolidine in 236b and 
piperidine in 236c would be minimal; indeed, the five-membered ring of the former 
may occupy a smaller volume than the six-membered piperidine of the latter and 
would be expected to cause fewer potential clashes in the hydrophobic pocket.  
5.5 Structure-activity relationship conclusions from preliminary tankyrase-2 ranging 
studies and associated molecular modelling  
Six individual trends were identified from the preliminary screening of the library of 
fifty-six candidate inhibitors which have all contributed to building-up a picture of the 
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ideal inhibitor for activity against tankyrase-2 (summarised in Figure 63). In Trend 1, 
the region of the nicotinamide-binding site that position-5 of the isoquinolin-1-one 
occupies was explored. It became apparent that a reasonably small and hydrophobic 
electron-neutral or electron-donating group, e.g. methyl or methoxy, is desirable at 
position-5 of the isoquinolin-1-one for optimal inhibitory activity. Substitutions that 
have the potential to donate hydrogen bonds, e.g. hydroxy and amino, are less well 
tolerated and reduce activity against tankyrase-2. Worse still is the detrimental effect 
on activity of incorporating a hydrophobic, electron-withdrawing group, e.g. nitro, in 
position-5 of the isoquinolin-1-one. In addition to the electronic preferences of this 
region of the nicotinamide-binding site is the effect of the size of the substituent. It 
would appear that for good activity against tankyrase-2, a sufficiently large substituent 
must be present in order to occupy the small cavity in this region of the nicotinamide-
binding site. For example, the small fluorine atom, which is not much larger than a 
hydrogen atom, has a poor effect on activity against tankyrase-2 as it does not ‘fill’ the 
cavity sufficiently. Thus a moderately sized, electron-neutral or electron-donating 
hydrophobic group is ideal for optimal activity against tankyrase-2. 
In Trend 2, the effect of positional isomers around a 3-phenyl group was explored. This 
position-3 group is known to occupy a hydrophobic pocket located adjacent to the 
nicotinamide-binding site. A clear trend was apparent in this case; regardless of the 
Figure 63: Refined 
pharmacophore for optimum 
tankyrase-2 binding with key 
SAR features illustrated. 
Features of inhibitors left 
unchanged e.g. fixed lactam 
which makes key hydrogen 
bonds in pocket have not 
been highlighted in this 
figure.  
Trend 2, 4, 5 and 6
• Para-substituted aryl ring preferable
• Meta- and ortho-substituents cause steric 
clashes in hydrophobic pocket
• Linear extension possible 
• Flexible linker between 3-substituent and 
isoquinolin-1-one core not well tolerated
• Bulky 3D groups e.g. ferrocene unfavourable
• Potential for incorporation of a water-
solubilising entity
Trend 1
• Small hydrophobic groups 
preferable e.g. methyl and 
methoxy
• EWG unfavourable
• Polar groups unfavourable
• Group must ‘fill’ cavity
Trend 3
• Methyl group here 
imposes twist on 
both 3-aryl group 
and on isoquinolin-
1-one framework 
which is tolerated 
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nature of the substitution on the 3-phenyl ring, activity increased as the substitution 
moved from the ortho to meta to para position around the ring (Figure 63). Clear steric 
clashes between substitutions in the ortho and meta positions and the edges of the 
hydrophobic pocket were apparent in the molecular models. Small molecule X-ray 
crystal structures generated for 206e and 207d also highlighted the dramatic differ-
ences in dihedral angle between the 3-phenyl group and the isoquinolin-1-one core in 
each case; the former completely out of plane with the isoquinolin-1-one in order to 
accommodate the bulky ortho-substituted chlorine atoms and the latter almost co-
planar. It is clear that, for optimum tankyrase-2 activity, a substitution in the para-
position is ideal, with a wide variety of substitutions well tolerated in this position.  
In Trend 3, following the observation from the small molecule X-ray crystal structures 
of 206e and 207d that a dramatic change in dihedral angle between the isoquinolin-1-
one framework and 3-phenyl group occurs when substituents are in the ortho- and 
para-positions, respectively, it was necessary to explore this effect further. Either the 
poor activity of 206e was caused by steric clashes of the two bulky chlorines with the 
edges of the hydrophobic pocket or from the effect of the loss of co-planarity between 
the two ring structures. The reasonable activity of 215 demonstrated that a certain 
amount of dihedral twist is tolerated within the hydrophobic pocket, indicating that it 
is steric clashes of substitutions in the ortho-position of the 3-phenyl ring that were the 
most deleterious to tankyrase-2 inhibitory activity (Figure 63).  
Following the observation in Trend 2 that para-substituents on the 3-phenyl ring of the 
isoquinolin-1-one scaffold were optimal for good activity against tankyrase-2, further 
investigation of the range of substituents that would be tolerated in this position was 
needed to identify Trend 4 (Figure 63). A diverse range of groups and atoms were in-
corporated in this position of the 3-phenyl including electron-withdrawing, electron-
donating, electron-neutral, polar and non-polar. Although a para-methyl or para-tri-
fluoromethyl group were superior for tankyrase-2 activity to all other groups and 
atoms investigated, it was clear that the nature of the group made much less differ-
ence to the activity of an inhibitor than the positional effect of the substitution on the 
3-phenyl ring. This suggested that no specific interactions are present between the 
para-substituent and the hydrophobic pocket in this region; indeed this was confirmed 
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by the molecular models. In addition, the size of the substituent appeared to be more 
important than the electronics of the group itself, with a variety of groups well tol-
erated. A slight loss of activity was noted as the para-substituent increased in size, e.g. 
t-butyl 206k and bromine 206h; however, this effect was minimal. Overall, the 
presence of any para-substitution confers improved activity than no substitution at all. 
In Trend 5, the effect of incorporating a heterocycle or organometallic at position-3 of 
the isoquinolin-1-one scaffold was explored (Figure 63). All heterocycles and 
organometallics investigated demonstrated poorer activity than a 3-phenyl group 
alone. It would appear that bulky 3D groups, such as the ferrocene in 262, confer very 
poor tankyrase-2 activity, which is probably due to steric clashes within the 
hydrophobic pocket. Although the incorporation of some heterocycles e.g. 206l and 
206m maintains reasonable activity, it is clear that they do not confer any additional 
benefits in terms of binding in the hydrophobic pocket over a 3-phenyl ring e.g. in 
206a. It is possible that the poorer tankyrase-2 inhibitory activity demonstrated by 
these groups is partly a result of less effective aromatic interactions e.g. π-π stacking. 
Overall, it is clear that there is no inhibitory advantage in incorporating a heterocycle 
into position-3 of the isoquinolin-1-one scaffold. 
Finally, the effect of extending the position-3 substituent further into the hydrophobic 
pocket on tankyrase-2 activity was explored in Trend 6 (Figure 63). Hydrophobic 
extensions made up of only carbon and hydrogen atoms were explored initially. It was 
clear that a lengthy substituent in this region, e.g. in 222, was well tolerated if the 
substituent was held in a rigid linear position through the hydrophobic pocket, 
although the pharmaceutical properties of such a large analogue were then 
compromised, e.g. aqueous solubility and potential access into the tankyrase-2 
catalytic site. A degree of flexibility between the isoquinolin-1-one and 3-substituent 
was poorly tolerated in the hydrophobic pocket, e.g. in 175, as this enabled a position-
3 substituent to ‘sway’ into the edges of the pocket. Encouragingly, a series of tertiary 
cyclic amines attached to a 3-phenyl group via a one-carbon linker were in general well 
accepted within the hydrophobic pocket and conferred promising tankyrase-2 activity. 
In addition, these cyclic tertiary amines would be protonated under physiological 
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conditions and as such introduce the possibility of incorporating a solubilising entity in 
this region of a potential inhibitor against tankyrase-2.  
The conclusions drawn above have aided development of a SAR for inhibition of 
tankyrase-2 activity (summarised in Figure 63). It must, however, be borne in mind 
that all enzyme assays suffer from some limitations. Specifically, with regards to the 
preliminary ranging studies conducted for this project, the use of a truncated form of 
tankyrase-2 may result in the overall secondary shape of the protein being slightly 
different to the endogenous enzyme. In particular, access of the inhibitors to the 
nicotinamide-binding site maybe somewhat different to that in the full-length enzyme 
and may have especially affected larger analogues e.g. 222. Although all the key 
binding pocket residues are intact, it is possible that some other residues surrounding 
this region of the protein which may influence access of inhibitors are not present. 
Additionally, this assay is limited to providing information with regards to inhibition of 
auto-PARsylation of tankyrase-2 as opposed to inhibition of any PARsylation of one of 
the tankyrases’ many binding partners, including NuMA, TRF-1 and AXIN. Nevertheless, 
the results are still useful for determining key trends and providing information with 
regards to the relative activities of potential inhibitors synthesised. 
5.6 Development of a condensed library of candidate inhibitors  
Following a campaign to develop and rationalise the tankyrase-2 inhibition profile of 
the entire analogue library, it became necessary to condense the library down to fif-
teen compounds that warranted more thorough biological exploration. Inhibitors were 
selected based on several factors, including excellent tankyrase-2 inhibition demon-
strated in preliminary ranging studies, interesting SAR features and the likelihood of 
straightforward pharmaceutical development, especially with regards to solubility.  
Inhibitors selected for the condensed library can be categorised as shown in Figure 64 
and are closely linked with the key trends identified in the preliminary ranging assays 
against tankyrase-2. Firstly, representative inhibitors with a para-substituted 3-phenyl 
group were selected as they demonstrated superior inhibitory activity in the 
preliminary tankyrase-2 ranging studies. On this basis, 206k, 206g and 206f were 
selected for further biological assessment, owing to their excellent inhibitory activity 
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(78%, 98% and 100% inhibition of tankyrase-2 activity at 10 nM, respectively). 
Although analogues in the 5-methoxy series with the same para-substituents showed 
equipotent inhibitory activity, the 5-methyl series was selected for further assessment 
as a greater quantity of pure material was available for manipulation and to ensure 
consistency within the condensed library to allow for accurate comparisons.  
Further to this, the positional isomers 206e, 206d and 206b, bearing an ortho-, meta- 
and para-chloro substituent, respectively (Figure 64), were selected so that a more 
thorough exploration of the effect of structure on activity against other PARP family 
members and in anti-proliferative studies could be made. It became clear from the 
preliminary ranging studies that the hydrophobic pocket adjacent to the nicotinamide-
binding site of tankyrase-2 was reasonably tolerant to a wide range of para-
substitutions and linear extensions and, as such, 222 was selected for further 
Figure 64: Condensed library of fifteen inhibitors selected for comprehensive biological evaluation. Key features 
warranting further investigation are labelled and analogues are organised into small groups that represent areas 
of interest.  
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investigation. Moreover, as heterocycles in position-3 had shown inferior activity, 
compared with a 3-phenyl group, the reasons for this warranted further investigation, 
as this was not entirely apparent from early molecular modelling studies. As such, 
206m and 206j were selected, again with maintenance of the 5-methyl group for con-
sistency across the condensed library.  
The apparent tolerance of a cyclic tertiary amine within the hydrophobic tunnel at the 
far side of the hydrophobic pocket of tankyrase-2 was an exciting development, as the 
incorporation of a water-solubilising group should improve the pharmaceutical proper-
ties of an inhibitor without compromising inhibitory activity. As such, these ‘water-
soluble’ analogues certainly warranted further exploration and, although both 236c 
and 236a demonstrated good inhibitory activity in preliminary ranging studies (61% 
and 70% inhibition of tankyrase-2 activity at 10 nM, respectively), 236c was selected as 
the candidate for taking forward into the condensed library (Figure 64). It was thought 
that the additional five CH2 groups in 236c conferred greater lipophilicity to the 
analogue than the two methyl groups of 236a, thought to be desirable within the 
hydrophobic pocket. Further to this, the dimethylamino functionality is a known 
hostage to drug metabolism and would probably be oxidatively demethylated rapidly 
by cytochrome P450 enzymes. Although not necessarily detrimental to the activity of 
the analogue, rapid metabolism would potentially reduce the area under the time-
concentration curve of the analogue for exerting its inhibitory effect on the tankyrase-
1/-2 enzyme in vivo. The great disparity in inhibitory activity between the 
piperidinylmethyl analogue 236c and the pyrrolidinylmethyl analogue 236b (61% and 
0% inhibition of tankyrase-2 activity at 10 nM, respectively) could not be rationalised 
using molecular modelling, as there were no specific features or interactions apparent 
in the hydrophobic pocket that could account for this and thus further testing was 
warranted.  
Finally, as diversity in position-5 appeared to elicit markedly different inhibitory effects 
on tankyrase-2, one analogue with each of the different position-5 substituents 
(methyl 206g, methoxy 207d, amino 167o and fluoro 208d) were selected, with a 3-(4-
methylphenyl) group maintained in each case for consistency (Figure 64). No analogue 
bearing a 5-nitro group was selected for the condensed library of inhibitors, as comp-
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ounds incorporating this group had shown very little activity in the ranging studies and 
it was unnecessary to investigate these further. In addition, aromatic nitro groups are 
known to be undesirable in final drug candidates, owing to the potential for both 
haematotoxicity263 and genotoxicity.264 One antibacterial drug, metronidazole, which is 
widely used in clinical practice, is a 5-nitroimidazole compound.265 The mutagenic and 
carcinogenic properties of this drug in were discovered to be due to the enzymatic 
reduction of the nitro group to reactive intermediates by various nitroreductases.266, 
267  
5.7 Comprehensive biological evaluation of the condensed library of inhibitors 
All results from the biological evaluation of the fifteen inhibitors in the condensed 
library are shown in Tables 8-12. A description and discussion of each individual 
biological assessment is given below.  
5.7.1 IC50 determination for candidate inhibitors 
against tankyrase-2  
Table 8 summarises the results of the biochemical 
evaluation of the fifteen inhibitors included in the 
condensed candidate library against tankyrase-2. 
Using the same colorimetric assay (full details in 
Section 7.5) that was used for conducting the 
preliminary ranging experiments, the IC50 values 
were determined for each analogue in the 
condensed library. Due to time constraints and 
difficulty with the supply chain of recombinant 
tankyrase-2 from the supplier (BPS Bioscience and 
AMS Bio Europe Ltd.), IC50 determination 
experiments were conducted only once with the 
mean of three individual wells calculated. For this 
reason, no standard deviation is reported. Each 
plate included a control compound XAV939 (1) and 
Table 8: IC50 determination of 
tankyrase-2 activity by the 
condensed library of candidate 
inhibitors 
Cpd. No. Tankyrase-2 IC50 
(µM) 
















 aXAV939 was used as a positive 
control. IC50 values were from one 
independent experiment with three 
wells for each concentration point. No 
standard deviation is reported. 
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background wells for comparison. Based on the results obtained for each individual 
inhibitor in the preliminary ranging studies, a set of six concentration points around 
the apparent IC50 were selected for determination of enzyme inhibition and data are 
reported as the IC50 (concentration required for 50% inhibition of the activity of the 
enzyme).  
In general, all IC50 values reported for tankyrase-2 in Table 8 agreed well with the 
values estimated from the preliminary ranging studies (Section 5.4 and Table 7), thus 
providing confidence that this assay, developed in-house, was generating consistent 
results. The most potent inhibitor tested was 206g with IC50 = 1.3 nM, which is almost 
12-fold more potent than the gold-standard inhibitor XAV939 (1) (IC50 = 15 nM) (refer 
to Figure 64 for structures). Other highly potent inhibitors against tankyrase-2 included 
208d (IC50 = 4 nM), 207d (IC50 = 5 nM), 206k (IC50 = 6 nM), 206f (IC50 = 9 nM), 222 (IC50 
= 10 nM) and 236c (IC50 = 10 nM). Indeed, these results demonstrated that almost half 
of the condensed library of candidate inhibitors showed more potent inhibition of 
tankyrase-2 than XAV939. All of these potent inhibitors have the key desirable SAR 
features illustrated in Figure 63, including a small hydrophobic group in position-5 and 
a para-substituted phenyl ring or extended phenyl ring in position-3 of the isoquinolin-
1-one scaffold. Inhibitors that demonstrated relatively poor inhibition of tankyrase-2 
included 206d (IC50 = 91 nM) and 206e (IC50 = 836 nM), again in agreement with the 
ranging studies conducted.  
The poor level of inhibition by 206d and 206e was predicted in the preliminary ranging 
studies and molecular modelling conducted previously and further strengthens the 
SAR developed following the ranging studies. The key SAR features of these inhibitors 
which are undesirable for tankyrase-2 inhibition include an ortho or meta-substituted 
3-aryl ring, which was found to be causing steric hindrance with the periphery of the 
hydrophobic pocket (Section 5.4.5). The IC50 results obtained for 206d and 206e 
further strengthen the argument against inclusion of groups in this orientation for 
candidate inhibitors. 
The inhibitory activity of the 3-(4-(pyrrolidinylmethyl)phenyl) analogue 236b, predicted 
to be poor in the preliminary ranging studies, was significantly worse in the IC50 
determination studies (IC50 = 1.2 µM) (Table 8). Moreover, the inhibitory activity of 
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236b was also very poor compared with the closely related 3-(4-piperidinylmethyl)-
phenyl analogue 236c, which showed potent inhibition of tankyrase-2 (IC50 = 10 nM). 
This unanticipated result cannot be rationalised using molecular modelling as both 
inhibitors appear to occupy an almost identical steric space. It is possible that the 6-
membered chair confirmation of the 3-(4-(piperidinylmethyl)phenyl analogue 236c, 
compared with the 5-membered puckered planar confirmation of the 3-(4-pyrrolidinyl-
methyl)phenyl analogue 236b, causes the former to occupy a slightly more favourable 
position within the pocket but this is purely speculative.  
5.7.2 IC50 determination for candidate 
inhibitors against tankyrase-1  
Using the commercially available Trevigen® 
Tankyrase-1 Colorimetric Activity Assay kit, 
IC50 values were determined for candidate 
inhibitors against full-length tankyrase-1 and 
are shown in Table 9. This is in contrast to 
the tankyrase-2 assay that was developed in-
house as this uses truncated tankyrase-2 
(SAM and catalytic PARP domains). The 
Trevigen® tankyrase-1 assay is an ELISA that 
detects poly(ADP-ribose) deposited onto 
immobilised histone proteins in a 96-well 
format. A colorimetric signal is generated 
using an anti-PAR monoclonal antibody, goat 
anti-mouse IgG-HRP conjugate and HRP 
substrate (full details in Section 7.6). In 
contrast to the tankyrase-2 assay developed 
in-house, this assay measures the extent to 
which histone proteins are PARsylated, as 
opposed to the extent of auto-PARsylation of 
the enzyme itself. Finally, the tankyrase-1 in 
Table 9: IC50 determination of tankyrase-1 
activity by the condensed library of 
candidate inhibitors. Tankyrase-2 activity is 






XAV939 (1)a 0.015 0.015 
167o 0.039 0.034 
206g 0.021 0.001 
207d 0.029 0.005 
208d 0.064 0.004 
206e 1.34 835.7 
206d 0.181 0.091 
206f 0.043 0.009 
206b 0.276 0.032 
222 >100b 0.010 
206j 0.102 0.029 
206m 0.080 0.019 
215 0.244 0.017 
236b 11.7 1.2 
236c 0.152 0.010 
206k 0.389 0.006 
 aXAV939 was used as a positive control. 
bLimited by solubility. IC50 values were from 
one independent experiment with three wells 
for each concentration point. No standard 
deviation is reported. 
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the Trevigen® assay is in solution, in contrast to the immobilised tankyrase-2 in the 
assay developed in-house. XAV939 (1) was used as a positive control in each 
experiment. In addition, enzyme-only and background wells were incorporated into 
each experiment.  
In general, those inhibitors that showed potent inhibition of tankyrase-2 also demon-
strated potent inhibition of tankyrase-1, albeit with higher IC50 values in all cases 
(Table 9). Those inhibitors showing the most potent tankyrase-1 inhibition included 
206g (IC50 = 21 nM), 207d (IC50 =29 nM), 167o (IC50 =40 nM), 206f (IC50 =43 nM) and 
208d (IC50 =64 nM) (refer to Figure 64 for structures). No inhibitors demonstrated a 
greater inhibition of tankyrase-1 than did the control XAV939 (1) (IC50 = 15 nM). 
The dual inhibition of tankyrase-1 and -2 by these inhibitors is not surprising 
considering the significant homologous nature of the two isoforms. This suggests that 
the key SAR features identified for tankyrase-2 in the preliminary ranging assays and 
molecular modelling studies are likely to be similar to those desirable for potent 
tankyrase-1 inhibition. There are, however, some exceptions (Table 9). Some of the 
candidate inhibitors in the condensed library showed moderate to excellent tankyrase-
2 inhibition but relatively weaker inhibition of tankyrase-1, including 206b (tankyrase-2 
IC50= 32 nM, tankyrase-1 IC50= 276 nM), 215 (tankyrase-2 IC50 = 17 nM, tankyrase-1 IC50 
= 244 nM), 236c (tankyrase-2 IC50= 10 nM, tankyrase-1 IC50 = 152 nM) and 206k 
(tankyrase-2 IC50 = 6 nM, tankyrase-1 IC50 = 389 nM). Although the biochemical assays 
used to measure the inhibitory activity of tankyrase-1 and -2 were different, the 
parameters within each were maintained constant and, as such, a comparison of 
general trends is still relevant. These results may indicate the possibility that some of 
the candidate inhibitors are, to some extent, selective for inhibition of tankyrase-2. 
Although a degree of selectivity between the two tankyrase isoforms was unexpected, 
it is an exciting development and the first known report of selective inhibitory activity.  
A closer inspection of the four inhibitors (206b, 215, 236c and 206k) showing this 
difference in inhibitory activity between tankyrase-1 and -2 does not reveal many 
notable common features; however, all these analogues have a relatively large and 
hydrophobic 3-aryl substituent, compared with many other inhibitors in the candidate 
library. Interestingly, the 4,5-dimethyl analogue 215 was included in this small group of 
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inhibitors showing a preference for tankyrase-2 over tankyrase-1. This is the only 
inhibitor in the entire candidate library that includes a 4-substituent and may indicate 
that the inclusion of this group and the associated twist that this confers to the 
isoquinolin-1-one is better tolerated in tankyrase-2 than in tankyrase-1. As for 
tankyrase-2, the 3-(4-(pyrrolidinylmethyl)phenyl) analogue 236b also showed very 
poor activity against tankyrase-1 (IC50 = 11.7 µM) (Table 9). Again, as seen in the 
tankyrase-2 inhibition assays, the 3-(4-(piperidinylmethyl)phenyl analogue 236c was 
significantly superior against tankyrase-1 than 236b. That said, 236b demonstrates 
significantly improved activity for tankyrase-2 compared with tankyrase-1 (IC50 = 1.2 
µM).  
One analogue that gave a surprising result of inactivity against tankyrase-1 was the 
bulky 222 (IC50 >100 µM) (Table 9). This was unexpected, as the inhibitory activity of 
222 against tankyrase-2 was very promising (IC50 = 10 nM). In the case of this analogue, 
it is possible that accessibility to the active site of full-length tankyrase-1 enzyme was 
limited by its rigid phenylethynylphenyl side chain. This may not have presented the 
same difficulty in the tankyrase-2 assay, as a truncated form of the enzyme was used. 
This result may also indicate the greater tolerance of the hydrophobic pocket adjacent 
to the nicotinamide-binding site in tankyrase-2 to bulky or rigid hydrophobic side-
chains, compared to the equivalent region in tankyrase-1.  
In general, inhibitors that were expected to be poor inhibitors of tankyrase-1, based on 
the comprehensive SAR developed following the preliminary ranging studies, did 
demonstrate relatively poor activity (Table 9). These inhibitors included 206d (IC50 = 
181 nM) and 206e (IC50 = 1.3 µM) which carried a meta-substituted and ortho-
substituted 3-phenyl group, respectively. These results suggest that the hydrophobic 
pocket adjacent to the nicotinamide-binding site in tankyrase-1, akin to that in 
tankyrase-2 is intolerant of ortho-substitutions, as they cause steric clashes with the 
edges of the pocket. Interestingly, the tankyrase-1 inhibitory activity of 206d (IC50 = 
181 nM) was greater than that of 206b (IC50 = 276 nM), which has supposedly optimal 
SAR features for tankyrase-2 binding i.e. para-substituted 3-aryl ring. This may 
strengthen the argument for a degree of selectivity for inhibition of tankyrase-2 being 
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demonstrated by some inhibitors in the library and that there may be some exploitable 
differences in the tankyrase-1 and -2 active sites, especially in the hydrophobic pocket.  
In summary, potent inhibition of tankyrase-1, in general, correlated strongly with 
potent inhibition of tankyrase-2, suggesting that dual inhibition of these two isoforms 
may be inevitable with many candidate inhibitors. Interestingly, some of the inhibitors 
in the condensed candidate library that demonstrated potent inhibition of tankyrase-2 
had relatively weak inhibitory activity against tankyrase-1. This may indicate a degree 
of selectivity between these two closely related isoforms and raise the possibility of 
developing compounds selective for tankyrase-1 or -2. This may be a very useful dev-
elopment as more becomes known about the biological roles of these two isoforms 
and individual inhibition becomes desirable.  
5.7.3 IC50 determination for candidate inhibitors against PARP-1 
PARP-1 was selected as an alternative NAD+-requiring enzyme that could be used in a 
counterscreen to determine the selectivity or, indeed, promiscuity of the condensed 
library of candidate inhibitors. Collateral inhibition of PARP-1, along with tankyrase-1 
or -2, may not be necessarily be a deleterious event, as inhibition of PARP-1 is known 
to hamper the repair of DNA damaged during chemotherapy and may, indeed, work 
synergistically with inhibition of the tankyrases to limit the lifespan of cancerous cells. 
Indeed, many inhibitors of PARP-1 and PARP-2 are in clinical trials in combination with 
chemotherapeutic agents as they prevent the repair of the DNA damage deliberately 
inflicted by these agents.45 Aside from the potential clinical impact of dual inhibition of 
PARP-1 and tankyrase-1 and -2, it is also desirable to develop a single-isoform-selective 
inhibitor from a drug design perspective as well. A selective inhibitor will make the 
results of early pre-clinical and clinical trials more straightforward to interpret, as the 
clinical effect can be directly linked to the inhibition of a single enzyme as opposed to 
several enzymes. This will directly translate into a more rapid transit through the drug 
development process.  
Further to this, much previous work within the research group had used PARP-1 in 
biological assessments and there was experience established with this assay. More-
over, the early design of the inhibitor library developed in this project was based on 
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inhibitors of PARP-1 and it was imp-
ortant to counterscreen against this 
enzyme to ensure that activity to-
wards it had been minimised by 
intelligent drug design. A commer-
cially available Trevigen® Universal 
Colorimetric PARP-1 assay kit was 
used for this purpose (full details in 
Section 7.7). This assay measures 
the incorporation of biotinylated 
poly(ADP-ribose) onto histone 
proteins that are immobilised on the 
surface of a 96-well plate. 
Promisingly, the majority of 
candidate inhibitors show little 
inhibitory activity towards the PARP-
1 isoform, with 167o, 206g, 206e 
and 206f demonstrating an IC50 
greater than 1 µM and 207d, 208d, 
206d, 206b, 222, 236b and 236c an 
IC50 greater than 10 µM (Table 10) 
(refer to Figure 64 for structures). 
These results show that these inhibitors have been successfully designed to have 
enhanced activity against tankyrase-1 and -2 as desired. There are, however, some 
exceptions that show good-to-moderate inhibition of PARP-1, including 206j (IC50 = 111 
nM), 206k (IC50 = 332 nM), 206m (IC50 = 720 nM) and 215 (IC50 = 860 nM). In the case of 
206j and 206m, this promiscuity may be justified not only by the small overall size of 
these inhibitors but also by looking at features within the nicotinamide-binding site of 
PARP-1. The incorporation of heteroatoms, in particular the nitrogen in the pyridine 
ring of 206j, may allow for hydrophilic interactions, either directly or through bridged 
hydrogen bonds, to be made with the lone pair of the pyridinyl nitrogen. This may 
Table 10: IC50 determination of inhibition of PARP-1 
activity of condensed library of candidate inhibitors. 
Tankyrase-1 and -2 activity are shown alongside for 
comparison. 
Cpd. No.  
 
IC50 (µM) 
PARP-1 Tankyrase-1 Tankyrase-2 
XAV939 (1)a NDc 0.015 0.015 
167o ca. 1.0 0.039 0.034 
206g 1-10 0.021 0.001 
207d >10 0.029 0.005 
208d >10 0.064 0.004 
206e <10 1.34 835.7 
206d >10 0.181 0.091 
206f 1.4 0.043 0.009 
206b >10 0.276 0.032 
222 >10 >100b 0.010 
206j 0.111 0.102 0.029 
206m 0.720 0.080 0.019 
215 0.860 0.244 0.017 
236b >10 11.7 1.2 
236c >10 0.152 0.010 
206k 0.332 0.389 0.006 
 aXAV939 was used as a positive control. bLimited by 
solubility. cNot determined. IC50 values were from one 
independent experiment with three wells for each 
concentration point. No standard deviation is reported. 
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increase the propensity of this inhibitor to bind in the catalytic pocket of PARP-1, as 
this region of the pocket is well-reported as containing more hydrophilic residues than 
the more hydrophobic nature of tankyrase-1 and -2.42, 61, 68, 107 In the case of 206m, it is 
likely that the small size of this inhibitor may contribute to its promiscuity. Indeed, a 
very similar analogue TIQ-A (14), which also carries a thiophene moiety in position-3 of 
the isoquinolin-1-one scaffold was described as ‘unselective’ against a panel of 
enzymes including PARP-1-4 and tankyrase-1 and -2.61 
The other two analogues that demonstrated moderate inhibition of PARP-1 were 215 
and 206k (Table 10). Unlike 206j and 206m, these analogues incorporate substituents 
that comprise solely of carbon and hydrogen in positions-3 and -4 of the isoquinolin-1-
one framework. As such, the moderate level of PARP-1 inhibitory activity noted cannot 
be rationalised owing the incorporation of a heteroatom into the structure. Moreover 
215 is likely to be fairly promiscuous, owing to its relatively small size compared with 
many other analogues in the condensed library, which may allow it to bind into the 
nicotinamide-binding site of many of the NAD+-requiring enzymes. The moderate 
inhibition of PARP-1 by the para-t-butyl analogue 206k was unexpected, as this 
inhibitor does not incorporate any specific features in either positions-3 or -5 of the 
isoquinolin-1-one that are likely to pick-up specific interactions in the PARP-1 
nicotinamide-binding site; known to comprise of more hydrophilic residues than 
tankyrase-1 and -2.42, 61, 68, 107 In addition, many of the highly selective tankyrase-1 and 
-2 inhibitors in the condensed candidate library that show poor inhibition of PARP-1 
have a similar structure to that of 206k, e.g. 206f and 206g.  
It is likely that those inhibitors demonstrating reasonable inhibition of PARP-1 are also 
promiscuous against other PARP family isoforms, rather than being specifically select-
ive towards PARP-1 itself. Indeed it is known that synthesising inhibitors that are sel-
ective for PARP-1 over other PARP family members e.g. PARP-2 is very challenging and 
often pan-PARP inhibition is inevitable.116, 140 Overall, the vast majority of the conden-
sed library of inhibitors show little propensity to inhibit PARP-1. This is an encouraging 
result as clean inhibition of a single isoform is always desirable for straightforward 
clinical assessment and to reduce the potential for off-target effects. 
 
 
- 200 - 
 
5.7.4 Assessment of the anti-proliferative activity of candidate inhibitors  
In addition to measuring the activity of candidate inhibitors against the target enzyme 
and counterscreening for selectivity in closely related enzymes, it was also important 
to assess the anti-proliferative effect of the inhibitors in the intact cell system. In 
addition, anti-proliferative studies will provide a greater insight into the accessibility of 
an inhibitor to the site of action. Indeed, a potent enzyme inhibitor that is unable to 
cross the cell membrane to exert its effect within the cell is futile. It is largely unknown 
whether tankyrase-1 and -2 inhibitors will indeed be anti-proliferative. Early results 
from an unpublished preliminary study in the group indicated towards a subset of 
PARP-1 inhibitors being anti-proliferative, with the suggestion that this effect may be 
related to inhibition of tankyrase-1 or -2 (see Section 2.6). That said, the gold-standard 
tankyrase-1 and -2 inhibitor XAV939 (1) only demonstrated an anti-proliferative effect 
in β-catenin-dependent (APC-deficient) DLD-1 cells under low-serum growth 
conditions and had no effect on the colony formation inβ-catenin-independent RKO 
cells.82 
It is not yet known whether a potent tankyrase-1 or -2 inhibitor will be anti-proliferat-
ive or not, owing to the multiple cellular effects of such inhibitors. In addition to the 
aforementioned effects on Wnt-signalling, the tankyrases also bind to and poly(ADP-
ribosyl)ate NuMA; a coiled-coil protein with an essential role in assembly of the mitotic 
spindle.69, 78, 81 The biological implications of inhibiting the resolution of sister telo-
meres and halting mitotic progression are likely to be immediate and an anti-prolifer-
ative effect would be expected. The tankyrases are also well known for their effect at 
human telomeres where they ADP-ribosylate TRF-1, allowing access to telomerase 
which subsequently lengthens the telomeres, thus promoting the survival of the 
cancer cell. 11, 73, 268 Although the treatment of intact cells over-expressing tankyrase-1 
with a PARP-1 inhibitor PJ-34 (17) was shown to reduce elongation of the telomeres, 
no retardation in cell growth was observed.73 This is probably due to the lack of 
potency of the agents and the low concentrations adopted in this study.73 It would be 
a reasonable assertion that a ‘lag’ phase might be expected between treatment with 
an inhibitor of the tankyrases and an anti-proliferative effect in the intact cell system, 
owing to the telomeres needing to reach a ‘critical’ length prior to the cell being 
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marked for removal via apoptosis. For this reason, an anti-proliferative effect may not 
be observed in a short study such as the MTS assessment. On balance, owing to the 
multiple cellular effects exerted by the tankyrases, one would expect that treatment 
with a potent inhibitor would demonstrate some anti-proliferative effect, even in a 
short study. Relatively little research has been conducted into this area, however, and 
further studies to establish the anti-proliferative effects of tankyrase inhibitors across 
multiple cell-lines are warranted. Cancerous cells that have mutations in Wnt may be 
more sensitive to the effects of tankyrase inhibitors; however, this has yet to be 
proven experimentally. 
If an inhibitor demonstrates anti-proliferative activity then it is desirable that this 
activity is highly selective for cancerous cells over normal somatic cells. This selectivity 
ratio is important for new oncology agents, as it is the global anti-proliferative effects 
of treatments currently used in the clinic that are responsible for the atrocious side 
effects which patients suffer from during and after chemotherapy regimens. Indeed, 
this fact alone has accelerated the campaign towards the development of more 
targeted therapies within oncology.  
The anti-proliferative activity of all inhibitors in the condensed library was investigated 
in HT29 human colon adenocarcinoma cells. The anti-proliferative activity in FEK4 cells, 
a non-cancerous human fibroblast cell line, was also investigated to determine 
selectivity. All activities are reported as an average IC50 (concentration required to 
inhibit proliferation by 50%) of three independent experiments ± standard deviation, 
except where indicated. The MTS assay was selected as the assay of choice for this 
Figure 65: Top; A generalised scheme 
representing an in vitro anti-proliferative 
assay protocol. Right; Following addition 
of the MTS reagent (yellow) reduction to 
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work, as it is a relatively straightforward technique and is amenable to a high through-
put of compounds. The assay (procedure described in Section 7.3.1) is based on viable 
cells producing either NADH or NADPH which pass their electrons to an intermediate 
electron-transfer reagent which is then able to reduce 3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (266), which is 
yellow, in the presence of phenazine ethosulfate, to a water-soluble formazan dye 267 
which is dark red (Figure 65). 
The assay is, therefore, based on the principle that viable cells will produce a greater 
amount of NADH and NADPH, which in turn will enable the reduction of the MTS 
reagent 266 to the formazan dye 267. The higher the amount of formazan dye in each 
individual well, the greater the intensity of the colorimetric output with an absorbance 
maximum of 490-500 nM in phosphate-buffered saline. The colorimetric output is 
recorded using a spectrophotometer; the crude results are then averaged for each 
concentration point (four wells) and the background value is subtracted to produce a 
single absorbance value which, when plotted against concentration, produces a dose-
response curve (Figure 66). The IC50 value can be read directly from this curve and is 
the concentration at which the light absorbance capacity of exposed cell cultures is 
reduced by 50% (Figure 66). A 50% reduction in the light absorbance capacity of the 
cells is assumed equivalent to a 50% reduction in cellular viability.  
The advantage of the MTS assay over other similar assays, such as the MTT assay, is 
that the formazan compound 267 produced is soluble, therefore no solubilisation steps 
 
 
Figure 66: Diagram of a 
representative IC50 
dose-response curve. 
The IC50 is determined 
as the concentration at 
which a 50% reduction 
in the light absorbance 
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are required and there is minimal manipulation of the assay itself. In addition, this 
assay is quick to perform, convenient and produces no radioactive waste.  
5.7.5 Determination of the anti-proliferative effect of candidate inhibitors on HT29 
human colon adenocarcinoma cells  
The HT29 cell line was derived from human colorectal adenocarcinoma tissue in 1964 
by Fogh, using the explant culture method.269 This cell line was chosen for initial invest-
igation owing to its high growth rate and relatively straightforward handling and sub-
culturing. Of note is that the HT29 cell line has no BRCA mutation but does have a class 
II mutation in APC that results in this cell type harbouring only mutant alleles of this 
protein.84 It is thus possible that these cells may be more sensitive to tankyrase-1 and -
2 inhibitors, as both AXIN and APC, acting as tumour suppressors, negatively regulate 
β-catenin. It is possible that these cells are more reliant on correctly functioning AXIN 
for the transcription of Wnt-related genes and that inhibition of AXIN through 
stabilisation using a tankyrase-1 /-2 inhibitor may limit their proliferative capacity.  
The anti-proliferative capacity of the candidate inhibitors investigated varied greatly 
(Table 11). Within the aforementioned groups selected for their representative SAR 
features, there are some key trends. Firstly, when looking at the nature of the 3-(4-
substituted phenyl)isoquinolin-1-one analogues, it is clear that, whilst 206b and 206f 
show no anti-proliferative activity in HT29 cells (IC50 = > 200 µM for both inhibitors), in 
contrast 206k and 206g do show considerable anti-proliferative activity (IC50 = 1.8 µM 
and 4.6 µM, respectively) (refer to Figure 64 for structures). The vast difference in anti-
proliferative activity between these four analogues was unexpected, as they all 
exhibited good to excellent tankyrase-1 and -2 inhibition. The incorporation of a 4-
methyl group into the isoquinolin-1-one framework in 215 retains the anti-proliferative 
activity (IC50 = 14.3 µM) demonstrated by 206k and 206g. XAV939 (1), which also 
comprises a 4-trifluoromethylphenyl group in the same position, demonstrates no 
anti-proliferative activity in this cell line (IC50 = >500 µM) under normal serum 
conditions. This result is consistent with the results obtained by Huang and colleagues 
which showed that XAV939 demonstrated no anti-proliferative effect in DLD-1 cells 
under normal serum conditions.82  
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Likewise, when examining the anti-proliferative 
effects of analogues in the condensed library with 
different groups in position-5 of the isoquinolin-1-
one framework (Figure 64), both 208d and 207d 
show negligible activity (IC50 = >500 µM and >100 
µM, respectively), whilst both 206g and 167o show 
considerable anti-proliferative activity (IC50 = 1.8 
µM and 0.65 µM respectively) (Table 11). This diff-
erence in anti-proliferative activity was unexpected, 
owing to the very similar tankyrase-1 and -2 inhib-
ition observed for these four inhibitors, suggesting 
that the anti-proliferative effect observed is not a 
consequence of tankyrase-1/-2 inhibition alone.  
Although the positional isomers 206d and 206b fail 
to demonstrate any anti-proliferative activity (IC50 = 
>100 µM and >200 µM, respectively), the ortho, 
ortho-dichloro analogue 206e is moderately active 
(IC50 = 37.7 µM) (Table 11). This suggests that the 
clear SAR developed for these positional isomers 
during the preliminary ranging studies (Section 5.4) 
and consolidated in the tankyrase-1 and -2 IC50 
determination studies (Section 5.7.1 and 5.7.2) does 
not correlate with their anti-proliferative activity.  
Encouragingly, the water-soluble 3-(4-piperidinyl-
methyl)phenyl 236c and 3-(4-pyrrolidinylmethyl)phenyl 236b demonstrated an anti-
proliferative effect in the HT29 cell line, however the former was much more active 
(IC50 = 8.2 µM and 214 µM respectively) (Table 11). This difference in anti-proliferative 
effect was surprising, in view of the apparent similarity in overall structure of these 
two analogues. Interestingly, the difference in anti-proliferative effect between these 
two analogues also mirrored their apparent difference in the tankyrase-1 and -2 inhib-
ition assays with 236c (IC50 tankyrase-1 = 152 nM; IC50 tankyrase-2 = 10 nM) demon-
Table 11: Determination of the anti-
proliferative effect of candidate 
inhibitors in HT29 Human Colon 
Carcinoma cells.  
 
Cpd. No.  IC50 (µM) 
 HT29 Human Colon 
Carcinoma  
XAV939 (1)a >500b 
167o 0.65 ± 0.19 
206g 1.8 ± 0.4 
207d >100b,c 
208d >500b 





206j 12.4 ± 3.5 
206m 39.8 ± 8.6 
215 14.3 ± 1.9 
236b 214 ± 16 
236c 8.2 ± 0.4 
206k 4.6 ± 1.1 
 aXAV939 was used as a positive control. 
IC50 is the concentration to inhibit 50% 
cell proliferation from three 
independent experiments ± standard 
deviation, except b two experiments. 
cLimited by solubility.  
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strating far superior activity to 236b (IC50 tankyrase-1 = 12 µM; IC50 tankyrase-2 = 1 
µM) in both cases. As both of these inhibitors are adequately soluble in aqueous 
medium, this result may demonstrate that there is a correlation between anti-
proliferative effect and inhibition of tankyrase-1 and -2 activity in this case. Indeed, 
this result may suggest that the lack of anti-proliferative activity demonstrated by 206f 
and 207d may be more a consequence of their poor solubility as opposed to their lack 
of intrinsic activity.  
Further to this observation was the poor anti-proliferative activity demonstrated by 
the bulky 222 (IC50 = >500 µM) (Table 11). This was in contrast to its apparent potent 
inhibition of tankyrase-2 (IC50 = 10 nM). This inhibitor also displayed surprisingly poor 
activity against tankyrase-1 (IC50 = >100 µM), postulated to be due to poor accessibility 
to the active site of full-length tankyrase-1 used in this assay (Section 5.7.2). The lack 
of anti-proliferative activity in the HT29 cells is probably a direct reflection of the poor 
aqueous solubility of this analogue owing to its relatively large and lipophilic structure. 
Indeed a large amount of precipitation was observed by eye whilst conducting the MTS 
assay with this analogue, which indicates that the final concentration of this inhibitor 
in solution in each well was much lower than intended.  
Both the 3-(pyridin-4-yl) compound 206j and the 3-(thiophen-3-yl) analogue 206m 
demonstrated good anti-proliferative activity in the HT29 cell line (IC50 = 12.4 µM and 
39.8 µM, respectively) (Table 11). This correlates well with the good-to-excellent 
inhibition of both tankyrase-1 and -2 demonstrated by both 206j (IC50 tankyrase-1 = 
102 nM; IC50 tankyrase-2 = 29 nM) and 206m (IC50 tankyrase-1 = 80 nM; IC50 tankyrase-
2 = 19 nM). In the case of 206j, which is also a good inhibitor of PARP-1 (IC50 = 111 
nM), it would be more difficult to extrapolate the source of the anti-proliferative 
effect, i.e. inhibition of which enzyme, owing to 206j binding to at least three enzymes 
within the whole cell system.  
The correlation between anti-proliferative activity in the HT29 cell line and inhibition 
of tankyrase-1 and -2 appears to be inconsistent within the condensed library of 
candidate inhibitors. This may be complicated somewhat by the limited solubility of 
many of the analogues in the condensed library, owing to their largely lipophilic 
structures. Indeed, in the case of the water-soluble analogues 236b and 236c, which 
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are both adequately soluble in aqueous media, there appears to be a clear correlation 
between potent tankyrase-1 and -2 inhibition and anti-proliferative effect in HT29 
cells. This correlation is also observed in 167o and 206g.  
Interestingly, a subset of the candidate inhibitors which appear to demonstrate some 
selectivity for inhibition of tankyrase-2 over tankyrase-1 also appear to show signific-
ant anti-proliferative effects in the HT29 cell line (IC50 206j = 12.4 µM; 206m = 39.8 
µM; 215 = 14.3 µM; 236c = 8.2 µM and 206k = 4.6 µM) (Table 11). Although difficult to 
justify based on differences in the structures of these inhibitors alone, one might post-
ulate from these results that tankyrase-2 inhibition may be an anti-proliferative event 
in normal serum conditions in the HT29 cell line but that tankyrase-1 inhibition is not. 
This possible differentiation between the biological effects of tankyrase-1 and -2 inhib-
ition in the whole cell system has not been examined previously, owing to the lack of 
tankyrase-1 or -2 selective inhibitors available; this is a potentially exciting 
development.  
5.7.6 Determination of the anti-proliferative effect of candidate inhibitors on FEK4 
fibroblasts 
The FEK4 cell line is a non-cancerous human skin fibroblast cell line that was originally 
isolated from the foreskin of a new-born baby in the laboratory of Tyrrell (ISREC, 
Switzerland).270 FEK4 fibroblasts are not immortalised and are, therefore, passage-
dependent. This cell line was selected due to its frequent use in the Department of 
Pharmacy and Pharmacology as a reliable control and as a relatively easy cell line to 
manipulate for tissue culture experiments. An ideal agent would not demonstrate any 
anti-proliferative activity in this non-cancerous cell line, whilst maintaining anti-
proliferative activity in the cancerous HT29 cell line. 
In addition to a discussion of the anti-proliferative effects of the candidate inhibitor 
library on the non-cancerous FEK4 cell line, the apparent selectivity of these agents 
towards the cancerous HT29 cells will also be discussed and compared. This is an 
important consideration for a new anti-cancer therapy, as global anti-proliferative 
activity is undesirable. Indeed, selective targeting of the cancerous cells by a 
therapeutic agent is the ultimate aim of a new therapy. This relative selectivity will be 
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discussed as a ‘selectivity ratio’ where the 
anti-proliferative activity in both the non-
cancerous FEK4 cells and the cancerous 
HT29 cells is converted into a ratio.  
The anti-proliferative activity in the FEK4 
cell line, as for the HT29 cell line, varied 
greatly between the candidate inhibitors in 
the condensed library (Table 12). The 
overall trends observed were, in general, in 
agreement with the trends observed in the 
HT29 cell-line studies. The analogues that 
demonstrated no anti-proliferative activity 
in the HT29 cell line generally also displayed 
no anti-proliferative activity against the 
FEK4 cell line, e.g. XAV939 (1), 207d, 208d, 
206d, 206f and 222 (refer to Figure 64 for 
structures). In the case of 222, poor 
solubility may account for its apparent 
inactivity in the FEK4 cell line as 
precipitation was observed during the 
experiment. One candidate inhibitor, 206b, 
was the only exception to this general 
trend, with greater anti-proliferative activity 
in the FEK4 cell line (IC50 = 48.9 µM) 
compared with the HT29 cell line (IC50 = > 200 µM). It was clear from these results that 
there is no correlation between positional isomers around the 3-phenyl of the 
isoquinolin-1-one scaffold and anti-proliferative effect in FEK4 cells. Indeed, out of the 
three positional isomers (206e, 206d and 206b), the former demonstrates the poorest 
tankyrase-1 and -2 activity but the most potent anti-proliferative activity in the FEK4 
cells (IC50 = 107 µM) and HT29 cells (IC50 = 37.7 µM). This is in contrast to tankyrase-1 
Table 12: Determination of anti-proliferative 
activity of candidate inhibitors in FEK4 Human 
Skin Fibroblasts. The anti-proliferative activity in 
HT29 Human Colon Carcinoma cells is shown 
alongside for comparison.  
 




 HT29 Human 
Colon 
Carcinoma  
XAV939 (1)a >500b >500b 
167o 1.42 ± 0.44 0.65 ± 0.19 
206g 6.0 ± 3.7 1.82 ± 0.41 
207d >500b >100b 
208d >500b >500b 
206e 107 ± 2.0b 37.7 ± 2.8 
206d >50b,c >100b 
206f >100b,c >200b 
206b 48.9 ± 0.3b >200b 
222 >50b,c >500b 
206j >200b,c 12.4 ± 3.5 
206m >500b 39.8 ± 8.6 
215 >200b,c 14.3 ± 1.9 
236b >500b 214 ± 16 
236c 26.7 ± 3.3b 8.2 ± 0.4 
206k >500 4.6 ± 1.1 
 aXAV939 was used as a positive control. IC50 is 
the concentration required to inhibit 50% cell 
proliferation from three independent 
experiments ± standard deviation, except btwo 
experiments. cLimited by solubility.  
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and -2 inhibition, where there is a clear trend between the position of the chlorine on 
the 3-phenyl of the isoquinolin-1-one scaffold and inhibitory activity.  
Some analogues were significantly anti-proliferative in the FEK4 cell line, although this 
activity must always be considered alongside the anti-proliferative activity of the 
inhibitor in the cancerous HT29 cell line (Table 12). The analogue that demonstrated 
the most potent anti-proliferative activity in the FEK4 cell line was 167o (IC50 = 1.42 
µM). This was not surprising considering that this analogue was also very active against 
the HT29 cells (IC50 = 0.65 µM). It would appear that the incorporation of the 5-amino 
group on the isoquinolin-1-one scaffold in 167o confers considerable anti-proliferative 
activity to the analogue. Unfortunately, the selectivity ratio (2:1) between the anti-
proliferative activity for HT29 cells over FEK4 cells is relatively poor and, as such, 167o 
is globally anti-proliferative. When the 5-amino group in 167o is substituted for a 5-
methyl in 206g, anti-proliferative activity in the FEK4 cells is maintained to some extent 
(IC50 = 6.0 µM). This inhibitor was also anti-proliferative in the HT29 cell line (IC50 = 1.8 
µM) but on this occasion the selectivity ratio (3:1) for the cancerous HT29 cells over 
the non-cancerous FEK4 cells was slightly improved, albeit marginally.  
Promisingly, the same subset of inhibitors that demonstrated significant anti-prolifer-
ative activity in the HT29 cell line and were also recognised as potentially tankyrase-2-
selective inhibitors were all inactive against the FEK4 cell line (IC50 206m, 236b and 
206k = >500 µM; 206j & 215 = >200 µM) (Table 12). Interestingly, four of these 
inhibitors also exhibited the most potent inhibitory activity against PARP-1 (IC50 206j = 
111 nM; 206m = 720 nM; 215 = 860 nM and 206k = 332 nM) of the condensed library 
of inhibitors. No anti-proliferative activity would be expected from inhibition of PARP-1 
especially in cells lacking a BRCA mutation e.g. HT29 cells. Of note is the significant 
selectivity ratio (109:1) in the anti-proliferative activity of 206k for cancerous HT29 
cells, compared with non-cancerous FEK4 cells. This remarkable selectivity ratio is even 
more surprising, considering the modest selectivity profile of 206g (3:1).  
The structural differences between 206k and 206g are modest and such a dramatic 
difference in the biological effects of these two inhibitors was not expected (Table 12). 
Interestingly 206g is a potent tankyrase-1 and -2 inhibitor (IC50 = 21 nM and 1 nM, 
respectively), whereas 206k is a potent inhibitor of tankyrase-2 but significantly less 
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potent against tankyrase-1 (IC50 = 6 nM and 389 nM, respectively). This may reinforce 
the earlier suggestion that inhibitors that appear to have selectivity for tankyrase-2 
over tankyrase-1 are inactive or poorly active in anti-proliferative studies in the non-
cancerous FEK4 cell line but strongly anti-proliferative in the cancerous HT29 cell line. 
This is a highly desirable feature and may indicate that selectivity for tankyrase-2 over 
tankyrase-1 correlates with a protective effect in the non-cancerous FEK4 cell line, an 
effect lost when activity against tankyrase-1 is equipotent to tankyrase-2.  
Akin to the anti-proliferative effects in HT29 cells, the water-soluble analogues 236b 
and 236c also showed remarkably different anti-proliferative results in the FEK4 cell 
line (Table 12). 236c is included in the aforementioned subset of analogues that display 
apparent selectivity for tankyrase-2 and, like other inhibitors included in this group, 
also demonstrates a promising selectivity profile (3:1) between anti-proliferative 
activity in the HT29 and FEK4 cells (IC50 = 8.2 µM and 26.7 µM, respectively). This 
inhibitor had also shown selectivity for tankyrase-2 over tankyrase-1 (IC50 = 10 nM and 
152 nM, respectively). As in the HT29 studies, the structurally similar inhibitor 236b 
showed a remarkably different anti-proliferative profile to that of 236c with no anti-
proliferative activity demonstrated in the FEK4 cell line (IC50 = >500 µM).  
The other three analogues that made up the subset of inhibitors with apparent 
tankyrase-2 selectivity included 206m, 206j and 215. In line with the anti-proliferative 
trends observed for all other tankyrase-2 ‘selective’ inhibitors, 206m, 206j and 215 
demonstrated no anti-proliferative activity against the non-cancerous FEK4 cell line (all 
IC50 = >500 µM), although they had all been moderately to highly anti-proliferative in 
the HT29 cell line (IC50 = 12.4 µM, 49.8 µM and 14.3 µM, respectively) (Table 12). The 
selectivity ratio for 206m, 206j and 215 therefore, between the HT29 cell line and the 
FEK4 cell line is 13:1, 17:1 and 14:1 respectively. These inhibitors also demonstrate a 
moderate level of PARP-1 inhibition compared with the negligible activity of the 
remainder of the library. This result is an exciting prospect for further development, as 
any agent demonstrating this high level of selectivity for cancerous cells must warrant 
further investigation.  
As was apparent in the HT29 anti-proliferative studies, there is also no clear trend 
observed between the anti-proliferative effect of the condensed candidate inhibitors 
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in the non-cancerous FEK4 cells and potent tankyrase-1 and -2 inhibition (as described 
in Section 5.7.5). That said there does appear to be a trend between those candidate 
inhibitors that are potent inhibitors of tankyrase-2, but only moderate inhibitors of 
tankyrase-1, with some PARP-1 activity and anti-proliferative effects in the FEK4 cell 
line. Inhibitors that are tankyrase-2-‘selective’ all demonstrated negligible anti-
proliferative activity in the non-cancerous FEK4 cells, compared with the significant 
anti-proliferative effects of these same inhibitors in the cancerous HT29 cell line.  
One possibility is that the effects of inhibiting tankyrases-1 and -2 in the intact cell 
system are quite different; potent tankyrase-2 inhibition alone may lead to an anti-
proliferative effect in the HT29 cells alone whereas dual-inhibition of both isoforms 
appears to confer a more global cytotoxicity to the inhibitors. These studies suggest 
that the effects of tankyrase-1 and -2 may be different in the two different cell types. It 
is possible that the inhibition of a single isoform may either confer some form of 
protection over one cell type or sensitise one particular cell type. Moreover a small 
amount of inhibition of PARP-1 activity appears to also be characteristic of those 
inhibitors that demonstrate an excellent selectivity profile between the cancerous and 
non-cancerous cells. Further studies are warranted to elucidate this effect.  
5.7.7 Summary of anti-proliferative studies conducted on HT29 and FEK4 cell lines 
It is apparent from the anti-proliferative studies conducted on the condensed library of 
inhibitors using the HT29 and FEK4 cell lines that there is no immediately clear correl-
ation between the key ‘Structure-Activity Relationship’ (SAR) features identified for 
potent inhibition of tankyrase-1 and -2 activity in Figure 63 and anti-proliferative activ-
ity in either of the cell lines (Tables 11 and 12). This was not entirely unexpected, 
owing to the lack of anti-proliferative activity under normal serum conditions demon-
strated by the potent tankyrase-1 and -2 inhibitor XAV939 (1).82 This well-reported 
inhibitor has many SAR features similar to those of the library of candidate inhibitors 
and, as such, the behaviour of the candidate inhibitors might be expected to be 
similar.  
That said, a very interesting pattern of anti-proliferative activity was observed: an 
effect not previously reported in the literature surrounding inhibitors of tankyrase-1 
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and -2. It would appear that some of the candidate inhibitors that are structurally very 
similar are able to elicit remarkably different anti-proliferative effects in both the HT29 
and FEK4 cell lines. The reason for this difference in activity is not immediately 
obvious; however, on closer inspection, it would appear that those inhibitors e.g. 206j, 
206m, 215, 236c and 206k that are highly anti-proliferative in the cancerous HT29 cell 
lines but much less active in the FEK4 cell line are also preferential inhibitors of 
tankyrase-2 over tankyrase-1. This subset of inhibitors does show some inhibition of 
tankyrase-1 but this is much less potent when compared with a number of inhibitors in 
the library with almost equipotent inhibition of the two isoforms. This difference in the 
biological outcome of inhibiting the two isoforms to a different extent was not 
expected and it represents an exciting development. Indeed the dual inhibition of both 
isoforms of tankyrase was anticipated to be inevitable and thought unlikely to be a 
detriment to a candidate inhibitor.229 This study has shown that the effects of inhibit-
ing the tankyrases selectively may lead to quite different outcomes in vivo. Those 
inhibitors that showed almost equipotent inhibition of tankyrase-1 and -2 e.g. 167o, 
206g and 207d were either highly anti-proliferative in both the cancerous HT29 cell 
line and non-cancerous FEK4 cell line or demonstrated almost no activity in either. This 
suggests that the difference in biological effect of inhibitors tankyrase-1 and -2 on 
cancerous HT29 cells, compared with non-cancerous FEK4 cells, is much more pro-
minent when inhibition of one isoform is preferential. Further to this, a certain amount 
of PARP-1 inhibitory activity, albeit modest in most cases, appears to contribute to the 
inhibitory profile of a subset of inhibitors e.g. 206j, 206m, 215 and 206k that have a 
steep selectivity gradient between cancerous and non-cancerous cells. It is possible 
that there is some form of synergistic effect which contributes to an anti-proliferative 
outcome when tankyrase-2 is inhibited strongly and PARP-1 very modestly.  
It is also possible that the relatively small size of some analogues, e.g. 206j and 206m, 
increases their propensity to bind to and inhibit other PARP family enzymes that are 
also present in the intact cell system and that this might complicate the overall 
biological outcome observed in the anti-proliferative studies. Indeed, some evidence 
for this is shown with 206j and 206m, both demonstrating the ability to inhibit 
tankyrase-1, -2 and PARP-1 (Table 10). In fact, 206j is the only analogue in the 
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condensed library that demonstrates equipotent inhibition of tankyrase-1 and PARP-1. 
Although inhibition of PARP-1 is not thought to be a cytotoxic event per se in cells 
lacking a BRCA mutation,136, 138-140 it cannot be excluded as a possible contributory 
factor to the potent anti-proliferative effect of this inhibitor in the HT29 cell line. 
Similarly, collateral inhibition of PARP-2 or PARP-3 may play a role, 271-273 although data 
are not available for inhibition of these isoforms by the present compounds. The 
situation is, of course, highly complex in the intact cell due to the presence of multiple 
enzymes in unknown concentrations.  
It is unknown whether the anti-proliferative effects that are observed with many of the 
candidate tankyrase-1/-2 inhibitors are a consequence of disruption of mitosis through 
inhibition of NuMA, disruption of telomere lengthening through the ubiquitinylation 
and destruction of TRF-1 or disruption of aberrant Wnt-signalling through stabilisation 
of AXIN or a combination of these cellular events. Although purely speculative, it 
would be expected that the shortening of telomeres, facilitated through the 
ubiquitinylation and destruction of TRF-1 might suffer from a lag phase prior to cell 
death becoming a realistic consequence. This is because several rounds of cell division 
would be expected prior to the ‘critical length’ of the telomere being reached that 
would trigger cell death.2, 69, 73 A more immediate effect on cell proliferation might be 
expected from disruption of the function of the mitotic spindle and centrosome and 
leading to mitotic arrest through inhibition of tankyrase-1/-2.78, 274 Further to this, 
specific inhibitors of the Wnt-system have shown anti-tumour activity in vivo, 84, 149 and 
thus inhibition of this system might also be expected to exert an immediate effect on 
cell proliferation.  
Owing to the possible lag time associated with possible telomere-shortening cell-killing 
effects, it is possible that the 72-hour assay may not have been sufficiently long to 
observe the full potential anti-proliferative effects of the tankyrase inhibitors. In 
addition, further studies are warranted to decipher the exact cellular events that are 
taking place and leading to this anti-proliferative activity. In addition to examining the 
effects of these analogues on cancerous cells bearing a Wnt-related mutation (which 
includes the HT29 cell line), it is also important to assess the effect of tankyrase-1 and -
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2 inhibition in cancerous cells with no Wnt-related mutations, such as many mammary 
cancers where such mutations are rare.84  
Further to this, all MTS assays were conducted in optimal serum conditions for both 
cell lines used and not in serum-deprived conditions, where Huang et al. observed the 
anti-proliferative effects of XAV939 in DLD-1 cells.82 Further studies might mimic the 
conditions reported by Huang et al.82 in order to compare directly the anti-proliferative 
profiles of candidate inhibitors with the control compound XAV939 (1). The rationale 
of using serum-deprived conditions is that they are more similar to the largely hypoxic 
and nutrient-deprived environment found in the centre of large solid tumours and thus 
potentially more applicable to the real clinical situation in which such inhibitors might 
be utilised.  
Overall, the anti-proliferative studies conducted in the cancerous HT29 cell line and 
non-cancerous FEK4 cell line have provided convincing evidence that there is a 
different biological outcome observed when the tankyrases are, to some extent, 
inhibited selectively. More specifically, it would appear that those inhibitors that are 
highly potent against the tankyrase-2 isoform and only moderately potent against 
tankyrase- 1 are, indeed, selectively anti-proliferative in the cancerous HT29 cell line 
and not in the non-cancerous FEK4 cell line. This is a highly desirable feature in a new 
anti-cancer therapy; the potential to target and kill cancerous cells whilst leaving 
adjacent not-cancerous tissue untouched is the ultimate goal of any anti-cancer drug 
discovery programme.  
5.7.8 National Cancer Institute Sixty Cell Line Panel (NCI60) 
Owing to the interesting results obtained for many of the condensed library of 
candidate inhibitors in the preliminary enzyme-inhibition studies, nine analogues from 
the condensed library of candidate inhibitors were submitted to the NCI for consider-
ation. The NCI developed the sixty cell line panel in the late 1980s and it was launched 
in 1990 as a rapid screening tool for the high-throughput assessment of novel, natural 
or synthetic compounds as anti-cancer entities.275 Potential compounds are screened 
for activity across sixty cell lines from eight different cancer types through the use of 
models in vitro, including cell culture in microtitre plates and high-throughput 
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cytotoxicity assays.275 The aim of this comprehensive screening programme was to 
identify novel chemotherapeutic agents that might have application in the treatment 
of multiple cancers.275 Several notable anti-cancer agents have been identified using 
the NCI60 panel, including the proteasome inhibitor bortezomib (Velcade; Millennium 
Pharmaceuticals), a first-line treatment for multiple myeloma.275  
To be accepted for screening, analogues must have shown sufficient promise in prelim-
inary enzyme inhibition or anti-proliferative studies. The NCI then requires a short 
description of the structural and potential anti-cancer properties of a particular 
analogue which they will then assess for novelty and check the archives to see whether 
they have previously screened the analogue or a closely related compound. Providing 
that an analogue meets the stringent criteria, then it will be accepted for testing. 
Initially, testing is conducted across the sixty cell lines at one concentration (10 µM), in 
order to determine whether a compound meets the required threshold of growth 
inhibition. If it does, then further testing is conducted at five concentrations which 
allows for the determination of a GI50, the concentration at which 50% inhibition of cell 
growth is observed. Any compound demonstrating interesting activity will be screened 
on a second occasion to ensure consistency and reliability. If successful at this stage, 
then a biological evaluation committee decides whether or not the analogue should 
progress to a hollow fibre assay in vivo. The NCI will then sponsor the clinical 
development of an analogue should it perform well in all the aforementioned screens.  
Of the nine analogues (167o, 206g, 206b, 206f, 207d, 206d, 206e, 222 and 208d) 
selected for testing by the NCI at the single (10 µM) concentration (see Appendix B), 
only 167o and 206g were selected for further screening across five concentrations 
(Refer to Figure 64 for structures). This was unsurprising, as these two analogues had 
demonstrated the highest anti-proliferative activity against HT29 cells in studies 
conducted in house (see Section 5.7.5). Both analogues displayed promising results 
across multiple cancer cell lines (Appendix B). In particular, 206g retarded the growth 
of approximately half of the cell lines explored (28 cell lines out of a total of 58); 
however, it was particularly active against the SF-539 cells (CNS cancer) (Mean Growth 
% - growth % = -63%) in the one-dose screen. 
 
 
- 215 - 
 
Likewise, 167o showed a similar activity across the cell line panel, demonstrating 
growth inhibition in nearly half of the cell lines explored (25 cell lines out of 58) but 
again demonstrated particularly good activity in the SF-539 cells (Mean Growth % - 
growth % = -56%) and MDA-MB-435 (Melanoma cell line) (Mean Growth % - growth % 
= -91%) in the one-dose screen (Appendix B). These promising results justified the 
further five-dose testing of both 167o and 206g by the NCI.  
In the five-dose testing, 206g demonstrated consistently low micromolar GI50 values 
across multiple cell lines, including the multidrug resistant cell line NCI/ADR-RES (GI50 = 
2.43 µM) (Table 13). Indeed, 206g demonstrated GI50 values of less than 5 µM in 77% 
of the cell lines tested. Particularly potent activity was observed in four distinct cell 
Table 13: NCI 60 cell line screen for 206g; GI50 is the concentration required to inhibit 
growth by 50%. 
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lines: K-562 (GI50 = 0.86 µM), HOP-62 (GI50 = 0.26 µM), MDA-MB-435 (GI50 = 0.32 µM) 
and UO-31 (GI50 = 0.34 µM). Poor activity was only noted for two cell lines; NCI-H322M 
and HCC-2998 (GI50 = >100 µM in both cases). Although generally active against the 
majority of the cell panel tested, the NCI has decided that no further testing of this 
analogue is indicated at present.  
Compound 167o also displayed low micromolar GI50 values across multiple cell lines 
including the multidrug-resistant cell line NCI/ ADR-RES (GI50 = 2.00 µM) in the five-
dose testing (Table 14). Indeed, 167o demonstrated GI50 values of less than 5 µM in 
83% of the cell lines tested. The most potent activity was observed in the SR (GI50 
=0.49 µM), MDA-MB-435 (GI50 = 0.29 µM), SK-MEL-5 (GI50 =0.95 µM) and A498 (GI50 
=0.77 µM) cell lines. Interestingly, the some of the most potent activity was observed 
in two melanoma cell lines (MDA-MB-435 and SK-MEL-5), whilst the poorest activity 
Table 14: NCI 60 cell line screen for 167o; GI50 is the concentration required to inhibit 
growth by 50%. 
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was also observed in two other melanoma lines (MALME3M: GI50 = >100 µM and 
UACC-257: GI50 = >100µM). Poor activity was also noted in the non-small cell lung 
cancer cell line, NCI-H322M (GI50 = >100µM). Although generally active against the 
majority of the cell panel tested, the NCI has decided that no further testing of this 
analogue is indicated at present.  
The remaining analogues tested by the NCI at a single concentration point were not 
deemed active enough in the sixty cell line panel and were thus not progressed to a 
five-dose test. This again was unsurprising as all of these inhibitors, with the exception 
of 206e which was moderately anti-proliferative, were inactive in studies in-house 
against both HT29 and FEK4 cells (Table 12). Unfortunately, the sub-group of inhibitors 
deemed to be tankyrase-2 selective and to also have remarkably selective anti-
proliferative activity against the HT29 cells compared with the FEK4 cells had not been 
discovered as having this activity prior to selection of compounds for the NCI60 screen. 
For this reason, none of this sub-group of inhibitors (206j, 206m, 215, 236c and 206k) 
were screened in the NCI60 studies during the course of this project. 
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6.0 Final conclusions  
The tankyrases have become an important therapeutic target in oncology, initially 
based on their role in telomere shortening and leading cells to crisis. More recently, 
roles of the tankyrases in the correct functioning of the mitotic spindle and in aberrant 
Wnt-signalling have expanded the therapeutic potential of tankyrase inhibitors. This 
potential, along with only a few reported tankyrase inhibitors to date, e.g. XAV939 (1), 
has instigated a race to design, synthesise and evaluate a series of new inhibitors. As 
such, a library of candidate inhibitors was designed to probe the tankyrase-1 and 
tankyrase-2 nicotinamide-binding sites and adjacent hydrophobic pockets. At first, 
these consisted of an isoquinolin-1-one scaffold with a substituted aryl ring in position-
3. This then evolved into an examination of all the positions around the isoquinolin-1-
one scaffold where there was potential to expand into or make interactions with the 
nicotinamide-binding site and hydrophobic pocket.  
A library of fifty-six novel analogues was synthesised using a variety of chemical routes 
in preparedness for biological testing. Palladium-catalysed chemistry, e.g. Suzuki-
Miyaura and Sonagashira cross-couplings, formed the mainstay of the preparation of 
early analogues. The versatile Suzuki-Miyaura cross-coupling was initially used to 
generate a series of 3-aryl-1-methoxy-5-nitroisoquinolin-1-ones with a variety of -
ortho, -meta and -para substitutions on the 3-aryl moiety. These substituents included 
electron-donating, electron-withdrawing, polar and non-polar groups, designed (in the 
corresponding isoquinolin-1-ones) to challenge the hydrophobic pocket adjacent to 
the nicotinamide-binding site and to probe for potential interactions. Small groups 
were investigated at first and, owing to the general tolerance of a large variety of 
groups, extensions that would probe further into the hydrophobic pocket were then 
synthesised, e.g. 222. Two further transformations; reduction of the 5-nitro group to 
reveal the solubilising 5-amino group and the un-masking of the fixed lactam were 
required to afford the final target compounds (167a-i, k-p and 175). The introduction 
of diversity in the analogues at a late stage in the synthetic route facilitated parallel 
synthesis using a “Starfish” five-plate multi-reactor system. 
Further to an exploration of the tolerance of the tankyrase-2 hydrophobic pocket to a 
variety of 3-substituted aryl groups introduced using Suzuki-Miyaura cross-coupling, 
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attention was turned to the position-5 group. Maintained as a 5-amino group thus far, 
it became desirable to test the tolerance of this region of the nicotinamide-binding site 
to other groups, as this was anticipated to be more tolerant to hydrophobic groups 
than the equivalent region of PARP-1. Not only were changes in position-5 expected to 
confer greater activity against the tankyrases, owing to the constitution of this region 
of the catalytic pocket, it was also hoped that they would reduce affinity for PARP-1 
and improve the selectivity of inhibitors towards the tankyrases. Although four distinct 
routes were proposed to access this new series of isoquinolin-1-ones, only carbanion 
chemistry provided an efficient procedure to access these compounds. Removal of the 
most acidic 2-CH3 proton from a series of 3-substituted-2-methyl-N,N-di-
methylbenzamides and subsequent quench with a series of benzonitriles afforded a 
diverse range of isoquinolin-1-ones in a one-pot procedure. A large number of diver-
sely substituted starting 2-methylbenzoic acids and benzonitriles were available and 
facilitated the rapid generation of the 5-methyl (206a-m), 5-methoxy (207a-i), 5-
hydroxy (209a-b) and 5-fluoro (208a-g) series of compounds. The loss of solubility, 
owing to replacement of the 5-amino group, was overcome by the incorporation of a 
series of tertiary aliphatic cyclic amines attached to the 3-phenyl group (235a-d). 
Conversion to the hydrochloride salts led to an improvement in the solubility of these 
analogues, tested in a short pre-formulation study.  
Attempts to incorporate a 3-ferrocenyl group into the isoquinolin-1-one scaffold were 
generally unsuccessful using a variety of palladium-catalysed cross-coupling reactions 
(Suzuki-Miyaura and Negishi) and only moderately successful with a Stille cross-
coupling reaction (significant contamination with the 3-butyl analogue from 
tributylstannylferrocene was observed, indicating the poor transferability of the 
ferrocenyl moiety). Adopting the carbanion chemistry, this 3-ferrocenyl group was 
incorporated efficiently into the isoquinolin-1-one scaffold in 262 and represented the 
first known attachment of these two units.  
Finally, following a successful campaign to synthesise a series of isoquinolin-1-ones 
with a variety of different groups in positions-3 and -5, it became desirable to incorpor-
ate groups into position-4 of the scaffold not only in order to explore the available 
space in this region of the nicotinamide-binding site but also to force the analogue to 
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adopt a conformation with a dihedral twist between the phenyl and isoquinolin-1-one 
ring systems. This position was accessed using carbanion chemistry; removal of the 
acidic proton from 2-ethyl-3,N,N-trimethylbenzamide (214) and subsequent quench 
with benzonitrile afforded the 4-methylisoquinolin-1-one 215. Although only one 
analogue was synthesised using this route, it demonstrates the accessibility of making 
changes to this position on the scaffold using this chemistry.  
A clear ‘Structure Activity Relationship’ (SAR) has been established for the entire 
inhibitor library by evaluating the inhibition of autopoly(ADP-ribosyl)ation activity of 
tankyrase-2 in an assay developed in-house. In addition, small-molecule X-ray crystal 
structures were obtained for suitable analogues and molecular modelling was 
performed to guide this exploration of SAR. Six key SAR trends were identified using 
the information derived from the preliminary ranging studies, molecular modelling and 
small-molecule crystal structures. For two compounds, 207b and 215, X-ray crystal 
structures of inhibitors bound in the active site of tankyrase-2 were also generated by 
a collaborator, Dr Lari Lehtiö (University of Oulu, Finland), to aid further understanding 
and development of SAR.  
The six key trends identified in the preliminary tankyrase-2 inhibitory studies are 
discussed in depth in Section 5.4. Key desirable features for an optimum inhibitor are 
summarised in Figure 63 and include: 1) A moderately sized electron-donating or 
electron-neutral substituent in position-5 of the isoquinolin-1-one; 2) A para-substit-
uted 3-aryl group; 3) Avoidance of ortho- and meta-substitutions on the 3-aryl group; 
4) A moderately-sized hydrophobic group in position-4 of the isoquinolin-1-one; 5) A 
moderately-sized group in the para-position of the 3-aryl group on the isoquinolin-1-
one; 6) Avoidance of large 3D bulk in position-3 of the isoquinolin-1-one and 7) 
Extensions into the hydrophobic pocket adjacent to the nicotinamide-binding site are 
tolerated but may worsen solubility unless a water-solubilising entity is incorporated.  
Molecular modelling was used to rationalise the results obtained and trends identified 
in the tankyrase-2 assays conducted. All inhibitors make the classical PARP motif of 
hydrogen bonding of the lactam carbonyl O with the hydroxy of Ser1068 and with the N-
H of Gly1032 and of the lactam N-H with the carbonyl oxygen of Gly1032. In addition, 
further π-stacking interactions are made between the 3-aryl group and Tyr1050 and 
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other hydrophobic interactions with Pro1034 and the 3-aryl group are observed for 
many inhibitors. Modelling studies have indicated the presence of a narrower 
hydrophobic tunnel that sits at the far side of the hydrophobic pocket. The para-
substituents on the 3-aryl group of many inhibitors in the candidate library lie within 
this narrower tunnel and extend towards solvent water. Indeed, it is possible that 
some analogues, e.g. 236d, have the potential to interact with water molecules at the 
remote end of the hydrophobic tunnel.  
Both regions of the nicotinamide-binding site and adjacent pocket in which the 
position-5 and -3 groups of the inhibitors are accommodated are dominated with 
hydrophobic residues, justifying the apparent superior inhibitory activity of analogues 
bearing hydrophobic groups in these positions. Although it is clear from molecular 
models generated that a co-planar confirmation between the isoquinolin-1-one and 3-
aryl group confers an excellent ‘fit’ in the nicotinamide-binding site and adjacent 
hydrophobic pocket, it is also apparent that a degree of dihedral twist is well tolerated, 
providing there are no ortho- or meta-substitutions on the 3-aryl group e.g. 215. 
Inhibitors bearing bulky ortho- and meta-substituents show severe steric clashes with 
the edges of the hydrophobic pocket in the molecular models, which rationalises the 
poor activity of certain inhibitors, e.g. 206e and 206d. Small-molecule crystal struc-
tures generated for 206e suggested that the severity of dihedral twist is actually 
greater when the inhibitor is not bound within the enzyme catalytic site. This may 
suggest that some degree of conformational constraint is imposed by the catalytic site 
on the inhibitor when bound.  
Sixteen inhibitors from the library of fifty-six analogues with the aforementioned struc-
tural features demonstrated very high activity against tankyrase-2 in the initial ranging 
studies conducted (>70% inhibition at 10 nM inhibitor concentration observed in each 
case). Following these promising results, the library of analogues was then condensed 
to provide a smaller number of inhibitors (fifteen in total) for further and more com-
prehensive biological evaluation including the measurement of IC50 values for 
inhibition of tankyrase-1, tankyrase-2 and in anti-proliferative studies. Counter-
screening against a related isoform, PARP-1, was also conducted. The condensed 
library was carefully selected with diversity in mind; SAR, potency in ranging studies 
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and good pharmaceutical properties were all considered (Figure 64). In addition, those 
inhibitors that had shown interesting results in the ranging studies that could not be 
entirely rationalised were selected for further investigation, e.g. 236b. In addition to 
further in-house biological studies a number of analogues showing promise in initial 
preliminary enzyme inhibition studies were sent to the NCI for consideration. Nine 
analogues were selected for one-dose testing in a sixty cell-line panel, of which two 
analogues, 167o and 206g, showed sufficient activity to warrant a further five-dose 
test. Both these analogues demonstrated low micromolar GI50 values across the 
majority of the cell lines tested, including good activity in the multi-drug resistant NCI / 
ADR-RES cell line derived from an ovarian tumour (GI50; 167o = 2.0 µM ; 206g = 2.4 
µM). 
In general, all tankyrase-2 IC50 values generated were in agreement with those values 
predicted in the earlier ranging studies conducted, with the most potent analogue 
206g demonstrating an IC50 of 1.3 nM; fifteen-fold superior to the control compound 
XAV939 (1). Indeed, seven analogues (206g, 207d, 208d, 206f, 222, 236c and 206k) 
demonstrated superior potency to XAV939 against tankyrase-2; however, none of 
these analogues was superior to XAV939 in inhibitory studies against tankyrase-1. 
Unsurprisingly, inhibitors that demonstrated potent inhibition of tankyrase-2 in 
general also demonstrated potent inhibition of tankyrase-1. This was anticipated at the 
beginning of the project owing to the apparently almost redundant nature of the two 
tankyrase enzyme isoforms. There were, however, some exceptions to this observation 
where the dual inhibition of tankyrase-1 and -2 did not appear to occur with equal 
potency. Indeed, a small subset of inhibitors (206j, 206m, 215, 236c and 206k) within 
the condensed library of candidate analogues appear to exhibit a notably greater 
inhibition of tankyrase-2 activity than of tankyrase-1 activity. This difference in 
inhibitory activity and apparent selectivity for tankyrase-2 over tankyrase-1 cannot be 
rationalised by looking at the structural features of this group of inhibitors as they are 
quite diverse. In fact the only common structural features in this subset of inhibitors 
are features shared by the entire condensed library of candidate inhibitors.  
Counter-screening of the condensed library of inhibitors showed that the majority of 
the analogues were poor inhibitors of PARP-1. This demonstrated that the design of 
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tankyrase-1/-2-selective inhibitors had been largely successful, considering that the 
starting point for design of inhibitors had been a subset of inhibitors designed 
specifically to be inhibitors of PARP-1. Some inhibitors did show some inhibitory 
activity against PARP-1, including 206j (IC50 = 111 nM), 206m (IC50 = 720 nM), 215 (IC50 
= 860 nM) and 206k (IC50 = 332 nM). Inhibition of PARP-1, in addition to the desired 
inhibition of tankyrase-1/-2, may not be detrimental to the potential clinical utility of 
an analogue; however, it may complicate the interpretation of further biological 
testing and future clinical trials.  
Anti-proliferative studies were also conducted on the condensed library of candidate 
inhibitors in both cancerous HT29 (human colon carcinoma) and non-cancerous FEK4 
(human fibroblast) cell lines. In general, inhibitors that demonstrated anti-proliferative 
activity in the HT29 cell line were also at least moderately anti-proliferative in the FEK4 
cells, e.g. 167o (IC50: HT29 = 0.7 µM; FEK4 = 1.4 µM). Likewise, inhibitors that had no 
anti-proliferative activity in the HT29 cell line were generally also inactive in the FEK4 
cell line, e.g. 208d (IC50: HT29 > 500 µM; FEK4 > 500 µM). In general, there was no 
correlation between inhibitors demonstrating potent inhibition of tankyrase-1/-2 and 
anti-proliferative activity in either the HT29 or FEK4 cell lines. There was, however, a 
small subset of inhibitors that demonstrated good selectivity for the cancerous HT29 
cells over the non-cancerous FEK4 cells e.g. 206j, 206m, 215, 236c and 206k. 
Interestingly, this group of inhibitors were the same group that had demonstrated 
relative selectivity for tankyrase-2 over tankyrase-1 in the enzyme inhibition assays. 
Further to this, four of this subset of inhibitors (206j, 206m, 215 and 206k) that 
demonstrated an excellent selectivity profile between the cancerous HT29 cells and 
non-cancerous FEK4 cells also exhibited inhibitory activity, albeit modest, against 
PARP-1. This may suggest that the optimum anti-proliferative activity in HT29 cells 
requires potent tankyrase-2 inhibition and a modest inhibition of PARP-1. This may 
suggest that the synergistic cellular effect of inhibition of tankyrase-2 and PARP-1 is 
particularly effective as an anti-proliferative therapy.  
These anti-proliferative studies have demonstrated that there is the potential to 
develop an agent which is highly selective for cancerous HT29 cells and inactive against 
the non-cancerous FEK4 cells. This cellular effect appears to be complex and, although 
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tankyrase-2 inhibition appears to be the major contributor to the anti-proliferation 
observed, it would appear that a modest inhibition of PARP-1 confers a protective 
effect on the non-cancerous cells. It is unlikely that this weak inhibition of PARP-1 is 
contributing to an anti-proliferative effect in the HT29 cells as many other analogues in 
the condensed library that show no activity against PARP-1 are equally anti-prolifer-
ative in the same cell line. Altogether, this is an exciting result as any potential chemo-
therapeutic agent demonstrating selective cancer cell killing is a step towards the tar-
geted therapies of future cancer treatments. If one were to select analogues from this 
study to further progress within the drug development pathway, then both 206k and 
236c would be strong candidates, owing to the excellent selectivity ratio between the 
cancerous HT29 cell line and non-cancerous FEK4 cell line of the former and the good 
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7.0 Experimental 
7.1 General synthetic experimental 
Chemical reagents, solvents and starting materials were purchased from the Sigma-
Aldrich Chemical Co., Goss Scientific, Alfa Aesar and Fisher Scientific and were used 
without further purification. Reactions were monitored by thin-layer chromatography 
(TLC) on silica gel 60Å (Silicagel 60 F254; particle size 40-63 µm) on pre-coated alum-
inium plates and viewed using UV light (λ = 254 nM). All experiments were conducted 
at rt unless otherwise stated. Solvents were removed under reduced pressure. MgSO4 
was used to dry solutions in organic solvents. Column chromatography was conducted 
using silica gel 60 (35-70 micron). Compounds to be purified were either loaded as an 
oil, as a solution in CH2Cl2 or dry loaded by adsorption onto silica.  
NMR data were obtained on either a Varian Mercury VX (400 MHz for 1H and 100 MHz 
for 13C) or a Bruker Avance III spectrometer (500 MHz for 1H, 125 MHz for 13C and 470 
MHz for 19F) using CD3OD, DMSO or CDCl3 containing tetramethylsilane as an internal 
standard. Chemical shifts are recorded in parts per million (ppm) with reference to 
tetramethylsilane. Coupling constants (J) are quoted to the nearest 0.5 J. Multiplicities 
are assigned as a singlet (s), doublet (d), doublet of doublets (dd), triplet (t), quartet (q) 
and multiplet (m).  
High resolution mass spectra were obtained by means of electrospray ionisation using 
a micrOTOF™ instrument from Bruker Daltonics (Bremen, Germany) coupled with an 
electrospray source (ESI-TOF), using an autosampler in an Agilent 1100 LC system and 
was calibrated using sodium formate solution. Data was processed using external 
calibration with the Bruker Daltronics software, DataAnalysis™ as part of the overall 
hardware control software, Compass 1.1™.  
Melting points were obtained using a heated stage microscope (Reichert-Jung). 
Solutions in organic solvents were dried with anhydrous MgSO4, unless otherwise 
stated. Solvents were evaporated under reduced pressure. IR spectra were recorded 
on a Perkin-Elmer Spectrum RXI FT-IR infra-red spectrometer using solids as KBr discs 
and values are given in cm-1. X-ray crystallography was performed using single crystals 
that were analysed at 150(2) K using graphite monochromated Mo(Kα) radiation and a 
Nonius Kappa CCD diffractometer. Structures were then solved using SHELXS-97 and 
refined using SHELXL-97.  
5-Aminoisoquinolin-1-one (18). Compound 168 (100 mg, 0.45 mmol) was stirred 
vigorously with Pd/C (10%, 113 mg) in EtOH (30 mL) under H2 for 6 h. Filtration 
(Celite) and evaporation yielded 18 (56 mg, 78%) as an off-white solid: Rf = 0.2 (EtOAc 
/ petroleum ether 1:1); mp 312-314C; 1H NMR (DMSO) 6.62 (1 H, d, J = 7.4 Hz, 4-H), 
7.18 (1 H, d, J = 7.4 Hz, 3-H), 7.33 (2 H, m, 6,7-H2), 7.81 (1 H, d, J = 7.7 Hz, 8-H), 11.16 (1 
H, s, N-H); 13C NMR (CDCl3) (HSQC / HMBC) 99.45 (4-C), 120.53 (8-C), 121.07 (6-C), 
126.76 (3-C), 126.83 (7-C), 128.05 (4a-C), 128.17 (8a-C), 135.28 (5-C), 161.73 (1-C).  
1, 3-Dichloro-5-nitroisoquinoline (120). Aq. HNO3 (67%, 25 mL) in conc. H2SO4 (15 mL) 
was added dropwise to 1,3-dichloroisoquinoline (119) (5.02 g, 25.3 mmol) in conc. 
H2SO4 (10 mL) at 5C. The mixture was stirred at 0-5°C for 30 min, allowed to warm to 
rt during 6 h, then poured onto ice. The precipitate was collected, washed (H2O), dried 
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and recrystallised (EtOAc / petroleum ether) to give 120 (5.03 g, 82%) as a yellow 
powder: Rf = 0.8 (EtOAc / petroleum ether, 1:19); mp 168-170°C (lit.1 mp 168-170C); 
1H NMR (CDCl3)  7.80 (1 H, t, J = 7.8 Hz, 7-H),8.55 (1 H, s, 4-H), 8.62 (1 H, dd, J = 7.8, 
1.8 Hz, 6-H), 8.72 (1 H, dt, J = 8.5, 1.1 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 
115.16 (4-C), 126.00 (4a-C), 126.64 (7-C), 129.63 (6-C), 131.60 (8a-C), 133.12 (8-C), 
144.01 (5-C), 147.08 (3-C), 151.75 (1-C).  
3-Chloro-1-methoxy-5-nitroisoquinoline (121). Na (280 mg, 1.1 mmol) was added to 
120 (250 mg, 1.0 mmol) in dry MeOH (10 mL). The mixture was boiled under reflux for 
16 h. The solvent was evaporated until 20 mL remained. CHCl3 was added and the 
solution was washed thrice (H2O). Drying and evaporation gave 121 (190 mg, 80%) as a 
fluffy yellow solid: Rf = 0.9 (EtOAc / petroleum ether, 1:1); mp 177-179°C (lit.185 mp 
172-174C); 1H NMR (CDCl3) 4.20 (3 H, s, Me), 7.62 (1 H, t, J = 7.9 Hz, 7-H), 8.14 (1H, 
s, 4-H), 8.52 (1H, dd, J = 7.8, 1.3 Hz, 6-H), 8.59 (1 H, dt, J = 8.3 Hz, 1.2 Hz, 8-H); 13C NMR 
(CDCl3) (HSQC / HMBC) 55.06 (Me), 108.70 (C-4), 119.44 (C-8a), 125.00 (C-7), 129.32 
(C-6), 131.49 (C-8), 131.95 (C-4a), 147.40 (C-3), 160.86 (C-1). 
1-Methoxy-5-nitro-3-phenylisoquinoline (141a). To 121 (144 mg, 0.60 mmol) in a dry 
flask was added tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) (57 mg, 60 
mol), 2-dicyclohexylphosphino-2′,6′-dimethoxybiphenyl (SPhos) (57 mg, 120 mol), 
phenylboronic acid (115 mg, 0.91 mmol) and K3PO4 (266 mg, 1.2 mmol). Degassed 
toluene (3.5 mL) was added and the mixture was stirred at 100°C for 48 h. The 
evaporation residue, in CHCl3, was filtered. Chromatography (EtOAc / petroleum ether 
1:24), followed by chromatography (EtOAc / petroleum ether 1:29) gave 141a (142 mg, 
84%) as a bright yellow solid: Rf = 0.8 (EtOAc / petroleum ether 1:19); mp 160-166°C; 
1H NMR (CDCl3) 4.28 (3 H, s, Me), 7.49 (4 H, m, Ph 3,4,5-H3, 7-H), 8.20 (2 H, dd, J = 
8.5, 1.5 Hz, Ph 2,6-H2), 8.47 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.51 (1 H, s, 4-H), 8.60 (1 H, 
dt, J = 8.2, 1.08 Hz, 8-H); 13C NMR (CDCl3) (HSQC/ HMBC) 54.43 (Me), 105.41 (4-C), 
120.29 (8a-C), 124.72 (7-C), 127.42 (Ph 2,6-C2), 128.85 (6-C), 129.02 (Ph 3,5-C2), 129.65 
(Ph 4-C), 131.49 (8-C), 131.84 (4a-C), 138.96 (Ph 1-C), 145.28 (5-C), 152.23 (3-C), 
160.81 (1-C); MS m/z 281.0918 (M + H) (C16H13N2O3 requires 281.0928). 
1-Methoxy-3-(2-methoxyphenyl)-5-nitroisoquinoline (141b). To 121 (102 mg, 0.43 
mmol) in a dry flask was added Pd2(dba)3 (11.5 mg, 13 mol), SPhos (22.8 mg, 56 
mol), 2-methoxybenzeneboronic acid (150.5 mg, 0.99 mmol) and K3PO4 (203.9 mg, 
0.96 mmol). Degassed toluene (3.0 mL) was added and the mixture was stirred at 
100°C for 16 h. The evaporation residue, in CHCl3, was filtered. Chromatography 
(EtOAc / petroleum ether 1:99) gave 141b (74 mg, 58%) as a yellow solid: Rf = 0.6 
(EtOAc / petroleum ether 1:19); mp 115-117°C; 1H NMR (CDCl3) 3.97 (3 H, s, Ph-
OMe), 4.23 (3 H, s, 1-OMe), 7.06 (1 H, d, J = 8.3 Hz, Ph 3-H), 7.11 (1 H, td, J = 7.6, 1.1 
Hz, Ph 5-H), 7.39 (1 H, td, J = 7.8, 1.8 Hz, Ph 4-H), 7.55 (1 H, t, J = 7.9 Hz, 7-H), 8.15 (1 H, 
dd, J = 7.8, 1.8 Hz, Ph 6-H), 8.43 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.59 (1 H, dt, J = 8.2, 1.1 
Hz, 8-H), 8.78 (1 H, s, 4-H); 13C NMR (CDCl3) (HSQC / HMBC) δ 54.06 (1-OMe), 55.71 (Ph 
OMe), 110.12 (4-C), 111.79 (Ph 3-C), 119.70 (8a-C), 120.87 (Ph 5-C), 124.36 (7-C), 
128.18 (6-C), 130.17 (Ph 4-C), 130.91 (8-C), 131.22 (Ph 6-C), 146.81 (5-C), 157.82 (Ph 2-
C), 160.04 (1-C); MS m/z 333.0858 (M + Na) (C17H14N2NaO4 requires 333.0852), 
311.1030 (M + H) (C17H15N2O4 requires 311.1034) 
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1-Methoxy-3-(3-methoxyphenyl)-5-nitroisoquinoline (141c). To 121 (103 mg, 0.43 
mmol) in a dry flask was added Pd2(dba)3 (11.6 mg, 13 mol), SPhos (22 mg, 54 mol), 
3-methoxybenzeneboronic acid (153 mg, 1.0 mmol) and K3PO4 (203 mg, 0.96 mmol). 
Degassed toluene (3.0 mL) was added and the mixture was stirred at 100°C for 16 h. 
The evaporation residue, in CHCl3, was filtered. Chromatography (EtOAc / petroleum 
ether 1:99) gave 141c (81 mg, 81%) as a yellow solid: Rf = 0.3 (EtOAc / petroleum ether 
1:19); mp 87-90°C; 1H NMR (CDCl3)  3.93 (3 H, s, Ph OMe), 4.28 (3 H, s, 1-OMe), 7.00 
(1 H, m, Ph 6-H), 7.42 (1 H, t, J = 8.0 Hz, Ph 5-H), 7.57 (1 H, t, J = 8.0 Hz, 7-H), 7.78 (2 H, 
m, Ph 2& 4-H2), 8.48 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.51 (1 H, s, 4-H), 8.61 (1 H, dt, J = 
8.2, 1.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.16 (Ph-OMe), 56.00 (1-OMe), 
105.38 (4-C), 112.98 (Ph 4-C), 114.79 (Ph 6-C), 119.62 (Ph 2-C), 124.53 (7-C), 128.54 (6-
C), 129.76 (Ph 5-C), 131.20 (8-C), 139.72 (Ph 3-C), 144.35 (5-C), 160.26 (1-C); MS m/z 
311.1030 (M + H) (C17H15N2O4 requires 311.1034). 
3-(2-Chlorophenyl)-1-methoxy-5-nitroisoquinoline (141d). Method A. To 121 (102 
mg, 0.43 mmol) in a dry flask was added Pd2(dba)3 (13 mg, 14 mol), SPhos (22 mg, 54 
mol), 2-chlorobenzeneboronic acid (202 mg, 1.3 mmol) and K3PO4 (202 mg, 0.95 
mmol). Degassed toluene (3.0 mL) was added and the mixture was stirred at 100°C. 
After 4.5 h, further Pd2(dba)3 (33.5 mg, 40 mol) and SPhos (20.5 mg, 40 mol) were 
added and the mixture was stirred at 100C for a further 11.5 h. The evaporation 
residue, in CHCl3, was filtered. Chromatography (EtOAc / petroleum ether 1:99) gave 
141d (31 mg, 23%) as a yellow solid: Rf = 0.5 (EtOAc / petroleum ether 1:19); mp 122-
127°C; 1H NMR (CDCl3) 4.21 (3 H, s, Me), 7.39 (1 H, t, J = 7.2 Hz, Ph 5-H), 7.40 (1 H, t, J 
= 7.0 Hz, Ph 4-H), 7.53 (1 H, dd, J = 7.5, 1.5 Hz, Ph 6-H), 7.63 (1 H, t, J = 7.9 Hz, 7-H), 
7.73 (1 H, dd, J = 7.8, 1.7 Hz, Ph 3-H), 8.37 (1 H, s, 4-H), 8.49 (1 H, dd, J = 7.8, 1.3 Hz, 6-
H), 8.65 (1 H, dt, J = 8.2, 1.1 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.39 (OMe), 
110.19 (4-C), 119.79 (8a-C), 125.05 (7-C), 126.84 (Ph 4-C), 128.46 (6-C), 129.62 (Ph 5-
C), 130.48 (Ph 6-C), 130.74 (4a-C), 131.13 (8-C), 131.67 (Ph 3-C), 144.95 (5-C), 160.29 
(1-C); MS m/z 315.0533 (M + H) (C16H12N2O335Cl requires 315.0538). 
3-(2-Chlorophenyl)-1-methoxy-5-nitroisoquinoline (141d). Method B. To 164 (200 
mg, 0.71 mmol) in a dry flask was added Pd2(dba)3 (65.0 mg, 71 mol), SPhos (66.0 mg, 
0.14 mmol), 2-chlorobenzeneboronic acid (165.7 mg, 1.06 mmol) and K3PO4 (450.3 mg, 
2.12 mmol). Dry DMF (7.5 mL) was added and the mixture was stirred at 135°C for 16 
h. The evaporation residue, in CHCl3, was filtered through Celite. Chromatography 
(EtOAc / petroleum ether 3:197 → 1:19) gave 141d (132 mg, 60%) as a yellow solid 
with properties as above. 
3-(3-Chlorophenyl)-1-methoxy-5-nitroisoquinoline (141e). Method A. To 121 (104 
mg, 0.44 mmol) in a dry flask was added Pd2(dba)3 (44.0 mg, 48 mol), SPhos (40.3 mg, 
98 mol), 3-chlorobenzeneboronic acid (198 mg, 1.3 mmol) and K3PO4 (180 mg, 0.85 
mmol). Degassed toluene (3.0 mL) was added and the mixture was stirred at 100°C for 
40 h. The evaporation residue, in CHCl3, was filtered. Chromatography (Et2O / petrol-
eum ether 1: 99) gave 141e (46 mg, 34%) as a yellow solid: Rf = 0.5 (EtOAc / petroleum 
ether 1:19); mp 134-141°C; 1H NMR (CDCl3) 4.18 (3 H, s, Me), 7.41 (2 H, m, Ph 5,6-
H2), 7.58 (1 H, t, J = 8.0 Hz, 7-H), 8.03 (1 H, dt, J = 6.9, 1.9 Hz, Ph 4-H), 8.18 (1 H, s, Ph 2-
H), 8.47 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.48 (1 H, s, 4-H), 8.60 (1 H, dt, J = 8.2, 1.1, 8-H); 
13C NMR (CDCl3) (HSQC / HMBC) 54.29 (Me), 105.53 (4-C), 120.18 (8a-C), 124.90 (7-
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C), 125.05 (Ph 4-C), 127.21 (Ph 2-C), 128.73 (6-C), 129.24 (Ph 6-C), 129.93 (Ph 5-C), 
131.26 (8-C), 131.33 (4a-C), 134.81 (Ph 3-C), 140.43 (3a-C), 144.95 (5-C), 150.30 (3-C), 
160.58 (1-C); MS m/z 315.0529 (M + H) (C16H1235ClN2O3 requires 315.0538). 
3-(3-Chlorophenyl)-1-methoxy-5-nitroisoquinoline (141e). Method B. To 164 (200 mg, 
0.71 mmol) in a dry flask was added Pd2(dba)3 (65.0 mg, 71 mol), SPhos (66.0 mg, 
0.14 mmol), 3-chlorobenzeneboronic acid (165.7 mg, 1.06 mmol) and K3PO4 (450.3 mg, 
2.12 mmol). Dry DMF (7.5 mL) was added and the mixture was stirred at 135°C for 16 
h. The evaporation residue, in CHCl3, was filtered through Celite. Chromatography 
(EtOAc / petroleum ether 3:197 → 1:19) gave 141e (116 mg, 52%) as a yellow solid 
with properties as above. 
3-(3-Cyanophenyl)-1-methoxy-5-nitroisoquinoline (141f). Method A. To 121 (152 mg, 
0.64 mmol) in a dry flask was added Pd2(dba)3 (58.3 mg, 64 mol), SPhos (60.8 mg, 148 
mol), 3-cyanobenzeneboronic acid (147 mg, 1.3 mmol) and K3PO4 (270 mg, 1.3 
mmol). Degassed toluene (4.5 mL) was added and the mixture was stirred at 100°C for 
16 h. The evaporation residue, in CHCl3, was filtered. Chromatography (EtOAc / 
petroleum ether 1:40) gave 141f (15.6 mg, 8%) as a yellow solid: Rf = 0.7 (EtOAc / pet-
roleum ether 1:19); mp 195-196C; IR νmax 2848.2 (OCH3), 2229.4 (CN), 1573.61 & 
1371.32 (NO2); 1H NMR (CDCl3)4.29 (3 H, s, Me), 7.62 (1 H, t, J = 8.0 Hz, Ph 5-H), 7.64 
(1 H, t, J = 8.0 Hz, 7-H), 7.72 (1 H, dt, J = 7.8, 1.3 Hz, Ph 6-H), 8.38 (1 H, dt, J = 8.2, 1.2 
Hz, Ph 4-H), 8.52 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.55 (1 H, s, 4-H), 8.56 (1 H, s, Ph 2-H), 
8.65 (1 H, dt, J = 8.2, 1.1 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.44 (Me), 105.90 
(4-C), 113.31 (Ph 3-C), 120.62 (8a-C), 121.03 (CN), 125.39 (7-C), 128.88 (6-C), 129.55 
(Ph 2,5-C2), 130.98 (Ph 6-C), 130.24 (4a-C), 131.30 (8-C), 132.45 (Ph 4-C), 140.32 (Ph 1-
C), 145.67 (5-C), 151.62 (3-C), 160.92 (1-C). 
3-(3-Cyanophenyl)-1-methoxy-5-nitroisoquinoline (141f). Method B. To 164 (200 mg, 
0.71 mmol) in a dry flask was added Pd2(dba)3 (64.7 mg, 71 mol), SPhos (66.0 mg, 
0.14 mmol), 3-cyanobenzeneboronic acid (148.4 mg, 1.06 mmol) and K3PO4 (448.3 mg, 
2.11 mmol). Dry DMF (6.0 mL) was added and the mixture was stirred at 135°C for 16 
h. The evaporation residue, in CHCl3, was filtered through Celite. Chromatography 
(EtOAc / petroleum ether 1:99 → 7.5:72.5) gave 141f (20 mg, 9%) as a yellow solid 
with properties as above. 
3-(4-Cyanophenyl)-1-methoxy-5-nitroisoquinoline (141g). To 3-bromo-1-methoxy-5-
nitroisoquinoline 121 (151.0 mg, 0.63 mmol) were added Pd2(dba)3 (58 mg, 0.063 
mmol), SPhos (58 mg, 0.014 mmol), 4-cyanobenzeneboronic acid (150 mg, 1.27 mmol) 
and potassium phosphate (279 mg, 1.3 mmol). Degassed toluene (4.5 mL) was added 
and the mixture was stirred at 100°C for 16 h. The evaporation residue, in chloroform, 
was filtered. Chromatography (ethyl acetate / petroleum ether 1:99) gave 141g (53 
mg, 28%) as a yellow solid: Rf = 0.6 (EtOAc / petroleum ether 0.5:9.5); mp 206-210C; 
1H NMR (CDCl3) 4.30 (3 H, s, Me), 7.66 (1 H, t, J = 8.0 Hz, 7-H), 7.81 (2 H, d, J = 8.6 Hz, 
Ph 2,6-H2), 8.32 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 8.53 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.59 (1 
H, s, 4-H), 8.66 (1 H, d, J = 8.2 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.36 (Me), 
106.64 (4-C), 112.68 (CN), 118.79 (Ph 4-C), 120.80 (8a-C), 125.56 (7-C), 127.58 (Ph 2,6-
H2), 128.85 (6-C), 129.67 (4a-C), 131.26 (8-C), 132.53 (Ph 3,5-H2), 142.86 (3-C), 145.16 
(5-C), 149.59 (Ph 1-C), 160.84 (1-C). 
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1-Methoxy-5-nitro-3-(2-trifluoromethylphenyl)isoquinoline (141h). Method A. To 121 
(103 mg, 0.43 mmol) in a dry flask was added Pd2(dba)3 (42.2 mg, 46 mmol), SPhos 
(41.9 mg, 102 mol), 2-trifluoromethylbenzeneboronic acid (160.2 mg, 0.84 mmol) and 
K3PO4 (179 mg, 0.84 mmol). Degassed toluene (3.0 mL) was added and the mixture 
was stirred at 100°C for 16 h. The evaporation residue, in CHCl3, was filtered. 
Chromatography (Et2O / petroleum ether 1:199) gave 141h (63 mg, 42%) as a yellow 
solid: Rf = 0.3 (EtOAc / petroleum ether 1:19); mp 95-99°C; 1H NMR (CDCl3) 4.18 (3 H, 
s, Me), 7.57 (1 H, tt, J = 7.0, 1.4 Hz, Ph 5-H), 7.64 (3 H, m, Ph 4,6-H2 and 7-H), 7.83 (1 H, 
d, J = 7.9 Hz, Ph 3-H), 8.18 (1 H, s, 4-H), 8.51 (1 H, dd, J = 7.8, 1.2 Hz, 6-H), 8.66 (1 H, dt, 
J = 8.3, 1.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.44 (Me), 109.28 (4-C), 119.80 
(8a-C), 124.15 (q, J = 270.4 Hz, CF3), 125.11 (7-C), 126.89 (q, J = 5.0 Hz, Ph 3-C), 128.56 
(Ph 5-C), 128.58 (6-C), 128.76 (q, J = 30.6 Hz, Ph 2-C), 130.86 (4a-C), 131.29 (8-C), 
131.62 (Ph 6-C), 131.75 (Ph 4-C), 139.69 (Ph 1-C), 144.96 (5-C), 153.10 (3-C), 160.05 (1-
C); 19F NMR (CDCl3)  -56.75 (s, CF3); MS m/z 349.0798 (M + H)+ (C17H12F3N2O3 requires 
349.0802). 
1-Methoxy-5-nitro-3-(2-trifluoromethylphenyl)isoquinoline (141h). Method B. To 164 
(175 mg, 0.62 mmol) in a dry flask was added Pd2(dba)3 (56.6 mg, 62 mol), SPhos 
(57.7 mg, 124 mol), 2-trifluoromethylbenzeneboronic acid (176.1 mg, 0.93 mmol) and 
K3PO4 (393.6 mg, 1.85 mmol). Dry DMF (5.0 mL) was added and the mixture was 
stirred at 135°C for 16 h. The evaporation residue, in CHCl3, was filtered through 
Celite. Chromatography (EtOAc / petroleum ether 1:99 → 1:19) gave 141h (90 mg, 
42%) as a yellow solid with properties as above. 
1-Methoxy-5-nitro-3-(3-trifluoromethylphenyl)isoquinoline (141i). Method A. To 121 
(101 mg, 0.42 mmol) in a dry flask was added Pd2(dba)3 (41.0 mg, 45 mol), SPhos 
(40.2 mg, 99 mol), 3-trifluoromethylbenzeneboronic acid (161 mg, 0.85 mmol) and 
K3PO4 (179 mg, 0.84 mmol). Degassed toluene (3.0 mL) was added and the mixture 
was stirred at 100°C for 16 h. The evaporation residue, in CHCl3, was filtered. 
Chromatography (Et2O / petroleum ether 1:199) gave 141i (80.4 mg, 55%) as a yellow 
solid: Rf = 0.5 (EtOAc / petroleum ether 1:19); mp 135-137°C; 1H NMR (CDCl3) 4.29 (3 
H, s, Me), 7.62 (2 H, m, 7-H + Ph 5-H), 7.70 (1 H, d, J = 8.0 Hz, Ph 4-H), 8.34 (1 H, d, J = 
7.9 Hz, Ph 6-H), 8.47 (1 H, s, Ph 2-H), 8.49 (1 H, dd, J = 7.7, 1.2 Hz, 6-H), 8.53 (1 H, s, 4-
H), 8.62 (1 H, dt, J = 7.2, 1.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.31 (Me), 
105.70 (4-C), 120.30 (8a-C), 123.98 (q, J = 3.9 Hz, Ph 2-C), 124.19 (q, J = 270.4 Hz, CF3), 
125.08 (7-C), 125.84 (q, J = 3.9 Hz, Ph 4-C), 126.89, 128.77 (6-C), 128.78, 29.20 (Ph 5-C), 
130.12 (Ph 6-C), 131.27 (8-C), 131.27 (4a-C), 131.30 (q, J = 32.3 Hz, Ph 3-C), 139.47 (Ph 
1-C), 145.04 (5-C), 150.25 (3-C), 160.75 (1-C); 19F NMR (CDCl3) δ -62.66 (s, CF3); MS m/z 
349.0826 (M + H)+ (C17H12F3N2O3 requires 349.0802). 
1-Methoxy-5-nitro-3-(3-trifluoromethylphenyl)isoquinoline (141i). Method B.To 164 
(300 mg, 1.06 mmol) in a dry flask was added Pd2(dba)3 (97.1 mg, 106 µmol), SPhos 
(98.9 mg, 0.21 mmol), 3-(trifluoromethyl)benzeneboronic acid (403 mg, 2.12 mmol) 
and potassium phosphate (675 mg, 3.2 mmol). Dry DMF (8.0 mL) was added and the 
mixture was stirred at 135°C for 16 h. The mixture was filtered through Celite and the 
solvent was evaporated. Chromatography (ethyl acetate / petroleum ether 2:98) gave 
141i (232 mg, 63%) as a yellow solid with properties as above. 
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1-Methoxy-5-nitro-3-(4-bromophenyl)isoquinoline (141j). To 164 (201 mg, 0.71 
mmol) in a dry flask was added Pd2(dba)3 (65.0 mg, 71 mol), SPhos (66.1 mg, 0.14 
mmol), 4-bromobenzeneboronic acid (213.8 mg, 1.07 mmol) and K3PO4 (451.5 mg, 
2.13 mmol). Degassed toluene (5.0 mL) was added and the mixture was stirred at 
100°C for 16 h. The evaporation residue, in CHCl3, was filtered through Celite. 
Chromatography (EtOAc / petroleum ether 1:49) gave 141j (60 mg, 24%) as a yellow 
solid: Rf = 0.3 (EtOAc / petroleum ether 1:19); mp 186-187 °C; 1H NMR (CDCl3) 4.22 (3 
H, s, Me), 7.54 (1 H, t, J = 8.0 Hz, 7-H), 7.58 (2 H, dd, J = 6.7, 2.0 Hz, Ph 3,5-H2), 8.03 (2 
H, dd, J = 6.7, 2.0 Hz, Ph 2,6-H2), 8.43 (1 H, dd, J = 8.3, 1.3 Hz, 6-H), 8.44 (1 H, s, 4-H), 
8.56 (1 H, dt, J = 8.2, 1.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.16 (Me), 105.05 
(4-C), 120.06 (8a-C), 123.76 (Ph 4-C), 124.69 (7-C), 128.58 (Ph 2,6-C2), 128.66 (6-C), 
131.19 (8-C), 131.42 (4a-C), 131.83 (Ph 3,5-C2), 137.52 (Ph 1-C), 145.02 (5-C), 150.69 
(3-C), 160.57 (1-C); MS m/z 380.9842 (M + Na) (C16H11N2O3Na79Br requires 380.9851), 
358.9999 (M + H) (C16H12N2O379Br requires 359.0031).  
1-Methoxy-5-nitro-3-(4-fluorophenyl)isoquinoline (141k). To 164 (301 mg, 1.06 
mmol) in a dry flask was added Pd2(dba)3 (97.1 mg, 106 mol), SPhos (98.9 mg, 0.21 
mmol), 4-fluorobenzeneboronic acid (296.6 mg, 2.12 mmol) and K3PO4 (675.1 mg, 3.18 
mmol). Dry DMF (8.0 mL) was added and the mixture was stirred at 135°C for 16 h. The 
evaporation residue, in CHCl3, was filtered through Celite. Chromatography (EtOAc / 
petroleum ether 1:99 → 1:49) gave 141k (126 mg, 40 %) as a yellow solid: Rf = 0.5 
(EtOAc / petroleum ether 1:19); mp 199-200°C; 1H NMR (CDCl3) 4.27 (3 H, s, Me), 
7.19 (2 H, t, J = 8.5 Hz, Ph 3,5-H2), 7.57 (1 H, t, J = 8.0 Hz, 7-H), 8.19 (2 H, m, Ph 2,6-H2), 
8.47 (1 H, s, 4-H), 8.49 (1 H, dd, J = 8.0, 1.0 Hz, 6-H), 8.61 (1 H, d, J = 8.0 Hz, 8-H); 13C 
NMR (CDCl3) (HSQC / HMBC)54.11 (Me), 104.79 (4-C), 115.68 (d, J = 21.5 Hz, Ph 3,5-
C2), 119.91 (4a-C), 124.53 (7-C), 128.72 (6-C), 128.97 (d, J = 8.3 Hz, Ph 2,6-C2), 131.26 
(8-C), 131.56 (8a-C), 134.81 (Ph 1-C), 144.91 (5-C), 150.93 (3-C), 160.58 (1-C), 163.75 
(d, J = 248.3 Hz, Ph 4-C); MS m/z 299.0808 (M + H) (C16H12FN2O3 requires 299.0832). 
1-Methoxy-5-nitro-3-(4-hydroxyphenyl)isoquinoline (141l). Method A. To 164 (102 
mg, 0.36 mmol) in a dry flask was added Pd2(dba)3 (32.1 mg, 36 mol), SPhos (33.5 mg, 
0.07 mmol), 4-hydroxybenzeneboronic acid (74.3 mg, 0.54 mmol) and K3PO4 (228.6 
mg, 1.08 mmol). Degassed toluene (3.0 mL) was added and the mixture was stirred at 
100°C for 16 h. The evaporation residue, in CHCl3, was filtered through Celite. 
Chromatography (EtOAc / petroleum ether 1:49 → 1:3) gave 141l (10 mg, 9%) as a 
bright red solid: Rf = 0.1 (EtOAc / petroleum ether 1:19); mp 218-220°C; 1H NMR 
(DMSO) 4.23 (3 H, s, Me), 6.95 (2 H, dd, J = 8.8, 2.0 Hz, Ph 3,5-H2), 7.72 (1 H, t, J = 8.0 
Hz, 7-H), 8.08 (2 H, dd, J = 8.8, 2.0 Hz, Ph 2,6-H2), 8.24 (1 H, s, 4-H), 8.59 (2 H, m, 6,8-
H2). 9.87 (1 H, br s, O-H); 13C NMR (DMSO) (HSQC / HMBC) 54.05 (Me), 102.51 (4-C), 
115.73 (Ph 3,5-C2), 118.51 (8a-C), 125.13 (7-C), 128.30 (Ph 2,6-C2), 128.79 (4a-C), 
129.11 (6-C), 130.72 (8-C), 130.81 (Ph 1-C), 144.43 (5-C), 150.95 (3-C), 159.06 (Ph 4-C), 
159.93 (1-C); MS m/z 297.0861 (M + H) (C16H13N2O4 requires 297.0875). 
1-Methoxy-5-nitro-3-(4-hydroxyphenyl)isoquinoline (141l). Method B. To 121 (300 
mg, 1.26 mmol) in a dry flask was added Pd2(dba)3 (115.1 mg, 0.13 mmol), SPhos 
(117.3 mg, 0.25 mmol), 4-hydroxybenzeneboronic acid (260.1 mg, 1.86 mmol) and 
K3PO4 (800.5 mg, 3.77 mmol). Dry DMF (7.0 mL) was added and the mixture was 
stirred at 135°C for 16 h. The evaporation residue, in CHCl3, was filtered through 
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Celite. Chromatography (EtOAc / petroleum ether 2:98 → 40:60) gave 141l (200 mg, 
54%) as a bright red solid with properties as above. 
1-Methoxy-5-nitro-3-(4-chlorophenyl)isoquinoline (141m). To 164 (95.8 mg, 0.34 
mmol) in a dry flask was added Pd2(dba)3 (31.0 mg, 34 mol), SPhos (31.5 mg, 68 
mol), 4-chlorobenzeneboronic acid (79.3 mg, 0.51 mmol) and K3PO4 (215 mg, 1.01 
mmol). Degassed toluene (3.0 mL) was added and the mixture was stirred at 100°C for 
16 h. The evaporation residue, in CHCl3, was filtered through Celite. Chromatography 
(EtOAc / petroleum ether 1:39) gave 141m (104 mg, 98%) as a yellow solid: Rf = 0.8 
(EtOAc / petroleum ether 1:19); mp 168-169°C; 1H NMR (CDCl3)  4.24 (3 H, s, Me), 
7.46 (2 H, dd, J = 6.8, 2.0 Hz, Ph 2,6-H2), 7.56 (1 H, t, J = 7.9 Hz, 7-H), 8.13 (2 H, dd, J = 
6.8, 2.0 Hz, Ph 3,5-H2), 8.46 (1 H, dd, J = 7.7, 1.2 Hz, 6-H), 8.47 (1 H, s, 4-H), 8.59 (1 H, 
dt, J = 8.2, 0.92 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 54.15 (1-OMe), 105.06 (4-
C), 120.04 (4a-C), 124.66 (7-C), 128.31 (Ph 3,5-C2), 128.65 (6-C), 128.87 (Ph 2,6-C2), 
131.18 (8-C), 131.29 (8a-C), 135.41 (Ph 4-C), 137.07 (3-C), 150.67 (5-C), 160.81 (1-C); 
MS m/z 315.0531 (M + H) (C16H1135ClN2O3 315.0536). 
1-Methoxy-5-nitro-3-(4-trifluoromethylphenyl)isoquinoline (141n). To 164 (300 mg, 
1.06 mmol) in a dry flask was added Pd2(dba)3 (97.1 mg, 106 µmol), SPhos (98.9 mg, 
0.21 mmol), 4-(trifluoromethyl)benzeneboronic acid (403 mg, 2.12 mmol) and 
potassium phosphate (675 mg, 3.2 mmol). Dry DMF (8.0 mL) was added and the 
mixture was stirred at 135°C for 16 h. The mixture was filtered through Celite and the 
solvent was evaporated. Chromatography (ethyl acetate / petroleum ether 3:197) gave 
141n (209 mg, 57%) as a yellow solid: Rf = 0.5 (EtOAc / petroleum ether 1:19); mp 125-
127°C; 1H NMR (CDCl3)  4.25 (3 H, s, Me), 7.58 (1 H, t, J = 7.9 Hz, 7-H), 7.72 (2 H, d, J = 
8.2 Hz, Ph 3,5-H2), 8.25 (2 H, d, J = 8.1 Hz, Ph 2,6-H2), 8.46 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 
8.50 (1 H, s, 4-H), 8.58 (1 H, dt, J = 8.2, 1.1 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC)  
54.23 (Me), 105.94 (4-C), 120.18 (8a-C), 125.11 (7-C), 125.57 (q, J = 3.6 Hz, Ph 3,5-C2), 
126.42 (q, J = 275.0 Hz, CF3), 127.20 (Ph 2,6-C2), 128.75 (6-C), 131.17 (4a-C), 131.20 (8-
C), 141.79 (Ph 1-C), 144.82 (5-C), 150.01 (3-C), 160.56 (1-C); 19F NMR (CDCl3)  -62.56 
(s, CF3); MS m/z 371.0601 (M + Na) (C17H11F3N2O3Na requires 371.0620), 349.0775 (M 
+ H) (C17H12F3N2O3 requires 349.0780). 
1-Methoxy-5-nitro-3-(4-methylphenyl)isoquinoline (141o). To 164 (201 mg, 0.71 
mmol) in a dry flask was added Pd2(dba)3 (65.0 mg, 71 mol), SPhos (66.1 mg, 0.14 
mmol), 4-methylbenzeneboronic acid (144.6 mg, 1.06 mmol) and K3PO4 (451.5 mg, 
2.13 mmol). Degassed toluene (5.0 mL) was added and the mixture was stirred at 
100°C for 16 h. The evaporation residue, in CHCl3, was filtered through Celite. 
Chromatography (EtOAc / petroleum ether 1:49) gave 141o (202 mg, 96%) as a yellow 
solid: Rf = 0.3 (EtOAc / petroleum ether 1:19); mp 164-166°C; 1H NMR (CDCl3) 2.41 (3 
H, s, PhMe), 4.24 (3 H, s, OMe), 7.29 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 7.51 (1 H, t, J = 8.0 
Hz, 7-H), 8.08 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.44 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.46 (1 
H, s, 4-H), 8.57 (1 H, dt, J = 8.2, 1.1 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 21.27 
(PhMe), 54.04 (OMe), 104.50 (4-C), 119.83 (8a-C), 124.11 (7-C), 126.98 (Ph 2,6-C2), 
128.49 (6-C), 129.42 (Ph 3,5-C2), 131.16 (8-C), 131.57 (4a-C), 135.87 (Ph 1-C), 139.45 
(Ph 4-C), 146.23 (5-C), 152.00 (3-C), 160.41 (1-C); MS m/z 295.1067 (M + H) 
(C17H15N2O3 requires 295.1082). 
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3-(2,6-Dichlorophenyl)-1-methoxy-5-nitroisoquinoline (141p). To 164 (240 mg, 0.85 
mmol) in a dry flask was added Pd2(dba)3 (77.7 mg, 85 µmol), Sphos (79.1 mg, 0.17 
mmol), 2,6-dichlorobenzeneboronic acid (243 mg, 1.27 mmol) and K3PO4 (541 mg, 2.54 
mmol). Dry DMF (8.0 mL) was added and the mixture was stirred at 135°C for 16 h. The 
mixture was filtered through Celite and the solvent was evaporated. Chromatography 
(EtOAc / petroleum ether 1: 99) gave 141p (35 mg, 12%) as a yellow solid: Rf = 0.7 
(EtOAc / petroleum ether 1:19); mp 122-124°C; 1H NMR (CDCl3)  4.17 (3 H, s, Me), 
7.30 (1 H, t, J = 8.7 Hz, Ph 4-H), 7.44 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.66 (1 H, t, J = 8.1 
Hz, 7-H), 8.08 (1 H, s, 4-H), 8.52 (1 H, dd, J = 7.8, 1.3 Hz, 6-H), 8.67 (1 H, dt, J = 8.2, 1.1 
Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC)  54.61 (Me), 111.16 (4-C), 120.08 (8a-C), 
125.36 (7-C), 128.24 (Ph 3,5-C2), 128.56 (6-C), 129.82 (Ph 4-C), 130.75 (4a-C), 131.32 
(8-C), 134.86 (Ph 2,6-C2), 138.19 (Ph 1-C), 144.94 (5-C), 149.95 (3-C), 160.73 (1-C); MS 
m/z 348.9740 (M - H) (C16H1135Cl37ClN2O3 requires 348.9961). 
1-Methoxy-5-nitro-3-(4-nitrophenyl)isoquinoline (141q). To 164 (250 mg, 0.88 mmol) 
in a dry flask was added Pd2(dba)3 (80.6 mg, 90 µmol), SPhos (82.4 mg, 0.18 mmol), 4-
nitrobenzeneboronic acid (221.1 mg, 1.32 mmol) and K3PO4 (562.3 mg, 2.65 mmol). 
Dry DMF (7.5 mL) was added and the mixture was stirred at 135°C for 16 h. The 
evaporation residue, in CHCl3, was filtered through Celite. Chromatography (EtOAc / 
petroleum ether 1:99 → 1:9) gave 141q (29.4 mg, 10%) as a yellow solid: Rf = 0.6 
(EtOAc / petroleum ether 1:19); mp 196-198°C; IR νmax 1516 & 1342 (NO2); 1H NMR 
(CDCl3) 4.29 (3 H, s, Me), 7.66 (1 H, t, J = 8.0 Hz, 7-H), 8.35 (4 H, s, 2,3,5,6-H4), 8.52 (1 
H, dd, J = 7.8, 1.2 Hz, 6-H), 8.62 (1 H, d, J = 0.9 Hz, 4-H), 8.65 (1 H, dt, J = 8.2, 1.1 Hz); 
13C NMR (CDCl3) (HSQC / HMBC) 54.43 (Me), 107.07 (4-C), 120.56 (4a-C), 123.99 (Ph 
3,5-C2), 125.75 (7-C), 127.79 (Ph 2,6-C2), 128.94 (6-C), 131.19 (8a-C), 131.31 (8-C), 
144.62 (Ph 1-C), 145.13 (5-C), 148.22 (Ph 4-C), 149.18 (3-C), 160.84 (1-C).  
Isoquinoline-1,3-dione (homophthalimide) (160). 2-Carboxyphenylacetic acid (homo-
phthalic acid) 159 (1.02 g, 5.7 mmol) was heated with finely ground urea (390 mg, 6.5 
mmol) at 175-185C for 15 min. Cooling and recrystallisation (MeOH) gave 160 (372 
mg, 41%) as an off-white solid: Rf = 0.6 (1:1 EtOAc/ petroleum ether); mp 213-216C 
(lit.276 mp 236-238C); 1H NMR (DMSO) 4.09 (2 H, s, CH2), 7.44 (1 H, d, J = 7.6 Hz, 5-
H), 7.51 (1 H, t, J = 7.6 Hz, 7-H), 7.70 (1 H, td, J = 7.6, 1.2 Hz, 6-H), 8.07 (1 H, dd, J = 7.8, 
1.1 Hz, 8-H), 11.36 (1 H, s, N-H); 13C NMR (DMSO) (HSQC / HMBC) 35.92 (4-C), 124.95 
(8a-C), 127.16 (7-C), 127.41 (8-C), 127.87 (5-C), 133.47 (6-C), 136.66 (4a-C), 165.34 (1-
C), 170.99 (3-C).  
1,3-Dibromoisoquinoline (162). Method A. PBr3 (10 mL) was added slowly to 160 (1.41 
g, 8.7 mmol) and the mixture was heated at reflux for 16 h. Evaporation and quenching 
(sat. aq. NaHCO3), followed by extraction thrice with CHCl3 and chromatography 
(EtOAc / petroleum ether 3:17), followed by chromatography (EtOAc / petroleum 
ether 1:49) gave 162 (358 mg, 14%) as a crystalline white solid: Rf = 0.9 (EtOAc / 
petroleum ether 3:7); mp 148-150C (lit.277 mp 147-147.5°C); 1H NMR (DMSO) 7.93 
(1 H, td, J = 6.9, 1.3 Hz, 6-H), 8.00 (1 H, td, J = 6.9, 1.2 Hz, 7-H), 8.10 (1 H, dt, J = 8.1, 0.6 
Hz, 5-H), 8.27 (1 H, d, J = 8.4 Hz, 8-H), 8.38 (1 H, s, 4-H); 13C NMR (DMSO) (HSQC / 
HMBC) 124.66 (4-C), 126.85 (5-C), 127.13 (8a-C), 127.68 (4a-C), 127.89 (8-C), 130.69 
(6-C), 132.69 (7-C), 138.74 (3-C), 143.18 (1-C). Further elution gave 161 (3-
bromoisoquinoline) (66 mg, 4%) as a crystalline white solid: Rf = 0.8 (EtOAc / 
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petroleum ether 3:7); mp 61-63C (lit. 278 mp 63-64C ; 1H NMR (DMSO) (NOE) 7.80 
(1 H, td, J = 8.0 Hz, 6-H), 7.90 (1 H, dt, J = 8.3 Hz, 1.2 Hz, 7-H), 8.03 (1 H, d, J = 8.3 Hz, 5-
H), 8.23 (1 H, d, J = 8.3 Hz, 8-H), 8.27 (1 H, s, 4-H), 9.24 (1 H, s, 1-H); 13C NMR (DMSO) 
(HSQC / HMBC) 123.53 (4-C), 125.76 (5-C), 127.25 (4a-C), 127.80 (8-C), 128.13 (6-C), 
131.68 (7-C), 135.19 (3-C), 137.46 (8a-C), 153.19 (1-C). 
1,3-Dibromoisoquinoline (162). Method B. Isoquinoline-1,3-dione (160) (1.1 g, 6.70 
mmol) was heated at reflux with POBr3 (6.9 g, 24.00 mmol) in 1,4-dioxane (15 mL) 
under Ar for 5 h. The mixture was then quenched with MeOH, then H2O. The mixture, 
in H2O, was extracted with CH2Cl2 (100 mL thrice). Evaporation and re-crystallisation 
(EtOAc, 35 mL) gave 162 (402 mg, 21%) as an off-white solid, with properties as above. 
1,3-Dibromo-5-nitroisoquinoline (163). Aq. HNO3 (67%, 78 mg, 0.87 mmol) in conc. 
H2SO4 (93 mg, 0.95 mmol) at 0°C was added dropwise to 162 (251 mg, 0.87 mmol) in 
conc. H2SO4 (3.0 mL) at 0C. The mixture was stirred at 0°C for 2 h, allowed to warm to 
rt for 1 h, then poured onto ice. The precipitate was collected, washed (H2O) and dried 
to yield 163 (285 mg, 98%) as a yellow solid: Rf = 0.6 (EtOAc / petroleum ether 1:9); mp 
226-228C; IR νmax 1516 & 1334 (NO2), 730 (CBr); 1H NMR (DMSO) 8.00 (1 H, t, J = 7.9 
Hz, 7-H), 8.54 (1 H, s, 4-H), 8.64 (1 H, d, J = 8.6 Hz, 6-H), 8.73 (1 H, dd, J = 7.8, 0.9 Hz, 8-
H); 13C NMR (DMSO) (HSQC / HMBC) 119.57 (4-C), 126.19 (4a-C), 128.93 (7-C), 130.41 
(8a-C), 130.64 (8-C), 135.28 (6-C), 135.58 (3-C), 144.09 (1-C), 144.76 (5-C). 
3-Bromo-1-methoxy-5-nitroisoquinoline (164). Na (27 mg, 1.2 mmol) was dissolved in 
dry MeOH (3.0 mL) and this solution of NaOMe was added to 163 (186 mg, 0.58 mmol) 
in dry MeOH (4.0 mL). The mixture was heated at 40°C for 10 min. EtOAc was added to 
the cooled mixture and the solution was washed thrice (brine). Evaporation and 
recrystallisation (MeOH) gave 164 (64 mg, 38%) as a fluffy yellow solid: Rf = 0.8 (EtOAc 
/ petroleum ether 1:4); mp 188-192°C; IR νmax 2815 (O-Me), 1563 & 1356 (NO2); 1H 
NMR (CDCl3) 4.15 (3 H, s, Me), 7.58 (1 H, t, J = 8.1 Hz, 7-H), 8.26 (1 H, s, 4-H), 8.46 (1 
H, dd, J = 7.8, 1.2 Hz, 6-H), 8.53 (1 H, dd, J = 8.2, 0.9 Hz, 8-H); 13C NMR (CDCl3) (HSQC / 
HMBC) 55.06 (Me), 112.64 (4-C), 119.42 (4a-C), 125.11 (7-C), 129.17 (6-C), 131.49 (8-
C), 131.71 (8a-C), 137.45 (3-C), 143.75 (5-C), 160.25 (1-C). 
5-Nitro-3-phenylisoquinolin-1-one (165a). Method A. Aq. HBr (48%, 8.0 mL) was 
stirred with 141a (120 mg, 0.43 mmol) at 80°C for 16 h. Evaporation and chromato-
graphy (EtOAc / petroleum ether 2:3  EtOAc) yielded 165a (59 mg, 52%) as powdery 
yellow needles: Rf = 0.3 (EtOAc / petroleum ether 7:13); mp >340°C; 1H NMR (DMSO)  
7.22 (1 H, s, 4-H), 7.51 (3 H, m, Ph 3,4,5-H3), 7.64 (1 H, t, J = 8.0 Hz, 7-H), 7.76 (2 H, m, 
Ph 2,6-H2), 8.46 (1 H, d, J = 8.0 Hz, 6-H), 8.57 (1 H, d, J = 8.2 Hz, 8-H), 12.03 (1 H, s, N-
H); 13C NMR (DMSO) (HSQC / HMBC) 97.46 (4-C), 125.73 (7-C), 126.61 (8a-C), 127.21 
(Ph 2,6-C2), 128.95 (Ph 3,4,5-C3), 130.19 (6-C), 131.60 (4a-C), 133.54 (8-C), 144.39 (5-C), 
155.90 (1-C); MS m/z 265.0619 (M - H) (C15H9N2O3 requires 265.0613). 
5-Nitro-3-phenylisoquinolin-1-one (165a). Method B. HBr in AcOH (33%, 1.0 mL) was 
stirred with 141a (38.5 mg, 0.14 mmol) at 65°C for 16 h. Evaporation yielded 165a (23 
mg, 63%) as powdery yellow needles, with properties as above. 
3-(4-Fluorophenyl)-5-nitroisoquinolin-1-one (165k). Compound 141k (16 mg, 0.05 
mmol) was stirred with HBr/ AcOH (33%, 1.0 mL) at 65°C for 7 h. Evaporation yielded 
165k (7.8 mg, 55%) as a dark yellow solid: Rf = 0.3 (EtOAc / petroleum ether 1:4); mp 
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>360C; IR νmax 3440 (NH), 1676 (C=O), 1513 & 1325 (NO2), 1238 (CF); 1H NMR (DMSO) 
 7.19 (1 H, s, 4-H), 7.36 (2 H, t, J = 8.6 Hz, Ph 3,5-H2), 7.65 (1 H, J = 7.9 Hz, 7-H), 7.84 (2 
H, dd, J = 8.2, 5.3 Hz, Ph 2,6-H2), 8.46 (1 H, d, J = 7.8 Hz, 8-H), 8.59 (1 H, d, J = 7.7 Hz, 6-
H), 11.95 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 96.94 (4-C), 115.56 (d, J = 
21.8 Hz, Ph 3,5-C2), 125.41 (7-C), 126.38 (8a-C), 129.36 (8-C), 129.43 (Ph 2,6-C2), 129.86 
(4a-C), 130.63 (Ph 1-C), 132.83 (6-C), 143.07 (3-C), 144.55 (5-C), 160.99 (1-C), 162.94 
(d, J = 246.6 Hz, Ph 4-C); 19F NMR (DMSO)  -110.96 (m, F); MS m/z 283.0524 (M - H)- 
(C15H8FN2O3 requires 283.0524). 
5-Nitro-3-(4-trifluorophenyl)isoquinolin-1-one (165n). Compound 141n (78 mg, 0.22 
mmol) was stirred with HBr/ AcOH (33%, 3.5 mL) at 65°C for 7 h. Evaporation yielded 
165n (34.5 mg, 47 %) as a dark yellow solid: Rf = 0.3 (EtOAc / petroleum ether 1:4); mp: 
292-294C; IR νmax 3440 (NH), 1651 (C=O), 1522 & 1327 (NO2), 1269, 1116 & 1073 (CF); 
1H NMR (DMSO)  7.30 (1 H, s, 4-H), 7.70 (1 H, t, J = 8.0 Hz, 7-H), 7.89 (2 H, d, J = 8.5 
Hz, Ph 3,5-H2), 7.99 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 8.49 (1 H, d, J = 7.5 Hz, 8-H), 8.60 (1 
H, d, J = 7.5 Hz, 6-H), 12.26 (1 H, br, N-H); 13C NMR (DMSO) (HSQC / HMBC) 98.63 (4-
C), 124.01 (q, J = 270.8 Hz, CF3), 125.81 (q, J = 3.6 Hz, Ph 3,5-C2), 126.36 (7-C), 126.89 
(8a-C), 128.27 (Ph 2,6-C2), 129.99 (8-C), 130.04 (q, J = 31.8 Hz, Ph 4-C), 130.59 (4a-C), 
133.19 (6-C), 137.44 (Ph 1-C), 142.64 (3-C), 144.94 (5-C), 161.33 (1-C); 19F NMR (DMSO) 
 -61.22 (s, CF3); MS m/z 333.0493 (M – H)- (C16H8F3N2O3 requires 333.0493). 
5-Amino-1-methoxy-3-phenylisoquinoline (166a). Compound 141a (46.5 mg, 0.17 
mmol) was stirred vigorously with Pd/C (10%, 51 mg) in EtOH (8 mL) under H2 for 16 h. 
Filtration (Celite) and evaporation gave 166a (5-amino-1-methoxy-3-phenylisoquinol-
ine) (39.1 mg, 94 %) as a buff solid: Rf = 0.30 (EtOAc / petroleum ether 1:19); mp 132-
133C; 1H NMR (CDCl3) 4.22 (3 H, s, Me), 6.96 (1 H, dd, J = 7.5, 1.0 Hz, 6-H), 7.31 (1 H, 
t, J = 7.6 Hz, 7-H), 7.37 (1 H, tt, J = 7.3, 1.3 Hz, Ph 4-H), 7.47 (2 H, t, J = 7.3 Hz, Ph 3,5-
H2), 7.63 (1 H, s, 4-H), 7.71 (1 H, dt, J = 8.2, 0.9 Hz, 8-H), 8.16 (2 H, dd, J = 8.5, 1.4 Hz, Ph 
2,6-H2); 13C NMR (CDCl3) (HSQC / HMBC) 53.56 (O-CH3), 103.92 (4-C), 114.67 (6-C), 
115.13 (8-C), 120.58 (4a-C), 126.54 (Ph 2,6-C2 & 7-C3), 128.17 (Ph 4-C), 128.52 (Ph 3,5-
C2), 136.03 (3-C), 139.65 (Ph 1-C), 140.59 (5-C), 161.14 (1-C); MS m/z 251.1173 (M + H) 
(C16H15N2O requires 251.1186).  
Hydrogenation of 1-methoxy-5-nitro-3-(3-chlorophenyl)isoquinoline (141e): 5-
Amino-1-methoxy-3-phenylisoquinoline (166a). Compound 141e (43.4 mg, 0.14 
mmol) was stirred vigorously with Pd/C (10%, 48 mg) in EtOH (8 mL) under H2 for 16 h. 
Filtration (Celite), evaporation and chromatography (EtOAc / petroleum ether 1:19 → 
EtOAc) gave 166a (27 mg, 79%) as an off-white solid, with properties as above.  
Hydrogenation of 1-methoxy-5-nitro-3-(2-chlorophenyl)isoquinoline (141d): 5-
Amino-1-methoxy-3-phenylisoquinoline (166a). Compound 141d (36.3 mg, 0.12 
mmol) was stirred vigorously with Pd/C (10%, 40 mg) in EtOH (7 mL) under H2 for 16 h. 
The mixture was filtered (Celite) and the solvent was evaporated. Dry flash 
chromatography (EtOAc / petroleum ether 1:39 → 2:3) gave 166a (6.0 mg, 20%) as an 
off-white solid, with properties as above. 
5-Amino-1-methoxy-3-(2-methoxyphenyl)isoquinoline (166b). Compound 141b (40.3 
mg, 0.136 mmol) was stirred vigorously with Pd/C (10%, 44 mg) in EtOH (9 mL) under 
H2 for 5 h. Filtration (Celite) and evaporation yielded 166b (33.5 mg, 88%) as a pale 
yellow solid: Rf = 0.4 (1:9 EtOAc/ petroleum ether); mp 119-121C; 1H NMR (CDCl3) 
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3.93 (3 H, s, Ph-OMe), 4.18 (3 H, s, 1-OMe), 6.92 (1 H, dd, J = 7.5, 0.8 Hz, 6-H), 7.04 (1 
H, d, J = 8.2 Hz, Ph 3-H), 7.12 (1 H, td, J = 7.4, 1.0 Hz, Ph 5-H), 7.30 (1 H, t, J = 7.8 Hz, 7-
H), 7.35 (1 H, td, J = 8.3, 1.8 Hz, Ph 4-H), 7.69 (1 H, d, J = 8.2 Hz, 8-H), 7.93 (1 H, s, 4-H), 
8.14 (1 H, dd, J = 7.7, 1.7 Hz, Ph 6-H); 13C NMR (CDCl3) (HSQC / HMBC) 53.55 (1-OMe), 
55.79 (Ph-OMe), 109.00 (4-C), 111.67 (Ph 3-C), 113.74 (6-C), 114.28 (8-C), 119.15 (8a-
C), 120.95 (Ph 5-C), 126.60 (7-C), 128.15 (4a-C), 128.91 (3-C), 129.04 (Ph 4-C), 131.05 
(Ph 6-C), 141.42 (5-C), 144.22 (Ph 1-C), 157.20 (Ph 2-C), 160.29 (1-C); MS m/z 303.1119 
(M + Na) (C17H16N2NaO2 requires 303.1110). 
5-Amino-1-methoxy-3-(3-methoxyphenyl)isoquinoline (166c). Compound 141c (40.1 
mg g, 0.136 mmol) was stirred vigorously with Pd/C (10%, 44 mg) in EtOH (9 mL) under 
H2 for 5 h. Filtration (Celite) and evaporation yielded 166c (31 mg, 81%) as a pale 
yellow solid: Rf = 0.3 (EtOAc / petroleum ether 1:9); mp 146 -149C; 1H NMR (CDCl3) 
3.91 (3 H, s, Ph O-CH3), 4.21 (3 H, s, O-CH3), 6.93 (2 H, m, Ph 6-H & 6-H), 7.31 (1 H, t, J 
= 7.8 Hz, 7-H), 7.39 (1 H, t, J = 8.0 Hz, Ph 5-H), 7.60 (1 H, s, 4-H), 7.71 (3 H, m, Ph 4, 2-H2 
& 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 53.60 (1-OMe), 55.31 (Ph-OMe), 104.17 (4-
C), 112.39 (Ph 2-C), 113.47 (Ph 6-C), 114.05 (6-C), 114.47 (8-C), 118.94 (Ph 4-C), 119.57 
(8a-C), 126.75 (7-C), 128.36 (4a-C), 129.54 (Ph 5-C), 141.22 (Ph 1-C), 141.58 (5-C), 
146.53 (3-C), 159.92 (Ph 3-C), 160.68 (1-C); MS m/z 303.1110 (M + Na) (C17H16N2NaO2 
requires 303.1110), 281.1278 (M + H) (C17H17N2O2 requires 281.1290). 
Hydrogenation of 1-Methoxy-5-nitro-3-(2-chlorophenyl)isoquinoline (141d): 5-
Amino-1-methoxy-3-(2-chlorophenyl)isoquinoline (166d). Compound 141d (75 mg, 
0.24 mmol) was stirred vigorously with Pt/C (1%, 84 mg) in EtOH (6.0 mL) under H2 for 
5 h. Filtration (Celite) and evaporation gave 166d (70 mg, 100%) as a dark yellow 
solid: Rf = 0.3 (EtOAc/ petroleum ether 1:4); mp: 102-103°C; 1H NMR (CDCl3) 4.18 
(OMe), 6.93 (1 H, dd, J = 7.5 Hz, 6-H), 7.35 (3 H, m, 7-H & Ph 4,5-H2), 7.51 (1 H, dd, J = 
8.0, 1.0 Hz, Ph 3-H), 7.56 (1 H, s, 4-H), 7.73 (1 H, d, J = 8.0 Hz, 8-H), 7.76 (1 H, dd, J = 
7.5, 1.5 Hz, Ph 6-H); 13C NMR (CDCl3) (HSQC / HMBC)53.78 (Me), 109.13 (4-C), 113.89 
(6-C), 114.14 (8-C), 119.29 (8a-C), 126.75 (Ph 4-C), 127.17 (7-C), 127.59 (4a-C), 128.83 
(Ph 5-C), 130.27 (Ph 3-C), 131.75 (Ph 6-C), 132.32 (Ph 2-C), 139.34 (Ph 1-C), 141.65 (5-
C), 145.86 (3-C), 160.57 (1-C); MS m/z 307.0592 (M + Na) (C16H13NaN2O35Cl requires 
307.0614), 287.0759 (M + H) (C16H14N2O37Cl requires 287.0765), 285.0803 (M + H) 
(C16H14N2O35Cl requires 285.0795). 
Hydrogenation of 1-Methoxy-5-nitro-3-(3-chlorophenyl)isoquinoline (141e): 5-
Amino-1-methoxy-3-(3-chlorophenyl)isoquinoline (166e). Compound 141e (75 mg, 
0.24 mmol) was stirred vigorously with Pt/C (1%, 83.5 mg) in EtOH (6.0 mL) under H2 
for 5 h. Filtration (Celite) and evaporation gave 166e (62 mg, 91%) as a dark yellow 
solid: Rf = 0.3 (EtOAc/ petroleum ether 1:4); mp 94-95°C; 1H NMR (CDCl3) 4.20 (3 H, s, 
Me), 6.93 (1 H, dd, J = 7.5, 0.5 Hz, 6-H), 7.33 (3 H, m, 7-H & Ph 5,6-H2), 7.57 (1 H, s, 4-
H), 7.69 (1 H, d, J = 8.5 Hz, 8-H), 8.01 (1 H, d, J = 7.5 Hz, Ph 3-H), 8.14 (1 H, s, Ph 2-H), 
13C NMR (CDCl3) (HSQC / HMBC)53.69 (Me), 104.39 (4-C), 114.31 (6-C), 114.53 (8-C), 
119.72 (8a-C), 124.47 (Ph 6-C), 126.57 (Ph 2-C), 127.07 (7-C), 128.01 (Ph 4-C), 128.19 
(4a-C), 129.74 (Ph 5-C), 134.56 (Ph 3-C), 141.47 (Ph 1-C), 141.57 (5-C), 145.18 (3-C), 
160.78 (1-C); MS m/z 287.0760 (M + H) (C16H14N2O37Cl requires 287.0765), 285.0793 
(M + H) (C16H14N2O35Cl requires 285.0795).  
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5-Amino-3-(3-cyanophenyl)-1-methoxyisoquinoline (166f). Compound 141f (34 mg, 
0.11 mmol) was stirred vigorously with Pd/C (10%, 38 mg) in ethanol (5.0 mL) under H2 
for 6.5 h. Filtration (Celite), evaporation and chromatography (ethyl acetate / 
petroleum ether 1:39 → 1:4) gave 166f (11.2 mg, 37%) as a golden buff solid: Rf = 0.5 
(EtOAc / petroleum ether 1:84); mp 183-184°C; 1H NMR (CDCl3)  4.22 (3 H, s, Me), 
6.96 (1 H, dd, J = 7.5, 1.0 Hz, 6-H), 7.35 (1 H, t, J = 7.6 Hz, 7-H), 7.56 (1 H, t, J = 7.4 Hz, 
Ph 5-H), 7.62 (1 H, s, 4-H), 7.63 (1 H, dt, J = 7.9, 1.5 Hz, Ph 6-H), 7.70 (1 H, dt, J = 8.2, 0.9 
Hz, 8-H), 8.36 (1 H, dt, J = 7.9, 1.3 Hz, Ph 4-H), 8.46 (1 H, t, J = 1.3 Hz, Ph 2-H); 13C NMR 
(CDCl3) (HSQC / HMBC)  53.80 (Me), 104.72 (4-C), 112.74 (Ph 3-C), 114.52 (6-C), 
114.58 (8-C), 119.14 (CN), 120.03 (8a-C), 127.53 (7-C), 128.08 (4a-C), 129.31 (Ph 5-C), 
130.26 (Ph 2-C), 130.49 (Ph 4-C), 131.27 (Ph 6-C), 140.84 (Ph 1-C), 141.81 (5-C), 144.22 
(3-C), 161.09 (1-C); MS m/z 276.1128 (M + H)+ (C17H14N3O requires 276.1137). 
Hydrogenation of 1-Methoxy-5-nitro-3-(4-cyanophenyl)isoquinoline (141g): 5-Amino-
1-methoxy-3-(4-cyanophenyl)isoquinoline (166g). Compound 141g (43.5 mg, 0.14 
mmol) was stirred vigorously with Pd/C (10%, 48 mg) in EtOH (3 mL) under H2 for 6 h. 
Filtration (Celite) and evaporation gave 166g (5-amino-1-methoxy-3-(4-
cyanophenyl)isoquinoline) (26.4 mg, 68%) as a yellow solid: Rf = 0.1 (EtOAc/ petroleum 
ether 1:19); mp 197-198 °C; 1H NMR (CD3OD)  4.20 (3 H, s, Me), 6.99 (1 H, d, J = 7.6 
Hz, 6-H), 7.33 (1 H, t, J = 8.0 Hz, 7-H), 7.55 (1 H, d, J = 8.9 Hz, 8-H), 7.80 (2 H, dd, J = 6.8, 
1.8 Hz, Ph 3,5-H2), 8.12 (1 H, s, 4-H), 8.41 (2 H, dd, J = 6.8, 1.8 Hz, Ph 2,6-H2); 13C NMR 
(CDCl3) (HSQC / HMBC) 54.09 (Me), 107.96 (4-C), 112.31 (Ph 4-C), 113.72 (8-C), 
114.75 (6-C), 120.08 (CN), 121.72 (8a-C), 128.01 (Ph 2,6-C2), 129.22 (7-C), 130.98 (4a-
C), 133.46 (Ph 3,5-C2), 140.32 (Ph 1-C), 144.84 (5-C), 144.92 (3-C), 145.69 (5-C), 162.22 
(1-C); MS m/z 276.1119 (M + H) (C17H14N3O requires 276.1139). 
5-Amino-3-(4-cyanophenyl)-1-methoxyisoquinoline (166g). Compound 141g (37 mg, 
0.12 mmol) was stirred vigorously with Pd/C (10%, 41 mg) in ethanol (5.5 mL) under H2 
for 6.5 h. Filtration (Celite), evaporation and chromatography (ethyl acetate / 
petroleum ether 1:39 → 1:4) gave 166g (17.3 mg, 52%) as an amber-coloured solid: Rf 
= 0.5 (EtOAc / petroleum ether 1:4); mp 203-204°C; 1H NMR (CDCl3)  4.21 (3 H, s, Me), 
6.96 (1 H, dd, J = 7.6, 1.0 Hz, 6-H), 7.36 (1 H, t , J = 7.6 Hz, 7-H), 7.67 (1 H, s, 4-H), 7.70 
(1 H, dt, J = 7.3, 0.9 Hz, 8-H), 7.74 (2 H, d, J = 8.7 Hz, Ph 3,5-H2), 8.25 (2 H, d, J = 8.7 Hz, 
Ph 2,6-H2); 13C NMR (CDCl3) (HSQC / HMBC)  53.76 (Me), 105.55 (4-C), 111.27 (Ph 4-
C), 114.58 (6-C), 114.61 (8-C), 119.17 (CN), 120.18 (4a-C), 126.89 (Ph 2,6-C2), 127.77 (7-
C), 127.98 (8a-C), 132.39 (Ph 3,5-C2), 141.93 (5-C). 143.93 (Ph 1-C), 144.45 (3-C), 161.04 
(1-C); MS m/z 298.0951 (M + Na) (C17H13N3ONa requires 298.0957), 276.1124 
(C17H14N3O requires 276.1137).  
Hydrogenation of 1-methoxy-5-nitro-3-(2-trifluoromethylphenyl)isoquinoline (141h): 
5-Amino-1-methoxy-3-(2-trifluoromethylphenyl)isoquinoline (166h). Compound 141h 
(48 mg, 0.14 mmol) was stirred vigorously with Pt/C (1%, 53 mg) in EtOH (6.0 mL) 
under H2 for 4 h. Filtration (Celite) and evaporation gave 166h (29 mg, 66%) as a dark 
yellow solid: Rf = 0.5 (EtOAc / petroleum ether 1:4); mp: 172-174°C; 1H NMR (CDCl3) 
4.13 (Me), 6.96 (1 H, dd, J = 7.5, 0.5 Hz, 6-H), 7.28 (1 H, s, 4-H), 7.37 (1 H, t, J = 7.5 Hz, 
7-H), 7.51 (1 H, t, J = 7.5 Hz, Ph 5-H), 7.63 (2 H, m, Ph 4,6-H2), 7.73 (1 H, d, J = 8.5 Hz, 8-
H), 7.81 (1 H, d, J = 8.0 Hz, Ph 3-H); 13C NMR (CDCl3) (HSQC / HMBC)53.85 (Me), 
108.10 (4-C), 114.03 (6-C), 114.32 (8-C), 119.34 (8a-C), 124.28 (q, J = 272 Hz, CF3), 
126.69 (q, J = 5.1 Hz, Ph 3-C), 127.17 (7-C), 127.57 (4a-C), 127.81 (Ph 5-C), 128.54 (q, J = 
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30.1 Hz, Ph 2-C), 131.41 (Ph 6-C), 131.90 (Ph 4-C), 140.55 (Ph 1-C), 141.56 (5-C), 147.56 
(3-C), 160.35 (1-C); 19F NMR (CDCl3)  -56.62 (s, CF3); MS m/z 341.0872 (M + Na)+ 
(C17H13F3N2NaO requires 341.0880). 
5-Amino-1-methoxy-3-(3-trifluoromethylphenyl)isoquinoline (166i). Compound 141i 
(152 mg, 0.44 mmol) was stirred vigorously with Pd/C (10%, 165 mg) in ethanol (8.0 
mL) under H2 for 5.5 h. Filtration (Celite) and evaporation gave 166i (120 mg, 87%) as 
a pale buff solid: Rf = 0.8 (EtOAc / petroleum ether 1:4); mp 89-91°C; 1H NMR (CDCl3)  
4.22 (3 H, s, Me), 6.94 (1 H, d, J = 7.4 Hz, 6-H), 7.33 (1 H, t, J = 7.8 Hz, 7-H), 7.55 (1 H, t, J 
= 7.7 Hz, Ph 5-H), 7.62 (2 H, m, 4-H + Ph 4-H), 7.70 (1 H, d, J = 8.2 Hz, 8-H), 8.32 (1 H, d, 
J = 7.6 Hz, Ph 6-H), 8.40 (1 H, s, Ph 2-H); 13C NMR (CDCl3) (HSQC / HMBC)  53.70 (Me), 
104.50 (4-C), 114.37 (6-C), 114.57 (8-C), 119.87 (8a-C), 123.23 (q, J = 3.9 Hz, Ph 2-C), 
124.39 (q, J = 270.8 Hz, CF3), 124.63 (q, J = 3.9 Hz, Ph 4-C), 127.24 (7-C), 128.22 (4a-C), 
129.00 (Ph 5-C), 129.66 (Ph 6-C), 130.95 (q, J = 31.8 Hz, Ph 3-C), 140.44 (Ph 1-C), 141.75 
(5-C), 145.16 (3-C), 160.97 (1-C); 19F NMR (CDCl3)  -62.50 (s, CF3); MS m/z 319.1048 (M 
+ H) (C17H14F3N2O requires 319.1058). 
Hydrogenation of 1-methoxy-5-nitro-3-(4-bromophenyl)isoquinoline (141j) : 5-
Amino-1-methoxy-3-(4-bromophenyl)isoquinoline (166j). Compound 141j (18.1 mg, 
0.05 mmol) was stirred vigorously with Pt/C (1%, 20 mg) in EtOH (3.0 mL) under H2 for 
4 h. Filtration (Celite) and evaporation gave 166j (16.1 mg, 98%) as a dark yellow 
solid: Rf = 0.4 (EtOAc/ petroleum ether 1:9); mp 145-147°C; 1H NMR (MeOD) 4.18 (3 
H, s, Me), 6.96 (1 H, dd, J = 7.5, 1.0 Hz, 6-H), 7.28 (1 H, t, J = 8.0 Hz, 7-H), 7.54 (1 H, dt, J 
= 8.0, 1.0 Hz, 8-H), 7.60 (2 H, d, J = 9.5 Hz, Ph 2,6-H2), 7.99 (1 H, s, 4-H), 8.14 (2 H, d, J = 
9.5 Hz, Ph 3,5-H2); 13C NMR (CD3OD) (HSQC / HMBC) 53.98 (Me), 106.18 (4-C), 113.83 
(8-C), 114.72 (6-C), 120.92 (8a-C), 122.95 (Ph 4-C), 129.18 (Ph 3,5-C2), 129.57 (4a-C), 
132.60 (Ph 2,6-C2), 140.28 (3-C), 145.05 (5-C), 145.96 (Ph 1-C), 161.96 (1-C); MS m/z 
329.0124 (M - H)- (C16H12N2O81Br requires 329.0113).  
Hydrogenation of 1-methoxy-5-nitro-3-(4-hydroxyphenyl)isoquinoline (141k): 5-
Amino-3-(4-fluorophenyl)-1-methoxyisoquinoline (166k). Compound 141k (108 mg, 
0.36 mmol) was stirred vigorously with Pd/C (10%, 118 mg) in ethanol (8.0 mL) under 
H2 for 6 h. Filtration (Celite) and evaporation gave 166k (90 mg, 69%) as an off-white 
solid: Rf = 0.5 (EtOAc / petroleum ether 1:9); mp 154-155°C; 1H NMR (CDCl3)  4.21 (3 
H, s, Me), 6.94 (1 H, dd, J = 7.5, 1.0 Hz, 6-H), 7.15 (2 H, m, Ph 3,5-H2), 7.31 (1 H, t, J = 
7.5 Hz, 7-H), 7.54 (1 H, s, 4-H), 7.69 (1 H, dt, J = 8.2, 1.0 Hz, 8-H), 8.13 (2 H, m, Ph 2,6-
H2); 13C NMR (CDCl3) (HSQC / HMBC)  53.62 (Me), 103.64 (4-C), 114.31 (6-C), 114.67 
(8-C), 115.42 (d, J = 21.5 Hz, Ph 3,5-C2), 119.40 (8a-C), 126.72 (7-C), 128.62 (d, J = 10.4 
Hz, Ph 2,6-C2), 128.53 (4a-C), 135.85 (d, J = 3.3 Hz, Ph 1-C), 141.37 (5-C), 145.98 (3-C), 
160.82 (1-C), 163.04 (d, J = 246.0 Hz, Ph 4-C); 19F NMR (CDCl3)  -114.31 (m, F); MS m/z 
269.1074 (M + H)+ (C16H14FN2O requires 269.1092); MS m/z 267.0925 (M - H)- 
(C16H12FN2O requires 267.0932). 
Hydrogenation of 1-methoxy-5-nitro-3-(4-hydroxyphenyl)isoquinoline (141l): 5-
Amino-1-methoxy-3-(4-hydroxyphenyl)isoquinoline (166l). Compound 141l (65 mg, 
0.22 mmol) was stirred vigorously with Pd/C (10%, 71.5 mg) in EtOH (5.0 mL) under H2 
for 6 h. Filtration (Celite) and evaporation gave 166l (63 mg, 98%) as a dark yellow 
solid: Rf = 0.1 (EtOAc/ petroleum ether 1:4); mp 225-226°C; 1H NMR (CD3OD) 4.17 (3 
H, s, Me), 6.87 (2 H, dd, J = 7.0, 2.0 Hz, Ph 3,5-H2), 6.94 (1 H, d, J = 7.0 Hz, 6-H), 7.22 (1 
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H, t, J = 8.0 Hz, 7-H), 7.53 (1 H, d, J = 8.5 Hz, 8-H), 7.81 (1 H, s, 4-H), 8.07 (2 H, dd, J = 
7.0, 2.0 Hz, Ph 2,6-H2); 13C NMR (CD3OD) (HSQC / HMBC) 53.84 (Me), 104.35 (4-C), 
114.14 (8-C), 114.63 (6-C), 116.24 (Ph 3,5-C2), 120.52 (4a-C), 127.40 (7-C), 128.85 (Ph 
2,6-C2), 130.19 (8a-C), 132.74 (Ph 1-C), 144.38 (5-C), 147.73 (3-C), 158.86 (Ph 4-C), 
161.74 (1-C); MS m/z 267.1123 (M + H) (C16H15N2O2 requires 267.1134). 
Hydrogenation of 1-methoxy-5-nitro-3-(4-chlorophenyl)isoquinoline (141m): 5-
Amino-1-methoxy-3-(4-chlorophenyl)isoquinoline (166m). Compound 141m (35.2 mg, 
0.11 mmol) was stirred vigorously with Pt/C (1%, 38 mg) in EtOH (3.0 mL) under H2 for 
4 h. Filtration (Celite) and evaporation gave 166m (28 mg, 93%) as a dark yellow solid: 
Rf = 0.5 (EtOAc/ petroleum ether 1:9); mp 198-200°C; 1H NMR (CDCl3) 4.16 (3 H, s, 
Me), 6.92 (1 H, d, J = 7.1 Hz, 6-H), 7.28 (1 H, t, J = 7.8 Hz, 7-H), 7.37 (2 H, d, J = 8.5 Hz, 
Ph 3,5-H2), 7.56 (1 H, s, 4-H), 7.66 (1 H, d, J = 7.6 Hz, 8-H), 8.04 (2 H, d, J = 8.5 Hz, Ph 
2,6-H2); 13C NMR (CDCl3) (HSQC / HMBC) 53.48 (Me), 103.05 (4-C), 114.96 (6-C), 
115.32 (8-C), 121.05 (8a-C), 127.82 (7-C), 127.85 (Ph 2,6-C2), 128.65 (Ph 3,5-C2), 131.82 
(4a-C), 134.21 (Ph 4-C), 138.32 (Ph 1-C), 141.72 (5-C), 152.16 (3-C), 160.23 (1-C); MS 
m/z 287.0740 (M + H) (C16H14N2O37Cl requires 287.0765), 285.0770 (M + H) 
(C16H14N2O35Cl requires 285.0795). 
Hydrogenation of 1-methoxy-5-nitro-3-(4-trifluoromethylphenyl)isoquinoline (141n): 
5-Amino-1-methoxy-3-(4-trifluorophenyl)isoquinoline (166n). Compound 141n (151 
mg, 0.43 mmol) was stirred vigorously with Pd/C (10%, 165 mg) in ethanol (8.0 mL) 
under H2 for 5.5 h. Filtration (Celite) and evaporation gave 166n (120 mg, 87%) as a 
buff solid: Rf = 0.9 (EtOAc / petroleum ether 1:4); mp 141-142°C; 1H NMR (CDCl3)  
4.21 (3 H, s, Me), 6.95 (1 H, dd, J = 7.5, 0.8 Hz, 6-H), 7.34 (1 H, t, J = 7.7 Hz, 7-H), 7.65 (1 
H, s, 4-H), 7.71 (3 H, m, 8-H + Ph 3,5-H2), 8.25 (2 H, d, J = 8.2 Hz, Ph 2,6-H2); 13C NMR 
(CDCl3) (HSQC / HMBC)  53.70 (Me), 104.97 (4-C), 114.40 (6-C), 114.58 (8-C), 119.96 
(8a-C), 123.26 (q, J = 269.9 Hz, CF3), 125.48 (q, J = 3.9 Hz, Ph 3,5-C2), 126.68 (Ph 2,6-C2), 
127.37 (7-C), 128.16 (4a-C), 129.86 (q, J = 31.9 Hz, Ph 4-C), 141.78 (5-C), 143.06 (Ph 1-
C), 145.21 (3-C), 160.97 (1-C); 19F NMR (CDCl3)  -62.40 (s, CF3); MS m/z 317.0907 (M - 
H) (C17H12F3N2O requires 317.0902). 
Hydrogenation of 1-methoxy-5-nitro-3-(4-methylphenyl)isoquinoline (141o): 5-
Amino-1-methoxy-3-(4-methylphenyl)isoquinoline (166o). Compound 141o (70.4 mg, 
0.24 mmol) was stirred vigorously with Pd/C (10%, 14 mg) in EtOH (5.0 mL) under H2 
for 5 h. Filtration (Celite) and evaporation gave 166o (51 mg, 81%) as a dark yellow 
solid: Rf = 0.2 (EtOAc/ petroleum ether 1:19); mp 172-174°C; 1H NMR (CDCl3) 2.38 (3 
H, s, PhMe), 4.17 (3 H, s, OMe), 6.89 (1 H, dd, J = 7.5, 1.0 Hz, 6-H), 7.25 (3 H, m, Ph 3,5-
H2, 7-H), 7.54 (1 H, s, 4-H), 7.65 (1 H, dt, J = 7.2, 1.0 Hz, 8-H), 8.00 (2 H, dd, J = 8.2, 1.8 
Hz, Ph 2,6-H2); 13C NMR (CDCl3) (HSQC / HMBC) 21.18 (PhMe), 53.51 (OMe), 103.35 
(4-C), 113.94 (6-C), 114.52 (8-C), 119.59 (8a-C), 126.40 (Ph 2,6-C2), 128.72 (7-C), 129.25 
(Ph 3,5-C2), 132.15 (4a-C), 136.98 (Ph 1-C), 138.09 (Ph 4-C), 141.42 (5-C), 147.82 (3-C), 
159.75 (1-C); MS m/z 287.1156 (M + Na) (C17H16N2ONa requires 287.1161). 
Hydrogenation of 1-methoxy-5-nitro-3-(4-methylphenyl)isoquinoline (141p): 5-
Amino-3-(2,6-dichlorophenyl)-1-methoxyisoquinoline (166p). Compound 141p (30.1 
mg, 0.09 mmol) was stirred vigorously with Pd/C (10%, 33 mg) in ethanol (5.0 mL) 
under H2 for 5.0 h. Filtration (Celite) and evaporation gave 166p (27.1 mg, 94%) as a 
dark orange solid: Rf = 0.9 (EtOAc / petroleum ether 1:4); mp 103-104°C; 1H NMR 
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(CDCl3)  4.12 (3 H, s, Me), 6.95 (1 H, dd, J = 7.5, 1.0 Hz, 6-H), 7.19 (1 H, d, J = 0.9 Hz, 4-
H), 7.25 (1 H, t, J = 8.6 Hz, Ph 4-H), 7.36 (1 H, t, J = 7.6 Hz, 7-H), 7.42 (2 H, d, J = 8.3 Hz, 
Ph 3,5- H2), 7.74 (1 H, dt, J = 8.2, 1.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC)  54.02 
(Me), 109.70 (4-C), 114.00 (6-C), 114.37 (8-C), 127.36 (7-C), 128.15 (Ph 3,5-C2), 129.30 
(Ph 4-C), 119.69 (8a-C), 127.62 (4a-C), 135.25 (Ph 2,6-C2), 138.92 (Ph 1-C), 141.65 (5-C), 
144.58 (3-C), 160.94 (1-C); MS m/z 321.0356 (M + H) (C16H13N2O35Cl37Cl requires 
321.0375), 319.0387 (M + H) (C16H13N2O35Cl2 requires 319.0405). 
5-Amino-3-phenylisoquinolin-1-one hydrobromide (167a). Compound 166a (38.4 mg, 
0.15 mmol) was stirred with HBr / AcOH (33%, 1.5 mL) at 65°C for 6 h. Evaporation 
yielded 167a (35.9 mg, 99%) as a yellowish brown solid: Rf = 0.7 (EtOAc / petroleum 
ether 1:1); mp 274-275C; IR νmax 3425 (NH), 2923 (NH3+), 1629 (CO); 1H NMR (CD3OD) 
7.10 (1 H, s, 4-H), 7.28 (1 H, d, J = 7.7 Hz, 6-H), 7.38 (1 H, t, J = 7.8 Hz, 7-H), 7.55 (3 H, 
m, Ph 3,4,5-H3), 7.80 (1 H, d, J = 7.6 Hz, 8-H), 7.87 (2 H, m, Ph 2,6-H2), 11.55 (1 H, s, N-
H); 13C NMR (CD3OD) (HSQC / HMBC)98.36 (4-C), 127.45 (4a-C), 127.67 (7-C), 128.13 
(Ph 2,6-C2), 128.96 (8-C), 129.46 (6-C), 130.32 (Ph 3,4,5-C3), 131.34 (Ph 4-C), 134.00 
(8a-C), 135.28 (Ph 1-C), 144.34 (5-C), 164.63 (1-C); MS m/z 259.0836 (M + H) 
(C15H12N2NaO requires 259.0848). 
5-Amino-3-(2-methoxyphenyl)isoquinolin-1-one hydrobromide (167b). Compound 
166b (33.5 mg, 0.12 mmol) was stirred with HBr / AcOH (33%, 1.1 mL) at 65°C for 5 h. 
Evaporation yielded 167b (31 mg, 72 %) as a pale buff solid: Rf = 0.4 (EtOAc / 
petroleum ether 4:1); mp 172-175 C; IR νmax 3372.43 (NH), 2922.13 (NH3+), 2845 (O-
CH3), 1634.25 (CO); 1H NMR (CD3OD) 3.91 (3 H, s, Me), 6.79 (1 H, d, J = 0.5 Hz, 4-H), 
7.11 (1 H, td, J = 7.5, 0.9 Hz, Ph 5-H), 7.18 (1 H, d, J = 8.3 Hz, Ph 3-H), 7.52 (1 H, td, J = 
7.6, 1.7 Hz, Ph 4-H), 7.56 (1 H, dd, J = 7.6, 1.7 Hz, Ph 6-H), 7.62 (1 H, t, J = 7.9 Hz, 7-H), 
7.82 (1 H, dd, J = 7.7, 1.2 Hz, 6-H), 8.44 (1 H, d, J = 7.3 Hz, 8-H); 13C NMR (CD3OD) (HSQC 
/ HMBC) 56.20 (Me), 99.86 (4-C), 112.74 (Ph 3-C), 122.06 (Ph 5-C), 124.11 (Ph 1-C), 
127.25 (8a-C), 127.33 (4a-C), 127.54 (7-C), 128.60 (6-C), 129.33 (8-C), 131.26 (Ph 6-C), 
132.91 (Ph 4-C), 134.01 (5-C), 142.77 (3-C), 158.49 (Ph 2-C), 163.82 (1-C); MS m/z 
267.1126 (M + H) (C16H15N2O2 requires 267.1135).  
5-Amino-3-(3-methoxyphenyl)isoquinolin-1-one hydrobromide (167c). Compound 
166c (31 mg, 0.11 mmol) was stirred with HBr / AcOH (33%, 1.1 mL) at 65°C for 5 h. 
Evaporation yielded 167c (29 mg, 73 %) as a pale buff solid: Rf = 0.7 (EtOAc / petroleum 
ether 4:1); mp 202-205C; IR νmax 3417 (NH), 2908 (NH3+), 2841 (O-Me), 1633 (CO); 1H 
NMR (CD3OD) 3.89 (3 H, s, Me), 6.13 (1 H, s, N-H), 6.95 (1 H, s, 4-H), 7.10 (1 H, dt, J = 
8.2, 0.6 Hz, Ph 4-H), 7.35 (2 H, m, Ph 2,6-H2), 7.46 (1 H, t, J = 7.9 Hz, Ph 5-H), 7.61 (1 H, 
t, J = 7.9 Hz, 7-H), 7.83 (1 H, dd, J = 7.7, 1.0 Hz, 6-H), 8.42 (1 H, d, J = 8.1 Hz, 8-H); 13C 
NMR (CD3OD) (HSQC / HMBC) 56.14 (Me), 98.49 (4-C), 113.73 (Ph 2-C), 116.98 (Ph 4-
C), 120.39 (Ph 6-C), 127.56 (8a-C), 127.66 (4a-C), 127.82 (7-C), 128.96 (6-C), 129.47 (8-
C), 131.60 (Ph 5-C), 134.01 (5-C), 136.68 (Ph 1-C), 144.29 (3-C), 161.82 (Ph 3-C), 164.54 
(1-C); MS m/z 267.1115 (M + H) (C16H13N2O2 requires 267.1135). 
5-Amino-3-(2-chlorophenyl)isoquinolin-1-one hydrobromide (167d). Compound 166d 
(40.4 mg, 0.14 mmol) was stirred with HBr / AcOH (33%, 1.6 mL) at 65°C for 5 h. 
Evaporation yielded 167d (47.5 mg, 95%) as a yellowish brown solid: Rf = 0.7 (EtOAc / 
petroleum ether 1:1); mp 227-228°C; IR νmax 3369 (NH), 2819 (NH3+), 1635 (C=O), 762 
(C-Cl); 1H NMR (CD3OD) 6.71 (1 H, s, 4-H), 7.51 (2 H, m, Ph 4,5-H2), 7.60 (2 H, m, Ph 
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3,6-H2), 7.66 (1 H, t, J = 8.0 Hz, 7-H), 7.85 (1 H, d, J = 7.5 Hz, 6-H), 8.45 (1 H, d, J = 8.5 
Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC)100.92 (4-C), 127.61 (8a-C), 127.80 (4a-C) 
128.14 (7-C), 128.55 (Ph 5-C), 128.83 (6-C), 129.34 (8-C), 131.22 (Ph 3-C), 132.35 (Ph 6-
C), 132.51 (Ph 4-C), 133.54 (5-C), 134.17 (Ph 2-C), 134.98 (Ph 1-C), 142.26 (3-C), 163.87 
(1-C); MS m/z 273.0597 (M + H) (C15H12N2O37Cl requires 273.0609), 271.0623 (M + H) 
(C15H12N2O35Cl requires 271.0638).  
5-Amino-3-(3-chlorophenyl)isoquinolin-1-one hydrobromide (167e). Compound 166e 
(38.5 mg, 0.14 mmol) was stirred with HBr / AcOH (33%, 1.5 mL) at 65°C for 5 h. 
Evaporation yielded 167e (46.1 mg, 97%) as a yellowish brown solid: Rf = 0.8 (EtOAc / 
petroleum ether 1:1); mp 328-330C; IR νmax 3441 (NH), 2852 (NH3+), 1676 (C=O), 778 
(C-Cl); 1H NMR (CD3OD) 6.93 (1 H, s, 4-H), 7.55 (2 H, m, Ph 4,5-H2), 7.63 (1 H, t, J = 7.5 
Hz, 7-H), 7.71 (1 H, m, Ph 6-H), 7.79 (1 H, d, J = 7.5 Hz, 6-H), 7.83 (1 H, s, Ph 2-H), 8.41 
(1 H, d, J = 8.0 Hz, 8-H); 13C NMR (CD3OD) (HSQC / HMBC)98.93 (4-C), 126.52 (Ph 6-
C),128.09 (7-C), 128.17 (Ph 2-C), 128.47 (6-C), 128.93 (8-C), 131.16 (Ph 4-C), 131.84 (Ph 
5-C), 133.56 (5-C), 136.19 (Ph 1-C), 137.24 (Ph 3-C), 142.63 (3-C), 166.31 (1-C); MS m/z 
273.0584 (M + H) (C15H12N2O37Cl requires 273.0609), 271.0616 (M + H) (C15H12N2O35Cl 
requires 271.0638). 
5-Amino-3-(3-aminocarbonylphenyl)isoquinolin-1-one hydrobromide (167f). Com-
pound 166f (11.2 mg, 0.04 mmol) was stirred with HBr / AcOH (33%, 1.5 mL) at 65°C 
for 16 h. Evaporation yielded 167f (13.5 mg, 99%) as an amber-coloured solid: Rf = 0.6 
(EtOAc / petroleum ether 2:3); mp >360 C; IR νmax 3351 (NH), 3048 (NH3+), 1664 
(C=O);mp >360C; IR (KBr) 3351, 3173, 1664 cm-1; 1H NMR (DMSO)  4.2 (3 H, br, 
+NH3), 7.11 (1 H, s, 4-H), 7.43 (2 H, m, Ph 4,5-H2), 7.55 (1 H, br, CONHH), 7.61 (1 H, t, J 
= 7.7 Hz, 7-H), 7.95 (3 H, m, 6,8-H2 + Ph 6-H), 8.03 (1 H, br, CONHH), 8.32 (1 H, s, Ph 2-
H), 11.63 (1 H, s, 2-H); 13C NMR (DMSO) (HSQC / HMBC)  98.16 (4-C), 121.83 (Ph 3-C), 
122.64 (Ph 5-C), 125.83 (Ph 2-C), 126.00 (6-C), 126.85 (Ph 4-C), 128.26 (8-C), 128.87 (7-
C), 129.29 (Ph 6-C), 133.85 (5-C), 134.93 (Ph 1-C), 139.18 (3-C), 162.33 (1-C), 167.52 
(CONH2); MS m/z 278.0947 (M - H)- (C16H12N3O2 requires 278.0930). 
5-Amino-3-(4-aminocarbonylphenyl)isoquinolin-1-one hydrobromide (167g). Com-
pound 166g (14 mg, 0.05 mmol) was stirred with HBr / AcOH (33%, 1.0 mL) at 65°C for 
16 h. Evaporation yielded 167g (17.0 mg, 99%) as an amber-coloured solid: Rf = 0.6 
(EtOAc / petroleum ether 2:3); mp 271-273C; IR νmax 3346 (NH), 3169 (NH3+), 1662 
(C=O); mp >230C; 1H NMR (DMSO)  4.4 (3 H, m, +NH3), 7.14 (1 H, d, J = 7.8 Hz, 6-H), 
7.17 (1 H, s, 4-H), 7.30 (1 H, t, J = 7.8 Hz, 7-H), 7.46 (1 H, br, CONHH), 7.66 (1 H, d, J = 
7.7 Hz, 8-H), 7.92 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 7.99 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 8.08 
(1 H, br, CONHH), 11.55 (1 H, bs, NH); 13C NMR (DMSO) (HSQC / HMBC) 98.81 (4-C), 
119.83 (8-C), 120.91 (6-C), 126.12 (Ph 4-C), 126.30 (Ph 2,6-C2), 127.09 (7-C), 127.89 (Ph 
3,5-C2), 134.48 (3-C), 136.30 (Ph 1-C), 138.15 (5-C), 162.50 (1-C), 167.13 (CONH2); MS 
m/z (M - H)- (C16H12N3O2 requires 278.0930). 
5-Amino-3-(2-trifluoromethylphenyl)isoquinolin-1-one hydrobromide (167h). 
Compound 166h (22.4 mg, 0.07 mmol) was stirred with hydrogen bromide in acetic 
acid (33%, 1.25 mL) at 65°C for 5 h. Evaporation yielded 167h (25.2 mg, 94%) as a buff 
solid: Rf = 0.8 (EtOAc / petroleum ether 1:1); mp 205-207C; IR νmax 3403 (NH), 2970 
(NH3+), 1637 (C=O), 1313, 1119, 1174 (C-F); 1H NMR (CD3OD) 6.65 (1 H, s, 4-H), 7.69 
(4 H, m, 7-H + Ph 4,5,6-H3), 7.85 (1 H, d, J = 8.5 Hz, 6-H), 7.88 (1 H, d, J = 8.0 Hz, Ph 3-H), 
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8.45 (1 H, d, J = 8.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC)100.84 (4-C), 125.24 (q, 
J = 271.3 Hz, CF3), 127.40 (q, J = 5.3 Hz, Ph 1-C), 127.56 (q, J = 4.8 Hz, Ph 3-C), 128.21 
(7-C), 128.94 (6-C), 129.36 (8-C), 131.44 (Ph 6-C), 130.10 (q, J = 30.6 Hz, Ph 2-C), 132.95 
(5-C), 133.23 (Ph 4-C), 133.50 (Ph 5-C), 141.90 (3-C), 163.54 (1-C); 19F NMR (CD3OD) -
59.36 (s, CF3); MS m/z 305.0872 (M + H)+ (C16H12F3N2O requires 305.0904). 
5-Amino-3-(3-trifluoromethylphenyl)isoquinolin-1-one hydrobromide (167i). 
Compound 166i (70.5 mg, 0.22 mmol) was stirred with HBr / AcOH (33%, 3.75 mL) at 
65°C for 7 h. Evaporation yielded 167i (82.4 mg, 97%) as a buff solid: Rf = 0.7 (EtOAc / 
petroleum ether 1:1); mp 315-317C; IR νmax 3412 (NH), 3170 (NH3+), 1671 (C=O), 1332, 
1170, 1119 (CF); 1H NMR (DMSO)  7.05 (1 H, d, J = 7.7 Hz, 6-H), 7.16 (1 H, s, 4-H), 7.25 
(1 H, t, J = 7.8 Hz, 7-H), 7.57 (1 H, d, J = 7.7 Hz, 8-H), 7.71 (1 H, t, J = 7.8 Hz, Ph 5-H), 
7.77 (1 H, d, J = 7.9 Hz, Ph 4-H), 8.11 (1 H, d, J = 8.0 Hz, Ph 6-H), 8.17 (1 H, s, Ph 2-H), 
11.56 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC)  99.07 (4-C), 116.52 (8-C), 
119.27 (6-C), 123.25 (8a-C), 123.26 (q, J = 3.9 Hz, Ph 2-C), 124.08 (q, J = 270.9 Hz, CF3), 
125.67 (q, J = 3.9 Hz, Ph 4-C), 126.19 (4a-C), 127.27 (7-C), 129.74 (q, J = 31.8 Hz, Ph 3-
C), 129.89 (Ph 5-C), 130.52 (Ph 6-C), 134.85 (5-C), 136.28 (Ph 1-C), 137.31 (3-C), 162.53 
(1-C); 19F NMR (DMSO)  -61.03 (s, CF3); MS m/z 303.0740 (M - H) (C16H10F3N2O 
requires 303.0743). 
5-Amino-3-(4-fluorophenyl)isoquinolin-1-one hydrobromide (167k). Compound 166k 
(65 mg, 0.24 mmol) was stirred with HBr / AcOH (33%, 3.5 mL) at 65°C for 5 h. 
Evaporation yielded 167k (80 mg, 98%) as a buff solid: Rf = 0.9 (EtOAc / petroleum 
ether 1:1); mp 127-128C; IR νmax 3439 (NH), 3062 (NH3+), 1338 (CF); 1H NMR (CD3OD) 
6.99 (1 H, s, 4-H), 7.34 (3 H, m, 8 & Ph 3,5-H3), 7.39 (1 H, t, J = 8.5 Hz, 7-H), 7.45 (1 H, 
d, J = 8.5 Hz, 6-H), 7.89 (2 H, m, Ph 2&6-H2), 11.71 (1 H, bs, NH); 13C NMR (DMSO) 
(HSQC / HMBC) 98.62 (4-C), 115.48 (8-C), 115.68 (d, J = 6.1 Hz, Ph 3,5-C2), 124.75 (Ph 
1-C), 125.72 (3-C), 126.66 (7-C), 128.99 (d, J = 17.2 Hz, Ph 2,6-C2), 130.11 (6-C), 137.96 
(Ph 4-C), 141.34 (5-C), 162.63 (1-C); 19F NMR (DMSO)  -112.47 (m, F); MS m/z 
253.0756 (M – H)- (C15H10FN2O requires 253.0777). 
5-Amino-3-(4-hydroxyphenyl)isoquinolin-1-one hydrobromide (167l). Compound 166l 
(55 mg, 0.21 mmol) was stirred with HBr / AcOH (33%, 2.5 mL) at 65°C for 16 h. 
Evaporation yielded 167l (68.5 mg, 98%) as a coffee-coloured solid: Rf = 0.7 (EtOAc / 
petroleum ether 1:1); mp > 360C; IR νmax 3421 (OH), 3291 (NH), 2927 (NH3+), 1630 
(C=O); 1H NMR (DMSO) 6.88 (3 H, m, 4-H & Ph 3,5-H2), 7.36 (2 H, m, 6,7-H2), 7.67 (2 
H, d, J = 9.0 Hz, Ph 2,6-H2), 7.88 (1 H, d, J = 9.0 Hz, 8-H), 11.46 (1 H, br s, NH); 13C NMR 
(CDCl3) (HSQC / HMBC)96.01 (4-C), 115.55 (Ph 3-5-C2), 124.59 (7-C), 125.36 (6-C), 
125.94 (8-C), 128.09 (Ph 2-6-H2), 134.26 (5-C), 139.99 (3-C), 158.69 (Ph 4-C), 162.45 (1-
C); MS m/z 253.0958 (M + H) (C15H13N2O2 requires 253.0977).  
5-Amino-3-(4-chlorophenyl)isoquinolin-1-one hydrobromide (167m). Compound 
166m (39 mg, 0. 14 mmol) was stirred with HBr / AcOH (33%, 2.0 mL) at 65°C for 6 h. 
Evaporation yielded 167m (47.1 mg, 98 %) as a reddish- brown solid: Rf = 0.7 (EtOAc/ 
petroleum ether 3:2); mp 311-312°C; IR νmax 3425 (NH), 2921 (NH3+), 1630 (C=O), 804 
(C-Cl); 1H NMR (DMSO) 7.05 (1 H, s, 4-H), 7.29 (1 H, d, J = 7.4 Hz, 6-H), 7.35 (1 H, t, J = 
7.7 Hz, 7-H), 7.58 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 7.79 (1 H, d, J = 7.7 Hz, 8-H), 7.84 (2 H, 
d, J = 8.6 Hz, Ph 2,6-H2), 11.57 (1 H, br s, N-H); 13C NMR (DMSO) (HSQC / HMBC) 98.36 
(4-C), 119.82 (8-C), 120.94 (6-H), 125.98 (8a-C), 126.92 (7-C), 127.68 (4a-C), 128.36 (Ph 
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2,6-C2), 128.75 (Ph 3,5-C2), 132.77 (Ph 1-C), 133.93 (Ph 4-C), 136.71 (5-C), 138.30 (3-C), 
160.61 (1-C); MS m/z 273.0596 (C15H12N2O37Cl requires 273.0609), 271.0622 (M + H) 
(C15H12N2O35Cl requires 271.0640). 
5-Amino-3-(4-trifluoromethylphenyl)isoquinolin-1-one hydrobromide (167n). Com-
pound 166n (85.2 mg, 0.27 mmol) was stirred with HBr / AcOH (33%, 4.0 mL) at 65°C 
for 7 h. Evaporation yielded 167n (100.7 mg, 98%) as a buff solid: Rf = 0.7 (EtOAc / pet-
roleum ether 1:1); mp >360C; ; IR νmax 3414 (NH), 3165 (NH3+), 1647 (C=O), 1327, 
1170, 1116 (CF); 1H NMR (DMSO)  7.17 (2 H, m, 4,6-H2), 7.32 (1 H, t, J = 7.5 Hz, 7-H), 
7.67 (1 H, d, J = 7.5 Hz, 8-H), 7.88 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 8.04 (2 H, d, J = 8.0 Hz, 
Ph 2,6-H2), 11.63 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC)  99.53 (4-C), 117.08 
(8-C), 118.87 (6-C), 123.51 (8a-C), 124.11 (q, J = 270.6 Hz, CF3), 125.64 (q, J = 3.5 Hz, Ph 
3,5-C2), 126.28 (4a-C), 127.41 (7-C + Ph 2,6-C2), 129.20 (q, J = 31.8 Hz, Ph 4-C), 136.82 
(Ph 1-C), 137.83 (3-C), 139.92 (5-C), 162.46 (1-C); 19F NMR (DMSO)  -61.02 (s, CF3); MS 
m/z 303.0756 (M - H) (C16H10F3N2O requires 303.0745). 
5-Amino-3-(4-methylphenyl)isoquinolin-1-one hydrobromide (167o). Compound 
166o (from HAP2-129-01) (45 mg, 0. 17 mmol) was stirred with HBr / AcOH (33%, 2.0 
mL) at 65°C for 5 h. Evaporation yielded 167o (29.4 mg, 69 %) as a reddish- brown 
solid: Rf = 0.8 (EtOAc / petroleum ether 1:1); mp 318-320°C; IR νmax 3425 (NH), 3192 
(NH3+), 1631 (C=O); 1H NMR (CD3OD) 2.50 (3 H, s, PhMe), 6.98 (1 H, s, 4-H), 7.44 (2 H, 
d, J = 7.9 Hz, Ph 3,5-H2), 7.65 (1 H, t, J = 7.9 Hz, 7-H), 7.75 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 
7.85 (1 H, dd, J = 7.7, 1.0 Hz, 6-H), 8.45 (1 H, d, J = 8.1 Hz, 8-H); 13C NMR (CD3OD) (HSQC 
/ HMBC) 21.34 (PhMe), 97.87 (4-C), 127.25 (8a-C), 127.51 (7-C), 127.94 (Ph 2,6-C2), 
128.25 (6-C), 128.35 (4a-C), 128.77 (8-C), 130.92 (Ph 3,5-C2), 132.45 (Ph 1-C), 133.72 
(5-C), 141.84 (Ph 4-C), 144.15 (3-C), 164.56 (1-C); MS m/z 251.1202 (M + H) (C16H15N2O 
requires 251.1184).  
5-Amino-3-(2,6-dichlorophenyl)isoquinolin-1-one hydrobromide (167p). Compound 
166p (12.7 mg, 0.04 mmol) was stirred with HBr / AcOH (33%, 1.0 mL) at 65°C for 5 h. 
Evaporation yielded 167p (9.0 mg, 58%) as an amber-coloured solid: Rf = 0.7 (EtOAc / 
petroleum ether 2:3); mp 226-228C; IR νmax 3372 (NH), 3071 (NH3+), 1635 (C=O), 786 
(CCl); 1H NMR (CD3OD) 6.73 (1 H, s, 4-H), 7.56 (1 H, t, J = 6.6 Hz, Ph 4-H), 7.63 (2 H, d, 
J = 7.0 Hz, Ph 3,5-H2), 7.74 (1 H, t, J = 7.9 Hz, 7-H), 7.91 (1 H, d, J = 7.5Hz, 6-H), 8.53 (1 
H, d, J = 8.0 Hz, 8-H); 13C NMR (CD3OD) (HSQC / HMBC) 101.69 (4-C), 127.63 (4a-C), 
128.44 (7-C), 128.98 (6-C), 129.47 (8-C), 129.57 (Ph 3,5-C2), 133.13 (Ph 4-C), 133.42 (5-
C), 133.88 (Ph 1-C), 136.46 (Ph 2,6-C2), 139.26 (3-C), 164.19 (1-C); MS m/z 327.0065 (M 
+ Na) (C15H1035Cl2N2ONa requires 327.0068). 
3-Chloro-5-nitroisoquinolin-1-one (168). 121 (505 mg, 2.1 mmol) was stirred with HBr 
/ AcOH (33%, 1.0 mL) at 65°C for 16 h. Evaporation and recrystallisation (EtOAc) 
yielded 168 (211 mg, 44%) as powdery yellow needles: Rf = 0.1 (EtOAc / petroleum 
ether 1:9); mp 271-272C; 1H NMR (CDCl3) 7.25 (1 H, s, 4-H), 7.68 (1 H, t, J = 8.0 Hz, 7-
H), 8.48 (1 H, dd, J = 8.0, 1.5 Hz, 6-H), 8.53 (1 H, ddd, J = 7.0, 1.5, 0.5 Hz, 8-H), 12.82 (1 
H, s, N-H); 13C NMR (CDCl3) (HSQC / HMBC) 102.65 (4-C), 126.29 (7-C), 130.19 (6-C), 
130.76 (4a, 8a-C2), 133.63 (8-C), 143.63 (5-C), 146.61 (3-C), 160.84 (1-C); MS m/z 
222.9870 (M - H) (C9H435ClN2O3 requires 222.9910).  
Mixture of aniline (170) and 4-chloroaniline (171). 1-Chloro-4-nitrobenzene (169) (230 
mg, 1.46 mmol) was stirred vigorously with Pd/C (10%, 2.6 mg) in EtOH (4 mL) under 
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H2 for 5 h at rt. Filtration (Celite) and evaporation gave 170: Rf = 0.1 (EtOAc/ 
petroleum ether 1:19); 1H NMR (DMSO)  7.24 (2 H, d, J = 7.6 Hz, 2,6-H2), 7.39 (3 H, t, J 
= 7.2 Hz, 3,4,5-H3); 13C NMR (DMSO) (HSQC/ HMBC) 121.50 (2,6-C2), 125.72 (1-C), 
129.50 (3,4,5-C3) and 171 (4-chloroaniline): Rf = 0.1 (EtOAc/ petroleum ether 1:19); 1H 
NMR (DMSO) 6.85 (2 H, dd, J = 6.7, 2.0 Hz, 2, 6-H2), 7.19 (2 H, d, J = 8.7 Hz, 3,5-H2); 
13C NMR (DMSO) (HSQC / HMBC) 118.63 (2,6-C2), 123.44 (1-C), 128.51 (3,5-C2), 
141.96 (4-C) in 50:50 proportions. 
4-Chloroaniline (171). 1-Chloro-4-nitrobenzene (169) (230 mg, 1.46 mmol) was stirred 
vigorously with Pt/C (1%, 23 mg) in EtOH (4 mL) under H2 for 5 h at rt. Filtration 
(Celite) and evaporation gave 4-chloroaniline as a colourless solid: Rf = 0.1 (EtOAc/ 
petroleum ether 1:19); mp 67-68°C (lit.279 mp 69-70°C); 1H NMR (DMSO) 6.57 (2 H, d, 
J = 8.8 Hz, 2,6-H2), 7.02 (2 H, d, J = 8.8 Hz, 3,5-H2); 13C NMR (DMSO) 115.51 (2,6-C2), 
119.18 (4-C), 128.49 (3,5-C2), 147.10 (1-C).  
1-Methoxy-5-nitro-3-(phenylethynyl)isoquinoline (172a). To 164 (100 mg, 0.35 mmol) 
in a dry flask was added Pd2Cl2(PPh3)2 (12.6 mg, 18 mol), CuI (6.72 mg, 35.3 mol) 
and sodium ascorbate (3.96 mg, 20 mol). Degassed THF (3.0 mL) and Pri2NH (2.0 mL) 
was added and the mixture was stirred at 40-50°C for 30 min, after which 
phenylacetylene (72.1 mg, 0.35 mmol) was added in one portion and the mixture was 
stirred for a further 16 h at 40-50°C. The evaporation residue, in CHCl3, was filtered 
through Celite. Chromatography (EtOAc / petroleum ether 1:99 → 1:19) gave 172a 
(100 mg, 93%) as a bright yellow solid: Rf = 0.3 (EtOAc / petroleum ether 1:19); mp 
153-154°C; 1H NMR (CDCl3) 4.22 (1 H, s, Me), 7.38 (3 H, m, Ph 3,4,5-H3), 7.60 (1 H, t, J 
= 8.0 Hz, 7-H), 7.64 (2 H, m, Ph 2,6-H2), 8.32 (1 H, s, 4-H), 8.48 (1 H, dd, J = 7.8, 1.2 Hz, 
6-H), 8.59 (1 H, dt, J = 7.1, 1.0 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC)54.63 (Me), 
89.26 (PhCH≡CH), 90.14 (PhCH≡CH), 113.94 (4-C), 120.27 (4a-C), 122.19 (Ph 1-C), 
125.51 (7-C), 128.39 (Ph 3,4&5-C3), 128.82 (6-C), 130.52 (8a-C), 131.30 (8-C), 132.13 
(Ph 2&6-C2), 137.55 (3-C), 144.15 (5-C), 160.76 (1-C); MS m/z 305.0901 (M + H) 
(C18H13N2O3 requires 305.0926). 
1-Methoxy-3-(phenylethynyl)isoquinoline (172b). PdCl2(PPh3)2 (29.5 mg, 42 mol), 
CuI (16 mg, 84 mol) and sodium ascorbate (10 mg, 54 mol) were added to 177 (200 
mg, 0.84 mmol) in a dry flask. Degassed THF (7.5 mL) and dry diisopropylamine (5.0 
mL) were added and the mixture was stirred at 50°C for 30 min. Phenylethyne (86 mg, 
0.84 mmol) was added and the mixture was stirred for 72 h at 50 °C. Filtration through 
Celite, evaporation and chromatography (ethyl acetate / petroleum ether 1:99 → 
1:49) gave 172b (80 mg, 37%) as a yellow oil: Rf = 0.9 (EtOAc / petroleum ether 1:99); 
1H NMR (CDCl3) (COSY / NOESY) 4.21 (3 H, s, Me), 7.39 (3 H, m, Ph 3,4,5-H3), 7.54 (1 
H, t, J = 8.2, 1.4 Hz, 7-H), 7.55 (1 H, s, 4-H), 7.66 (3 H, m, 6-H & Ph 2,6-H2), 7.70 (1 H, d, J 
= 8.0 Hz, 5-H), 8.24 (1 H, dt, J = 8.3 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 53.97 
(Me), 88.07 (ethyne 2-C), 89.60 (ethyne 1-C), 119.36 (8a-C), 119.45 (4-C), 122.79 (Ph 1-
C), 124.21 (8-C), 125.99 (5-C), 127.27 (7-C), 128.25 (Ph 3,5-C2), 128.51 (Ph 4-C), 130.79 
(6-C), 131.90 (Ph 2,6-C2), 133.17 (4a-C), 137.57 (3-C), 160.66 (1-C); MS m/z 260.1070 
(M + H) (C18H14NO requires 260.1075).  
Hydrogenation of 1-methoxy-5-nitro-3-(phenylethynyl)isoquinoline (172a): 5-Amino-
1-methoxy-3-phenethylisoquinoline (173). Compound 172a (65 mg, 0.21 mmol) was 
stirred vigorously with Pd/C (10%, 71.5 mg) in EtOH (5.0 mL) under H2 for 6 h. Filtration 
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(Celite) and evaporation gave 173 (51 mg, 87%) as a buff oil: Rf = 0.7 (EtOAc/ 
petroleum ether 1:4); 1H NMR (CDCl3) 3.15 (4 H, m, ethyl-H4), 4.15 (Me), 6.88 (1 H, 
dd, J = 7.5, 1.0 Hz, 6-H), 6.90 (1 H, s, 4-H), 7.26 (6 H, m, 7-H & Ph 2,3,4,5,6- H5), 7.69 (1 
H, d, J = 8.5 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 35.65 (CH2CH2Ph), 39.92 
(CH2CH2Ph), 53.47 (OMe), 105.65 (4-C), 113.64 (6-C), 114.38 (8-C), 118.79 (8a-C), 
125.72 (Ph 4-C), 125.85 (7-C), 128.24 (Ph 2,6-C2), 128.30 (4a-C), 128.51 (Ph 3,5-C2), 
140.79 (5-C), 142.17 (Ph 1-C), 150.72 (3-C), 160.69 (1-C); MS m/z 279.1560 (M + H) 
(C18H19N2O requires 279.1497). 
5-Amino-3-(2-phenylethyl)isoquinolin-1-one hydrobromide (175). Compound 173 (40 
mg, 0.14 mmol) was stirred with HBr / AcOH (33%, 2.0 mL) at 65°C for 16 h. 
Evaporation yielded 175 (35 mg, 70 %) as a dark mahogany coloured solid: Rf = 0.7 
(EtOAc / petroleum ether 1:1); mp >360C; IR νmax 3421 (NH), 3022 (NH3+), 1676 (C=O); 
1H NMR (CD3OD) (COSY / NOESY) 2.95 (2 H, m, CH2CH2Ph), 3.06 (2 H, m, CH2CH2Ph), 
6.48 (1 H, s, 4-H), 7.19 (1 H, t, J = 7.0 Hz, Ph 4-H), 7.24 (4 H, m, Ph 2,3,5,6-H5), 7.56 (1 H, 
t, J = 8.0 Hz, 7-H), 7.75 (1 H, dd, J = 8.0, 1.0 Hz, 6-H), 8.38 (1 H, d, J = 8.0 Hz, 8-H); 13C 
NMR (CD3OD) (HSQC / HMBC) 35.83 (CH2CH2Ph), 36.51 (CH2CH2Ph), 97.82 (4-C), 
126.76 (7-C), 127.07 (Ph 3-C), 127.48 (6-C), 129.36 (8-C), 129.43 (Ph 2,6-C2), 129.62 (Ph 
3,5-C2), 134.04 (5-C), 141.57 (Ph 1-C), 145.88 (3-C), 164.03 (1-C); MS m/z 265.1320 (M 
+ H) (C17H17N2O requires 265.1341). 
3-Bromo-1-methoxyisoquinoline (177). Method A. To 1,3-dibromoisoquinoline (162) 
(1.00 g, 3.48 mmol) stirring in dry MeOH (7.0 mL) was added Na (400 mg, 17.4 mmol) 
in dry MeOH (10 mL) at rt. The mixture was boiled under reflux for 16 h. The 
evaporation residue, in EtOAc, was washed thrice with brine and dried. Evaporation 
gave 177 (446 mg, 54%) as a white solid. Rf = 0.6 (EtOAc / petroleum ether 1:19); mp: 
70-72°C (lit.280 mp 73-74C); 1H NMR (CDCl3)4.14 (3 H, s, Me), 7.43 (1 H, d, J = 0.8 Hz, 
4-H), 7.52 (1 H, m, 7-H), 7.64 (2 H, m, 5,6-H2), 7.18 (1 H, dq, J = 8.3, 1.1 Hz, 8-H); 13C 
NMR (CDCl3) (HSQC / HMBC) 54.49 (Me), 117.25 (4-C), 118.37 (8a-C), 124.43 (8-C), 
125.25 (5-C), 126.80 (7-C), 131.24 (6-C), 132.21 (4a-C), 139.41 (3-C), 160.40 (1-C). 
3-Bromo-1-methoxyisoquinoline (177). Method B. Na (88 mg, 3.8 mmol) was 
dissolved with reaction in dry MeOH (2.5 mL). The resulting solution of NaOCH3 was 
added to 1,3-dibromoisoquinoline (162) (1.00 g, 3.5 mmol) in dry toluene (5 mL) in a 
sealed tube and the stirred mixture heated to 110°C for 2.5 h. The mixture was cooled 
to rt and H2O (0.25 mL) was added, followed by EtOAc. The solution was washed thrice 
with saturated brine and was dried. Evaporation of the solvent gave 177 (745 mg, 90%) 
as white crystals with properties as above. 
Methyl 2-bromo-3-methylbenzoate (190). SOCl2 (222 mg, 1.9 mmol) was added to 2-
bromo-3-methylbenzoic acid (188) (200 mg, 0.93 mmol) in dry MeOH (1.8 mL) at 5-10 
°C. The mixture was then stirred at 65°C for 3 h. The solvent was evaporated. The 
residue, in EtOAc, was washed thrice with saturated aq. NaHCO3 and dried. The solvent 
was evaporated to give 190 (180 mg, 85%) as a pale yellow oil (lit.281 oil): Rf = 0.9 
(EtOAc / petroleum ether 1:9); 1H NMR (CDCl3)  2.46 (3 H, s, 3-Me), 3.92 (3 H, s, 
OMe), 7.23 (1 H, t, J = 7.7 Hz, 5-H), 7.33 (1 H, dd, J = 7.6, 1.1 Hz, 4-H), 7.45 (1 H, dd, J = 
7.6, 1.2 Hz, 6-H); 13C NMR (CDCl3) (HSQC/ HMBC)  23.77 (3-Me), 52.49 (OMe), 123.06 
(1-C), 126.81 (5-C), 127.85 (6-C), 133.10 (4-C), 134.00 (2-C), 139.72 (3-C), 167.74 (C=O). 
 
 
- 245 - 
 
3,N-Dimethoxybenzamide (196a). Methoxylamine hydrochloride (136 mg, 1.6 mmol) 
was stirred with 3-methoxybenzoyl chloride (195a) (256 mg, 1.5 mmol) in DCM (1.0 
mL). After 15 min, the mixture was cooled to 0°C and pyridine (269 mg, 3.4 mmol) 
added dropwise; the mixture was then warmed to rt. After 2 h, the mixture was 
diluted with DCM, washed with H2O and dried (sodium sulfate). Evaporation and 
chromatography (EtOAc / petroleum ether 1:19 → 2:3) gave 196a (137 mg, 52%) as a 
pale yellow oil (lit.282 oil): Rf = 0.1 (EtOAc / petroleum ether 1:4); 1H NMR (CDCl3)  3.78 
(3 H, s, 3-OMe), 3.81 (3 H, s, N-OMe), 7.00 (1 H, d, J = 7.0 Hz, 4-H), 7.27 (3 H, m, 2,5,6-
H3), 9.76 (1 H, br, NH); 13C NMR (CDCl3) (HSQC / HMBC)  55.40 (3-OMe), 64.36 (N-
OMe), 112.24 (4-C), 118.34 (2-C), 119.05 (6-C), 129.63 (5-C), 133.15 (1-C), 159.75 (3-C), 
166.28 (C=O).  
N-Methoxybenzamide (196b). To a stirred solution of benzoyl chloride (195b) (0.21 
mL, 1.78 mmol) in CH2Cl2 at rt was added N-methoxyamine hydrochloride (165 mg, 
1.97 mmol). After 15 min, the mixture was cooled to 0°C and pyridine (0.34 mL, 4.1 
mmol) was added dropwise. The mixture was warmed to rt. After 2 h, the reaction 
mixture was diluted with DCM, washed with H2O and dried. Evaporation and 
chromatography (EtOAc: petroleum ether 1:19 → 2:3) gave 196b (92.5 mg, 34%) as a 
yellow oil (lit.283 oil): Rf = 0.1 (EtOAc / petroleum ether 1:4); 1H NMR (CDCl3) 3.85 (3 
H, s, Me), 7.41 (2 H, t, J = 7.5 Hz, 3,5-H2), 7.50 (1 H, t, J = 7.5 Hz, 4-H), 7.74 (2 H, d, J = 
7.5 Hz, 2,6-H2), 9.25 (1 H, bs, NH); 13C NMR (CDCl3) (HSQC / HMBC) 64.50 (Me), 
127.07 (2,6-C2), 128.64 (3,5-C2), 131.79 (1-C), 132.05 (4-C), 166.52 (C=O). 
N,7-Dimethoxy-4-methyl-3-phenylisoquinolin-1-one (197a). To 196a (110 mg, 0.61 
mmol) was added Pd(OAc)2, (13.7 mg, 61 µmol) and NaI (90.9 mg, 0.61 mmol). Dry 
DMF (3 mL) was added and the mixture was allowed to reach 120 °C over 30 min, then 
1-phenylpropyne (211.5 mg, 0.21 mL, 1.82 mmol) was added dropwise and mixture 
was stirred for a further 72 h. Filtration through Celite, followed by chromatography 
(EtOAc: petroleum ether 1:19 → 3:17) gave 197a (31.5 mg, 18%) as a buff solid. Rf = 
0.3 (EtOAc / petroleum ether 1:4); mp 126-128°C; 1H NMR (CDCl3) 2.07 (3 H, s, 4-Me), 
3.66 (3 H, s, N-OMe), 3.95 (3 H, s, 7-OMe), 7.32 (1 H, dd, J = 8.9, 2.8 Hz, 6-H), 7.38 (2 H, 
m, Ph 3,5-H2), 7.46 (3 H, m, Ph 2,4,6-H3), 7.63 (1 H, d, J = 8.9 Hz, 5-H), 7.93 (1 H, d, J = 
2.8 Hz, 8-H); 13C NMR (CDCl3) (HSQC / HMBC) 14.44 (4-Me), 55.68 (7-OMe), 63.19 (N-
OMe), 107.75 (8-C), 110.27 (4-C), 122.77 (6-C), 125.28 (5-C), 127.83 (8a-C), 128.06 (Ph 
2,6-C2), 128.62 (Ph 4-C), 130.30 (Ph 3,5-C2), 130.48 (4a-C), 132.27 (Ph 1-C), 136.80 (3-
C), 157.62 (7-C), 158.50 (1-C); MS m/z 318.1101 (C18H17NO3Na requires 318.1106), 
296.1281 (C18H18NO3 requires 296.1287).  
2-Methoxy-4-methyl-3-phenylisoquinolin-1-one (197b). Compound 196b (92.5 mg, 
0.61 mmol), Pd(OAc)2 (13.7 mg, 61 µmol) and NaI (92 mg, 0.61 mmol) in dry DMF (3.0 
mL) was heated to 120°C during 30 min. 1-Phenylpropyne (213 mg, 1.8 mmol) was 
added dropwise and mixture was stirred at 120°C for 72 h. Filtration through Celite, 
followed by chromatography (EtOAc / petroleum ether 1:24 → 1:9) and recrystallisat-
ion (EtOAc) gave 197b (30.5 mg, 19%) as a pale buff solid: Rf = 0.5 (EtOAc / petroleum 
ether 1:4); mp 142-145°C (lit.226 177-178C); 1H NMR (CDCl3)  2.09 (3 H, s, 4-Me), 3.67 
(3 H, s, OMe), 7.40 (2 H, m, Ph 3,5-H2), 7.47 (3 H, m, Ph 2,4,6-H3), 7.53 (1 H, m, 7-H), 
7.71 (2 H, m, 5,6-H2), 8.55 (1 H, dt, J = 7.9, 0.9 Hz, 8-H; 13C NMR (CDCl3) (HSQC / HMBC) 
 14.37 (4-Me), 63.28 (OMe), 110.28 (4-C), 123.57 (5-C), 126.61 (7-C), 126.63 (8a-C), 
127.99 (8-C), 128.14 (Ph 2,6-C2), 128.75 (Ph 4-C), 130.10 (Ph 3,5-C2), 132.24 (4a-C), 
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132.34 (6-C), 136.44 (Ph 1-C), 139.15 (3-C), 157.99 (1-C); MS m/z 266.1167 (M + H) 
(C17H16NO2 requires 266.1181). 
3-Methoxy-N,N,2-trimethylbenzamide (205a). SOCl2 (2.74 g, 23 mmol) was added to 
3-methoxy-2-methylbenzoic acid (204a) (1.00 g, 6.0 mmol) at 0°C. The mixture was 
heated at reflux for 16 h, then the excess SOCl2 was evaporated. The residue, in DCM 
(3.0 mL), was added dropwise to a stirred solution of dimethylamine in H2O (40%, 3.7 
mL) at 10°C. The mixture was then stirred at rt for 3.5 h. The mixture was diluted with 
DCM, then washed thrice with H2O and dried. The solvent was evaporated to give 205a 
(980 mg, 85%) as a pale yellow oil: Rf = 0.9 (EtOAc / petroleum ether 1:4); 1H NMR 
(CDCl3)  2.12 (3 H, s, 2-Me), 2.81 (3 H, s, NMe), 3.12 (3 H, s, NMe), 3.82 (3 H, s, OMe), 
6.76 (1 H, dd, J = 7.6, 0.8 Hz, 4-H), 6.81 (1 H, d, J = 8.2 Hz, 6-H), 7.18 (1 H, t, J = 7.6 Hz, 
5-H); 13C NMR (CDCl3) (HSQC / HMBC)  12.42 (Me), 34.44 (N-Me), 38.24 (N-Me), 55.44 
(OMe), 110.10 (6-C), 117.73 (4-C), 122.69 (2-C), 126.97 (5-C), 137.99 (1-C), 157.76 (3-
C), 171.23 (C=O); MS m/z 216.0988 (M + Na) (C11H15NNaO2 requires 216.0995). 
2,3,N,N-Tetramethylbenzamide (205b). SOCl2 (3.0 g, 25 mmol) was added to 2,3-
dimethylbenzoic acid (180c) (1.00 g, 6.7 mmol) at 0°C. The mixture was then heated at 
reflux for 16 h, then the excess SOCl2 was evaporated. The residue, in DCM (1.0 mL), 
was added dropwise to a stirred solution of dimethylamine in H2O (40 %, 3.7 mL) at 0-
20 °C. The mixture was then stirred at rt for 1 h. The mixture was diluted with DCM, 
then washed thrice with H2O and dried. The solvent was evaporated to give 205b (990 
mg, 84%) as a pale yellow oil: Rf = 0.9 (EtOAc / petroleum ether 1:4); 1H NMR (CDCl3) 
(COSY / NOESY)  2.16 (3 H, s, 2-Me), 2.27 (3 H, s, 3-Me), 2.81 (3 H, s, N-Me), 3.12 (3 H, 
s, N-Me’), 6.99 (1 H, dd, J = 7.2, 1.8 Hz, 4-H), 7.10 (1 H, t, J = 7.5 Hz, 5-H), 7.13 (1 H, dd, 
J = 7.6, 1.8 Hz, 6-H); 13C NMR (CDCl3) (HSQC / HMBC)  16.00 (2-Me), 20.03 (3-Me), 
34.48 (N-Me’), 38.37 (N-Me), 123.40 (4-C), 125.82 (5-C), 130.01 (6-C), 132.25 (2-C), 
137.02 (1-C), 137.42 (3-C), 171.99 (C=O); MS m/z 178.1226 (M + H) (C11H16NO requires 
178.1232). 
3-Fluoro-2,N,N-trimethylbenzamide (205c). Thionyl chloride (3.0 g, 25 mmol) was 
added to 3-fluoro-2-methylbenzoic acid (204c) (1.00 g, 6.5 mmol) at 0°C. The mixture 
was heated at reflux for 16 h, then the excess thionyl chloride was evaporated. The 
residue, in DCM (1.0 mL), was added dropwise to a stirred solution of dimethylamine 
in H2O (40%, 3.7 mL) at 10°C. The mixture was then stirred at rt for 2.5 h. The mixture 
was diluted with DCM, then washed thrice with H2O and dried. The solvent was 
evaporated to give 205c (1.00 g, 85%) as a pale orange oil: Rf = 0.9 (EtOAc / petroleum 
ether 1:4); 1H NMR (CDCl3)  2.19 (3 H, d, J = 2.0 Hz, 2-Me), 2.82 (3 H, s, NMe), 3.13 (3 
H, s, NMe), 6.96 (1 H, d, J = 7.6 Hz, 6-H), 7.01 (1 H, ddd, J = 7.4, 6.1, 0.8 Hz, 4-H), 7.18 (1 
H, m, 5-H); 13C NMR (CDCl3) (HSQC / HMBC)  11.20 (d, J = 4.5 Hz, 2-Me), 34.54 (N-Me), 
38.28 (N-Me), 115.31 (d, J = 22.5 Hz, 4-C), 121.39 (d, J = 3.6 Hz, 6-C), 121.59 (d, J = 18.3 
Hz, 2-C), 127.45 (d, J = 8.6 Hz, 5-C), 138.90 (d, J = 3.9 Hz, 1-C), 161.25 (d, J = 244.5 Hz, 3-
C), 169.98 (d, J = 3.3 Hz, C=O); 19F NMR (CDCl3)  -115.66 (d, J = 6.1 Hz, 3-F); MS m/z (M 
+ H) 182.0973 (C10H13FNO requires 182.0976). 
5-Methyl-3-phenylisoquinolin-1-one (206a). Butyllithium (1.6 M in hexanes, 0.90 mL, 
1.4 mmol) was added to dry diisopropylamine (172 mg, 1.7 mmol) in dry THF (2.0 mL) 
at -78C and the mixture was stirred at this temperature for 10 min. Compound 205b 
(250 mg, 1.4 mmol) in dry THF (2.0 mL) was added and the mixture was stirred for 1 h 
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at -78°C. Benzonitrile (144 mg, 1.4 mmol) in dry THF (2.0 mL) was added at -78 °C and 
the mixture was stirred for 1 h at this temperature, then at rt for 2 h. H2O (1.0 mL) was 
added. The mixture was extracted with DCM. The extract was washed thrice with 
saturated brine and dried. The solvent was evaporated and the solid material was 
recrystallised (EtOH, 25 mL) to give 206a (68 mg, 20%) as white crystals: mp 214-
215°C; IR νmax 3452 (NH), 1653 (C=O); 1H NMR (DMSO) (COSY / NOESY)  2.56 (3 H, s, 
Me), 6.86 (1 H, s, 4-H), 7.37 (1 H, t, J = 7.7 Hz, 7-H), 7.49 (3 H, m, Ph 3,4,5-H3), 7.56 (1 H, 
d, J = 7.1 Hz, 6-H), 7.82 (2 H, dd, J = 6.6, 1.6 Hz, Ph 2,6-H2), 8.07 (1 H, d, J = 8.0 Hz, 8-H), 
11.60 (1 H, s, N-H); 13C NMR (DMSO) (HSQC / HMBC)  18.76 (Me), 100.00 (4-C), 124.57 
(8-C), 125.00 (8a-C), 125.90 (7-C), 126.86 (Ph 2,6-C2), 128.72 (Ph 3,5-C2), 129.21 (Ph 4-
C), 133.20 (6-C), 133.75 (4a-C), 134.20 (Ph 1-C), 136.61 (5-C), 139.87 (3-C), 162.94 (1-
C); MS m/z 258.0834 (M + Na) (C16H13NNaO requires 258.0889). 
3-(4-Chlorophenyl)-5-methylisoquinolin-1-one (206b). Butyllithium (1.6 M in hexanes, 
1.1 mL, 1.7 mmol) was added to dry diisopropylamine (202 mg, 2.0 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (300 mg, 1.7 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Chlorobenzonitrile (233 mg, 1.7 mmol) in dry THF (2.0 
mL) was added at -78°C and the mixture was stirred for 1 h at this temperature, then 
at rt for 2 h. H2O (1.0 mL) was added, followed by CH2Cl2 (20 mL). The precipitate was 
collected by filtration and dried to give 206b (456 mg, 99%) as a white solid. Rf = 0.6 
(EtOAc / petroleum ether 3:7); mp >360°C; IR νmax 3479 (NH), 1668 (C=O), 746 (CCl); 1H 
NMR (DMSO) (COSY)  2.61 (3 H, s, Me), 6.93 (1 H, s, 4-H), 7.44 (1 H, t, J = 7.6 Hz, 7-H), 
7.61 (3 H, d, J = 8.5 Hz, 6-H + Ph 2,6-H3), 7.90 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 8.12 (1 H, d, 
J = 7.8 Hz, 8-H), 11.70 (1 H, s, N-H); 13C NMR (DMSO) (HSQC / HMBC)  18.80 (Me), 
100.49 (4-C), 124.60 (8-C), 125.11 (8a-C), 126.19 (7-C), 128.73 (Ph 2,6-C2), 128.78 (Ph 
3,5-C2), 133.01 (4a-C), 133.34 (6-C), 133.96 (Ph 1,4-C2), 136.49 (5-C), 138.67 (3-C), 
162.95 (1-C); MS m/z 268.0533 270.0499 (M – H)- (C16H1137ClNO requires 270.0500), (M 
– H)- (C16H1135ClNO requires 268.0535). 
3-(2-Chlorophenyl)-5-methylisoquinolin-1-one (206c). Butyllithium (1.6 M in hexanes, 
0.7 mL, 1.1 mmol) was added to dry diisopropylamine (141 mg, 1.4 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 2-Chlorobenzonitrile (155 mg, 1.1 mmol) in dry THF (2.0 
mL) was added at -78°C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was washed (EtOH, 20 mL) and dried to give 206c (4.9 mg, 2%) as a white solid: 
mp 178-180°C; IR νmax 3432 (NH), 1658 (C=O), 746 (CCl); 1H NMR (DMSO) (COSY) 2.53 
(3 H, s, Me), 6.58 (1 H, s, 4-H), 7.41 (1 H, t, J = 7.7 Hz, 7-H), 7.47 (1 H, td, J = 7.5, 1.3 Hz, 
Ph 4-H), 7.51 (1 H, td, J = 7.5, 2.0 Hz, Ph 5-H), 7.59 (3 H, m, 6-H + Ph 3,6-H2), 8.08 (1 H, 
d, J = 8.0 Hz, 8-H), 11.59 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.69 (Me), 
102.43 (4-C), 124.61 (8-C), 125.33 (8a-C), 126.25 (7-C), 127.34 (Ph 4-C), 129.70 (Ph 6-
C), 130.84 (Ph 5-C), 131.56 (Ph 3-C), 132.29 (Ph 2-C), 133.22 (6-C), 133.69 (4a-C), 
134.24 (Ph 1-C), 136.31 (5-C), 138.15 (3-C), 162.24 (1-C); MS m/z 292.0500 (M + Na) 
(C16H12NNaO35Cl requires 292.0505).  
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3-(3-Chlorophenyl)-5-methylisoquinolin-1-one (206d). Butyllithium (1.6 M in hexanes, 
0.7 mL, 1.1 mmol) was added to dry diisopropylamine (141 mg, 1.4 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 3-Chlorobenzonitrile (155 mg, 1.1 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was recrystallised (EtOH, 30 mL) to give 206d (33 mg, 11%) as a white solid: mp 
275-276°C; IR νmax 3471 (NH), 1668 (C=O), 778 (CCl); 1H NMR (DMSO) (COSY) 2.57 (3 
H, s, Me), 6.93 (1 H, s, 4-H), 7.39 (1 H, t, J = 7.6 Hz, 7-H), 7.52 (2 H, m, Ph 4,5-H2), 7.57 
(1 H, d, J = 7.2 Hz, 6-H), 7.80 (1 H, m, Ph 6-H), 7.93 (1 H, s, Ph 2-H), 8.07 (1 H, d, J = 8.0 
Hz, 8-H), 11.61 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.82 (Me), 100.92 (4-
C), 124.57 (8-C), 125.28 (8a-C), 125.64 (Ph 6-C), 126.32 (7-C), 126.74 (Ph 2-C), 129.01 
(Ph 4-C), 130.54 (Ph 5-C), 133.33 (6-C), 133.55 (Ph 1-C), 134.14 (4a-C), 136.20 (Ph 3-C), 
136.41 (5-C), 138.31 (3-C), 162.87 (1-C); MS m/z 292.0453 (M + Na) (C16H1235ClNNaO 
requires 292.0505), 270.0661 (M + H) (C16H1335ClNO requires 270.0686). 
3-(2,6-Dichlorophenyl)-5-methylisoquinolin-1-one (206e). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (141 mg, 1.4 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 2,6-Dichlorobenzonitrile (194 mg, 1.1 mmol) in dry THF 
(2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This 
mixture was washed thrice with saturated brine and dried. The solvent was 
evaporated and the residue was recrystallised (EtOH, 20 mL) to give 206e (35 mg, 10%) 
as a pale buff solid: mp 202-204°C; IR νmax 3458 (NH), 1634 (C=O), 783 & 754 (CCl); 1H 
NMR (DMSO) (COSY) 2.47 (3 H, s, Me), 6.58 (1 H, s, 4-H), 7.43 (1 H, t, J = 7.6 Hz, 7-H), 
7.55 (1 H, t, J = 7.2 Hz, Ph 4-H), 7.58 (1 H, d, J = 7.3 Hz, 6-H), 7.59 (2 H, d, J = 7.6 Hz, Ph 
3,5-H2), 8.09 (1 H, d, J = 7.9 Hz, 8-H), 11.62 (1 H, br, NH); 13C NMR (DMSO) (HSQC / 
HMBC) 18.66 (Me), 102.81 (4-C), 124.61 (8-C), 125.58 (8a-C), 126.45 (7-C), 128.28 (Ph 
3,5-C2), 131.67 (Ph 4-C), 133.19 (Ph 1-C), 133.29 (6-C), 133.75 (4a-C), 134.69 (Ph 2,6-
C2), 135.20 (3-C), 136.24 (5-C), 162.37 (1-C); MS m/z 326.0991 (M + Na) 
(C16H1135Cl2NNaO requires 326.0115), 304.0286 ((M + H) (C16H1235Cl2NO requires 
304.0296). 
5-Methyl-3-(4-trifluoromethylphenyl) isoquinolin-1-one (206f). Butyllithium (1.6 M in 
hexanes, 1.1 mL, 1.7 mmol) was added to dry diisopropylamine (202 mg, 2.0 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (300 mg, 1.7 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Trifluoromethylbenzonitrile (289 mg, 1.7 mmol) in dry 
THF (2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this 
temperature, then at rt for 16 h. H2O (1.0 mL) was added. The mixture was extracted 
with CH2Cl2. The extract was washed thrice with saturated brine and dried. The solvent 
was evaporated and residue was recrystallised (EtOH, 25 mL) to give 206f (242 mg, 
47%) as white crystals: Rf = 0.9 (EtOAc / petroleum ether 2:3); mp 251-252°C; IR νmax 
3291 (NH), 1642 (C=O), 1330, 1165, 1066 (CF); 1H NMR (DMSO) (COSY)  2.56 (3 H, s, 
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Me), 6.96 (1 H, s, 4-H), 7.40 (1 H, t, J = 7.6 Hz, 7-H), 7.57 (1 H, d, J = 7.2 Hz, 6-H), 7.84 (2 
H, d, J = 8.3 Hz, Ph 3,5-H2), 8.03 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.08 (1 H, d, J = 8.0 Hz, 8-
H), 11.75 (1 H, bs, N-H); 13C NMR (DMSO) (HSQC / HMBC) 18.77 (Me), 101.54 (4-C), 
124.62 (8-C), 125.23 (q, J = 295.9 Hz, CF3), 125.51 (8a-C), 125.56 (q, J = 3.6 Hz, Ph 3,5-
C2), 126.54 (7-C), 129.25 (q, J = 31.6 Hz, Ph 4-C), 133.40 (6-C), 134.21 (4a-C), 136.29 (5-
C), 138.10 (Ph 1-C), 138.36 (3-C), 162.91 (1-C); 19F NMR (DMSO) -61.0808 (s, CF3); MS 
m/z 302.0808 (M – H)- (C17H11F3NO requires 302.0793). 
5-Methyl-3-(4-methylphenyl)isoquinolin-1-one (206g). Butyllithium (1.6 M in hexanes, 
0.9 mL, 1.4 mmol) was added to dry diisopropylamine (172 mg, 1.7 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (250 mg, 1.4 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Methylbenzonitrile (164 mg, 1.4 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was recrystallised (EtOH, 30 mL) to give 206g (90 mg, 26%) as off-white 
crystals: mp 205-207°C; IR νmax 3517 (NH), 1632 (C=O); 1H NMR (DMSO) (COSY) 2.36 
(3 H, s, Ph-Me), 2.55 (3 H, s, 5-Me), 6.82 (1 H, s, 4-H), 7.30 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 
7.35 (1 H, t, J = 7.6 Hz, 7-H), 7.54 (1 H, d, J = 7.2 Hz, 6-H), 7.72 (2 H, d, J = 8.2 Hz, Ph 2,6-
H2), 8.06 (1 H, d, J = 8.0 Hz, 8-H), 11.54 (1 H, br, N-H); 13C NMR (DMSO) (HSQC / HMBC) 
18.86 (Ph-Me), 20.85 (5-Me), 99.48 (4-C), 124.62 (8-C), 124.89 (8a-C), 125.79 (7-C), 
126.76 (Ph 2,6-C2), 129.36 (Ph 3,5-C2), 131.38 (Ph 1-C), 133.23 (6-C), 133.69 (4a-C), 
136.77 (5-C), 138.94 (Ph 4-C), 139.92 (3-C), 163.05 (1-C); MS m/z 250.1226 (M + H) 
(C17H16NO requires 250.1232). 
3-(4-Bromophenyl)-5-methylisoquinolin-1-one (206h). Butyllithium (1.6 M in hexanes, 
0.9 mL, 1.4 mmol) was added to dry diisopropylamine (162 mg, 1.6 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (241 mg, 1.4 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Bromobenzonitrile (248 mg, 1.4 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM (20 mL). The 
solid was collected by filtration, then recrystallised (EtOH, 20 mL) and dried to give 
206h (181 mg, 42%) as a white solid: mp 278-279°C; IR νmax 3462 (NH), 1665.08 (CO), 
747.8 (CBr); 1H NMR (DMSO) (COSY) 2.55 (3 H, s, Me), 6.88 (1 H, s, 4-H), 7.38 (1 H, t, J 
= 7.7 Hz, 7-H), 7.56 (1 H, d, J = 7.2 Hz, 6-H), 7.69 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 7.78 (2 H, 
d, J = 8.5 Hz, Ph 3,5-H2), 8.07 (1 H, d, J = 8.0 Hz, 8-H), 11.59 (1 H, br, NH); 13C NMR 
(DMSO) (HSQC / HMBC) 18.81 (Me), 100.47 (4-C),122.66 (Ph 4-C), 124.62 (8-C), 
125.13 (8a-C), 126.20 (7-C), 129.03 (Ph 3,5-C2), 131.66 (Ph 2,6-C2), 133.34 (6-C), 133.43 
(Ph 1-C), 133.97 (4a-C), 136.51 (5-C), 138.81 (3-C), 162.99 (1-C); MS m/z 335.9966 (M + 
Na) (C16H1279BrNNaO requires 336.0000). 
3-(4-Methoxyphenyl)-5-methylisoquinolin-1-one (206i). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (141 mg, 1.4 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Methoxybenzonitrile (151 mg, 1.1 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
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at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was washed (EtOH, 20 mL) to give 206i (48 mg, 17%) as a white solid: mp 207-
208°C; IR νmax 3432 (NH), 1654 (C=O); 1H NMR (DMSO) (COSY) 2.54 (1 H, s, 5-Me), 
3.82 (3 H, s, OMe), 6.77 (1 H, s, 4-H), 7.04 (2 H, d, J = 8.8 Hz, Ph 3,5-H2), 7.33 (1 H, t, J = 
7.6 Hz, 7-H), 7.53 (1 H, d, J = 7.1 Hz, 6-H), 7.78 (2 H, d, J = 8.8 Hz, Ph 2,6-H2), 8.05 (1 H, 
d, J = 8.0 Hz, 8-H), 11.45 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.81 (5-Me), 
55.34 (OMe), 98.87 (4-C), 114.15 (Ph 3,5-C2), 124.57 (8-C), 124.63 (8a-C), 125.51 (7-C), 
126.51 (Ph 1-C), 128.23 (Ph 2,6-C2), 133.15 (6-C), 133.49 (4a-C), 136.86 (5-C), 139.70 
(3-C), 160.14 (Ph 4-C), 163.02 (1-C); MS m/z 553.2099 (2 M + Na) (C34H30N2NaO4 
requires 553.2104); 288.0994 (M + Na) (C17H15NNaO2 requires 288.1000), 266.1179 (M 
+ H) (C17H16NO2 requires 266.1181). 
5-Methyl-3-(pyridin-4-yl)isoquinolin-1-one (206j). Butyllithium (1.6 M in hexanes, 0.7 
mL, 1.1 mmol) was added to dry diisopropylamine (142 mg, 1.4 mmol) in dry THF (2.0 
mL) at -78C and the mixture was stirred at this temperature for 10 min. Compound 
205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture was stirred 
for 1 h at -78°C. 4-Cyanopyridine (118 mg, 1.1 mmol) in dry THF (2.0 mL) was added at 
-78 °C and the mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O 
(1.0 mL) was added. The mixture was diluted with DCM. This mixture was washed 
thrice with saturated brine and dried. The solvent was evaporated and the residue was 
recrystallised (EtOH, 20 mL) to give 206j (16.5 mg, 6%) as white crystals: mp 268-
269°C; IR νmax 3450 (NH), 1654 (CO); 1H NMR (DMSO) (COSY) 2.59 (3 H, s, Me), 7.11 (1 
H, s, 4-H), 7.44 (1 H, t, J = 7.7 Hz, 7-H), 7.60 (1 H, d, J = 7.2 Hz, 6-H), 7.87 (2 H, d, J = 6.2 
Hz, Ph 3,5-H2), 8.10 (1 H, d, J = 8.0 Hz, 8-H), 8.69 (2 H, d, J = 6.2 Hz,, Ph 2,6-H2), 11.70 (1 
H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.76 (Me), 101.87 (4-C), 120.96 
(pyridine 3,5-C2), 124.65 (8-C), 125.83 (8a-C), 126.91 (7-C), 133.49 (6-C), 134.50 (4a-C), 
136.06 (5-C), 137.06 (pyridine 1-C), 141.03 (3-C), 150.13 (pyridine 2,6-C2), 162.85 (1-C); 
MS m/z 235.0864 (M – H)- (C15H11N2O requires 235.0871).  
3-(4-t-Butylphenyl)-5-methylisoquinolin-1-one (206k). Butyllithium (2.5 M in hexanes, 
0.46 mL, 1.14 mmol) was added to dry diisopropylamine (127.5 mg, 1.3 mmol) in dry 
THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (200 mg, 1.13 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-t-Butylbenzonitrile (180 mg, 1.13 mmol) in dry THF (2.0 
mL) was added at -78°C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was washed (EtOH, 40 mL) to give 206k (96.5 mg, 29%) as a white solid: mp 
204-206°C; IR νmax 3295 (NH), 1642 (C=O); 1H NMR (DMSO) (COSY) 1.33 (9 H, s, But), 
2.55 (3 H, s, 5-Me), 6.82 (1 H, s, 4-H), 7.35 (1 H, t, J = 7.6 Hz, 7-H), 7.51 (2 H, d, J = 7.6 
Hz, Ph 3,5-H2), 7.54 (1 H, d, J = 7.2 Hz, 6-H), 7.75 (2 H, d, J = 7.6 Hz, Ph 2,6-H2), 8.06 (1 
H, d, J = 8.0 Hz, 8-H), 11.48 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.75 
(Me), 30.97 (CMe3), 34.44 (CMe3), 99.60 (4-C), 124.56 (8-C), 124.86 (8a-C), 125.51 (Ph 
3,5-C2), 125.72 (7-C), 126.56 (Ph 2,6-C2), 131.44 (Ph 1-C), 133.15 (6-C), 133.60 (4a-C), 
136.69 (5-C), 139.84 (3-C), 151.87 (Ph 4-C), 162.97 (1-C); MS m/z 292.1686 (M + H) 
(C20H22NO requires 292.1703). 
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3-(Benzo-1,3-dioxol-5-yl)-5-methylisoquinolin-1-one (206l). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (141 mg, 1.4 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 5-Cyanobenzo-1,3-dioxole (166 mg, 1.1 mmol) in dry THF 
(2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. The 
solid was collected by filtration, washed (EtOH, 40 mL) and dried to give 206l (199 mg, 
63%) as a white solid: mp >360°C; IR νmax 3494 (NH), 1664 (C=O); 1H NMR (DMSO) 
(COSY) 2.54 (1 H, s, Me), 6.10 (2 H, s, CH2), 6.78 (1 H, s, 4-H), 7.02 (1 H, d, J = 8.2 Hz, 
benzodioxole 6-H), 7.33 (1 H, t, J = 7.7 Hz, 7-H), 7.34 (1 H, dd, J = 8.1, 1.8 Hz, 
benzodioxole 7-H), 7.43 (1 H, d, J = 1.8 Hz, benzodioxole 4-H), 7.52 (1 H, d, J = 7.2 Hz, 6-
H), 8.04 (1 H, d, J = 8.0 Hz, 8-H), 11.44 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 
18.83 (Me), 99.37 (4-C), 101.52 (CH2), 107.27 (benzodioxole 4-C), 108.46 
(benzodioxole 7-C), 121.07 (benzodioxole 6-C), 124.56 (8-C), 124.72 (8a-C), 125.60 (7-
C), 128.40 (benzodioxole 5-C), 133.12 (6-C), 133.62 (4a-C), 136.80 (5-C), 139.77 (3-C), 
147.71 (benzodioxole 7a-C), 148.17 (benzodioxole 3a-C), 163.14 (1-C); MS m/z 
278.0797 (M – H)- (C17H12NO3 requires 278.0817). 
5-Methyl-3-(thiophen-3-yl)isoquinolin-1-one (206m). Butyllithium (2.5 M in hexanes, 
0.46 mL, 1.14 mmol) was added to dry diisopropylamine (127.5 mg, 1.3 mmol) in dry 
THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 206b (200 mg, 1.13 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 3-Thiophenecarbonitrile (123 mg, 1.13 mmol) in dry THF 
(2.0 mL) was added at -78°C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM and 
washed thrice with saturated brine. The solvent was evaporated from the organic layer 
was then evaporated and the residue was washed (EtOH, 20 mL) to give 206m (16.9 
mg, 6%) as a pale buff solid: mp >360°C; IR νmax 3448 (NH), 1647 (C=O); 1H NMR 
(DMSO) (COSY) 2.56 (3 H, s, Me), 6.99 (1 H, s, 4-H), 7.34 (1 H, t, J = 7.6 Hz, 7-H), 7.54 
(1 H, d, J = 7.1 Hz, 6-H), 7.70 (1 H, m, thiophene 4-H), 7.78 (1 H, d, J = 4.6 Hz, thiophene 
5-H), 8.04 (1 H, d, J = 8.0 Hz, 8-H), 8.28 (1 H, d, J = 1.5 Hz, thiophene 2-H), 11.47 (1 H, 
br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.80 (Me), 99.09 (4-C), 123.46 (thiophene 
2-C), 124.58 (8-C), 124.95 (8a-C), 125.74 (7-C), 126.16 (thiophene 5-C), 127.27 
(thiophene 4-C), 133.25 (6-C), 133.73 (4a-C), 134.95 (thiophene 1-C), 135.37 (3-C), 
136.72 (5-C), 162.80 (1-C); MS m/z 264.0454 (C14H11NOSNa requires 264.0459).  
5-Methoxy-3-phenylisoquinolin-1-one (207a). Butyllithium (1.6 M in hexanes, 0.8 mL, 
1.3 mmol) was added to dry diisopropylamine (156 mg, 1.55 mmol) in dry THF (2.0 mL) 
at -78C and the mixture was stirred at this temperature for 10 min. Compound 205a 
(250 mg, 1.3 mmol) in dry THF (2.0 mL) was added and the mixture was stirred for 1 h 
at -78°C. Benzonitrile (133 mg, 1.3 mmol) in dry THF (2.0 mL) was added at -78 °C and 
the mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O (1.0 mL) 
was added. The mixture was diluted with DCM. This mixture was washed thrice with 
saturated brine and dried. The solvent was evaporated and the residue was 
recrystallised (EtOH, 40 mL) to give 207a (97 mg, 30%) as pale peach-coloured crystals: 
mp 219-220°C; IR νmax 3503 (NH), 1643 (CO); 1H NMR (DMSO) (COSY) 3.94 (3 H, s, 
Me), 6.94 (1 H, s, 4-H), 7.27 (1 H, dd, J = 8.0, 0.8 Hz, 6-H), 7.43 (1 H, t, J = 8.0 Hz, 7-H), 
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7.47 (3 H, m, Ph 3,4,5-H3), 7.77 (3 H, m, 8-H + Ph 2,6-H2), 11.59 (1 H, br, N-H); 13C NMR 
(DMSO) (HSQC / HMBC) 55.94 (Me), 96.95 (4-C), 112.28 (6-C), 118.23 (8-C), 125.81 
(4a-C), 126.68 (Ph 2,6-C2), 126.85 (7-C), 128.40 (8a-C), 128.83 (Ph 3,5-C2), 129.23 (Ph 4-
C), 134.07 (Ph 1-C), 139.62 (3-C), 154.39 (5-C), 162.50 (1-C); MS m/z 274.0846 (M + Na) 
(C16H13NaNO2 requires 274.0844). 
3-(4-Chlorophenyl)-5-methoxyisoquinolin-1-one (207b). Butyllithium (1.6 M in 
hexanes, 0.8 mL, 1.3 mmol) was added to dry diisopropylamine (156 mg, 1.55 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205a (250 mg, 1.3 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Chloromethylbenzonitrile (178 mg, 1.3 mmol) in dry THF 
(2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This 
mixture was washed thrice with saturated brine and dried. The solvent was 
evaporated and the residue was washed (EtOH) and dried to give 207b (86 mg, 23%) as 
an off-white solid: Rf = 0.3 (EtOAc / petroleum ether 3:7); mp 243-245°C; IR νmax 3291 
(NH), 1666 (C=O), 739 (CCl); 1H NMR (DMSO) (COSY)  4.00 (3 H, s, Me), 7.01 (1 H, s, 4-
H), 7.33 (1 H, d, J = 7.4 Hz, 6-H), 7.50 (1 H, t, J = 8.0 Hz, 7-H), 7.60 (2 H, d, J = 6.8 Hz, Ph 
3,5-H2), 7.84 (3 H, m, 8-H + Ph 2,6-H2), 11.71 (1 H, br, N-H); 13C NMR (DMSO) (HSQC / 
HMBC) 55.95 (Me), 97.34 (4-C), 112.39 (6-C), 118.23 (8-C), 125.89 (4a-C), 127.11 (7-
C), 128.20 (8a-C), 128.56 (Ph 2,6-C2), 128.79 (Ph 3,5-C2), 132.88 (Ph 1-C), 133.91 (Ph 4-
C), 138.42 (3-C), 154.44 (5-C), 162.44 (1-C); MS m/z 308.0413 (M + Na) 
(C16H1235ClNNaO2 requires 308.0449). 
5-Methoxy-3-(4-trifluoromethylphenyl)isoquinolin-1-one (207c). Butyllithium (1.6 M 
in hexanes, 0.8 mL, 1.3 mmol) was added to dry diisopropylamine (157 mg, 1.55 mmol) 
in dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 
min. Compound 205a (250 mg, 1.3 mmol) in dry THF (2.0 mL) was added and the 
mixture was stirred for 1 h at -78°C. 4-Trifluoromethylbenzonitrile (221 mg, 1.3 mmol) 
in dry THF (2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this 
temperature, then at rt for 16 h. H2O (1.0 mL) was added. H2O (1.0 mL) was added. The 
mixture was extracted with DCM. The extract was washed thrice with saturated brine 
and dried. The solvent was evaporated. The residue was recrystallised (EtOH, 25 mL) to 
give 207c (113 mg, 27%) as white crystals: Rf = 0.7 (EtOAc / petroleum ether 3:7); mp 
259-260°C; IR νmax 3304 (NH), 1660 (C=O), 1328, 1165, 1116 (CF); 1H NMR (DMSO) 
(COSY)  3.95 (3 H, s, Me), 7.04 (1 H, s, 4-H), 7.30 (1 H, d, J = 8.0 Hz, 6-H), 7.48 (1 H, t, J 
= 8.0 Hz, 7-H), 7.80 (1 H, d, J = 8.0 Hz, 8-H), 7.83 (2 H, d, J = 8.3 Hz, Ph3,5-H2), 7.98 (2 H, 
d, J = 8.2 Hz, Ph 2,6-H2), 11.75 (1 H, bs, N-H); 13C NMR (DMSO) (HSQC / HMBC)  55.93 
(Me), 98.28 (4-C), 112.46 (6-C), 118.18 (8-C), 124.03 (q, J = 270.5 Hz, CF3), 125.51 (q, J = 
3.8 Hz, Ph 3,5-C2), 126.15 (4a-C), 127.40 (7-C), 127.49 (Ph 2,6-C2), 127.93 (8a-C), 129.14 
(q, J = 31.9 Hz, Ph 4-C), 137.85 (Ph 1-C), 137.96 (3-C), 154.54 (5-C), 162.30 (1-C); 19F 
NMR (DMSO)  -61.20 (s, CF3); MS m/z 318.0740 (M - H)- (C17H11F3NO2 requires 
318.0747). 
5-Methoxy-3-(4-methylphenyl)isoquinolin-1-one (207d). Butyllithium (1.6 M in 
hexanes, 0.8 mL, 1.3 mmol) was added to dry diisopropylamine (156 mg, 1.55 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205a (250 mg, 1.3 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Methylbenzonitrile (151 mg, 1.3 mmol) in dry THF (2.0 
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mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was recrystallised (EtOH, 25 mL) to give 207d (16 mg, 5%) as pale yellow 
crystals: mp 249-251°C; IR νmax 3503 (NH), 1642 (C=O); 1H NMR (DMSO) (COSY) 2.36 
(3 H, s, Ph-Me), 3.94 (3 H, s, OMe), 6.92 (1 H, s, 4-H), 7.25 (1 H, dd, J = 8.0, 0.9 Hz, 6-H), 
7.29 (2 H, d, J = 7.9 Hz, Ph 3,5-H2), 7.41 (1 H, t, J = 8.0 Hz, 7-H), 7.66 (2 H, d, J = 8.2 Hz, 
Ph 2,6-H2), 7.77 (1 H, dt, J = 8.0, 0.8 Hz, 8-H), 11.54 (1 H, br, N-H); 13C NMR (DMSO) 
(HSQC / HMBC) 20.81 (Me), 55.92 (OMe), 96.35 (4-C), 112.22 (6-C), 118.23 (8-C), 
125.66 (4a-C), 126.51 (Ph 2,6-C2), 126.64 (7-C), 128.52 (8a-C), 129.40 (Ph 3,5-C2), 
131.22 (Ph 1-C), 138.88 (3-C), 139.62 (Ph 4-C), 154.33 (5-C), 162.54 (1-C); MS m/z 
288.0995 (M + Na) (C17H15NaNO2 requires 288.1001) 
3-(4-Bromophenyl)-5-methoxyisoquinolin-1-one (207e). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (131 mg, 1.3 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205a (200 mg, 1.0 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Bromobenzonitrile (188 mg, 1.0 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was washed (EtOH, 30 mL) and dried to give 207e (48 mg, 14%) as a white 
solid: mp 263-264°C; IR νmax 3526 (NH), 1665 (C=O), 739 (CBr); 1H NMR (DMSO) 3.94 
(3 H, s, Me), 6.95 (1 H, s, 4-H), 7.27 (1 H, d, J = 7.8 Hz, 6-H), 7.45 (1 H, t, J = 8.0 Hz, 7-H), 
7.69 (4 H, m, Ph 2,3,5,6-H4), 7.78 (1 H, d, J = 8.0 Hz, 8-H), 11.64 (1 H, br, NH); 13C NMR 
(DMSO) (HSQC / HMBC) 55.95 (Me), 97.30 (4-C), 112.39 (6-C), 118.23 (8-C), 122.58 
(Ph 4-C), 125.90 (4a-C), 127.11 (7-C), 128.19 (8a-C), 128.79 (Ph 2,6-C2), 131.70 (Ph 3,5-
C2), 133.24 (Ph 1-C), 138.49 (3-C), 154.44 (5-C), 162.44 (1-C); MS m/z 682.9978 (2 M + 
Na) (C32H2479Br81BrN2NaO4 requires 682.9981); 661.0145 (2 M + H) (C32H2579Br81BrN2O4 
requires 661.0161); 351.9959 (M + Na) (C16H1279BrNNaO2 requires 351.9949); 332.0098 
(M + H) (C16H1381BrNO2 requires 332.0110); 330.0113 (M + H) (C16H1379BrNO2 requires 
330.0130). 
5-Methoxy-3-(pyridin-4-yl)isoquinolin-1-one (207f). Butyllithium (1.6 M in hexanes, 
0.8 mL, 1.3 mmol) was added to dry diisopropylamine (157 mg, 1.55 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205a (250 mg, 1.3 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Cyanopyridine (135 mg, 1.3 mmol) in dry THF (2.0 mL) 
was added at -78 °C and the mixture was stirred for 1 h at this temperature, then at rt 
for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture was 
washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was washed (EtOH, 40 mL) to give 207f (284 mg, 87%) as a white solid: mp 
>360°C; IR νmax 3431 (NH), 1673 (C=O); 1H NMR (DMSO) (COSY) 3.96 (3 H, s, Me), 7.16 
(1 H, s, 4-H), 7.31 (1 H, d, J = 7.9 Hz, 6-H), 7.50 (1 H, t, J = 8.0 Hz, 7-H), 7.80 (3 H, m, 8-H 
+ pyridine 3,5-H2), 8.66 (2 H, d, J = 6.1 Hz, pyridine 2,6-H2), 11.74 (1 H, br, NH); 13C NMR 
(DMSO) (HSQC / HMBC) 56.04 (Me), 98.74 (4-C), 112.64 (6-C), 118.26 (8-C), 120.76 
(pyridine 3,5-C2), 126.55 (4a-C), 127.70 (8a-C), 127.93 (7-C), 136.82 (pyridine 1-C), 
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140.86 (3-C), 150.19 (pyridine 2,6-C2), 154.70 (5-C), 162.39 (1-C); MS m/z 253.0972 (M 
+ H) (C15H13N2O2 requires 253.0977). 
3-(4-t-Butylphenyl)-5-methoxyisoquinolin-1-one (207g). Butyllithium (2.5 M in 
hexanes, 0.42 mL, 1.04 mmol) was added to dry diisopropylamine (125.5 mg, 1.2 
mmol) in dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 
10 min. Compound 205a (200 mg, 1.03 mmol) in dry THF (2.0 mL) was added and the 
mixture was stirred for 1 h at -78°C. 4-t-Butylbenzonitrile (164 mg, 1.03 mmol) in dry 
THF (2.0 mL) was added at -78°C and the mixture was stirred for 1 h at this 
temperature, then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted 
with DCM and washed thrice with saturated brine. The solvent was evaporated from 
the dried the organic layer was then evaporated and the residue was washed (EtOH, 
30 mL) to give 207g (72.3 mg, 23%) as a white solid solid: mp 249-250°C; IR νmax 3451 
(NH), 1633 (C=O); 1H NMR (DMSO) (COSY) 1.33 (9 H, s, But), 3.96 (3 H, s, OMe), 6.95 
(1 H, s, 4-H), 7.27 (1 H, d, J = 7.9 Hz, 6-H), 7.44 (1 H, t, J = 8.0 Hz, 7-H), 7.52 (2 H, d, J = 
8.5 Hz, Ph 3,5-H2), 7.72 (2 H, d, J = 8.5 Hz, Ph 2,6-H2), 7.79 (1 H, d, J = 8.0 Hz, 8-H), 11.54 
(1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 30.96 (CMe3), 34.43 (CMe3), 55.90 
(OMe), 96.43 (4-C), 112.19 (6-C), 118.19 (8-C), 125.59 (Ph 3,5-C2), 125.59 (8a-C), 126.30 
(Ph 3,5-C2), 126.63 (7-C), 128.46 (4a-C), 131.19 (Ph 1-C), 139.45 (3-C), 151.85 (Ph 4-C), 
154.28 (5-C), 162.47 (1-C); MS m/z 308.1639 (C20H22NO2 requires 308.1652). 
3-(Benzo-1,3-dioxol-5-yl)-5-methoxyisoquinolin-1-one (207h). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (125 mg, 1.2 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205a (200 mg, 1.0 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 5-Cyanobenzo-1,3-dioxole (152 mg, 1.0 mmol) in dry THF 
(2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This 
mixture was washed thrice with saturated brine and dried. The solvent was 
evaporated and the residue was washed (EtOH, 25 mL) and dried to give 207h (32 mg, 
11%) as an off-white solid: mp 282-284°C; IR νmax 3445 (NH), 1631 (C=O); 1H NMR 
(DMSO) 3.93 (3 H, s, Me), 6.09 (2 H, s, CH2), 6.86 (1 H, s, 4-C), 7.01 (1 H, d, J = 8.1 Hz, 
Ph 5-H), 7.25 (1 H, d, J = 7.2 Hz, 6-H), 7.27 (1 H, dd, J = 8.2, 1.9 Hz, Ph 6-H), 7.33 (1 H, d, 
J = 1.8 Hz, Ph 2-H), 7.40 (1 H, t, J = 8.0 Hz, 7-H), 7.74 (1 H, d, J = 8.0 Hz, 8-H), 11.45 (1 H, 
br, NH); 13C NMR (DMSO) (HSQC / HMBC / DEPT)  55.91 (OMe), 96.29 (4-C), 101.53 
(CH2), 107.03 (Ph 4-C), 108.54 (Ph 7-C), 112.17 (6-C), 118.21 (8-C), 120.92 (Ph 6-C), 
125.54 (4a-C), 126.52 (7-C), 128.20 (Ph 5-C), 128.54 (8a-C), 139.42 (3-C), 147.72 (Ph 7a-
C), 148.16 (Ph 3a-C), 154.27 (5-C), 162.51 (1-C); MS m/z 613.1595 (2 M + Na) 
(C34H26N2NaO8 requires 613.1587); 591.1768 (2 M + H) (C34H27N2O8 requires 591.1767); 
318.0765 (M + Na) (C17H13NNaO4 requires 318.0742); 296.0907 (M 
5-Methoxy-3-(thiophen-3-yl)isoquinolin-1-one (207i). Butyllithium (2.5 M in hexanes, 
0.42 mL, 1.04 mmol) was added to dry diisopropylamine (125.5 mg, 1.24 mmol) in dry 
THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205a (200 mg, 1.03 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 3-Thiophenecarbonitrile (112 mg, 1.03 mmol) in dry THF 
(2.0 mL) was added at -78°C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM and 
washed thrice with saturated brine. The solvent was evaporated from the dried 
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organic layer and the residue was washed (EtOH, 25 mL) to give 207i (37.3 mg, 14%) as 
a buff solid: mp 286-287°C; IR νmax 3503 (NH), 1652 (C=O), 746; 1H NMR (DMSO) (COSY) 
3.94 (3 H, s, Me), 7.04 (1 H, s, 4-H), 7.24 (1 H, d, J = 7.9 Hz, 6-H), 7.40 (1 H, t, J = 8.0 
Hz, 7-H), 7.66 (2 H, m, thiophene 4,5-H2), 7.75 (1 H, d, J = 8.0 Hz, 8-H), 8.23 (1 H, d, J = 
1.2 Hz, thiophene 2-H), 11.48 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 55.88 
(Me), 95.99 (4-C), 112.28 (6-C), 118.24 (8-C), 123.36 (thiophene 2-C), 125.71 (8a-C), 
125.78 (thiophene 5-C), 126.63 (7-C), 127.44 (thiophene 4-C), 128.44 (4a-C), 134.71 
(thiophene 1-C), 135.20 (3-C), 154.30 (5-C), 162.29 (1-C); MS m/z 280.0399 
(C14H11NNaO2S requires 280.0409).  
5-Fluoro-3-phenylisoquinolin-1-one (208a). Butyllithium (1.6 M in hexanes, 0.9 mL, 1.4 
mmol) was added to dry diisopropylamine (172 mg, 1.7 mmol) in dry THF (2.0 mL) at -
78C and the mixture was stirred at this temperature for 10 min. Compound 205c (250 
mg, 1.4 mmol) in dry THF (2.0 mL) was added and the mixture was stirred for 1 h at -
78°C. Benzonitrile (142 mg, 1.4 mmol) in dry THF (2.0 mL) was added at -78 °C and the 
mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O (1.0 mL) was 
added. The mixture was diluted with DCM. This mixture was washed thrice with satur-
ated brine and dried. The solvent was evaporated and the residue was recrystallised 
(EtOH, 30 mL) to give 208a (113 mg, 34%) as an off-white solid: mp 216-217°C; IR νmax 
3485 (NH), 1665 (C=O), 1240 (CF); 1H NMR (DMSO) (COSY)  6.91 (1 H, s, 4-H), 7.55 (4 
H, m, 7-H + Ph 3,4,5-H3), 7.66 (1 H, m, 6-H), 7.87 (2 H, m, Ph 2,6-H2), 8.10 (1 H, d, J = 7.9 
Hz, 8-H), 11.84 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 94.80 (d, J = 5.3 Hz. 4-
C), 117.64 (d, J = 19.3 Hz, 6-C), 122.78 (d, J = 3.4 Hz, 8-H), 126.61 (d, J = 3.3 Hz, 8a-C), 
126.82 (d, J = 7.9 Hz, 7-C), 126.95 (d, J = 16.4 Hz, 4a-C), 126.96 (Ph 2,6-C2), 128.83 (Ph 
3,5-C2), 129.64 (Ph 4-C), 133.59 (Ph 1-C), 141.40 (3-C), 157.31 (d, J = 247.8 Hz, 5-C), 
161.78 (d, J = 2.8 Hz, 1-C); 19F NMR (DMSO)  -121.96 (dd, J = 9.9, 5.2 Hz, F); MS m/z 
238.0670 (M – H) (C15H9FNO requires 238.0668).  
3-(4-Chlorophenyl)-5-fluoroisoquinolin-1-one (208b). Butyllithium (1.6 M in hexanes, 
0.9 mL, 1.4 mmol) was added to dry diisopropylamine (170 mg, 1.7 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. Com-
pound 205c (250 mg, 1.4 mmol) in dry THF (2.0 mL) was added and the mixture was 
stirred for 1 h at -78°C. 4-Chloromethylbenzonitrile (190 mg, 1.4 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM (20 mL). The 
solid was collected by filtration, washed (EtOH) and dried to give 208b (269 mg, 71%) 
as a white solid: Rf = 0.6 (EtOAc / petroleum ether 3:7); mp 296-297°C; IR νmax 3291 
(NH), 1665 (C=O), 1243 (CF), 743 (CCl); 1H NMR (DMSO) (COSY)  6.86 (1 H, s, 4-H), 
7.49 (1 H, m, 7-H), 7.57 (3 H, m, 6-H + Ph 3,5-H2), 7.84 (2 H, d, J = 8.6 Hz, Ph 2,6-H2), 
8.05 (1 H, d, J = 7.9 Hz, 8-H), 11.63 (1 H, br, N-H); 13C NMR (DMSO) (HSQC / HMBC)  
94.91 (d, J = 5.4 Hz, 4-C), 117.36 (d, J = 19.6 Hz, 6-C), 122.53 (d, J = 3.5 Hz, 8-C), 126.73 
(d, J = 8.0 Hz, 7-C), 126.52 (8a-C), 126.65 (d, J = 16.2 Hz, 4a-C), 128.51 (Ph 3,5-C2), 
128.57 (Ph 2,6-C2), 132.26 (Ph 1-C), 134.15 (Ph 4-C), 140.00 (3-C), 157.15 (d, J = 248.4 
Hz, 5-C), 161.42 (1-C); 19F NMR (DMSO)  -122.79 (m, F); MS m/z 274.0514 (M – H)- 
(C15H837ClFNO requires 274.0249), 272.0762 (M – H)- (C15H835ClFNO requires 272.0784). 
5-Fluoro-3-(4-trifluoromethylphenyl)isoquinolin-1-one (208c). Butyllithium (1.6 M in 
hexanes, 0.9 mL, 1.4 mmol) was added to dry diisopropylamine (170 mg, 1.7 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
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Compound 205c (250 mg, 1.4 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Trifluoromethylbenzonitrile (236 mg, 1.4 mmol) in dry 
THF (2.0 mL) was added at -78°C and the mixture was stirred for 1 h at this 
temperature, then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted 
with DCM (20 mL). The solid was collected by filtration, washed (EtOH) and dried to 
give 208c (424 mg, 99%) as a white solid: Rf = 0.6 (EtOAc / petroleum ether 3:7); mp 
>360°C; IR νmax 3421 (NH), 1650 (C=O), 1333, 1236, 1164, 1113 (CF); 1H NMR (DMSO) 
(COSY)  6.97 (1 H, s, 4-H), 7.55 (1 H, td, J = 7.6, 5.7 Hz, 7-H), 7.63 (1 H, t, J = 8.7 Hz, 6-
H), 7.86 (2 H, d, J = 8.1 Hz, Ph 3,5-H2), 8.05 (3 H, m, Ph 2,6-H2 + 8-H), 11.92 (1 H, br, 
NH); 13C NMR (DMSO) (HSQC / HMBC)  96.30 (d, J = 4.9 Hz, 4-C), 117.86 (d, J = 19.5 
Hz, 6-C), 122.83 (d, J = 3.4 Hz, 8-C), 124.07 (q, J = 270.1 Hz, CF3), 125.63 (q, J = 3.5 Hz, 
Ph 3,5-H2), 126.59 (d, J = 16.3 Hz, 4a-C), 126.91 (8a-C), 127.52 (d, J = 7.6 Hz, 7-C), 
127.99 (Ph 2,6-C2), 129.58 (q, J = 31.9 Hz, Ph 4-C), 137.47 (1-C), 139.86 (3-C), 157.44 (d, 
J = 248.5 Hz, 5-C), 161.70 (1-C); 19F NMR (DMSO)  -61.19 (3 F, s, CF3), -121.55 (1 F, m, 
F); MS m/z 306.0559 (M - H)- (C16H8F4NO requires 306.0548). 
5-Fluoro-3-(4-methylphenyl)isoquinolin-1-one (208d). Butyllithium (1.6 M in hexanes, 
0.7 mL, 1.1 mmol) was added to dry diisopropylamine (142 mg, 1.4 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205c (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Methylbenzonitrile (129 mg, 1.1 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was recrystallised (EtOH, 25 mL) to give 208d (50 mg, 18%) as white crystals: 
mp 232-233°C; IR νmax 3481 (NH), 1668 (C=O), 1235 (CF); 1H NMR (DMSO) (COSY) 2.37 
(3 H, s, Me), 6.81 (1 H, s, 4-H), 7.30 (2 H, d, J = 8.0 Hz, Ph 3,5-H2), 7.48 (1 H, m, 7-H), 
7.58 (1 H, t, J = 8.1 Hz, 6-H), 7.71 (2 H, d, J = 8.0 Hz, Ph 2,6-H2), 8.03 (1 H, d, J = 8.0 Hz, 
8-H), 11.70 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 20.83 (Me), 94.19 (d, J = 
5.1 Hz, 4-C), 117.57 (d, J = 19.5 Hz, 6-C), 122.77 (d, J = 3.3 Hz, 8-C), 126.46 (d, J = 3.4 Hz, 
8a-C); 126.59 (d, J = 7.6 Hz, 7-C), 126.79 (Ph 2,6-C2), 127.06 (d, J = 16.5 Hz, 4a-C), 
129.40 (Ph 3,5-H2), 130.74 (Ph 1-C), 139.38 (Ph 4-C), 141.40 (3-C), 157.26 (d, J = 248.1 
Hz, 5-C), 161.81 (d, J = 2.8 Hz, 1-C); 19F NMR (DMSO)  -122.08 (dd, J = 10.4, 5.2 Hz, F); 
MS m/z 252.0807 (M – H)- (C16H11FNO requires 252.0824). 
3-(4-Bromophenyl)-5-fluoroisoquinolin-1-one (208e). Butyllithium (1.6 M in hexanes, 
0.64 mL, 1.2 mmol) was added to dry diisopropylamine (121 mg, 1.2 mmol) in dry THF 
(2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205c (180 mg, 1.0 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Bromobenzonitrile (186 mg, 1.0 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM (20 mL). The 
solid was collected by filtration, washed (EtOH, 40 mL) and dried to give 208e (238 mg, 
61%) as a white solid: mp >360°C; IR νmax 3544 (NH), 1664 (C=O), 743 (CBr); 1H NMR 
(DMSO) (COSY) 6.86 (1 H, s, 4-H), 7.47 (1 H, m, 7-H), 7.52 (1 H, t, J = 8.1 Hz, 6-H), 7.67 
(2 H, d, J = 8.6 Hz, Ph 2,6-H2), 7.78 (2 H, d, J = 8.6 Hz, Ph 3,5-H2), 8.03 (1 H, d, J = 7.9 Hz, 
8-H), 11.87 (1 H, bs, NH); 13C NMR (DMSO) (HSQC / HMBC) 94.61 (d, J = 5.1 Hz, 4-C), 
117.08 (d, J = 19.3 Hz, 6-C), 122.60 (d, J = 3.5 Hz, 8-C), 122.66 (Ph 4-C), 126.45 (d, J = 
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7.9 Hz, 7-C), 126.53 (8a-C), 126.80 (d, J = 16.3 Hz, 4a-C), 128.85 (Ph 3,5-C2), 131.45 (Ph 
2,6-C2), 133.27 (Ph 1-C), 140.87 (3-C), 157.20 (d, J = 248.3 Hz, 5-C), 162.10 (1-C); 19F 
NMR (DMSO)  -121.89 (m, F); MS m/z 317.9760 (M – H)- (C15H881BrFNO requires 
317.9753), 315.9773 (M – H)- (C15H879BrFNO requires 315.9773). 
5-Fluoro-3-(4-methoxyphenyl)isoquinolin-1-one (208f). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (131 mg, 1.3 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205c (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Methoxybenzonitrile (147 mg, 1.1 mmol) in dry THF (2.0 
mL) was added at -78 °C and the mixture was stirred for 1 h at this temperature, then 
at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This mixture 
was washed thrice with saturated brine and dried. The solvent was evaporated and the 
residue was washed (EtOH, 5 mL) and dried to give 208f (8.1 mg, 3%) as an off-white 
solid: mp 238-240°C; IR νmax 3444 (NH), 1645 (C=O), 1233 (CF); 1H NMR (DMSO) 3.82 
(3 H, s, Me), 6.78 (1 H, s, 4-H), 7.05 (2 H, d, J = 8.9 Hz, Ph 3,5-H2), 7.45 (1 H, m, 7-H), 
7.57 (1 H, t, J = 8.9 Hz, 6-H), 7.77 (2 H, d, J = 8.9 Hz, Ph 2,6-H2), 8.02 (1 H, d, J = 8.0 Hz, 
8-H), 11.66 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 55.37 (Me), 93.59 (d, J = 
5.3 Hz, 4-C), 114.23 (Ph 3,5-C2), 117.52 (d, J = 19.6 Hz, 6-C), 122.74 (d, J = 3.2 Hz, 8-C), 
125.84 (Ph 1-C), 126.24 (d, J = 3.6 Hz, 8a-C), 126.32 (d, J = 7.6 Hz, 7-C), 129.20 (d, J = 
16.5 Hz, 4a-C), 128.35 (Ph 2,6-C2), 141.19 (3-C), 157.19 (d, J = 247.5 Hz, 5-C), 160.41 (Ph 
4-C), 161.82 (1-C); 19F NMR (DMSO)  -122.20 (dd, J = 9.9, 5.2 Hz, F); MS m/z 292.0744 
(M + Na) (C16H12FNNaO2 requires 292.0750). 
5-Fluoro-3-(pyridin-4-yl)isoquinolin-1-one (208g). Butyllithium (1.6 M in hexanes, 0.7 
mL, 1.1 mmol) was added to dry diisopropylamine (131 mg, 1.3 mmol) in dry THF (2.0 
mL) at -78C and the mixture was stirred at this temperature for 10 min. Compound 
205c (200 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture was stirred for 
1 h at -78°C. 4-Cyanopyridine (114 mg, 1.1 mmol) in dry THF (2.0 mL) was added at -78 
°C and the mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O (1.0 
mL) was added. The mixture was diluted with DCM. This mixture was washed thrice 
with saturated brine and dried. The solvent was evaporated and the residue was 
washed (EtOH, 50 mL) and dried to give 208g (264 mg, 99%) as a white solid: mp 
>360°C; IR νmax 3435 (NH), 1675 (C=O), 1244 (CF); 1H NMR (DMSO) 7.10 (1 H, s, 4-H), 
7.55 (1 H, m, 7-H), 7.64 (1 H, t, J = 8.0 Hz, 6-H), 7.86 (2 H, d, J = 6.2 Hz, pyridine 3,5-H2), 
8.06 (1 H, d, J = 7.8 Hz, 8-H), 8.70 (2 H, d, J = 6.2 Hz, pyridine 2,6-H2), 11.90 (1 H, br, 
NH); 13C NMR (DMSO) (HSQC / HMBC) 96.61 (4-C), 117.89 (d, J = 19.8 Hz, 6-C), 121.10 
(pyridine 3,5-C2), 122.86 (8-C), 126.40 (d, J = 15.9 Hz, 4a-C), 127.26 (8a-C), 127.86 (d, J 
= 7.9 Hz, 7-C), 138.75 (3-C), 140.57 (pyridine 1-C), 150.19 (pyridine 2,6-C2), 157.52 (d, J 
= 248.8 Hz, 5-C), 161.79 (1-C); 19F NMR (DMSO) -121.19 (m, F) ; MS m/z 239.0622 (M 
– H) (C14H8FN2O requires 239.0621). 
5-Hydroxy-3-phenylisoquinolin-1-one (209a). Compound 207a (25 mg, 0.10 mmol) 
was heated with BBr3 (1.0 M in DCM, 2.0 mL) at reflux for 16 h. The solvent was 
evaporated. The residue was treated with aq. NaOH (2.5 M, 3.5 mL) at 0°C and the 
mixture was stirred for 3 h. The solution was acidified by addition of aq. HCl (2 M). The 
solid was collected by filtration. Chromatography (EtOAc / petroleum ether 2:3 → 1:1) 
gave 209a (20 mg, 84%) as a pale yellow solid: Rf = 0.9 (EtOAc / petroleum ether 3:2); 
mp 248-249°C; IR νmax 3410 (OH), 3318 (NH), 1677 (C=O); 1H NMR (CD3OD) 7.11 (1 H, 
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dd, J = 7.8, 1.0 Hz, 6-H), 7.19 (1 H, d, J = 0.6 Hz, 4-H), 7.33 (1 H, t, J = 7.9 Hz, 7-H), 7.45 
(1 H, t, J = 8.5 Hz, Ph 4-H), 7.51 (2 H, t, J = 8.6 Hz, Ph 3,5-H2), 7.72 (2 H, d, J = 8.4 Hz, Ph 
2,6-H2), 7.79 (1 H, dt, J = 8.1, 0.8 Hz, 8-H); 13C NMR (CD3OD) (HSQC / HMBC)  100.75 
(4-C), 117.44 (6-C), 118.52 (8-C), 126.97 (4a-C), 127.65 (Ph 2,6-C2), 128.25 (7-C), 129.73 
(8a-C), 130.10 (Ph 3,5-C2), 130.30 (Ph 4-C), 136.05 (Ph 1-C), 139.93 (3-C), 154.58 (5-C), 
165.74 (1-C); MS m/z 497.1477 (2 M + Na) (C30H22N2NaO4 requires 497.1478), 
260.0689 (M + Na) (C15H11NNaO2 requires 260.0689), 238.0883 (M + H) (C15H12NO2 
requires 238.0868); MS m/z 236.0705 (M – H)- (C15H10NO2 requires 236.0712). 
5-Hydroxy-3-(4-trifluoromethylphenyl)isoquinolin-1-one (209b). Compound 207c (51 
mg, 0.16 mmol) was heated with BBr3 in DCM (1.0 M, 4.0 mL) at reflux for 16 h. The 
solvent was evaporated. The residue was treated with aq. NaOH (2.5 M, 3.5 mL) at 0°C 
and the mixture was stirred for 3 h. The solution was acidified by addition of aq. HCl (2 
M). The solid was collected by filtration. Chromatography (EtOAc / petroleum ether 2:3 
→ 1:1) gave 209b (3.9 mg, 8%) as a pale buff solid: Rf = 0.7 (EtOAc / petroleum ether 
1:1); mp 258-260°C; IR νmax 3399 (OH), 3197 (NH), 1640 (C=O), 1329, 1113 & 1068 (CF); 
1H NMR (CD3OD)  7.14 (1 H, dd, J = 7.8, 1.0 Hz, 6-H), 7.29 (1 H, s, 4-H), 7.37 (1 H, t, J = 
7.9 Hz, 7-H), 7.81 (3 H, m, 8-H + Ph 3,5-H2), 7.92 (2 H, d, J = 8.2 Hz, Ph 2,6-H2); 13C NMR 
(CD3OD) (HSQC / HMBC)  102.03 (4-C), 117.66 (6-C), 118.54 (8-C), 125.54 (q, J = 268.9 
Hz, CF3), 126.94 (q, J = 3.8 Hz, Ph 3,5-C2), 127.41 (4a-C), 128.36 (Ph 2,6-C2), 128.90 (7-
C), 129.23 (8a-C), 131.88 (q, J = 32.4 Hz, Ph 4-C), 138.33 (3-C), 139.73 (Ph 1-C), 154.84 
(5-C), 165.60 (1-C); MS m/z 328.0568 (M + Na) (C16H10F3NNaO2 requires 328.0561), 
306.0740 (M + H) (C16H11F3NO2 requires 306.0742); MS m/z 304.0577 (M – H)- 
(C16H9F3NO2 requires 304.0585). 
2-Ethyl-N,N,3-trimethylbenzamide (214). Butyllithium (1.6 M in hexanes, 1.65 mL, 
2.64 mmol) was added to dry diisopropylamine (463 mg, 3.30 mmol) in dry THF (2.0 
mL) at -78C and the mixture was stirred at this temperature for 10 min. Compound 
205b (390 mg, 2.20 mmol) in dry THF (3.0 mL) was added and the mixture was stirred 
for 1 h at -78°C. Iodomethane (343.5 mg, 2.42 mmol) in dry THF (2.0 mL) was added at 
-78 °C and the mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O 
(1.0 mL) was added. The mixture was diluted with DCM. This mixture was washed 
thrice with saturated brine and dried. Evaporation and chromatography (EtOAc / 
petroleum ether 1:9 → 1:1) gave 214 (100 mg, 24%) as a colourless oil: Rf = 0.6 (EtOAc 
/ petroleum ether 1:9). 1H NMR (CDCl3) (COSY/ NOESY)1.14 (3 H, t, J = 7.6 Hz, 
CH2CH3), 2.34 (3 H, s, 3-Me), 2.60 (2 H, m, CH2CH3), 2.81 (3 H, s, N-Me), 3.13 (3 H, s, N-
Me’), 6.96 (1 H, d, J = 7.3 Hz, 4-H), 7.10 (1 H, t, J = 7.5 Hz, 5-H), 7.14 (1 H, d, J = 7.3 Hz, 
6-H); 13C NMR (CDCl3) (HSQC / HMBC / DEPT) 14.25 (CH2CH3), 19.26 (3-Me), 23.55 
(CH2CH3), 34.56 (N-Me axial), 38.91 (N-Me equatorial), 123.62 (4-C), 125.84 (5-C), 
130.74 (6-C), 136.64 (3-C), 136.92 (1-C), 138.52 (2-C), 171.98 (C=O); MS m/z 192.1491 
(M + H) (C12H17NO requires 192.1310).  
4,5-Dimethyl-3-phenylisoquinolin-1-one (215). Sec-butyllithium (1.4 M in cyclohexane, 
0.47 mL, 0.66 mmol) was added to 214 (115 mg, 0.6 mmol) in dry THF (1.0 mL) at -78C 
and the mixture was stirred at this temperature for 30 min. Benzonitrile (62 mg, 0.6 
mmol) in dry THF (1.0 mL) was added at -78°C and the mixture was stirred for 1 h at 
this temperature, then at rt for 16 h. The reaction mixture was then cooled to 0C and 
quenched with D2O (0.11 mL, 6.0 mmol) and left to stir for 10 min. The mixture was 
diluted with DCM and washed thrice with saturated brine. The solvent was evaporated 
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from the dried organic layer and the residue was washed (EtOH, 20 mL) to give 215 
(19.5 mg, 13%) as a white solid: mp >360°C; IR νmax 3453 (NH), 1644 (C=O); 1H NMR 
(DMSO) (COSY) 2.25 (3 H, s, 4-Me), 2.76 (3 H, s, 5-Me), 7.37 (1 H, t, J = 6.8 Hz, 7-H), 
7.47 (5 H, m, Ph-H5), 7.53 (1 H, d, J = 7.1 Hz, 6-H), 8.18 (1 H, d, J = 6.9 Hz, 8-H), 11.21 (1 
H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.98 (4-Me), 24.54 (5-Me), 108.26 (4-
C), 125.52 (8-C), 125.86 (7-C), 127.04 (8a-C), 128.33 (Ph 3,5-C2), 128.65 (Ph 4-C), 129.74 
(Ph 2,6-C2), 134.92 (4a-C), 135.65 (Ph 1-C), 136.41 (6-C), 138.17 (5-C), 138.34 (3-C), 
161.39 (1-C); MS m/z 250.1219 (C17H16NO requires 250.1232). 
4-(Phenylethynyl)benzonitrile (221). PdCl2(PPh3)2 (96.5 mg, 0.14 mmol), CuI (52 mg, 
0.3 mmol), sodium ascorbate (33 mg, 0.16 mmol) and 4-bromobenzonitrile (220) (500 
mg, 2.75 mmol) were mixed in a dry flask. Degassed THF (10 mL) and dry diisopropyl-
amine (5.0 mL) were added and the mixture was stirred at 50 °C for 30 min. Phenyl-
ethyne (281 mg, 2.75 mmol) was added and the mixture was stirred for 16 h at 50°C. 
The mixture was filtered through Celite. Evaporation and chromatography (EtOAc / 
petroleum ether 1:199 → 1:99) gave 221 (394 mg, 70%) as an off-white solid: Rf = 0.8 
(EtOAc / petroleum ether 1:99); mp 78-79°C (lit.284 mp 109-110C); 1H NMR (CDCl3)  
7.38 (3 H, m, Ph 3,4,5-H3), 7.55 (2 H, m, Ph 2,6-H2), 7.60 (4 H, m, NCPh 2,3,5,6-H4); 13C 
NMR (CDCl3) (HSQC / HMBC)  87.66 (ethyne 1-C), 93.69 (ethyne 2-C), 111.34 (CN), 
118.42 (NCPh 1-C), 122.11 (Ph 1-C), 128.11 (NCPh 4-C), 128.42 (Ph 3,5-C2), 129.04 (Ph 
4-C), 131.69 (Ph 2,6-C2), 131.93 (NCPh 2,6-C2), 131.95 (NCPh 3,5-C2). 
5-Methyl-3-(4-phenylethynylphenyl)isoquinolin-1-one (222). Butyllithium (1.6 M in 
hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine (141 mg, 1.4 mmol) in 
dry THF (2.0 mL) at -78C and the mixture was stirred at this temperature for 10 min. 
Compound 205b (230 mg, 1.1 mmol) in dry THF (2.0 mL) was added and the mixture 
was stirred for 1 h at -78°C. 4-Phenylethynylbenzonitrile (221) (194 mg, 1.1 mmol) in 
dry THF (2.0 mL) was added at -78 °C and the mixture was stirred for 1 h at this 
temperature, then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted 
with DCM. The solid was collected by filtration, washed (EtOH, 30 mL) and dried to give 
222 (117 mg, 31%) as a white solid: mp 285-287°C; IR νmax 3467 (NH), 1649 (C=O); 1H 
NMR (DMSO) (COSY) (2.57, s, Me), 6.94 (1 H, s, 4-H), 7.39 (1 H, t, J = 7.6 Hz, 7-H), 7.45 
(3 H, m, Ph 3,4,5-H3), 7.56 (1 H, d, J = 7.4 Hz, 6-H), 7.59 (2 H, m, Ph 2,6-H2), 7.67 (2 H, d, 
J = 8.0 Hz, Ar 3,5-H2), 7.90 (2 H, d, J = 8.0 Hz, Ar 2,6-H2), 8.08 (1 H, d, J = 7.9 Hz, 8-H), 
11.62 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 18.82 (Me), 88.99 (ethyne 1-C), 
90.86 (ethyne 2-C), 100.64 (4-C), 122.09 (Ph 1-C), 122.92 (Ar 4-C), 124.61 (8-C), 125.18 
(8a-C), 126.21 (7-C), 126.15 (Ar 2,6-C2), 128.84 (Ph 3,5-C2), 129.03 (Ph 10-C), 131.47 (Ph 
2,6-C2), 131.66 (Ar 3,5-C2), 133.29 (6-C), 134.03 (4a-C), 134.17 (Ar 1-C), 136.50 (5-C), 
139.00 (3-C), 163.00 (1-C); MS m/z 358.1218 (M + Na) (C24H17NNaO requires 
358.1208), 336.1402 (M + H) (C24H18NO requires 336.1388). 
4-Dimethylaminomethylbenzonitrile (234a). 4-Bromomethylbenzonitrile (233) (1.00 g, 
5.1 mmol) was stirred with aq. dimethylamine (40%, 4.0 mL) for 16 h. The mixture was 
diluted with H2O and extracted with DCM. The extract was washed with aq. citric acid 
(10%). The combined aq. solutions were basified by addition of aq. sodium hydroxide 
(15%) and extracted with DCM. The combined solutions in DCM were driedand the 
solvent was evaporated to give 234a (420 mg, 51%) as a colourless oil. (lit.285 oil): 1H 
NMR (CDCl3) 2.24 (6 H, s, NMe2), 3.47 (2 H, s, CH2), 7.43 (2 H, d, J = 8.2 Hz, 3,5-H2), 
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7.61 (2 H, d, J = 8.2 Hz, 2,6-H2); 13C NMR (CDCl) (HSQC / HMBC) 45.42 (NMe2), 63.83 
(CH2), 110.92 (1-C), 118.95 (CN), 129.51 (3,5-C2), 132.13 (2,6-C2), 144.62 (4-C). 
4-(Pyrrolidin-1-ylmethyl)benzonitrile (234b). 4-Bromomethylbenzonitrile (233) (1.00 
g, 5.1 mmol) in dry THF (15 mL) was stirred with Et3N (1.08 g, 10.7 mmol) and 
pyrrolidine (760 mg, 10.7 mmol) for 2 d. This mixture was diluted with EtOAc, washed 
thrice with H2O and dried. Evaporation of the solvent gave 234b (935 mg, 98%) as an 
orange oil (lit.286 oil): 1H NMR (CDCl3)  1.79 (4 H, m, pyrrolidine 3,4-H4), 2.50 (4 H, m, 
pyrrolidine 2,5-H4), 3.65 (2 H, s, PhCH2), 7.44 (2 H, d, J = 8.5 Hz, Ph 3,5-H2), 7.59 (2 H, d, 
J = 8.4 Hz, Ph 2,6-H2); 13C NMR (CDCl3) (HSQC / HMBC) 23.53 (pyrrolidine 3,4-C2), 
54.24 (pyrrolidine 2,5-C2), 60.23 (PhCH2), 110.67 (Ph 1-C), 119.05 (CN), 129.29 (Ph 3,5-
C2), 132.10 (Ph 2,6-C2), 145.29 (Ph 4-C). 
4-(Piperidin-1-ylmethyl)benzonitrile (234c). 4-Bromomethylbenzonitrile (233) (500 
mg, 2.6 mmol) was stirred with K2CO3 (388 mg, 2.8 mmol) and piperidine (238 mg, 2.8 
mmol) in dry DMF (6.0 mL) at rt for 3 h, then at 90°C for 72 h. The mixture was then 
cooled to rt. H2O (18 mL) was added and the mixture was stirred for 30 min. This 
mixture was diluted with EtOAc. The suspension was washed thrice with saturated 
brine and dried. Evaporation of the solvent gave 234c (340 mg, 67%) as a pale orange 
oil (lit.287 oil): 1H NMR (CDCl3)  1.44 (2 H, m, piperidine 4-H2), 1.57 (4 H, m, piperidine 
3,5-H4), 2.36 (4 H, m, piperidine 2,6-H4), 3.50 (2 H, s, PhCH2), 7.44 (2 H, d, J = 8.0 Hz, Ph 
3,5-H2), 7.59 (2 H, d, J = 8.3 Hz, Ph 2,6-H2); 13C NMR (CDCl3) (HSQC / HMBC)  24.20 
(piperidine 4-C), 25.94 (piperidine 3,5-C2), 54.60 (piperidine 2,6-C2), 63.25 (PhCH2), 
110.58 (Ph 1-C), 119.07 (CN), 129.46 (Ph 3,5-C2), 131.99 (Ph 2,6-C2), 144.84 (Ph 4-C). 
4-((4-Methylpiperazin-1-yl)methyl)benzonitrile (234d). To 4-bromomethylbenzonitrile 
(233) (1.0 g, 5.1 mmol) and Et3N (1.03 g, 10.2 mmol) in dry DCM (10 mL) was added 1-
methylpiperazine (760 mg, 7.6 mmol) and the mixture was stirred for 24 h. This 
mixture was diluted with DCM and washed thrice with saturated aq. NaHCO3 and H2O. 
Drying and evaporation gave 234d (650 mg, 59%) as a white solid: mp 65-67°C (lit.288 
mp 66-68C): 1H NMR (CDCl3)  2.29 (3 H, s, Me), 2.47 (8 H, m, piperazine 2,3,5,6-H8), 
3.54 (2 H, s, PhCH2), 7.43 (2 H, d, J = 8.2 Hz, Ph 3,5-H2), 7.58 (2 H, d, J = 8.2 Hz, Ph 2,6-
H2); 13C NMR (CDCl3) (HSQC / HMBC) 45.98 (Me), 53.08 (piperazine 2,6-C2), 55.05 
(piperazine 3,5-C2), 62.38 (PhCH2), 110.85 (Ph 1-C), 118.97 (CN), 129.49 (Ph 3,5-C2), 
132.10 (Ph 2,6-C2), 144.23 (Ph 4-C). 
3-(4-Dimethylaminomethylphenyl)-5-methylisoquinolin-1-one hydrochloride (236a). 
Butyllithium (1.6 M in hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine 
(142 mg, 1.4 mmol) in dry THF (2.0 mL) at -78C and the mixture was stirred at this 
temperature for 10 min. Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was 
added and the mixture was stirred for 1 h at -78°C. 4-Dimethylaminomethyl-
benzonitrile (234a) (181 mg, 1.1 mmol) in dry THF (2.0 mL) was added at -78°C and the 
mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O (1.0 mL) was 
added. The mixture was diluted with DCM. This mixture was washed thrice with 
saturated brine and dried. The solvent was evaporated and the residue was washed 
(EtOH, 25 mL) and dried to give 235a (15 mg, 4%) as a white solid: mp 169-170°C. The 
solid was then treated for 16 h with aq. HCl (6.0 M, 2.0 mL) to give the hydrochloride 
salt 236a: mp 292-293°C; IR νmax 3426 (NH), 1634 (C=O); 1H NMR (DMSO) 2.17 (6 H, s, 
NMe2), 2.56 (3 H, s, 5-Me), 3.44 (2 H, s, CH2), 6.85 (1 H, s, 4-H), 7.36 (1 H, t, J = 7.7 Hz, 
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7-H), 7.40 (2 H, d, J = 8.3 Hz, Ph 3,5-H2), 7.55 (1 H, d, J = 7.2 Hz, 6-H), 7.78 (2 H, d, J = 
8.3 Hz, Ph 2,6-H2), 8.06 (1 H, d, J = 8.0 Hz, 8-H), 11.50 (1 H, br, NH); 13C NMR (DMSO) 
(HSQC / HMBC / DEPT)  18.80 (5-Me), 45.05 (NMe2), 62.97 (CH2), 99.76 (4-C), 124.59 
(8-C), 124.95 (8a-C), 125.84 (7-C), 126.66 (Ph 2,6-C2), 129.00 (Ph 3,5-C2), 132.78 (Ph 4-
C), 133.21 (6-C), 133.73 (4a-C), 136.69 (5-C), 139.76 (Ph 1-C), 140.33 (3-C), 162.97 (1-
C); MS m/z 595.3227 (2 M + H) (C38H42N4O2 requires 595.3230), 293.1668 (M + H) 
(C19H21N2O requires 293.1654). 
5-Methyl-3-(4-(pyrrolidin-1-ylmethyl)phenyl)isoquinolin-1-one hydrochloride (236b). 
Butyllithium (2.5 M in hexanes, 0.46 mL, 1.14 mmol) was added to dry 
diisopropylamine (127.5 mg, 1.3 mmol) in dry THF (2.0 mL) at -78C and the mixture 
was stirred at this temperature for 10 min. Compound 205b (200 mg, 1.13 mmol) in 
dry THF (2.0 mL) was added and the mixture was stirred for 1 h at -78°C. 4-(Pyrrolidin-
1-ylmethyl)benzonitrile (234b) (210.5 mg, 1.13 mmol) in dry THF (2.0 mL) was added at 
-78°C and the mixture was stirred for 1 h at this temperature, then at rt for 16 h. H2O 
(1.0 mL) was added. The mixture was diluted with DCM. This mixture was washed 
thrice with saturated brine; the solvent was evaporated from the organic layer and the 
residue was washed (EtOH, 25 mL) to give 235b (31.6 mg, 9%) as a pale yellow solid: 
mp > 360 °C; IR νmax 3413 (NH), 1640 (C=O); The solid was then treated for 16 h with 
aq. HCl (6.0 M, 2.0 mL) to give the hydrochloride salt 236b: mp >360°C.; 1H NMR 
(DMSO) 1.70 (4 H, m, pyrrolidine 3,4-H4), 2.44 (4 H, m, pyrrolidine 2,5-H4), 2.54 (3 H, 
s, Me), 3.61 (2 H, s, PhCH2), 6.83 (1 H, s, 4-H), 7.35 (1 H, t, J = 7.7 Hz, 7-H), 7.41 (2 H, d, J 
= 8.2 Hz, Ph 3,5-H2), 7.54 (1 H, d, J = 7.2 Hz, 6-H), 7.76 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 
8.05 (1 H, d, J = 7.9 Hz, 8-H), 11.52 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 
18.77 (Me), 23.12 (pyrrolidine 3,4-C2), 53.50 (pyrrolidine 2,5-C2), 59.15 (PhCH2), 
99.72 (4-C), 124.55 (8-C), 124.92 (8a-C), 125.80 (7-C), 126.64 (Ph 2,6-C2), 128.71 (Ph 
3,5-C2), 132.64 (Ph 1-C), 133.30 (6-C), 133.68 (4a-C), 136.81 (5-C), 139.86 (3-C), 140.96 
(Ph 4-C), 163.24 (1-C); MS m/z 319.1788 (C21H23N2O requires 319.1810).  
5-Methyl-3-(4-(piperidin-1-ylmethyl)phenyl)isoquinolin-1-one hydrochloride (236c). 
Butyllithium (1.6 M in hexanes, 0.7 mL, 1.1 mmol) was added to dry diisopropylamine 
(142 mg, 1.4 mmol) in dry THF (2.0 mL) at -78C and the mixture was stirred at this 
temperature for 10 min. Compound 205b (200 mg, 1.1 mmol) in dry THF (2.0 mL) was 
added and the mixture was stirred for 1 h at -78°C. 4-(Piperidin-1-ylmethyl)benzonitrile 
(234c) (226 mg, 1.1 mmol) in dry THF (2.0 mL) was added at -78 °C and the mixture was 
stirred for 1 h at this temperature, then at rt for 16 h. H2O (1.0 mL) was added. The 
mixture was diluted with DCM. This mixture was washed thrice with saturated brine 
and dried. The solvent was evaporated and the residue was washed (EtOH, 20 mL) and 
dried to give 235c (78 mg, 21%) as a white solid: mp 196-197°C. The solid was then 
treated for 16 h with aq. HCl (6.0 M, 2.0 mL) to give the hydrochloride salt 236c: 
mp>360°C.; IR νmax 3440 (NH), 1644 (C=O); 1H NMR (DMSO) 1.40 (2 H, m, piperidine 
4-H2), 1.50 (4 H, m, piperidine 3,5-H4), 2.34 (4 H, m, piperidine 2,6-H4), 2.55 (3 H, s, 
Me), 3.47 (2 H, s, PhCH2), 6.84 (1 H, s, 4-H), 7.36 (1 H, t, J = 7.7 Hz, 7-H), 7.40 (2 H, d, J = 
8.2 Hz, Ph 3,5-H2), 7.54 (1 H, d, J = 7.1 Hz, 6-H), 7.76 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.06 
(1 H, d, J = 7.9 Hz, 8-H), 11.48 (1 H, bs, N-H); 13C NMR (DMSO) (HSQC / HMBC)  18.76 
(Me), 23.96 (piperidine 4-C), 25.55 (piperidine 3,5-C2), 53.91 (piperidine 2,6-C2), 62.37 
(PhCH2), 99.73 (4-C), 124.56 (8-C), 124.90 (8a-C), 125.79 (7-C), 126.61 (Ph 2,6-C2), 
129.01 (Ph 3,5-C2), 132.67 (Ph 1-C), 133.18 (6-C), 133.68 (4a-C), 136.66 (5-C), 139.78 
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(Ph 4-C), 140.06 (3-C), 162.95 (1-C); MS m/z 665.3884 (2 M + H) (C44H49N4O2 requires 
665.3855), 355.1805 (M + Na) (C22H24N2NaO requires 355.1786). 
5-Methyl-3-(4-((4-methylpiperazin-1-yl)methyl)phenyl)isoquinolin-1-one 
hydrochloride (236d). Butyllithium (2.5 M in hexanes, 0.46 mL, 1.14 mmol) was added 
to dry diisopropylamine (128 mg, 1.3 mmol) in dry THF (2.0 mL) at -78C and the 
mixture was stirred at this temperature for 10 min. Compound 205b (200 mg, 1.13 
mmol) in dry THF (2.0 mL) was added and the mixture was stirred for 1 h at -78°C. 4-
((4-Methylpiperazin-1-yl)methyl)benzonitrile (234d) (243 mg, 1.13 mmol) in dry THF 
(2.0 mL) was added at -78°C and the mixture was stirred for 1 h at this temperature, 
then at rt for 16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM. This 
mixture was washed thrice with saturated brine and the solvent was evaporated from 
the dried organic layer. The residue was washed (EtOH, 20 mL) to give 235d (8 mg, 2%) 
as a white solid: mp >360°C. The solid was further treated for 16 h with aq. HCl (6 M, 
1.0 mL) to give the hydrochloride salt 236d: mp >360°C; IR νmax 3419 (NH), 1636 (C=O); 
1H NMR (DMSO) 2.14 (3 H, s, NMe), 2.35 (8 H, m, piperazin-1-yl-H8), 2.54 (3 H, s, 5-
Me), 3.49 (PhCH2), 6.83 (1 H, s, 4-H), 7.35 (1 H, t, J = 7.7 Hz, 7-H), 7.39 (2 H, d, J = 8.2 
Hz, Ph 3,5-H2), 7.54 (1 H, d, J = 7.2 Hz, 6-H), 7.76 (2 H, d, J = 8.2 Hz, Ph 2,6-H2), 8.05 (1 
H, d, J = 7.9 Hz, 8-H), 11.51 (1 H, br, N-H); 13C NMR (DMSO) (HSQC / HMBC) 18.76 (5-
Me), 40.08 (NMe), 52.57 (piperazine 2,6-C2), 54.70 (piperazine 3,5-C2), 61.57 (PhCH2), 
99.75 (4-C), 124.56 (8-C), 124.92 (8a-C), 125.81 (7-C), 126.65 (Ph 2,6-C2), 129.65 (Ph 
3,5-C2), 132.79 (Ph 1-C), 133.18 (6-C), 133.69 (4a-C), 136.65 (5-C), 139.67 (Ph 4-C), 
139.75 (3-C), 162.94 (1-C); MS m/z 348.2076 (C22H26N3O requires 348.2076). 
3-Nitro-2,N,N-trimethylbenzamide (238). 3-Nitro-2-methylbenzoic acid (237) (2.0 g, 11 
mmol) was heated at reflux with SOCl2 (4.5 mL) for 16 h. The excess SOCl2 was 
evaporated. This material, in DCM (7.0 mL) was added dropwise to a vigorously stirred 
solution of dimethylamine in H2O (40%, 7.6 mL) at 10°C. This mixture was then stirred 
at rt for 5 h. The mixture was extracted with DCM. This solution was washed thrice 
with saturated brine and dried. Filtration and evaporation gave 238 (2.09 g, 91%) as a 
pale orange oil (lit.230 oil): Rf = 0.2 (EtOAc / petroleum ether 1:4); 1H NMR (CDCl3)  
2.31 (3 H, s, 2-Me), 2.75 (3 H, N-Me), 3.03 (N-Me), 7.51 (2 H, m, 5,6-H2), 7.94 (1 H, dd, J 
= 7.0, 2.5 Hz, 4-H); 13C NMR (CDCl3) (HSQC / HMBC)  15.31 (Me), 34.06 (N-Me), 37.80 
(N-Me), 124.21 (4-C), 127.56 (5-C), 128.07 (2-C), 130.39 (6-C), 139.92 (1-C), 150.08 (3-
C), 167.96 (C=O).  
3-Ferrocenyl-1-methoxy-5-nitroisoquinoline (240). To 3-bromo-1-methoxy-5-nitroiso-
quinoline 164 (101.4 mg, 0.36 mmol) in a dry flask was added Pd2(dba)3 (32.8 mg, 36 
mol) and SPhos (33.4 mg, 0.07 mmol). Degassed toluene (4.0 mL) was added and the 
mixture was stirred at 100°C for 30 min, after which 1-(tributylstannyl)ferrocene (247) 
(130 mg, 0.39 mmol) in toluene (1.0 mL) was added and the mixture was stirred for a 
further 72 h at 100°C. The evaporation residue, in CHCl3, was filtered through Celite. 
Chromatography (EtOAc / petroleum ether 1:49 → 7:13) gave an inseparable 1:1 
mixture of 240 and 3-butyl-1-methoxy-5-nitroisoquinoline (252) as a yellow solid: Rf = 
0.9 (EtOAc / petroleum ether 1:9); 1H NMR (CDCl3) (COSY / NOESY) 0.93 (3 H, t, J = 
7.0 Hz, 252 Bu 4-H3), 1.41 (2 H, sextet, J = 7.5 Hz, 252 Bu 3-H2), 1.78 (2 H, qn, J = 7.5 Hz, 
252 Bu 2-H2), 2.83 (2 H, t, J = 7.5 Hz, 252 Bu 1-H2), 4.06 (5 H, s, 240 Fc’-H5), 4.18 (3 H, s, 
240 / 252 Me), 4.22 (3 H, s, 240 / 252 Me), 4.46 (2 H, t, J = 1.5 Hz, 240 Fc 3,4-H2), 5.05 
(2 H, t, J = 1.5 Hz, 240 Fc 2,5-H2), 7.49 (2 H, m, 240/ 252 7-H2), 7.80 (1 H, s, 252 4-H), 
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8.11 (1 H, s, 240 4-H), 8.41 (2 H, m, 240/ 252 6-H2), 8.54 (2 H, m, 240 / 252 8-H2); 13C 
NMR (CDCl3) (HSQC / HMBC)14.01 (252 Bu 4-C), 22.43 (252 Bu 3-C), 31.38 (252 Bu 2-
C), 38.26 (252 Bu 1-C), 53.84 (240/ 252 O-Me), 53.92 (240/ 252 O-Me), 67.82 (240 Fc 
2,5-C2), 69.78 (240 Fc’-C5), 70.25 (240 Fc 3,4-C2), 83.86 (240 Fc 1-C), 103.50 (240 4-C), 
106.68 (252 4-C), 119.25 (240 4a/8a-C), 119.36 (252 4a/8a-C), 123.66 (240/ 252 7-C2), 
128.19 (240/ 252 6-C2), 131.19 (240/ 252 8-C2), 143.93 (240 5-C), 144.32 (252 5-
C),155.12 (240 3-C), 157.96 (252 3-C), 160.05 (252 1-C), 160.33 (240 1-C); MS m/z 240 
411.0396 (M + Na) (C20H1656FeN2O3 requires 411.0408), 389.0579 (M + H) 
(C20H1756FeN2O3 requires 389.0587), MS m/z 252 261.1212 (M + H) (C14H16N2O3 
requires 261.1239). 
1-(Tributylstannyl)ferrocene (247). N,N,N’,N’-Tetramethylethylenediamine (TMEDA) 
(2.02 mL, 13.5 mmol) was stirred with anhydrous hexane (2.0 mL) at 0°C. To this 
mixture was then added n-butyllithium (2.5 M in hexane, 5.4 mL) slowly. The n-butyl-
lithium-TMEDA complex was allowed to form during 10 min, after which ferrocene (1.0 
g, 5.4 mmol) in anhydrous hexane (50 mL) was added slowly with ice cooling during 20 
min. The mixture was then stirred at 20C for 4 h, then cooled to 0°C and treated with 
Bu3SnCl (3.08 mL, 11.34 mmol) during 5 min, then warmed to 20C for a further 4 h. 
The mixture was then washed thrice with brine and was dried over K2CO3. The solvent 
was evaporated to afford a crude product which contained varying amounts of 
ferrocene (249), 1,1-bis(tributylstannyl)ferrocene (251) and the desired product 247. 
Column chromatography (petroleum ether) gave 247 (224.5 mg, 9%, ~70% purity) as a 
bright yellow oil: Rf = 0.6 (petroleum ether); 1H NMR (CDCl3) 0.92 (9 H, t, J = 7.3 Hz, 3 
x Bu 4-H3), 1.02 (6 H, t, J = 8.3 Hz, 3 × Bu 1-H2), 1.36 (6 H, m, 3 × Bu 3-H2), 1.58 (6 H, m, 
3 × Bu 2-H2), 4.01 (2 H, t, J = 1.6 Hz, Fc 3,4-H2), 4.10 (5 H, s, Fc’-H5), 4.33 (2 H, t, J = 1.6 
Hz, Fc 2,5-H2); 13C NMR (CDCl3) (HSQC / HMBC) 10.25 3 × Bu 1-C ), 13.71 (3 × Bu 4-C), 
27.42 (3 × Bu 3-C ), 29.20 (3 × Bu 2-C), 67.89 (Fc’-C5),68.73 (Fc 1-C), 70.23 (Fc 3,4-C2), 
74.38 (Fc 2,5-C2); MS m/z 475.1483 (M + H) (C22H3657FeSn requires 475.8297). This 
material was sufficiently pure for further reactions. 
Ferrocene-carboxamide (260). Ferrocene-carboxylic acid (259) (500.0 mg, 2.2 mmol) 
was stirred with oxalyl chloride (633.5 mg, 5.0 mmol) for 1 h. The excess reagent was 
then evaporated. The residual red oil, in dry THF (5.0 mL), was added dropwise to a 
stirred solution of NH3 in Et2O. After 15 min, H2O (20 mL) wad added and organic layer 
was washed thrice (H2O). Drying and evaporation gave 260 (370 mg, 74%) as a pale 
orange solid: Rf = 0.3 (EtOAc / petroleum ether 3:2); mp 168-169°C (lit.289 mp 168-
171°C); 1H NMR (DMSO) 4.15 (5 H, s, Fc’-H5), 4.32 (2 H, br, Fc 3,4-H2), 4.74 (2 H, br, Fc 
2,5-H2), 6.91 (1 H, br, NH), 7.28 (1 H, br, NH); 13C NMR (DMSO) (HSQC / HMBC) 68.49 
(Fc 2,5-C2), 69.31 (Fc’-C5), 69.91 (Fc 3,4-C2), 76.42 (Fc 1-C), 171.01 (C=O). 
Ferrocenenitrile (261). Compound 260 (352 mg, 1.5 mmol) was stirred with POCl3 (3.5 
mL) at 120°C for 2 h, followed by cooling to 0°C and quench with H2O (1.0 mL). The 
crude mixture was diluted with EtOAc and washed thrice with H2O. The organic layer 
was dried and the solvent was evaporated to give 261 (360 mg, 99%) as a dark orange 
solid: Rf = 0.9 (EtOAc / petroleum ether 1:1); mp 105-107°C (lit.290 mp 106.4–106.7C); 
1H NMR (DMSO) 4.34 (5 H, s, Fc’-H5), 4.50 (2 H, s, Fc 3,4-H2), 4.83 (2 H, s, Fc 2,5-H2); 
13C NMR (DMSO) (HSQC / HMBC) 51.05 (Fc 1-C), 70.32 (Fc’-C5), 71.00 (Fc 3,4-C2), 
71.61 (Fc 2,5-C2), 120.21 (CN). 
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3-Ferrocenyl-5-methylisoquinolin-1-one (262). Butyllithium (2.5 M in hexanes, 0.46 
mL, 1.14 mmol) was added to dry diisopropylamine (127 mg, 1.3 mmol) in dry THF (2.0 
mL) at -78C and the mixture was stirred at this temperature for 10 min. Compound 
205b (200 mg, 1.13 mmol) in dry THF (2.0 mL) was added and the mixture was stirred 
for 1 h at -78°C. Ferrocenenitrile (261) (238.5 mg, 1.13 mmol) in dry THF (2.0 mL) was 
added at -78°C and the mixture was stirred for 1 h at this temperature, then at rt for 
16 h. H2O (1.0 mL) was added. The mixture was diluted with DCM and washed thrice 
with saturated brine. The solvent was evaporated from the dried organic layer to give 
262 (80.5 mg, 21%) as a dark orange solid: mp >360°C; IR νmax 3454 (NH), 1633 (C=O); 
1H NMR (DMSO) (COSY) 2.50 (3 H, s, Me), 4.16 (5 H, s, Fc’-H5), 4.45 (2 H, s, Fc 3,4-H2), 
5.11 (2 H, s, Fc 2,5-H2), 6.72 (1 H, s, 4-H), 7.30 (1 H, t, J = 7.3 Hz, 7-H), 7.50 (1 H, d, J = 
6.6 Hz, 6-H), 8.02 (1 H, d, J = 7.7 Hz, 8-H), 11.08 (1 H, br, NH); 13C NMR (DMSO) (HSQC / 
HMBC) 18.81 (Me), 66.33 (Fc 2,5-C2), 69.59 (Fc’-C5), 69.74 (Fc 3,4-C2), 78.61 (Fc 1-C), 
97.03 (4-C), 124.44 (8a-C), 124.69 (8-C), 124.91 (7-C), 132.74 (4a-C), 133.12 (6-C), 
136.96 (5-C), 140.01 (3-C), 162.74 (1-C); MS m/z 366.0552 (C20H1756FeNONa requires 
366.0557). 
7.2 General biological experimental 
All reagents for biological experiments were purchased from the Sigma-Aldrich Chem-
ical Co., Fisher Ltd or Invitrogen and were of at least biochemical grade. Aq. solutions 
were made using 18.2 Mega-Ω.cm-1 Milli-Q H2O and the pH was adjusted as required 
with HCl or NaOH solutions. The pH was measured using a Corning pH meter 240 and 
Corning general purpose combination pH electrode which was calibrated at pH 4.0, 7.0 
and 10.0 at rt. Reagents and plasticware were sterilised by autoclaving at 121°C for 15 
min or were purchased already sterilised. Temperature sensitive reagents were 
sterilied through filtration (0.2 µM). All tissue culture experiments were conducted in a 
sterile hood. Optical density readings were measure at 450 nM (enzyme assays) and 
490 nM (cell-based assays) using a VERSAmax microplate plate reader.  
7.3 MTS cell Proliferation Assay 
The human colon carcinoma cell line HT29 (Cancer Research UK) were cultured and 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with high 
glucose (4.5 g L-1) and L-glutamine, 10% (v/v) foetal bovine serum (FBS), penicillin (100 
U mL-1) and streptomycin sulphate (100 µg mL-1) at 37°C in a humidified atmosphere 
containing 5% (v/v) CO2. The primary human skin fibroblasts (FEK4) were a kind gift 
from Prof. Rex M. Tyrrell and Dr C. Pourzand (University of Bath) and were cultured 
and maintained in Eagle’s Minimal Essential Medium (EMEM) supplemented with L-
glutamine, penicillin (100 U/ mL), streptomycin (100 µg/mL) and foetal bovine serum 
15% (v/v). Cells were maintained in T75 (Nunc; 75 cm2) tissue culture flasks and 
passaged once weekly with three new T75 flasks being seeded with the required cell 
numbers to reach confluence in preparation for twice or thrice weekly experiments. 
The seed density required for different cell lines had been previously determined to 
give an acceptable optical density value after a 3-day incubation and were calculated 
for 500 and 1500 cells per well in 50 µL for HT29 and FEK4 cells respectively. The MTS 
assay is based on the reagent: Promega ‘Cell Titer 96® Aq. One Solution Cell 
Proliferation Assay’291 and the procedure used was adopted from a protocol developed 
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by Dr. Pauline J. Wood.292 Centrifugation was carried out using a Jouan B3.11 
centrifuge at 1300 rpm unless otherwise specified. The determination of IC50 data was 
calculated using a four parameter logistic curve and SigmaPlot 11.0 software (SPSS 
Inc.) for windows. Means and standard deviations were calculated from background 
corrected absorbance.  
7.3.1 Procedure 
7.3.1.1 Preparation of cell suspensions 
Using aseptic technique, the medium was removed from a T75 flask of the required 
cell line and the cells washed with PBS (5 mL). Trypsin/ EDTA solution (5 mL; 0.05% and 
0.25% for HT29 and FEK4 cells respectively) was added and the misture placed at 37°C 
until the cells detached. Fresh medium (5 mL) was added to neutralise the Trypsin/ 
EDTA solution and suspend the cells. The suspension was transferred to a Universal 
tube and centrifuged at ~1300 rpm for 7-8 min. The supernatant was removed and the 
cell pellet was re-suspended in fresh medium (5 mL). This was then diluted (~1 in 10) 
and the cells counted using a haemocytometer. Further dilutions were made to give a 
suspension with the required number of cells per well for the experiment (see above).  
7.3.1.2 Preparation of test compounds 
Test agents were prepared at 100x final concentration in DMSO (Sigma Aldrich). A 
stock solution of 50 mM of inhibitor solution was prepared initially and then serially 
diluted to provide all other required 100x concentrations. For an unknown inhibitor 
the initial concentration range explored was 500 µM – 500 nM (Final concentrations in 
well). Following dilution into DMSO, the stock solutions were then diluted into tissue 
culture medium (1 in 50) in preparedness for introduction to the 96-well microtitre 
plate (Nunc).  
7.3.1.3 Preparation of Plates for Experiment 
1. The required number of cells (50 µL; suspended in medium) were seeded onto 
96-well microtitre plates and the plates incubated at 37°C, in a humidified 
atmosphere containing 5% (v/v) CO2 for 2-4 h.  
2. Quadruplicate samples were run by adding the following reagents: 
a. Culture medium only (negative control; 100 µL medium per well) 
b. Cell suspension only (positive control; 50 µL medium + 50  µL cell 
suspension) 
c. Cell suspension + 1% (v/v) DMSO vehicle (50 µL of 2% (v/v) DMSO in 
medium + 50 µL cell suspension).  
d. Cell suspension + test compound in 1% (v/v) DMSO vehicle (50 µL of test 
compound at 2x final concentration with 2% (v/v) DMSO in medium + 
50 µL cell suspension).  
Each well contained a final volume of 100 µL medium containing final 
vehicle concentration of 1% (v/v) DMSO. Plates were incubated at 37°C, 
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in a humidified atmosphere containing 5% (v/v) CO2 for 72 h. This 
exposure time appears to be adequate to demonstrate anti-proliferative 
activity and is a standard technique routinely employed by other 
research groups.  
3. MTS reagent (20 µL) was added to each well and the plates were incubated at 
37°C, in a humidified atmosphere containing 5% (v/v) CO2 for 2-4 h, to allow for 
colour development. 
4. Optical density readings were recorded at 490 nm. As the tissue culture 
medium only wells have a high OD450nm, this was subtracted from all other 
OD450nm. The means and standard deviations were then calculated from 
background corrected OD450nm values.  
5. IC50 values and curves were determined using a four-parameter logistic curve 
and SigmaPlot 11.0 software. Each assay was repeated on at least two, but 
ususally three separate occasions.  
Note: This assay is based upon the development of a coloured metabolite from viable 
cells, and as such cannot distinguish between inhibition of cell metabolism i.e. 
cytostasis and reduction in actual cell number i.e. cytotoxicity. This assay does 
however provide invaluable information when initially screening inhibitors and is a 
facile and quick technique to employ.  
7.4 Enzyme assay methods 
7.4.1 Preparation of test compounds 
A stock solution of 50 mM of inhibitor in DMSO was prepared and used for further 
dilutions. Stock solutions were prepared at 100x the final concentration required in the 
well for the experiment. For a range-finding experiment inhibitors were used at a final 
concentration of 1 µM, 100 nM and 10 nM. This range was then extended and 
adjusted accordingly for the IC50 determining experiments. Alongside inhibitors, 
background, enzyme-only and enzyme + 1% DMSO wells were included on each plate. 
All samples were ran in triplicate.  
7.5 Tankyrase-2 auto-PARsylation assay developed in-house 
Tankyrase-2 protein (catalytic + SAM domain) was supplied by BPS Bioscience and AMS 
Bio Europe Ltd. (Catalogue no. 80515) and stored at -78°C. Reagents used in this assay 
included ELISA-quality, half-volume, high-binding 96-well plates (Greiner bio-one), 
NAD+ (Enzo Life Sciences), biotinylated NAD+ (BioLog Life Science Institute), 
streptavidin / HRP solution and substrate solution A and B (Hydrogen peroxide 
solution; R&D Systems). Tankyrase-2 protein was suspended in reaction buffer (25 µL, 
50 mM TRIS-HCl pH 8.0, 5.0 mM MgCl2, 20µM ZnCl2). Wells were washed multiple 
times during the assay procedure using phosphate-buffered saline solution at pH 7.4 + 
0.05% v/v tween 20 (PBS-T). Non-specific protein-protein interactions were blocked 
using a suspension of skimmed milk powder (Marvel) in reaction buffer (5% w/v).  
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7.5.1 Procedure 
1. A suspension of tankyrase-2 protein (7.5 ng) in reaction buffer (25 µL) was 
loaded into ELISA-quality, half-volume, high-binding 96-well plates and held at 
5-8°C for 16h. 
2. The wells were then washed four times with PBS-T (250 µL). Marvel solution 
(100 µL) was added to each well and the mixture allowed to stand at rt for 1 h. 
The wells were then washed again with PBS-T (4 x 250 µL).  
3. Wells were loaded to a total reaction volume of 25 µL. This consisted of 
reaction buffer with 5 µL of varying concentrations of inhibitors (see Section 
7.4.1) from stock solutions in DMSO (to give a final DMSO concentration of 1%) 
and 5 µL of a solution of biotinylated-NAD+ and NAD+ (to give a final reaction 
concentration of 5 µM).  
4. The plates were then incubated at 30°C for 2 h.  
5. The plates were then washed with PBS-T (4 x 250 µL), then streptavidin/ HRP 
solution (100 µL) was added to each well. 
6. Plates were then held at rt for 2 h. 
7. Following a PBS-T wash (4 x 250 µL), a 1:1 mixture of substrate solutions A and 
B solution (100 µL) was added per well and the plates were held at rt for 30 min 
(protected from light).  
8. The reaction was stopped by addition of aq. H2SO4 (1.0 M, 25 µL) per well. 
9. OD450nm read within 20 min.  
10. The IC50 values were determined using a four-parameter logistic curve and 
SigmaPlot 11.0 software. 
7.6 Tankyrase-1 colorimetric activity assay kit 
Tankyrase-1 assays were performed using a commercial kit (Amsbio Europe Ltd., 
catalogue no. 4700-096-K), using pre-coated histone well plates. All reagents were 
supplied and used according to the manufacturers’ instructions; 20x I-PAR assay buffer 
(catalogue no. 4684-096-07) was diluted 1 in 20 with distilled H2O; assay substrate 
(catalogue no. 4700-096-02) was used as received; Antibody diluent was prepared 
from 5x stock solution (catalogue no. 4684-096-04) using distilled H2O; Anti-PAR 
monoclonal antibody was diluted 1000x with 1x antibody diluent; Goat anti-mouse 
IgG-HRP conjugate (catalogue no. 4684-096-05) was diluted 1000x with 1x antibody 
diluent; TACS-Sapphire™ (catalogue no. 4822-96-08) was used as received.  
7.6.1 Procedure  
1. I-PAR buffer (50 µL) was added to each well to rehydrate the histone coated 
wells and left for 30 min and rt, then removed by aspiration. 
2. The total reaction volume (50 µL) was made up as follows: tankyrase-1 protein 
(5 mU in 25 µL I-PAR assay buffer), solutions of test inhibitors (5 µL; see Section 
7.4.1) in I-PAR buffer (to give a final DMSO concentration of 1%) and assay 
substrate (15 µL). Background wells were treated with I-PAR assay buffer alone. 
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Maximum enzyme activity was established using wells treated with enzyme 
only + 1% DMSO. The plates were held at 30 min at rt.  
3. The plates were then washed with PBS-T (2 x 250 µL), then with PBS (2 x 250 
µL). 
4. Wells were then loaded with pre-diluted anti-PAR monoclonal antibody (50 µL) 
and plates held for 30 min at rt. 
5. The plates were then washed with PBS-T (2 x 250 µL), then with PBS (2 x 250 
µL). 
6. Wells were then loaded with pre-diluted anti-mouse IgG-HRP conjugate 
antibody (50 µL) and plates held for 30 min at rt.  
7. Pre-warmed TACS-sapphire (50 µL) then added to each well and the plates held 
for 15 min at rt (in the dark).  
8. The reaction was stopped by addition of HCl (0.2 M; 50 µL) per well. 
9. OD450nm read within 20 min.  
10. The IC50 values were determined using a four-parameter logistic curve and 
SigmaPlot 11.0 software. 
7.7 PARP-1 colorimetric assay kit  
PARP-1 assays were performed using a commercial kit (Amsbio Europe Ltd. catalogue 
no. 4677-096-K), using pre-coated histone well plates. All reagents were supplied and 
used according to the manufacturers’ instructions; 20x PARP assay buffer (catalogue 
no. 4671-096-02) was diluted to 1x with distilled H2O; 10x PARP cocktail (catalogue no. 
4671-096-03) was used as received; 10x activated-DNA (catalogue no. 4671-096-06) 
was used as received; Streptavidin-HRP solution (catalogue no. 4800-30-06) was 
diluted with 500x with 1x streptavidin-HRP diluent (catalogue no. 4671-096-04); TACS-
Sapphire™ (catalogue no. 4822-96-08) was used as received.  
7.7.1 Procedure  
1. PARP assay buffer (50 µL) was added to each well to rehydrate the histone-
coated plates for 30 min at rt, then removed by aspiration.  
2. The total reaction volume (50 µL) was made up as follows: PARP-1 protein (0.5 
mU in 25 µL 1x PARP assay buffer), solutions of test inhibitors (5 µL; see Section 
7.4.1) in PARP assay buffer (to give a final DMSO concentration of 1%) and 
substrate (20 µL; 2.5 µL 10x PARP cocktail, 2.5 µL 10x activated DNA and 15 µL 
PARP assay buffer). Background wells were treated with PARP assay buffer 
alone. Maximum enzyme activity was established using wells treated with 
enzyme only + 1% DMSO. A control PARP-1 inhibitor (5-AIQ) was also included. 
The plates were held at 1 h at rt.  
3. The plates were then washed with PBS-T (2 x 250 µL), then with PBS (2 x 250 
µL). 
4. Wells were then loaded with pre-diluted streptavidin-HRP solution (50 µL) and 
plates held for 1 h at rt. 
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5. The plates were then washed with PBS-T (2 x 250 µL), then with PBS (2 x 250 
µL). 
6. Pre-warmed TACS-sapphire (50 µL) then added to each well and the plates held 
for 15 min at rt (in the dark).  
7. The reaction was stopped by addition of HCl (0.2 M; 50 µL) per well. 
8. OD450nm read within 20 min.  
9. The IC50 values were determined using a four-parameter logistic curve and 
SigmaPlot 11.0 software. 
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Appendix C: X-Ray Crystallographic Data 
 
X-ray structure determination for 206e  
 
 Table 1:  Crystal data and structure refinement for 206e 
                                                                                                                         
 Identification code k12farm8 
 Empirical formula C34 H28 Cl4 N2 O3 
 Formula weight 654.38 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/n 
 Unit cell dimensions a = 14.1190(3)Å alpha = 90o 
       b = 13.6440(3)Å beta = 96.302(1)o 
       c = 15.7740(4)Å gamma = 90o 
 Volume 3020.33(12) Å3 
 Z 4 
 Density (calculated) 1.439 Mg/m3 
 Absorption coefficient 0.431 mm-1 
 F(000) 1352 
 Crystal size 0.25 x 0.15 x 0.08 mm 
 Theta range for data collection 3.62 to 26.37o 
 Index ranges -17<=h<=17; -17<=k<=17; -19<=l<=19 
 Reflections collected 56157 
 Independent reflections 6157 [R(int) = 0.0932] 
 Reflections observed (>2sigma) 4274 
 Data Completeness 0.997 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 0.928 and 0.832 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 6157 / 0 / 391 
 Goodness-of-fit on F2 1.034 
 Final R indices [I>2sigma(I)] R1 = 0.0502   wR2 = 0.1070 
 R indices (all data) R1 = 0.0868  wR2 = 0.1250 




Small crystal – poor diffraction at higher Bragg angles, hence data truncated at  = 26.4o. 
2 molecules in the asymmetric unit plus one solvent entity (ethanol). Hydrogen-bonding 
present. Methyl hydrogen atoms attached to C16 and C16A are disordered. 
 
 
  D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 O2-H2          0.840    1.988   174.03    2.825    O1A  
 
 N1-H1          0.880    1.947   170.53    2.819    O1A  
 
 N1A-H1A        0.880    2.030   160.14    2.874    O1  
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Table 2: Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 
103) for 206e. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
                                                                                                                         
  Atom   x   y   z  U(eq) 
Cl(1) 6739(1) 6508(1) 5251(1) 43(1) 
Cl(2) 6779(1) 3145(1) 7104(1) 35(1) 
O(1) 8901(1) 2703(1) 5088(1) 30(1) 
O(2) 6729(2) 3007(2) 3249(2) 51(1) 
N(1) 7908(2) 3810(2) 5586(1) 26(1) 
C(1) 6168(2) 5613(2) 5800(2) 31(1) 
C(2) 5211(2) 5739(2) 5874(2) 34(1) 
C(3) 4733(2) 5046(2) 6300(2) 38(1) 
C(4) 5216(2) 4233(2) 6660(2) 36(1) 
C(5) 6181(2) 4132(2) 6585(2) 29(1) 
C(6) 6690(2) 4804(2) 6142(2) 26(1) 
C(7) 7708(2) 4650(2) 6035(2) 25(1) 
C(8) 8425(2) 5243(2) 6344(2) 26(1) 
C(9) 9396(2) 5012(2) 6224(2) 24(1) 
C(10) 9587(2) 4125(2) 5812(2) 25(1) 
C(11) 8802(2) 3491(2) 5473(2) 26(1) 
C(12) 10522(2) 3860(2) 5709(2) 30(1) 
C(13) 11260(2) 4467(2) 6004(2) 33(1) 
C(14) 11076(2) 5357(2) 6393(2) 32(1) 
C(15) 10161(2) 5644(2) 6503(2) 26(1) 
C(16) 9966(2) 6627(2) 6895(2) 34(1) 
C(17) 7352(2) 2287(2) 2980(2) 47(1) 
C(18) 7566(3) 2559(3) 2092(2) 51(1) 
Cl(1A) 8342(1) -1484(1) 5145(1) 38(1) 
Cl(2A) 8970(1) 1794(1) 7072(1) 38(1) 
O(1A) 6463(1) 2497(1) 4942(1) 29(1) 
N(1A) 7483(2) 1314(2) 5481(1) 25(1) 
C(1A) 9101(2) -663(2) 5728(2) 26(1) 
C(2A) 10060(2) -884(2) 5836(2) 30(1) 
C(3A) 10687(2) -241(2) 6291(2) 34(1) 
C(4A) 10352(2) 597(2) 6654(2) 33(1) 
C(5A) 9385(2) 789(2) 6545(2) 28(1) 
C(6A) 8723(2) 187(2) 6066(2) 25(1) 
C(7A) 7699(2) 449(2) 5932(2) 25(1) 
C(8A) 6993(2) -75(2) 6225(2) 25(1) 
C(9A) 6024(2) 259(2) 6099(2) 24(1) 
C(10A) 5826(2) 1162(2) 5674(2) 24(1) 
C(11A) 6594(2) 1704(2) 5340(2) 25(1) 
C(12A) 4902(2) 1535(2) 5562(2) 29(1) 
C(13A) 4173(2) 1015(2) 5849(2) 31(1) 
C(14A) 4353(2) 114(2) 6253(2) 32(1) 
C(15A) 5261(2) -279(2) 6385(2) 27(1) 
C(16A) 5426(2) -1265(2) 6805(2) 35(1) 




- 315 - 
 
                                                                                                                       
                                                                                                                         
 Table 3: Bond lengths [Å] and angles [o] for 206e. 
   
Cl(1)-C(1) 1.745(3) Cl(2)-C(5) 1.744(3) 
O(1)-C(11) 1.250(3) O(2)-C(17) 1.414(4) 
N(1)-C(11) 1.366(3 N(1)-C(7) 1.392(3) 
C(1)-C(2) 1.380(4) C(1)-C(6) 1.402(4) 
C(2)-C(3) 1.378(4) C(3)-C(4) 1.391(4) 
C(4)-C(5) 1.388(4) C(5)-C(6) 1.398(4) 
C(6)-C(7) 1.481(4) C(7)-C(8) 1.345(4) 
C(8)-C(9) 1.439(4)  C(9)-C(10) 1.414(4) 
C(9)-C(15) 1.414(4)  C(10)-C(12) 1.396(4) 
C(10)-C(11) 1.461(4) C(12)-C(13) 1.371(4) 
C(13)-C(14) 1.398(4) C(14)-C(15) 1.379(4) 
C(15)-C(16) 1.514(4) C(17)-C(18) 1.511(5) 
Cl(1A)-C(1A) 1.741(3) Cl(2A)-C(5A) 1.737(3) 
O(1A)-C(11A) 1.254(3) N(1A)-C(11A) 1.360(3) 
N(1A)-C(7A) 1.394(3) C(1A)-C(2A) 1.381(4) 
C(1A)-C(6A) 1.405(4) C(2A)-C(3A) 1.388(4) 
C(3A)-C(4A) 1.384(4) C(4A)-C(5A) 1.384(4) 
C(5A)-C(6A) 1.401(4) C(6A)-C(7A) 1.482(4) 
C(7A)-C(8A) 1.349(4) C(8A)-C(9A) 1.435(4) 
C(9A)-C(15A) 1.417(4) C(9A)-C(10A) 1.416(4) 
C(10A)-C(12A) 1.394(4) C(10A)-C(11A) 1.457(4) 
C(12A)-C(13A) 1.367(4) C(13A)-C(14A) 1.394(4) 
C(14A)-C(15A) 1.385(4) C(15A)-C(16A) 1.506(4) 
C(11)-N(1)-C(7) 124.8(2) C(2)-C(1)-C(6) 122.9(3) 
C(2)-C(1)-Cl(1) 117.7(2) C(6)-C(1)-Cl(1) 119.4(2) 
C(3)-C(2)-C(1) 119.5(3) C(2)-C(3)-C(4) 120.1(3) 
C(5)-C(4)-C(3) 119.1(3) C(4)-C(5)-C(6) 122.7(3) 
C(4)-C(5)-Cl(2) 117.7(2) C(6)-C(5)-Cl(2) 119.5(2) 
C(5)-C(6)-C(1) 115.6(3) C(5)-C(6)-C(7) 121.5(2) 
C(1)-C(6)-C(7) 122.9(2) C(8)-C(7)-N(1) 119.6(2) 
C(8)-C(7)-C(6) 125.0(2) N(1)-C(7)-C(6) 115.3(2) 
C(7)-C(8)-C(9) 120.6(2) C(10)-C(9)-C(15) 119.1(2) 
C(10)-C(9)-C(8) 118.8(2) C(15)-C(9)-C(8) 122.1(2) 
C(12)-C(10)-C(9) 120.5(3) C(12)-C(10)-C(11) 119.6(2) 
C(9)-C(10)-C(11) 119.9(2) O(1)-C(11)-N(1) 119.5(2) 
O(1)-C(11)-C(10) 124.5(2) N(1)-C(11)-C(10) 116.0(2) 
C(13)-C(12)-C(10) 119.8(3) C(12)-C(13)-C(14) 120.2(3) 
C(15)-C(14)-C(13) 121.6(3) C(14)-C(15)-C(9) 118.8(2) 
C(14)-C(15)-C(16) 121.2(3) C(9)-C(15)-C(16) 120.0(2) 
O(2)-C(17)-C(18) 107.6(3) C(11A)-N(1A)-C(7A) 124.1(2) 
C(2A)-C(1A)-C(6A) 122.8(3) C(2A)-C(1A)-Cl(1A) 117.6(2) 
C(6A)-C(1A)-Cl(1A) 119.6(2) C(1A)-C(2A)-C(3A) 119.1(3) 
C(4A)-C(3A)-C(2A) 120.6(3) C(3A)-C(4A)-C(5A) 118.8(3) 
C(4A)-C(5A)-C(6A) 123.1(3) C(4A)-C(5A)-Cl(2A) 118.0(2) 
C(6A)-C(5A)-Cl(2A) 118.8(2) C(5A)-C(6A)-C(1A) 115.5(2) 
C(5A)-C(6A)-C(7A) 121.2(2) C(1A)-C(6A)-C(7A) 123.4(2) 
C(8A)-C(7A)-N(1A) 119.7(2) C(8A)-C(7A)-C(6A) 124.7(2) 
N(1A)-C(7A)-C(6A) 115.6(2) C(7A)-C(8A)-C(9A) 121.0(2) 
C(15A)-C(9A)-C(10A) 119.0(2) C(15A)-C(9A)-C(8A) 122.6(2) 
C(10A)-C(9A)-C(8A) 118.5(2) C(12A)-C(10A)-C(9A) 120.7(3) 
C(12A)-C(10A)-C(11A) 119.4(2) C(9A)-C(10A)-C(11A) 119.8(2) 
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O(1A)-C(11A)-N(1A) 120.2(2) O(1A)-C(11A)-C(10A) 123.0(2) 
N(1A)-C(11A)-C(10A) 116.9(2) C(13A)-C(12A)-C(10A) 119.7(3) 
C(12A)-C(13A)-C(14A) 120.2(3) C(15A)-C(14A)-C(13A) 122.0(3) 
C(14A)-C(15A)-C(9A) 118.4(3) C(14A)-C(15A)-C(16A) 120.6(3) 
C(9A)-C(15A)-C(16A) 121.1(3)   
                                                                                                                
 
Table 4: Anisotropic displacement parameters (Å2 x 103) for 206e. The anisotropic 
displacement factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
                                                                                                                         
  Atom  U11  U22  U33  U23  U13  U12 
Cl(1) 36(1) 30(1) 64(1) 15(1) 9(1) 7(1) 
Cl(2) 43(1) 27(1) 34(1) 4(1) 7(1) -2(1) 
O(1) 36(1) 20(1) 34(1) -4(1) 9(1) 2(1) 
O(2) 54(2) 55(2) 44(2) 11(1) 14(1) 15(1) 
N(1) 28(1) 19(1) 32(1) -1(1) 4(1) 1(1) 
C(1) 34(2) 25(2) 33(2) -2(1) 4(1) 0(1) 
C(2) 30(2) 35(2) 39(2) -5(1) 4(1) 6(1) 
C(3) 28(2) 47(2) 40(2) -9(2) 7(1) 2(1) 
C(4) 36(2) 39(2) 36(2) -6(1) 9(1) -9(1) 
C(5) 33(2) 24(1) 30(2) -6(1) 3(1) -1(1) 
C(6) 28(2) 20(1) 29(1) -5(1) 6(1) 0(1) 
C(7) 30(2) 19(1) 26(1) 2(1) 6(1) 3(1) 
C(8) 31(2) 20(1) 28(1) 0(1) 4(1) 3(1) 
C(9) 28(1) 22(1) 23(1) 4(1) 4(1) 2(1) 
C(10) 31(2) 21(1) 24(1) 4(1) 4(1) 1(1) 
C(11) 31(2) 20(1) 26(1) 5(1) 5(1) 5(1) 
C(12) 33(2) 28(2) 30(2) 2(1) 8(1) 7(1) 
C(13) 27(2) 37(2) 35(2) 3(1) 7(1) 5(1) 
C(14) 33(2) 33(2) 29(2) 2(1) 1(1) -2(1) 
C(15) 30(2) 25(1) 24(1) 3(1) 1(1) 2(1) 
C(16) 32(2) 27(2) 41(2) -3(1) 0(1) -3(1) 
C(17) 40(2) 40(2) 61(2) 4(2) 10(2) -1(2) 
C(18) 50(2) 61(2) 44(2) -9(2) 10(2) -11(2) 
Cl(1A) 35(1) 27(1) 53(1) -13(1) 1(1) 1(1) 
Cl(2A) 50(1) 25(1) 35(1) -7(1) -3(1) 5(1) 
O(1A) 34(1) 20(1) 32(1) 6(1) 2(1) 4(1) 
N(1A) 28(1) 19(1) 28(1) 2(1) 4(1) 3(1) 
C(1A) 30(2) 20(1) 29(2) 1(1) 2(1) 0(1) 
C(2A) 35(2) 22(1) 34(2) 2(1) 7(1) 7(1) 
C(3A) 30(2) 35(2) 37(2) 8(1) 2(1) 3(1) 
C(4A) 35(2) 30(2) 33(2) 1(1) -2(1) -5(1) 
C(5A) 34(2) 20(1) 28(2) 3(1) 2(1) 2(1) 
C(6A) 30(2) 22(1) 24(1) 3(1) 2(1) 2(1) 
C(7A) 32(2) 18(1) 23(1) -2(1) 2(1) 3(1) 
C(8A) 32(2) 17(1) 27(1) 1(1) 3(1) 4(1) 
C(9A) 29(2) 21(1) 22(1) -3(1) 4(1) 0(1) 
C(10A) 30(2) 21(1) 22(1) -4(1) 4(1) 2(1) 
C(11A) 32(2) 21(1) 21(1) -3(1) 0(1) 3(1) 
C(12A) 30(2) 29(2) 27(1) -3(1) -1(1) 6(1) 
C(13A) 26(2) 34(2) 33(2) -4(1) 2(1) 4(1) 
C(14A) 31(2) 36(2) 29(2) -5(1) 5(1) -6(1) 
C(15A) 32(2) 23(1) 26(1) -4(1) 2(1) 1(1) 
C(16A) 39(2) 31(2) 36(2) 4(1) 7(1) -5(1) 
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Table 5: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 
206e. 
                                                                                                                         
  Atom   x   y   z  U(eq) 
H(2) 6631 2896 3756 104(19) 
H(1) 7422 3459 5359 31 
H(2B) 4883 6299 5633 41 
H(3) 4072 5124 6347 46 
H(4) 4890 3753 6953 44 
H(8) 8289 5821 6646 32 
H(12) 10648 3260 5436 36 
H(13) 11897 4282 5943 39 
H(14) 11594 5774 6586 38 
H(16A) 9279 6701 6921 50 
H(16B) 10192 7153 6544 50 
H(16C) 10301 6663 7472 50 
H(16D) 10568 6977 7037 50 
H(16E) 9656 6525 7414 50 
H(16F) 9547 7015 6486 50 
H(17A) 7049 1633 2975 56 
H(17B) 7949 2267 3373 56 
H(18A) 6976 2542 1702 77 
H(18B) 8024 2092 1899 77 
H(18C) 7837 3221 2099 77 
H(1A) 7952 1627 5276 30 
H(2A) 10290 -1468 5602 36 
H(3A) 11350 -377 6354 41 
H(4A) 10780 1032 6972 40 
H(8A) 7139 -673 6519 30 
H(12A) 4779 2148 5287 35 
H(13A) 3543 1267 5772 38 
H(14A) 3837 -239 6443 38 
H(16G) 6106 -1427 6845 53 
H(16H) 5059 -1765 6464 53 
H(16I) 5220 -1245 7378 53 
H(16J) 4818 -1530 6946 53 
H(16K) 5864 -1193 7327 53 
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 Table 6: Dihedral angles [o] for 206e. 
                                                                                                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
C(6) - C(1) - C(2) - C(3) -0.1(4) 
Cl(1) - C(1) - C(2) - C(3) 179.8(2) 
C(1) - C(2) - C(3) - C(4) 0.7(4) 
C(2) - C(3) - C(4) - C(5) 0.1(4) 
C(3) - C(4) - C(5) - C(6) -1.6(4) 
C(3) - C(4) - C(5) - Cl(2) 175.9(2) 
C(4) - C(5) - C(6) - C(1) 2.1(4) 
Cl(2) - C(5) - C(6) - C(1) -175.4(2) 
C(4) - C(5) - C(6) - C(7) -176.8(3) 
Cl(2) - C(5) - C(6) - C(7) 5.8(4) 
C(2) - C(1) - C(6) - C(5) -1.2(4) 
Cl(1) - C(1) - C(6) - C(5) 178.9(2) 
C(2) - C(1) - C(6) - C(7) 177.6(3) 
Cl(1) - C(1) - C(6) - C(7) -2.3(4) 
C(11) - N(1) - C(7) - C(8) 4.3(4) 
C(11) - N(1) - C(7) - C(6) -174.6(2) 
C(5) - C(6) - C(7) - C(8) -117.3(3) 
C(1) - C(6) - C(7) - C(8) 63.9(4) 
C(5) - C(6) - C(7) - N(1) 61.6(3) 
C(1) - C(6) - C(7) - N(1) -117.2(3) 
N(1) - C(7) - C(8) - C(9) -0.7(4) 
C(6) - C(7) - C(8) - C(9) 178.2(2) 
C(7) - C(8) - C(9) - C(10) -3.1(4) 
C(7) - C(8) - C(9) - C(15) 176.7(2) 
C(15) - C(9) - C(10) - C(12) 2.4(4) 
C(8) - C(9) - C(10) - C(12) -177.8(2) 
C(15) - C(9) - C(10) - C(11) -176.3(2) 
C(8) - C(9) - C(10) - C(11) 3.5(4) 
C(7) - N(1) - C(11) - O(1) 177.1(2) 
C(7) - N(1) - C(11) - C(10) -3.8(4) 
C(12) - C(10) - C(11) - O(1) 0.2(4) 
C(9) - C(10) - C(11) - O(1) 178.9(2) 
C(12) - C(10) - C(11) - N(1) -178.9(2) 
C(9) - C(10) - C(11) - N(1) -0.3(4) 
C(9) - C(10) - C(12) - C(13) -0.6(4) 
C(11) - C(10) - C(12) - C(13) 178.1(2) 
C(10) - C(12) - C(13) - C(14) -1.1(4) 
C(12) - C(13) - C(14) - C(15) 1.0(4) 
C(13) - C(14) - C(15) - C(9) 0.9(4) 
C(13) - C(14) - C(15) - C(16) -177.6(3) 
C(10) - C(9) - C(15) - C(14) -2.5(4) 
C(8) - C(9) - C(15) - C(14) 177.7(2) 
C(10) - C(9) - C(15) - C(16) 176.0(2) 
C(8) - C(9) - C(15) - C(16) -3.8(4) 
C(6A) - C(1A) - C(2A) - C(3A) -0.4(4) 
Cl(1A) - C(1A) - C(2A) - C(3A) 179.4(2) 
C(1A) - C(2A) - C(3A) - C(4A) 1.8(4) 
C(2A) - C(3A) - C(4A) - C(5A) -0.9(4) 
C(3A) - C(4A) - C(5A) - C(6A) -1.4(4) 
C(3A) - C(4A) - C(5A) - Cl(2A) 175.2(2) 
C(4A) - C(5A) - C(6A) - C(1A) 2.7(4) 
Cl(2A) - C(5A) - C(6A) - C(1A) -173.95(19) 
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C(4A) - C(5A) - C(6A) - C(7A) -177.0(3) 
Cl(2A) - C(5A) - C(6A) - C(7A) 6.4(3) 
C(2A) - C(1A) - C(6A) - C(5A) -1.7(4) 
Cl(1A) - C(1A) - C(6A) - C(5A) 178.4(2) 
C(2A) - C(1A) - C(6A) - C(7A) 177.9(3) 
Cl(1A) - C(1A) - C(6A) - C(7A) -1.9(4) 
C(11A) - N(1A) - C(7A) - C(8A) 2.9(4) 
C(11A) - N(1A) - C(7A) - C(6A) -175.9(2) 
C(5A) - C(6A) - C(7A) - C(8A) -115.8(3) 
C(1A) - C(6A) - C(7A) - C(8A) 64.6(4) 
C(5A) - C(6A) - C(7A) - N(1A) 63.0(3) 
C(1A) - C(6A) - C(7A) - N(1A) -116.7(3) 
N(1A) - C(7A) - C(8A) - C(9A) -1.7(4) 
C(6A) - C(7A) - C(8A) - C(9A) 177.0(2) 
C(7A) - C(8A) - C(9A) - C(15A) 178.9(2) 
C(7A) - C(8A) - C(9A) - C(10A) -1.2(4) 
C(15A) - C(9A) - C(10A) - C(12A) 2.1(4) 
C(8A) - C(9A) - C(10A) - C(12A) -177.8(2) 
C(15A) - C(9A) - C(10A) - C(11A) -177.0(2) 
C(8A) - C(9A) - C(10A) - C(11A) 3.0(4) 
C(7A) - N(1A) - C(11A) - O(1A) 178.5(2) 
C(7A) - N(1A) - C(11A) - C(10A) -1.0(4) 
C(12A) - C(10A) - C(11A) - O(1A) -0.7(4) 
C(9A) - C(10A) - C(11A) - O(1A) 178.5(2) 
C(12A) - C(10A) - C(11A) - N(1A) 178.9(2) 
C(9A) - C(10A) - C(11A) - N(1A) -1.9(4) 
C(9A) - C(10A) - C(12A) - C(13A) -1.4(4) 
C(11A) - C(10A) - C(12A) - C(13A) 177.8(2) 
C(10A) - C(12A) - C(13A) - C(14A) 0.0(4) 
C(12A) - C(13A) - C(14A) - C(15A) 0.5(4) 
C(13A) - C(14A) - C(15A) - C(9A) 0.2(4) 
C(13A) - C(14A) - C(15A) - C(16A) -178.5(3) 
C(10A) - C(9A) - C(15A) - C(14A) -1.5(4) 
C(8A) - C(9A) - C(15A) - C(14A) 178.4(2) 
C(10A) - C(9A) - C(15A) - C(16A) 177.2(2) 
C(8A) - C(9A) - C(15A) - C(16A) -2.8(4) 
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X-ray structure determination for 207d  
 
Table 1: Crystal data and structure refinement for 207d. 
                                                                                                                         
 Identification code k12farm10 
 Formula weight 265.30 
 Temperature 150(2) K 
 Wavelength 0.71073 Å 
 Crystal system Monoclinic 
 Space group P21/n 
 Unit cell dimensions a = 12.5690(8)Å alpha = 90o 
       b = 17.0250(11)Å beta = 104.837(2)o 
       c = 13.3300(11)Å gamma = 90o 
 Volume 2757.3(3) Å3 
 Z 8 
 Density (calculated) 1.278 Mg/m3 
 Absorption coefficient 0.084 mm-1 
 F(000) 1120 
 Crystal size 0.30 x 0.08 x 0.08 mm 
 Theta range for data collection 3.52 to 25.03o 
 Index ranges -14<=h<=14; -20<=k<=20; -11<=l<=15 
 Reflections collected 12394 
 Independent reflections 4788 [R(int) = 0.1450] 
 Reflections observed (>2sigma) 1941 
 Data Completeness 0.982 
 Absorption correction Semi-empirical from equivalents 
 Max. and min. transmission 1.000 and 0.710 
 Refinement method Full-matrix least-squares on F2 
 Data / restraints / parameters 4788 / 0 / 365 
 Goodness-of-fit on F2 0.895 
 Final R indices [I>2sigma(I)] R1 = 0.0717   wR2 = 0.1299 
 R indices (all data) R1 = 0.2113  wR2 = 0.1699 





2 independent molecules in the asymmetric unit, which form hydrogen-bonded dimers. 
 
Crystal quality poor - small fragment taken from a non-merohedrally twinned needle. Unit cell 
parameters reflect the sample quality.  However, the structure is unambiguous. Data 
truncated to 25 degree Bragg angle. 
 
 
Hydrogen bonds with H..A < r(A) + 2.000 Angstroms  and  <DHA > 110 deg. 
 
 D-H           d(D-H)   d(H..A)   <DHA    d(D..A)   A 
 
 N1-H1          0.880    1.917   168.55    2.785    O1A  
 
 N1A-H1A        0.880    2.095   163.52    2.950    O1  
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Table 2:  Atomic coordinates ( x 104) and equivalent isotropic displacement parameters (Å2 x 
103) for 207d. U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
                                                                                                                         
                                                                                                                         
  Atom   x   y   z  U(eq) 
O(1) 4518(2) 1373(1) -78(2) 50(1) 
O(2) 701(2) 3499(1) -299(3) 76(1) 
N(1) 3249(2) 1302(2) 854(2) 42(1) 
C(1) 3670(3) 1634(2) 109(3) 46(1) 
C(2) 3060(3) 2313(2) -435(3) 44(1) 
C(3) 3416(3) 2679(2) -1231(3) 53(1) 
C(4) 2872(3) 3325(2) -1706(4) 65(1) 
C(5) 1944(4) 3608(2) -1412(4) 72(1) 
C(6) 1590(3) 3260(2) -636(4) 62(1) 
C(7) 2139(3) 2589(2) -126(3) 48(1) 
C(8) 1785(3) 2199(2) 675(3) 53(1) 
C(9) 2328(3) 1560(2) 1161(3) 44(1) 
C(10) 2011(3) 1117(2) 1975(3) 48(1) 
C(11) 1408(3) 1453(2) 2609(4) 68(1) 
C(12) 1129(4) 1037(3) 3386(4) 83(2) 
C(13) 1447(4) 257(3) 3583(4) 71(1) 
C(14) 2019(3) -74(2) 2953(4) 69(1) 
C(15) 2300(3) 331(2) 2160(4) 59(1) 
C(16) 1147(4) -195(3) 4464(5) 117(2) 
C(17) 19(4) 4110(3) -875(4) 103(2) 
O(1A) 4580(2) 54(1) 1769(2) 59(1) 
O(2A) 8876(2) -1580(1) 3110(2) 68(1) 
N(1A) 6113(2) 279(2) 1218(2) 44(1) 
C(1A) 5547(3) -119(2) 1807(3) 45(1) 
C(2A) 6148(3) -725(2) 2490(3) 48(1) 
C(3A) 5629(3) -1157(2) 3129(3) 54(1) 
C(4A) 6200(3) -1722(2) 3751(4) 59(1) 
C(5A) 7298(3) -1886(2) 3788(3) 59(1) 
C(6A) 7818(3) -1469(2) 3165(3) 56(1) 
C(7A) 7252(3) -868(2) 2501(3) 43(1) 
C(8A) 7758(3) -417(2) 1841(3) 49(1) 
C(9A) 7206(3) 148(2) 1208(3) 40(1) 
C(10A) 7670(3) 638(2) 512(3) 42(1) 
C(11A) 8796(3) 628(2) 582(4) 63(1) 
C(12A) 9240(3) 1053(2) -91(4) 66(1) 
C(13A) 8608(3) 1518(2) -851(4) 58(1) 
C(14A) 7495(3) 1542(2) -908(3) 56(1) 
C(15A) 7029(3) 1111(2) -254(3) 50(1) 
C(16A) 9095(3) 1960(2) -1614(4) 77(1) 
C(17A) 9459(3) -2218(2) 3716(4) 82(2) 
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 Table 3: Bond lengths [Å] and angles [o] for 207d. 
   
O(1)-C(1) 1.238(4) O(2)-C(6) 1.369(4) 
O(2)-C(17) 1.438(5 N(1)-C(1) 1.360(4) 
N(1)-C(9) 1.395(4) C(1)-C(2) 1.472(5) 
C(2)-C(3) 1.399(5) C(2)-C(7) 1.405(4) 
C(3)-C(4) 1.364(5) C(4)-C(5) 1.406(5) 
C(5)-C(6) 1.363(5) C(6)-C(7) 1.416(5) 
C(7)-C(8) 1.423(5) C(8)-C(9) 1.357(5) 
C(9)-C(10) 1.459(5)  C(10)-C(15) 1.392(5) 
C(10)-C(11) 1.394(5) C(11)-C(12) 1.373(6) 
C(12)-C(13) 1.394(6) C(13)-C(14) 1.360(5) 
C(13)-C(16) 1.529(6) C(14)-C(15) 1.382(5) 
O(1A)-C(1A) 1.239(4) O(2A)-C(6A) 1.364(4) 
O(2A)-C(17A) 1.438(4 N(1A)-C(1A) 1.367(4) 
N(1A)-C(9A) 1.394(4) C(1A)-C(2A) 1.453(5) 
C(2A)-C(7A) 1.404(4) C(2A)-C(3A) 1.406(5) 
C(3A)-C(4A) 1.350(5) C(4A)-C(5A) 1.397(5) 
C(5A)-C(6A) 1.377(5) C(6A)-C(7A) 1.420(5) 
C(7A)-C(8A) 1.434(5) C(8A)-C(9A) 1.348(5) 
C(9A)-C(10A) 1.476(5)  C(10A)-C(15A) 1.385(5) 
C(10A)-C(11A) 1.395(5) C(11A)-C(12A) 1.377(5) 
C(12A)-C(13A) 1.369(6) C(13A)-C(14A) 1.382(5) 
C(13A)-C(16A) 1.514(5) C(14A)-C(15A) 1.380(5) 
C(6)-O(2)-C(17) 117.7(4) C(1)-N(1)-C(9) 126.2(3) 
O(1)-C(1)-N(1) 121.0(3) O(1)-C(1)-C(2) 123.2(4) 
N(1)-C(1)-C(2) 115.8(3) C(3)-C(2)-C(7) 121.4(3) 
C(3)-C(2)-C(1) 119.8(3) C(7)-C(2)-C(1) 118.8(4) 
C(4)-C(3)-C(2) 119.5(4) C(3)-C(4)-C(5) 120.0(4) 
C(6)-C(5)-C(4) 121.2(4) C(5)-C(6)-O(2) 125.0(4) 
C(5)-C(6)-C(7) 120.1(4) O(2)-C(6)-C(7) 114.9(4) 
C(2)-C(7)-C(6) 117.8(4) C(2)-C(7)-C(8) 120.3(3) 
C(6)-C(7)-C(8) 122.0(4) C(9)-C(8)-C(7) 121.1(3) 
C(8)-C(9)-N(1) 117.8(3) C(8)-C(9)-C(10) 124.8(3) 
N(1)-C(9)-C(10) 117.4(3) C(15)-C(10)-C(11) 116.5(4) 
C(15)-C(10)-C(9) 121.4(3) C(11)-C(10)-C(9) 122.1(3) 
C(12)-C(11)-C(10) 121.9(4) C(11)-C(12)-C(13) 121.2(4) 
C(14)-C(13)-C(12) 116.7(4) C(14)-C(13)-C(16) 122.7(4) 
C(12)-C(13)-C(16) 120.6(4) C(13)-C(14)-C(15) 123.1(4) 
C(14)-C(15)-C(10) 120.5(4) C(6A)-O(2A)-C(17A) 116.0(3) 
C(1A)-N(1A)-C(9A) 125.8(3) O(1A)-C(1A)-N(1A) 120.5(3) 
O(1A)-C(1A)-C(2A) 122.8(3) N(1A)-C(1A)-C(2A) 116.6(3) 
C(7A)-C(2A)-C(3A) 120.9(3) C(7A)-C(2A)-C(1A) 118.9(3) 
C(3A)-C(2A)-C(1A) 120.2(3) C(4A)-C(3A)-C(2A) 119.3(4) 
C(3A)-C(4A)-C(5A) 122.0(4) C(6A)-C(5A)-C(4A) 119.5(4) 
O(2A)-C(6A)-C(5A) 125.5(4) O(2A)-C(6A)-C(7A) 114.0(3) 
C(5A)-C(6A)-C(7A) 120.6(3) C(2A)-C(7A)-C(6A) 117.8(3) 
C(2A)-C(7A)-C(8A) 119.6(3) C(6A)-C(7A)-C(8A) 122.6(3) 
C(9A)-C(8A)-C(7A) 121.8(3) C(8A)-C(9A)-N(1A) 117.4(3) 
C(8A)-C(9A)-C(10A) 125.0(3) N(1A)-C(9A)-C(10A) 117.6(3) 
C(15A)-C(10A)-C(11A) 116.5(3) C(15A)-C(10A)-C(9A) 122.9(3) 
C(11A)-C(10A)-C(9A) 120.6(4) C(12A)-C(11A)-C(10A) 121.5(4) 
C(13A)-C(12A)-C(11A) 122.1(4) C(12A)-C(13A)-C(14A) 116.4(4) 
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C(12A)-C(13A)-C(16A) 121.8(4) C(14A)-C(13A)-C(16A) 121.8(4) 
C(15A)-C(14A)-C(13A) 122.5(4) C(14A)-C(15A)-C(10A) 120.9(3) 
                                                                                                                                                                                                   
  
Table 4: Anisotropic displacement parameters (Å2 x 103) for 207d. The anisotropic 
displacement factor exponent takes the form: -2 gpi2 [ h2 a*2 U11 + ... + 2 h k a* b* U 
                                                                                                                         
  Atom  U11  U22  U33  U23  U13  U12 
O(1) 43(2) 49(2) 58(2) 2(1) 12(1) 3(1) 
O(2) 82(2) 59(2) 93(3) 16(2) 30(2) 29(2) 
N(1) 39(2) 35(2) 49(2) 6(2) 4(2) 2(1) 
C(1) 44(2) 41(2) 52(3) -5(2) 10(2) -8(2) 
C(2) 42(2) 39(2) 47(3) -4(2) 3(2) -1(2) 
C(3) 61(2) 44(2) 50(3) 5(2) 8(2) 0(2) 
C(4) 80(3) 53(3) 62(4) 5(2) 19(3) 3(2) 
C(5) 92(3) 56(3) 65(4) 12(2) 17(3) 20(2) 
C(6) 70(3) 48(2) 67(4) 0(2) 17(3) 9(2) 
C(7) 48(2) 36(2) 55(3) 1(2) 2(2) 3(2) 
C(8) 50(2) 47(2) 62(3) -3(2) 12(2) 5(2) 
C(9) 39(2) 45(2) 48(3) -3(2) 9(2) -1(2) 
C(10) 40(2) 45(2) 59(3) -6(2) 10(2) 2(2) 
C(11) 83(3) 62(3) 62(4) -2(3) 26(3) 15(2) 
C(12) 86(3) 105(4) 68(4) -2(3) 39(3) 19(3) 
C(13) 77(3) 81(3) 64(4) 9(3) 35(3) 6(3) 
C(14) 73(3) 64(3) 80(4) 13(3) 39(3) 8(2) 
C(15) 57(2) 50(2) 80(4) 2(2) 38(2) 2(2) 
C(16) 133(4) 135(5) 112(6) 43(4) 86(4) 29(4) 
C(17) 117(4) 91(4) 102(5) 35(3) 30(4) 69(3) 
O(1A) 43(2) 59(2) 77(2) 20(2) 19(1) 10(1) 
O(2A) 56(2) 73(2) 71(2) 30(2) 10(2) 20(1) 
N(1A) 44(2) 35(2) 51(2) 5(2) 11(2) 4(1) 
C(1A) 45(2) 40(2) 50(3) -3(2) 13(2) -4(2) 
C(2A) 50(2) 35(2) 62(3) 2(2) 19(2) 2(2) 
C(3A) 58(2) 52(2) 55(3) 4(2) 17(2) 4(2) 
C(4A) 70(3) 50(2) 60(3) 11(2) 21(2) -4(2) 
C(5A) 76(3) 48(2) 53(3) 8(2) 16(2) 4(2) 
C(6A) 54(2) 51(2) 63(3) 7(2) 16(2) 7(2) 
C(7A) 48(2) 38(2) 36(3) 0(2) -1(2) 4(2) 
C(8A) 41(2) 48(2) 57(3) 1(2) 9(2) 0(2) 
C(9A) 39(2) 45(2) 32(3) -8(2) 2(2) 3(2) 
C(10A) 41(2) 41(2) 46(3) -2(2) 12(2) 1(2) 
C(11A) 50(2) 63(3) 73(4) 24(2) 11(2) -4(2) 
C(12A) 44(2) 75(3) 74(4) 10(3) 6(2) -9(2) 
C(13A) 57(3) 52(2) 64(3) 9(2) 16(2) -4(2) 
C(14A) 62(3) 55(2) 53(3) 11(2) 18(2) 9(2) 
C(15A) 47(2) 50(2) 55(3) 5(2) 15(2) 9(2) 
C(16A) 74(3) 87(3) 70(4) 18(3) 20(3) -10(2) 
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Table 5: Hydrogen coordinates ( x 104) and isotropic displacement parameters (Å2 x 103) for 
207d. 
                                                                                                                         
  Atom   x   y   z  U(eq) 
H(1) 3591 886 1172 51 
H(3) 4032 2478 -1439 63 
H(4) 3119 3585 -2236 78 
H(5) 1558 4050 -1761 86 
H(8) 1157 2389 873 64 
H(11) 1183 1986 2499 81 
H(12) 712 1286 3798 99 
H(14) 2235 -608 3063 83 
H(15) 2695 70 1737 71 
H(16A) 374 -358 4245 175 
H(16B) 1257 144 5076 175 
H(16C) 1618 -660 4636 175 
H(17A) 436 4602 -799 155 
H(17B) -632 4180 -609 155 
H(17C) -210 3964 -1610 155 
H(1A) 5757 651 808 53 
H(3A) 4885 -1053 3123 65 
H(4A) 5844 -2017 4175 71 
H(5A) 7684 -2282 4239 71 
H(8A) 8504 -518 1850 59 
H(11A) 9268 320 1107 75 
H(12A) 10010 1022 -26 79 
H(14A) 7033 1868 -1417 67 
H(15A) 6257 1139 -330 60 
H(16D) 9513 1596 -1935 115 
H(16E) 9586 2374 -1247 115 
H(16F) 8502 2197 -2152 115 
H(17D) 9103 -2716 3453 123 
H(17E) 9449 -2151 4443 123 
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 Table 6: Dihedral angles [o] for 207d. 
                                                                                                                         
  Atom1  -  Atom2  -  Atom3  -  Atom4  Dihedral 
C(9) - N(1) - C(1) - O(1) 177.4(3) 
C(9) - N(1) - C(1) - C(2) -2.0(5) 
O(1) - C(1) - C(2) - C(3) 2.2(5) 
N(1) - C(1) - C(2) - C(3) -178.4(3) 
O(1) - C(1) - C(2) - C(7) -176.6(3) 
N(1) - C(1) - C(2) - C(7) 2.8(5) 
C(7) - C(2) - C(3) - C(4) 1.2(6) 
C(1) - C(2) - C(3) - C(4) -177.6(3) 
C(2) - C(3) - C(4) - C(5) -1.5(6) 
C(3) - C(4) - C(5) - C(6) 1.8(7) 
C(4) - C(5) - C(6) - O(2) 179.7(4) 
C(4) - C(5) - C(6) - C(7) -1.6(7) 
C(17) - O(2) - C(6) - C(5) 7.0(6) 
C(17) - O(2) - C(6) - C(7) -171.8(4) 
C(3) - C(2) - C(7) - C(6) -1.0(5) 
C(1) - C(2) - C(7) - C(6) 177.8(3) 
C(3) - C(2) - C(7) - C(8) 179.1(4) 
C(1) - C(2) - C(7) - C(8) -2.2(5) 
C(5) - C(6) - C(7) - C(2) 1.2(6) 
O(2) - C(6) - C(7) - C(2) -179.9(3) 
C(5) - C(6) - C(7) - C(8) -178.9(4) 
O(2) - C(6) - C(7) - C(8) 0.0(6) 
C(2) - C(7) - C(8) - C(9) 0.5(6) 
C(6) - C(7) - C(8) - C(9) -179.4(4) 
C(7) - C(8) - C(9) - N(1) 0.4(5) 
C(7) - C(8) - C(9) - C(10) -178.8(4) 
C(1) - N(1) - C(9) - C(8) 0.4(5) 
C(1) - N(1) - C(9) - C(10) 179.8(3) 
C(8) - C(9) - C(10) - C(15) 154.8(4) 
N(1) - C(9) - C(10) - C(15) -24.5(5) 
C(8) - C(9) - C(10) - C(11) -25.3(6) 
N(1) - C(9) - C(10) - C(11) 155.4(4) 
C(15) - C(10) - C(11) - C(12) 1.1(7) 
C(9) - C(10) - C(11) - C(12) -178.8(4) 
C(10) - C(11) - C(12) - C(13) 0.5(8) 
C(11) - C(12) - C(13) - C(14) -1.6(7) 
C(11) - C(12) - C(13) - C(16) 178.9(5) 
C(12) - C(13) - C(14) - C(15) 1.0(7) 
C(16) - C(13) - C(14) - C(15) -179.5(5) 
C(13) - C(14) - C(15) - C(10) 0.6(7) 
C(11) - C(10) - C(15) - C(14) -1.7(6) 
C(9) - C(10) - C(15) - C(14) 178.3(4) 
C(9A) - N(1A) - C(1A) - O(1A) 178.8(3) 
C(9A) - N(1A) - C(1A) - C(2A) 0.7(5) 
O(1A) - C(1A) - C(2A) - C(7A) -178.4(3) 
N(1A) - C(1A) - C(2A) - C(7A) -0.4(5) 
O(1A) - C(1A) - C(2A) - C(3A) 1.4(6) 
N(1A) - C(1A) - C(2A) - C(3A) 179.5(3) 
C(7A) - C(2A) - C(3A) - C(4A) -0.7(6) 
C(1A) - C(2A) - C(3A) - C(4A) 179.4(4) 
C(2A) - C(3A) - C(4A) - C(5A) 0.7(6) 
C(3A) - C(4A) - C(5A) - C(6A) -0.9(6) 
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C(17A) - O(2A) - C(6A) - C(5A) 3.8(6) 
C(17A) - O(2A) - C(6A) - C(7A) -175.9(4) 
C(4A) - C(5A) - C(6A) - O(2A) -178.7(4) 
C(4A) - C(5A) - C(6A) - C(7A) 1.0(6) 
C(3A) - C(2A) - C(7A) - C(6A) 0.9(6) 
C(1A) - C(2A) - C(7A) - C(6A) -179.3(4) 
C(3A) - C(2A) - C(7A) - C(8A) -180.0(4) 
C(1A) - C(2A) - C(7A) - C(8A) -0.1(5) 
O(2A) - C(6A) - C(7A) - C(2A) 178.7(3) 
C(5A) - C(6A) - C(7A) - C(2A) -1.1(6) 
O(2A) - C(6A) - C(7A) - C(8A) -0.4(6) 
C(5A) - C(6A) - C(7A) - C(8A) 179.8(4) 
C(2A) - C(7A) - C(8A) - C(9A) 0.3(6) 
C(6A) - C(7A) - C(8A) - C(9A) 179.4(4) 
C(7A) - C(8A) - C(9A) - N(1A) 0.0(5) 
C(7A) - C(8A) - C(9A) - C(10A) 179.7(3) 
C(1A) - N(1A) - C(9A) - C(8A) -0.6(5) 
C(1A) - N(1A) - C(9A) - C(10A) 179.8(3) 
C(8A) - C(9A) - C(10A) - C(15A) 168.2(4) 
N(1A) - C(9A) - C(10A) - C(15A) -12.2(5) 
C(8A) - C(9A) - C(10A) - C(11A) -10.0(6) 
N(1A) - C(9A) - C(10A) - C(11A) 169.7(3) 
C(15A) - C(10A) - C(11A) - C(12A) -1.4(6) 
C(9A) - C(10A) - C(11A) - C(12A) 176.9(4) 
C(10A) - C(11A) - C(12A) - C(13A) 1.2(7) 
C(11A) - C(12A) - C(13A) - C(14A) 0.1(7) 
C(11A) - C(12A) - C(13A) - C(16A) -177.7(4) 
C(12A) - C(13A) - C(14A) - C(15A) -1.3(6) 
C(16A) - C(13A) - C(14A) - C(15A) 176.5(4) 
C(13A) - C(14A) - C(15A) - C(10A) 1.2(6) 
C(11A) - C(10A) - C(15A) - C(14A) 0.2(6) 
C(9A) - C(10A) - C(15A) - C(14A) -178.0(3) 
                                                                                                                         
  
 
 
 
 
 
